


**CUMULATIVE
SUPPLEMENT 4
APRIL 2016**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Department of Health and Human Services

**Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy**

2016

Prepared By
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

Cumulative Supplement 4

April 2016

CONTENTS

| | <i>PAGE</i> |
|---|-------------|
| 1.0 INTRODUCTION..... | v |
| 1.1 How to use the Cumulative Supplement..... | v |
| 1.2 Cumulative Supplement Content | vi |
| 1.3 Applicant Name Changes | vii |
| 1.4 Levothyroxine Sodium..... | vii |
| 1.5 Availability of the Edition | viii |
| 1.6 Report of Counts for the Prescription Drug Product List..... | ix |
| 1.7 Cumulative Supplement Legend..... | x |
| | |
| DRUG PRODUCT LISTS | |
| Prescription Drug Product List | 1-1 |
| OTC Drug Product List | 2-1 |
| Drug Products with Approval under Section 505 of the Act | |
| Administered by the Center for Biologics Evaluation and Research List | 3-1 |
| Orphan Product Designations and Approvals List | 4-1 |
| Drug Products Which Must Demonstrate in vivo Bioavailability | |
| Only if Product Fails to Achieve Adequate Dissolution | 5-1 |
| | |
| PATENT AND EXCLUSIVITY INFORMATION ADDENDUM | |
| A. Patent and Exclusivity Lists | A-1 |
| B. Patent and Exclusivity Terms | B-1 |

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

36th EDITION

**CUMULATIVE SUPPLEMENT 04
April 2016**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 36th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

| <u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u> | <u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u> |
|--|--|
| BD RX INC (BD RX) | FRESENIUS KABI USA LLC (FRESENIUS KABI USA) |
| CITRON PHARMA LLC (CITRON PHARMA LLC) | CASPER PHARMA LLC (CASPER PHARMA LLC) |

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following

explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187) and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 076752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187) and Levothyroxine Sodium (Merck KGAA ANDA 076752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

| Trade Name | Applicant | Potency | TE Code | Appl No | Product No |
|----------------------|-------------|---------|---------|---------|------------|
| UNITHROID | STEVENS J | 0.025MG | AB1 | 021210 | 001 |
| LEVOTHYROXINE SODIUM | MYLAN | 0.025MG | AB1 | 076187 | 001 |
| LEVOXYL | KING PHARMS | 0.025MG | AB1 | 021301 | 001 |
| SYNTHROID | ABBOTT | 0.025MG | AB1 | 021402 | 001 |
| LEVO-T | ALARA PHARM | 0.025MG | AB1 | 021342 | 001 |
| | | | | | |
| SYNTHROID | ABBVIE | 0.025MG | AB2 | 021402 | 001 |
| LEVOTHYROXINE SODIUM | MYLAN | 0.025MG | AB2 | 076187 | 001 |
| LEVO-T | ALARA PHARM | 0.025MG | AB2 | 021342 | 001 |
| UNITHROID | STEVENS J | 0.025MG | AB2 | 021210 | 001 |
| | | | | | |
| LEVOXYL | KUNG PHARMS | 0.025MG | AB3 | 021301 | 001 |
| LEVO-T | ALARA PHARM | 0.025MG | AB3 | 021342 | 001 |
| UNITHROID | STEVENS J | 0.025MG | AB3 | 021210 | 001 |
| LEVOTHYROXINE SODIUM | MYLAN | 0.025MG | AB3 | 076187 | 001 |
| | | | | | |
| LEVOTHROID | LLOYD | 0.025MG | AB4 | 021116 | 001 |
| LEVOTHYROXINE SODIUM | MYLAN | 0.025MG | AB4 | 076187 | 001 |
| | | | | | |

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent

number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination

product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

| <u>CATEGORIES COUNTED</u> | <u>DEC 2015</u> | <u>MAR 2016</u> | <u>JUN 2016</u> | <u>SEP 2016</u> | <u>DEC 2016</u> |
|------------------------------------|--------------------------|--------------------------|-----------------|-----------------|-----------------|
| DRUG PRODUCTS LISTED SINGLE SOURCE | 17151 2664 (15.5%) | 17251 2693 (15.6%) | | | |
| MULTISOURCE | 14487 (84.5%) | 14558 (84.4%) | | | |
| THERAPEUTICALLY EQUIVALENT | 14366 (83.8%) | 14434 (83.7%) | | | |
| NOT THERAPEUTICALLY EQUIVALENT | 121 (0.7%) | 124 (0.7%) | | | |
| EXCEPTIONS ¹ | 73 (0.4%) | 73 (0.4%) | | | |
| NEW MOLECULAR ENTITIES APPROVED | 28 | 9 | | | |
| NUMBER OF APPLICANTS | 1011 | 1007 | | | |

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >D>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

| | |
|------|---|
| NEWA | New drug product approval usually in the supplement month. |
| CAHN | Applicant holder firm name has changed. |
| CAIN | Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name. |
| CDFR | Change. Dosage Form; Route of Administration. |
| CFTG | Change. A first time generic for the innovator product. A TE Code is added. |
| CMFD | Change. The product is moved from the Discontinued Section due to a change in marketing status. |
| CMS1 | Change. Miscellaneous addition to list. |
| CMS2 | Change. Miscellaneous deletion from list. |
| CPOT | Change. Potency amount/unit. |
| CRLD | Change. Reference Listed Drug. |
| CTEC | Change. Therapeutic Equivalence Code. |
| CTNA | Change. Trade Name. |
| DISC | Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition. |

ACETAMINOPHEN

SOLUTION;IV (INFUSION)
 ACETAMINOPHEN

| | | | | | | | | |
|----|---|-----------------|---------------------|---------|-----|--------------|-----|------|
| AP | | SANDOZ INC | 1GM/100ML (10MG/ML) | A204052 | 001 | Mar 22, 2016 | Mar | NEWA |
| AP | + | MALLINCKRODT IP | 1GM/100ML (10MG/ML) | N022450 | 001 | Nov 02, 2010 | Mar | CFTG |

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET;ORAL
 BUTALBITAL, ACETAMINOPHEN AND CAFFEINE
 @ INGENUS PHARMS NJ 325MG;50MG;40MG
 @ SUN PHARM INDS 325MG;50MG;40MG

| | | | | |
|---------|-----|--------------|-----|------|
| A040864 | 001 | Dec 01, 2008 | Jan | CAHN |
| A040601 | 001 | Jul 29, 2005 | Jan | CAHN |

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL
 FIORICET W/ CODEINE

| | | | | | | | | | |
|-----|----|---|---------------------|----------------------|---------|-----|--------------|-----|------|
| >D> | AB | + | ACTAVIS LABS UT INC | 325MG;50MG;40MG;30MG | N020232 | 001 | Jul 30, 1992 | Apr | CAHN |
| >A> | AB | + | ALLERGAN SALES LLC | 325MG;50MG;40MG;30MG | N020232 | 001 | Jul 30, 1992 | Apr | CAHN |

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL
 ACETAMINOPHEN AND CODEINE PHOSPHATE
 @ SUN PHARM INDS 300MG;60MG

| | | | | |
|---------|-----|--------------|-----|------|
| A089673 | 001 | Feb 10, 1988 | Mar | CAHN |
|---------|-----|--------------|-----|------|

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL
 ZYFREL

| | | | | | | | | | |
|-----|----|--|-------------------|-----------------------|---------|-----|--------------|-----|------|
| >A> | AA | | CYPRESS PHARM INC | 325MG/15ML;7.5MG/15ML | A090468 | 001 | Apr 14, 2016 | Apr | NEWA |
|-----|----|--|-------------------|-----------------------|---------|-----|--------------|-----|------|

TABLET;ORAL
 HYDROCODONE BITARTRATE AND ACETAMINOPHEN

| | | | | | | | | | |
|-----|----|--|------------------|-------------|---------|-----|--------------|-----|------|
| >A> | AA | | AMNEAL PHARMS NY | 325MG;7.5MG | A040746 | 002 | May 10, 2016 | Apr | NEWA |
| | AA | | RHODES PHARMS | 325MG;5MG | A202991 | 001 | Apr 12, 2016 | Mar | NEWA |
| | AA | | | 325MG;7.5MG | A202991 | 002 | Apr 12, 2016 | Mar | NEWA |
| | AA | | | 325MG;10MG | A202991 | 003 | Apr 12, 2016 | Mar | NEWA |

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL
 OXYCODONE AND ACETAMINOPHEN

| | | | | | | | | | |
|-----|----|---|------------------|-------------|---------|-----|--------------|-----|------|
| | AA | | ALVOGEN MALTA | 325MG;5MG | A202677 | 003 | Mar 08, 2016 | Feb | NEWA |
| | AA | | | 325MG;7.5MG | A202677 | 001 | Jul 26, 2012 | Jan | CAHN |
| | AA | | | 325MG;10MG | A202677 | 002 | Jul 26, 2012 | Jan | CAHN |
| >A> | AA | | AMNEAL PHARMS NY | 325MG;7.5MG | A040778 | 002 | Jun 27, 2014 | Apr | NEWA |
| | AA | | MAYNE PHARMA INC | 325MG;2.5MG | A090177 | 001 | Oct 20, 2008 | Feb | CAHN |
| | AA | | | 325MG;5MG | A090177 | 002 | Oct 20, 2008 | Feb | CAHN |
| | AA | | | 325MG;7.5MG | A090177 | 003 | Oct 20, 2008 | Feb | CAHN |
| | AA | | | 325MG;10MG | A090177 | 004 | Oct 20, 2008 | Feb | CAHN |
| | | @ | | 500MG;7.5MG | A090177 | 005 | Oct 20, 2008 | Feb | CAHN |
| | | @ | | 650MG;10MG | A090177 | 006 | Oct 20, 2008 | Feb | CAHN |

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE;ORAL
 ACETAZOLAMIDE

| | | | | | | | | | |
|----|--|--|------------------|-------|---------|-----|--------------|-----|------|
| AB | | | NOSTRUM LABS INC | 500MG | A204691 | 001 | Mar 29, 2016 | Mar | NEWA |
|----|--|--|------------------|-------|---------|-----|--------------|-----|------|

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS
 ACETYLCYSTEINE

| | | | | | | | | | |
|----|--|--|----------------------|---------------------|---------|-----|--------------|-----|------|
| AP | | | AUROBINDO PHARMA LTD | 6GM/30ML (200MG/ML) | A207358 | 001 | Feb 29, 2016 | Feb | NEWA |
|----|--|--|----------------------|---------------------|---------|-----|--------------|-----|------|

TABLET, EFFERVESCENT;ORAL
 CETYLEV

| | | | | | | | | | |
|--|--|---|------------------|-------|---------|-----|--------------|-----|------|
| | | | ARBOR PHARMS LLC | 500MG | N207916 | 001 | Jan 29, 2016 | Jan | NEWA |
| | | + | | 2.5GM | N207916 | 002 | Jan 29, 2016 | Jan | NEWA |

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE;ORAL
 SEMPREX-D

| | | | | | | | | | |
|--|--|---|---------------------|----------|---------|-----|--------------|-----|------|
| | | + | AUXILIUM PHARMS INC | 8MG;60MG | N019806 | 001 | Mar 25, 1994 | Mar | CAHN |
|--|--|---|---------------------|----------|---------|-----|--------------|-----|------|

ACYCLOVIR

| | | | | | | | | |
|-----|----------------------|--------------------|---------|---------|--------------|--------------|------|------|
| | CAPSULE;ORAL | | | | | | | |
| | ACYCLOVIR | | | | | | | |
| | @ RANBAXY | 200MG | A074975 | 001 | Sep 30, 1998 | Feb | DISC | |
| AB | ZYDUS PHARMS USA INC | 200MG | A204313 | 001 | Mar 25, 2016 | Mar | NEWA | |
| | OINTMENT;TOPICAL | | | | | | | |
| | ACYCLOVIR | | | | | | | |
| >A> | AB | FOUGERA PHARMS INC | 5% | A206633 | 001 | May 11, 2016 | Apr | NEWA |
| | TABLET;BUCCAL | | | | | | | |
| | SITAVIG | | | | | | | |
| | + | CIPHER PHARMS US | 50MG | N203791 | 001 | Apr 12, 2013 | Jan | CAHN |
| | TABLET;ORAL | | | | | | | |
| | ACYCLOVIR | | | | | | | |
| | @ SUN PHARM INDS LTD | 400MG | A074980 | 001 | Sep 30, 1998 | Feb | DISC | |
| | @ | 800MG | A074980 | 002 | Sep 30, 1998 | Feb | DISC | |

ACYCLOVIR SODIUM

| | | | | | | | | |
|-----|---|--------------------|---------|-----|--------------|-----|------|--|
| | INJECTABLE;INJECTION | | | | | | | |
| | ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE | | | | | | | |
| | @ HIKMA MAPLE | EQ 500MG BASE/VIAL | A074885 | 001 | Dec 19, 1997 | Feb | DISC | |
| | @ | EQ 1GM BASE/VIAL | A074885 | 002 | Dec 19, 1997 | Feb | DISC | |
| | ACYCLOVIR SODIUM | | | | | | | |
| >D> | @ BEDFORD | EQ 500MG BASE/VIAL | A074596 | 002 | Apr 22, 1997 | Apr | CAHN | |
| | @ | EQ 500MG BASE/VIAL | A074596 | 002 | Apr 22, 1997 | Feb | DISC | |
| >D> | @ | EQ 1GM BASE/VIAL | A074596 | 001 | Apr 22, 1997 | Apr | CAHN | |
| | @ | EQ 1GM BASE/VIAL | A074596 | 001 | Apr 22, 1997 | Feb | DISC | |
| AP | + | EQ 1GM BASE/VIAL | A074596 | 001 | Apr 22, 1997 | Feb | CTEC | |
| >A> | @ EUROHLTH INTL SARL | EQ 500MG BASE/VIAL | A074596 | 002 | Apr 22, 1997 | Apr | CAHN | |
| >A> | @ | EQ 1GM BASE/VIAL | A074596 | 001 | Apr 22, 1997 | Apr | CAHN | |
| AP | HIKMA PHARMS LLC | EQ 500MG BASE/VIAL | A205771 | 001 | Feb 29, 2016 | Feb | NEWA | |
| | + | EQ 1GM BASE/VIAL | A205771 | 002 | Feb 29, 2016 | Feb | CRLD | |
| AP | | EQ 1GM BASE/VIAL | A205771 | 002 | Feb 29, 2016 | Feb | NEWA | |

ADENOSINE

| | | | | | | | | | |
|-----|------------------------|--------------------|--------------------|--------------------|---------|--------------|--------------|------|------|
| | INJECTABLE;INJECTION | | | | | | | | |
| | ADENOSINE | | | | | | | | |
| >D> | AP | BEDFORD | 3MG/ML | A076404 | 001 | Jun 16, 2004 | Apr | CAHN | |
| >A> | AP | EUROHLTH INTL SARL | 3MG/ML | A076404 | 001 | Jun 16, 2004 | Apr | CAHN | |
| | SOLUTION;IV (INFUSION) | | | | | | | | |
| | ADENOSCAN | | | | | | | | |
| >D> | AP | + | ASTELLAS | 60MG/20ML (3MG/ML) | N020059 | 001 | May 18, 1995 | Apr | DISC |
| >A> | | @ | | 60MG/20ML (3MG/ML) | N020059 | 001 | May 18, 1995 | Apr | DISC |
| >D> | AP | + | | 90MG/30ML (3MG/ML) | N020059 | 002 | May 18, 1995 | Apr | DISC |
| >A> | | @ | | 90MG/30ML (3MG/ML) | N020059 | 002 | May 18, 1995 | Apr | DISC |
| | ADENOSINE | | | | | | | | |
| >D> | AP | TEVA PHARMS USA | 60MG/20ML (3MG/ML) | A077425 | 001 | Aug 29, 2013 | Apr | CRLD | |
| >A> | AP | + | | 60MG/20ML (3MG/ML) | A077425 | 001 | Aug 29, 2013 | Apr | CRLD |
| >D> | AP | | | 90MG/30ML (3MG/ML) | A077425 | 002 | Aug 29, 2013 | Apr | CRLD |
| >A> | AP | + | | 90MG/30ML (3MG/ML) | A077425 | 002 | Aug 29, 2013 | Apr | CRLD |

ALBUTEROL SULFATE

| | | | | | | | | |
|----|---------------------|----------------|----------------|---------|--------------|--------------|------|------|
| | SOLUTION;INHALATION | | | | | | | |
| | ALBUTEROL SULFATE | | | | | | | |
| | @ HI TECH PHARMA | EQ 0.083% BASE | A075063 | 001 | Feb 09, 1999 | Mar | DISC | |
| | @ LANDELA PHARM | EQ 0.083% BASE | A077569 | 001 | Apr 04, 2006 | Mar | DISC | |
| | @ MYLAN SPECLT | EQ 0.083% BASE | A072652 | 001 | Feb 21, 1992 | Mar | DISC | |
| AN | + | NEPHRON | EQ 0.083% BASE | A074880 | 001 | Sep 17, 1997 | Mar | CRLD |
| | @ TEVA PHARMS | EQ 0.083% BASE | A075343 | 001 | Nov 09, 1999 | Mar | DISC | |
| | @ WATSON LABS INC | EQ 0.083% BASE | A076370 | 001 | Nov 24, 2003 | Mar | DISC | |
| | TABLET;ORAL | | | | | | | |
| | ALBUTEROL SULFATE | | | | | | | |
| AB | SUN PHARM INDS | EQ 2MG BASE | A072637 | 002 | Dec 05, 1989 | Mar | CAHN | |
| AB | | EQ 4MG BASE | A072637 | 001 | Dec 05, 1989 | Mar | CAHN | |

ALFUZOSIN HYDROCHLORIDE

| | | | | | | | | |
|----|-------------------------------|------|---------|-----|--------------|-----|------|--|
| | TABLET, EXTENDED RELEASE;ORAL | | | | | | | |
| | ALFUZOSIN HYDROCHLORIDE | | | | | | | |
| AB | UNICHEM LABS LTD | 10MG | A203192 | 001 | Jan 28, 2016 | Jan | NEWA | |

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

| | | | | | | | |
|----|--------------------|-------|---------|-----|--------------|-----|------|
| AB | SUN PHARM INDS | 300MG | A071450 | 001 | Jan 09, 1987 | Mar | CAHN |
| AB | ZYLOPRIM | | | | | | |
| AB | SEBELA IRELAND LTD | 100MG | N016084 | 001 | | Jan | CAHN |
| AB | + | 300MG | N016084 | 002 | | Jan | CAHN |

ALMOTRIPTAN MALATE

TABLET; ORAL

ALMOTRIPTAN MALATE

| | | | | | | | |
|----|-------------------|----------------|---------|-----|--------------|-----|------|
| AB | AJANTA PHARMA LTD | EQ 6.25MG BASE | A205523 | 001 | Mar 03, 2016 | Feb | NEWA |
| AB | | EQ 12.5MG BASE | A205523 | 002 | Mar 03, 2016 | Feb | NEWA |

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

LOTRONEX

| | | | | | | | |
|----|--------------------|---------------|---------|-----|--------------|-----|------|
| AB | SEBELA IRELAND LTD | EQ 0.5MG BASE | N021107 | 002 | Dec 23, 2003 | Feb | CAHN |
| AB | + | EQ 1MG BASE | N021107 | 001 | Feb 09, 2000 | Feb | CAHN |

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

| | | | | | | | |
|--|-----------------------|-------|---------|-----|--------------|-----|------|
| | @ ACTAVIS LABS FL INC | 0.5MG | A077198 | 001 | May 13, 2010 | Jan | DISC |
| | @ | 1MG | A077198 | 002 | May 13, 2010 | Jan | DISC |
| | @ | 2MG | A077198 | 003 | May 13, 2010 | Jan | DISC |
| | @ | 3MG | A077198 | 004 | May 13, 2010 | Jan | DISC |
| | @ COREPHARMA | 0.5MG | A077996 | 001 | Jan 31, 2007 | Mar | DISC |
| | @ | 1MG | A077996 | 002 | Jan 31, 2007 | Mar | DISC |
| | @ | 2MG | A077996 | 003 | Jan 31, 2007 | Mar | DISC |
| | @ | 3MG | A077996 | 004 | Jan 31, 2007 | Mar | DISC |
| | @ IMPAX LABS | 0.5MG | A077968 | 004 | May 24, 2007 | Jan | DISC |
| | @ | 1MG | A077968 | 003 | May 24, 2007 | Jan | DISC |
| | @ | 2MG | A077968 | 002 | May 24, 2007 | Jan | DISC |
| | @ | 3MG | A077968 | 001 | May 24, 2007 | Jan | DISC |

ALPROSTADIL

INJECTABLE; INJECTION

EDEX

| | | | | | | | |
|----|-----------------------|--------------|---------|-----|--------------|-----|------|
| | @ AUXILIUM PHARMS INC | 0.005MG/VIAL | N020649 | 001 | Jun 12, 1997 | Mar | CAHN |
| AP | | 0.01MG/VIAL | N020649 | 002 | Jun 12, 1997 | Mar | CAHN |
| | + | 0.01MG/VIAL | N020649 | 005 | Jul 30, 1998 | Mar | CAHN |
| AP | | 0.02MG/VIAL | N020649 | 003 | Jun 12, 1997 | Mar | CAHN |
| | + | 0.02MG/VIAL | N020649 | 006 | Jul 30, 1998 | Mar | CAHN |
| AP | | 0.04MG/VIAL | N020649 | 004 | Jun 12, 1997 | Mar | CAHN |
| | + | 0.04MG/VIAL | N020649 | 007 | Jul 30, 1998 | Mar | CAHN |

SUPPOSITORY; URETHRAL

MUSE

| | | | | | | | |
|--|---------------|---------|---------|-----|--------------|-----|------|
| | + MEDA PHARMS | 0.125MG | N020700 | 001 | Nov 19, 1996 | Jan | CRLD |
| | + | 0.25MG | N020700 | 002 | Nov 19, 1996 | Jan | CRLD |
| | + | 0.5MG | N020700 | 003 | Nov 19, 1996 | Jan | CRLD |

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

| | | | | | | | |
|----|----------------|-------|---------|-----|--------------|-----|------|
| AB | BIONPHARMA INC | 100MG | A078720 | 001 | May 29, 2008 | Jan | CAHN |
|----|----------------|-------|---------|-----|--------------|-----|------|

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

| | | | | | | | | |
|-----|----|---------------|------------------|---------|-----|--------------|-----|------|
| >A> | AP | SAGENT PHARMS | EQ 250MG BASE/ML | A203323 | 001 | May 12, 2016 | Apr | NEWA |
|-----|----|---------------|------------------|---------|-----|--------------|-----|------|

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

| | | | | | | | | |
|--|---|-----------------|--|---------|-----|--------------|-----|------|
| | + | BAXTER HLTHCARE | 2.75%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;217MG/100ML;112MG/100ML | N020678 | 002 | Mar 26, 1997 | Mar | CMS1 |
|--|---|-----------------|--|---------|-----|--------------|-----|------|

CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

| | | | | | | | | |
|--|---|-----------------|---|---------|-----|--------------|-----|------|
| | + | BAXTER HLTHCARE | 2.75%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML; | N020678 | 005 | Mar 26, 1997 | Mar | CMS1 |
|--|---|-----------------|---|---------|-----|--------------|-----|------|

INJECTABLE; INJECTION

| | | | | | | | | |
|---|--|---|---------|-----|--------------|-----|------|--|
| | CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER | | | | | | | |
| | 217MG/100ML; 112MG/100ML | | | | | | | |
| | CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER | | | | | | | |
| + | BAXTER HLTHCARE | 2.75%; 33MG/100ML; 5GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML | N020678 | 001 | Mar 26, 1997 | Mar | CMS1 | |
| | CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER | | | | | | | |
| + | BAXTER HLTHCARE | 4.25%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML | N020678 | 009 | Mar 26, 1997 | Mar | CMS1 | |
| | CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER | | | | | | | |
| + | BAXTER HLTHCARE | 4.25%; 33MG/100ML; 20GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML | N020678 | 011 | Mar 26, 1997 | Mar | CMS1 | |
| | CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER | | | | | | | |
| + | BAXTER HLTHCARE | 4.25%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML | N020678 | 012 | Mar 26, 1997 | Mar | CMS1 | |
| | CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER | | | | | | | |
| + | BAXTER HLTHCARE | 4.25%; 33MG/100ML; 5GM/100ML; 51MG/100ML; 261MG/100ML; 297MG/100ML; 77MG/100ML | N020678 | 008 | Mar 26, 1997 | Mar | CMS1 | |
| | CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER | | | | | | | |
| + | BAXTER HLTHCARE | 5%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML | N020678 | 016 | Mar 26, 1997 | Mar | CMS1 | |
| | CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER | | | | | | | |
| + | BAXTER HLTHCARE | 5%; 33MG/100ML; 15GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML | N020678 | 017 | Mar 26, 1997 | Mar | CMS1 | |
| | CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER | | | | | | | |
| + | BAXTER HLTHCARE | 5%; 33MG/100ML; 20GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML | N020678 | 018 | Mar 26, 1997 | Mar | CMS1 | |
| | CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER | | | | | | | |
| + | BAXTER HLTHCARE | 5%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML | N020678 | 019 | Mar 26, 1997 | Mar | CMS1 | |
| | CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER | | | | | | | |
| + | BAXTER HLTHCARE | 5%; 33MG/100ML; 35GM/100ML; 51MG/100ML; 261MG/100ML; 340MG/100ML; 59MG/100ML | N020678 | 021 | Mar 26, 1997 | Mar | CMS1 | |

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

| | | | | | | | | |
|----|-----------------------------|-------|---------|-----|--------------|-----|------|--|
| | AMITRIPTYLINE HYDROCHLORIDE | | | | | | | |
| | @ SUN PHARM INDS INC | 10MG | A040816 | 002 | Jun 27, 2008 | Mar | DISC | |
| | @ | 10MG | A089399 | 002 | Jul 14, 1987 | Mar | DISC | |
| AB | @ | 10MG | A089399 | 002 | Jul 14, 1987 | Mar | CAHN | |
| | @ | 25MG | A040816 | 001 | Jun 27, 2008 | Mar | DISC | |
| | @ | 25MG | A089399 | 001 | Jul 14, 1987 | Mar | DISC | |
| AB | @ | 25MG | A089399 | 001 | Jul 14, 1987 | Mar | CAHN | |
| | @ | 50MG | A040816 | 003 | Jun 27, 2008 | Mar | DISC | |
| | @ | 50MG | A089399 | 003 | Jul 14, 1987 | Mar | DISC | |
| AB | @ | 50MG | A089399 | 003 | Jul 14, 1987 | Mar | CAHN | |
| | @ | 75MG | A040816 | 004 | Jun 27, 2008 | Mar | DISC | |
| | @ | 75MG | A089399 | 004 | Jul 14, 1987 | Mar | DISC | |
| AB | @ | 75MG | A089399 | 004 | Jul 14, 1987 | Mar | CAHN | |
| | @ | 100MG | A040816 | 005 | Jun 27, 2008 | Mar | DISC | |
| | @ | 100MG | A089399 | 005 | Jul 14, 1987 | Mar | DISC | |
| AB | @ | 100MG | A089399 | 005 | Jul 14, 1987 | Mar | CAHN | |
| | @ | 150MG | A040816 | 006 | Jun 27, 2008 | Mar | DISC | |
| | @ | 150MG | A089399 | 006 | Jul 14, 1987 | Mar | DISC | |
| AB | @ | 150MG | A089399 | 006 | Jul 14, 1987 | Mar | CAHN | |

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

| | | | | | | | | |
|--|------------------|---------------------|---------|-----|--------------|-----|------|--|
| | @ SUN PHARM INDS | EQ 12.5MG BASE; 5MG | A070765 | 001 | Dec 10, 1986 | Mar | CAHN | |
| | @ | EQ 25MG BASE; 10MG | A070766 | 001 | Dec 10, 1986 | Mar | CAHN | |

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

| | | | | | | | |
|---|----------------|----------|---------|-----|--------------|-----|------|
| @ | SUN PHARM INDS | 10MG;2MG | A071077 | 001 | Nov 12, 1986 | Mar | CAHN |
| @ | | 10MG;4MG | A071078 | 001 | Nov 12, 1986 | Mar | CAHN |
| @ | | 25MG;2MG | A070297 | 001 | Nov 12, 1986 | Mar | CAHN |
| @ | | 25MG;4MG | A071079 | 001 | Nov 12, 1986 | Mar | CAHN |

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

| | | | | | | | |
|----|----------------|---------------|---------|-----|--------------|-----|------|
| AB | INVAGEN PHARMS | EQ 2.5MG BASE | A206367 | 001 | Dec 10, 2015 | Feb | CAHN |
| AB | | EQ 5MG BASE | A206367 | 002 | Dec 10, 2015 | Feb | CAHN |
| AB | | EQ 10MG BASE | A206367 | 003 | Dec 10, 2015 | Feb | CAHN |
| @ | SUN PHARM INDS | EQ 2.5MG BASE | A078081 | 001 | Jan 31, 2008 | Mar | CAHN |
| @ | | EQ 5MG BASE | A078081 | 002 | Jan 31, 2008 | Mar | CAHN |
| @ | | EQ 10MG BASE | A078081 | 003 | Jan 31, 2008 | Mar | CAHN |

AMLODIPINE BESYLATE; VALSARTAN

TABLET; ORAL

AMLODIPINE BESYLATE AND VALSARTAN

| | | | | | | | | |
|-----|----|----------------------|--------------------|---------|-----|--------------|-----|------|
| >A> | AB | AUROBINDO PHARMA LTD | EQ 5MG BASE;160MG | A206512 | 001 | Apr 22, 2016 | Apr | NEWA |
| >A> | AB | | EQ 5MG BASE;320MG | A206512 | 002 | Apr 22, 2016 | Apr | NEWA |
| >A> | AB | | EQ 10MG BASE;160MG | A206512 | 003 | Apr 22, 2016 | Apr | NEWA |
| >A> | AB | | EQ 10MG BASE;320MG | A206512 | 004 | Apr 22, 2016 | Apr | NEWA |

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

| | | | | | | | |
|----|-----------------|------------------------------------|---------|-----|--------------|-----|------|
| AP | MA GENERAL HOSP | 30mCi-300mCi/8ML (3.75-37.5mCi/ML) | A207025 | 001 | Feb 03, 2016 | Jan | NEWA |
| AP | MIDWEST MEDCL | 30mCi-300mCi/8ML (3.75-37.5mCi/ML) | A204457 | 001 | Nov 18, 2015 | Jan | NEWA |

AMMONIUM LACTATE

CREAM; TOPICAL

AMMONIUM LACTATE

| | | | | | | | | | |
|-----|----|------------------|-------------|-------------|---------|--------------|--------------|------|------|
| >D> | AB | PERRIGO NEW YORK | EQ 12% BASE | A075774 | 001 | May 01, 2002 | Apr | CRLD | |
| >A> | AB | + | EQ 12% BASE | A075774 | 001 | May 01, 2002 | Apr | CRLD | |
| >D> | | LAC-HYDRIN | | | | | | | |
| >D> | AB | + | RANBAXY | EQ 12% BASE | N020508 | 001 | Aug 29, 1996 | Apr | DISC |
| >A> | | @ | EQ 12% BASE | N020508 | 001 | Aug 29, 1996 | Apr | DISC | |

LOTION; TOPICAL

AMMONIUM LACTATE

| | | | | | | | | | |
|-----|----|------------------|-------------|-------------|---------|--------------|--------------|------|------|
| >D> | AB | PERRIGO NEW YORK | EQ 12% BASE | A075570 | 001 | Jun 23, 2004 | Apr | CRLD | |
| >A> | AB | + | EQ 12% BASE | A075570 | 001 | Jun 23, 2004 | Apr | CRLD | |
| >D> | | LAC-HYDRIN | | | | | | | |
| >D> | AB | + | RANBAXY | EQ 12% BASE | N019155 | 001 | Apr 24, 1985 | Apr | DISC |
| >A> | | @ | EQ 12% BASE | N019155 | 001 | Apr 24, 1985 | Apr | DISC | |

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

| | | | | | | | |
|---|--------------------|-------|---------|-----|--------------|-----|------|
| @ | SUN PHARM INDS LTD | 250MG | A065016 | 001 | Apr 08, 1999 | Feb | DISC |
| @ | | 500MG | A065016 | 002 | Apr 08, 1999 | Feb | DISC |

TABLET; ORAL

AMOXICILLIN

| | | | | | | | |
|---|--------------------|-------|---------|-----|--------------|-----|------|
| @ | SUN PHARM INDS LTD | 500MG | A065059 | 001 | Nov 24, 2000 | Feb | DISC |
| @ | | 875MG | A065059 | 002 | Nov 24, 2000 | Feb | DISC |

TABLET, CHEWABLE; ORAL

AMOXICILLIN

| | | | | | | | |
|---|--------------------|-------|---------|-----|--------------|-----|------|
| @ | SUN PHARM INDS LTD | 125MG | A065021 | 001 | Dec 23, 1999 | Feb | DISC |
| @ | | 250MG | A065021 | 002 | Dec 23, 1999 | Feb | DISC |

TABLET, EXTENDED RELEASE; ORAL

MOXATAG

| | | | | | | | |
|---|----------------------|-------|---------|-----|--------------|-----|------|
| + | VERNALIS R AND D LTD | 775MG | N050813 | 001 | Jan 23, 2008 | Jan | CAHN |
|---|----------------------|-------|---------|-----|--------------|-----|------|

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

| | | | | | | | |
|----|----------------------|------------------------------|---------|-----|--------------|-----|------|
| AB | AUROBINDO PHARMA LTD | 200MG/5ML;EQ 28.5MG BASE/5ML | A201090 | 001 | Dec 20, 2011 | Feb | CDFR |
| AB | | 400MG/5ML;EQ 57MG BASE/5ML | A201090 | 002 | Dec 20, 2011 | Feb | CDFR |
| AB | | 600MG/5ML;EQ 42.9MG BASE/5ML | A201091 | 001 | Dec 20, 2011 | Feb | CDFR |
| | @ SUN PHARM INDS LTD | 200MG/5ML;EQ 28.5MG BASE/5ML | A065132 | 001 | Mar 19, 2003 | Feb | DISC |
| | @ | 400MG/5ML;EQ 57MG BASE/5ML | A065132 | 002 | Mar 19, 2003 | Feb | DISC |
| | @ | 600MG/5ML;EQ 42.9MG BASE/5ML | A065207 | 002 | Jan 30, 2007 | Feb | DISC |

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

@ SUN PHARM INDS LTD 875MG;EQ 125MG BASE

A065102 001 Sep 17, 2002 Feb DISC

TABLET, CHEWABLE; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

@ SUN PHARM INDS LTD 200MG;EQ 28.5MG BASE

A065161 001 Dec 03, 2003 Feb DISC

@ 400MG;EQ 57MG BASE

A065161 002 Dec 03, 2003 Feb DISC

AUGMENTIN '125'

DR REDDYS LABS INC 125MG;EQ 31.25MG BASE

N050597 001 Jul 22, 1985 Mar CTEC

AUGMENTIN '250'

+ DR REDDYS LABS INC 250MG;EQ 62.5MG BASE

N050597 002 Jul 22, 1985 Mar CRLD

AMPHETAMINE

TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE; ORAL

ADZENYS XR-ODT

NEOS THERAPS

EQ 3.1MG BASE

N204326 001 Jan 27, 2016 Jan NEWA

EQ 6.3MG BASE

N204326 002 Jan 27, 2016 Jan NEWA

EQ 9.4MG BASE

N204326 003 Jan 27, 2016 Jan NEWA

EQ 12.5MG BASE

N204326 004 Jan 27, 2016 Jan NEWA

EQ 15.7MG BASE

N204326 005 Jan 27, 2016 Jan NEWA

EQ 18.8MG BASE

N204326 006 Jan 27, 2016 Jan NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

| | | | | | | | |
|----|------------|-----------------------------|---------|-----|--------------|-----|------|
| AB | IMPAX LABS | 1.25MG;1.25MG;1.25MG;1.25MG | A076852 | 001 | Feb 16, 2016 | Feb | NEWA |
| AB | | 2.5MG;2.5MG;2.5MG;2.5MG | A076852 | 002 | Feb 16, 2016 | Feb | NEWA |
| AB | | 3.75MG;3.75MG;3.75MG;3.75MG | A076852 | 003 | Feb 16, 2016 | Feb | NEWA |
| AB | | 5MG;5MG;5MG;5MG | A076852 | 004 | Feb 16, 2016 | Feb | NEWA |
| AB | | 6.25MG;6.25MG;6.25MG;6.25MG | A076852 | 005 | Feb 16, 2016 | Feb | NEWA |
| AB | | 7.5MG;7.5MG;7.5MG;7.5MG | A076852 | 006 | Feb 16, 2016 | Feb | NEWA |
| AB | TEVA | 1.25MG;1.25MG;1.25MG;1.25MG | A077488 | 001 | Apr 29, 2013 | Feb | CTNA |
| AB | | 2.5MG;2.5MG;2.5MG;2.5MG | A077488 | 002 | Apr 29, 2013 | Feb | CTNA |
| AB | | 3.75MG;3.75MG;3.75MG;3.75MG | A077488 | 003 | Apr 29, 2013 | Feb | CTNA |
| AB | | 5MG;5MG;5MG;5MG | A077488 | 004 | Apr 29, 2013 | Feb | CTNA |
| AB | | 6.25MG;6.25MG;6.25MG;6.25MG | A077488 | 005 | Apr 29, 2013 | Feb | CTNA |
| AB | | 7.5MG;7.5MG;7.5MG;7.5MG | A077488 | 006 | Apr 29, 2013 | Feb | CTNA |

TABLET; ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

| | | | | | | | |
|----|-------------------|---------------------------------|---------|-----|--------------|-----|------|
| AB | ACTAVIS ELIZABETH | 1.25MG;1.25MG;1.25MG;1.25MG | A206340 | 001 | Feb 05, 2016 | Jan | NEWA |
| AB | | 1.875MG;1.875MG;1.875MG;1.875MG | A206340 | 002 | Feb 05, 2016 | Jan | NEWA |
| AB | | 2.5MG;2.5MG;2.5MG;2.5MG | A206340 | 003 | Feb 05, 2016 | Jan | NEWA |
| AB | | 3.125MG;3.125MG;3.125MG;3.125MG | A206340 | 004 | Feb 05, 2016 | Jan | NEWA |
| AB | | 3.75MG;3.75MG;3.75MG;3.75MG | A206340 | 005 | Feb 05, 2016 | Jan | NEWA |
| AB | | 5MG;5MG;5MG;5MG | A206340 | 006 | Feb 05, 2016 | Jan | NEWA |
| AB | | 7.5MG;7.5MG;7.5MG;7.5MG | A206340 | 007 | Feb 05, 2016 | Jan | NEWA |

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

AMPHOTEC

| | | | | | | | |
|-----|------------------|------------|---------|-----|--------------|-----|------|
| >D> | + ALKOPHARMA USA | 50MG/VIAL | N050729 | 001 | Nov 22, 1996 | Apr | DISC |
| >A> | @ | 50MG/VIAL | N050729 | 001 | Nov 22, 1996 | Apr | DISC |
| >D> | + | 100MG/VIAL | N050729 | 002 | Nov 22, 1996 | Apr | DISC |
| >A> | @ | 100MG/VIAL | N050729 | 002 | Nov 22, 1996 | Apr | DISC |

ARIPIPIRAZOLE

SOLUTION; ORAL

ARIPIPIRAZOLE

| | | | | | | | |
|----|-----------------|--------|---------|-----|--------------|-----|------|
| AA | + AMNEAL PHARMS | 1MG/ML | A203906 | 001 | Aug 14, 2015 | Feb | CRLD |
|----|-----------------|--------|---------|-----|--------------|-----|------|

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

| | | | | | | | |
|-----|--------------------|-------|---------|-----|--------------|-----|------|
| >D> | @ MYLAN PHARMS INC | 50MG | A200043 | 001 | Jun 01, 2012 | Apr | CMFD |
| >A> | AB | 50MG | A200043 | 001 | Jun 01, 2012 | Apr | CMFD |
| >D> | @ | 150MG | A200043 | 002 | Jun 01, 2012 | Apr | CMFD |
| >A> | AB | 150MG | A200043 | 002 | Jun 01, 2012 | Apr | CMFD |
| >D> | @ | 250MG | A200043 | 003 | Jun 01, 2012 | Apr | CMFD |
| >A> | AB | 250MG | A200043 | 003 | Jun 01, 2012 | Apr | CMFD |

NUVIGIL

| | | | | | | | |
|-----|----------|-------|---------|-----|--------------|-----|------|
| >D> | CEPHALON | 50MG | N021875 | 001 | Jun 15, 2007 | Apr | CTEC |
| >A> | AB | 50MG | N021875 | 001 | Jun 15, 2007 | Apr | CTEC |
| >D> | | 150MG | N021875 | 003 | Jun 15, 2007 | Apr | CTEC |
| >A> | AB | 150MG | N021875 | 003 | Jun 15, 2007 | Apr | CTEC |
| >D> | + | 250MG | N021875 | 004 | Jun 15, 2007 | Apr | CTEC |
| >A> | AB | 250MG | N021875 | 004 | Jun 15, 2007 | Apr | CTEC |

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION

M.V.I.-12 LYOPHILIZED

| | | | | | | | |
|---|---------------------|---|---------|-----|--------------|-----|------|
| @ | TELIGENT PHARMA INC | 100MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL; 15MG/VIAL; 5MCG/VIAL; 0.4MG/VIAL; 40MG/VIAL; 4MG/VIAL; 3.6MG/VIAL; 3MG/VIAL; 1MG/VIAL; 10MG/VIAL | N018933 | 002 | Aug 08, 1985 | Jan | CAHN |
|---|---------------------|---|---------|-----|--------------|-----|------|

ASENAPINE MALEATE

TABLET; SUBLINGUAL

SAPHRIS

| | | | | | | | |
|--|-----------------|-------------|---------|-----|--------------|-----|------|
| | FOREST LABS LLC | EQ 2.5 BASE | N022117 | 003 | Mar 12, 2015 | Mar | NEWA |
|--|-----------------|-------------|---------|-----|--------------|-----|------|

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

| | | | | | | | | |
|-----|------------------|-----------------------|-------------------|---------|--------------|--------------|------|------|
| @ | NOSTRUM LABS INC | 325MG; 50MG; 40MG | A078149 | 001 | Jun 13, 2007 | Jan | CAHN | |
| >D> | AA | + ACTAVIS LABS UT INC | 325MG; 50MG; 40MG | N017534 | 005 | Apr 16, 1986 | Apr | CAHN |
| >A> | AA | + ALLERGAN SALES LLC | 325MG; 50MG; 40MG | N017534 | 005 | Apr 16, 1986 | Apr | CAHN |
| | | FIORINAL | | | | | | |
| >D> | @ | ACTAVIS LABS UT INC | 325MG; 50MG; 40MG | N017534 | 003 | Apr 16, 1986 | Apr | CAHN |
| >A> | @ | ALLERGAN SALES LLC | 325MG; 50MG; 40MG | N017534 | 003 | Apr 16, 1986 | Apr | CAHN |

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

FIORINAL W/CODEINE

| | | | | | | | | |
|-----|----|-----------------------|-------------------------|---------|-----|--------------|-----|------|
| >D> | AB | + ACTAVIS LABS UT INC | 325MG; 50MG; 40MG; 30MG | N019429 | 003 | Oct 26, 1990 | Apr | CAHN |
| >A> | AB | + ALLERGAN SALES LLC | 325MG; 50MG; 40MG; 30MG | N019429 | 003 | Oct 26, 1990 | Apr | CAHN |

ASPIRIN; CARISOPRODOL

TABLET; ORAL

CARISOPRODOL AND ASPIRIN

| | | | | | | | |
|----|-------------------|--------------|---------|-----|--------------|-----|------|
| AB | INGENUS PHARMS NJ | 325MG; 200MG | A040832 | 001 | Jan 07, 2010 | Jan | CAHN |
|----|-------------------|--------------|---------|-----|--------------|-----|------|

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

| | | | | | | | | |
|----|-------------------|--------------------------|--------------------|---------|--------------|--------------|------|------|
| AB | INGENUS PHARMS NJ | 325MG; 200MG; 16MG | A040860 | 001 | Jan 07, 2010 | Mar | CMFD | |
| | @ | 325MG; 200MG; 16MG | A040860 | 001 | Jan 07, 2010 | Jan | CAHN | |
| AB | + SANDOZ | 325MG; 200MG; 16MG | A040118 | 001 | Apr 16, 1996 | Mar | CTEC | |
| | + | 325MG; 200MG; 16MG | A040118 | 001 | Apr 16, 1996 | Jan | CRLD | |
| | | SOMA COMPOUND W/ CODEINE | | | | | | |
| | @ | MEDA PHARMS | 325MG; 200MG; 16MG | N012366 | 002 | Jul 11, 1983 | Jan | DISC |

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

ASPIRIN AND DIPYRIDAMOLE

| | | | | | | | | |
|-----|----|---------------|-------------|---------|-----|--------------|-----|------|
| >D> | AB | AMNEAL PHARMS | 25MG; 200MG | A206392 | 001 | Mar 08, 2016 | Apr | DISC |
| >A> | @ | | 25MG; 200MG | A206392 | 001 | Mar 08, 2016 | Apr | DISC |
| | AB | | 25MG; 200MG | A206392 | 001 | Mar 08, 2016 | Feb | NEWA |

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

@ SUN PHARM INDS

325MG; 4.5MG; 0.38MG

A040260 001 Jul 17, 1998 Mar CAHN

@

325MG; 4.5MG; 0.38MG

A087794 001 May 26, 1982 Mar CAHN

ATENOLOL

TABLET; ORAL

ATENOLOL

AB ALVOGEN MALTA

25MG

A073646 001 Jul 31, 1992 Jan CAHN

AB

50MG

A072303 001 Jul 15, 1988 Jan CAHN

AB

100MG

A072304 001 Jul 15, 1988 Jan CAHN

TENORMIN

AB ALVOGEN MALTA

25MG

N018240 004 Apr 09, 1990 Jan CAHN

AB

50MG

N018240 001 Jan CAHN

AB

+

100MG

N018240 002 Jan CAHN

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

AB ALVOGEN MALTA

50MG; 25MG

A072301 001 May 31, 1990 Jan CAHN

AB

100MG; 25MG

A072302 001 May 31, 1990 Jan CAHN

AB

SUN PHARM INDS

100MG; 25MG

A073582 001 Apr 29, 1993 Mar CAHN

TENORETIC 100

AB + ALVOGEN MALTA

100MG; 25MG

N018760 001 Jun 08, 1984 Jan CAHN

TENORETIC 50

AB ALVOGEN MALTA

50MG; 25MG

N018760 002 Jun 08, 1984 Jan CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

@ SUN PHARM INDS

0.025MG; 2.5MG

A085506 001 Mar CAHN

AURANOFIN

CAPSULE; ORAL

RIDAURA

+ SEBELA IRELAND LTD

3MG

N018689 001 May 24, 1985 Jan CAHN

AXITINIB

TABLET; ORAL

INLYTA

>A> PF PRISM CV

1MG

N202324 001 Jan 27, 2012 Apr CAHN

>A> +

5MG

N202324 002 Jan 27, 2012 Apr CAHN

>D>

PFIZER

1MG

N202324 001 Jan 27, 2012 Apr CAHN

>D> +

5MG

N202324 002 Jan 27, 2012 Apr CAHN

AZACITIDINE

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

>A> AP MYLAN INSTITUTIONAL 100MG/VIAL

A204949 001 Apr 28, 2016 Apr NEWA

POWDER; IV (INFUSION), SUBCUTANEOUS

AZACITIDINE

>A> ACTAVIS LLC 100MG/VIAL

N208216 001 Apr 29, 2016 Apr NEWA

AZATHIOPRINE

TABLET; ORAL

IMURAN

AB + SEBELA IRELAND LTD

25MG

N016324 002 Jan CAHN

AB

+

50MG

N016324 001 Jan CAHN

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION

IMURAN

@ SEBELA IRELAND LTD

EQ 100MG BASE/VIAL

N017391 001 Jan CAHN

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

EDARBI

| | | | | | | |
|---|------------------|-------------------|---------|-----|--------------|----------|
| | ARBOR PHARMS LLC | EQ 40MG MEDOXOMIL | N200796 | 001 | Feb 25, 2011 | Jan CAHN |
| + | | EQ 80MG MEDOXOMIL | N200796 | 002 | Feb 25, 2011 | Jan CAHN |

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL

EDARBYCLOL

| | | | | | | |
|---|------------------|--------------------------|---------|-----|--------------|----------|
| | ARBOR PHARMS LLC | EQ 40MG MEDOXOMIL;12.5MG | N202331 | 001 | Dec 20, 2011 | Jan CAHN |
| + | | EQ 40MG MEDOXOMIL;25MG | N202331 | 002 | Dec 20, 2011 | Jan CAHN |

AZITHROMYCIN

FOR SUSPENSION; ORAL

AZITHROMYCIN

| | | | | | | | |
|-----|----|-----------|-------------------|---------|-----|--------------|----------|
| >D> | AB | LUPIN LTD | EQ 100MG BASE/5ML | A065488 | 001 | May 15, 2015 | Apr CTEC |
| >A> | BX | | EQ 100MG BASE/5ML | A065488 | 001 | May 15, 2015 | Apr CTEC |
| >D> | AB | | EQ 200MG BASE/5ML | A065488 | 002 | May 15, 2015 | Apr CTEC |
| >A> | BX | | EQ 200MG BASE/5ML | A065488 | 002 | May 15, 2015 | Apr CTEC |

AZTREONAM

INJECTABLE; INJECTION

AZTREONAM

| | | | | | | |
|---|--------------------|----------|---------|-----|--------------|----------|
| @ | EUROHLTH INTL SARL | 1GM/VIAL | A065286 | 001 | Mar 23, 2011 | Mar DISC |
| @ | | 2GM/VIAL | A065286 | 002 | Mar 23, 2011 | Mar DISC |

BACLOFEN

INJECTABLE; INTRATHECAL

BACLOFEN

| | | | | | | | |
|-----|----|-------------|-----------|---------|-----|--------------|----------|
| >A> | AP | SINETICA SA | 0.05MG/ML | A091193 | 001 | May 03, 2016 | Apr NEWA |
| >A> | AP | | 0.5MG/ML | A091193 | 002 | May 03, 2016 | Apr NEWA |
| >A> | AP | | 2MG/ML | A091193 | 003 | May 03, 2016 | Apr NEWA |

TABLET; ORAL

BACLOFEN

| | | | | | | | |
|----|--|--------------------|------|---------|-----|--------------|----------|
| AB | | NORTHSTAR HLTHCARE | 10MG | A078401 | 002 | Sep 18, 2009 | Jan NEWA |
|----|--|--------------------|------|---------|-----|--------------|----------|

BARIIUM SULFATE

FOR SUSPENSION; ORAL

E-Z-HD

| | | | | | | |
|---|--------|--------------|---------|-----|--------------|----------|
| + | BRACCO | 334GM/BOTTLE | N208036 | 001 | Jan 11, 2016 | Jan NEWA |
|---|--------|--------------|---------|-----|--------------|----------|

SUSPENSION; ORAL

READI-CAT 2

| | | | | | | |
|---|--------|----------------|---------|-----|--------------|----------|
| + | BRACCO | 2% (9GM/450ML) | N208143 | 001 | Jan 15, 2016 | Jan NEWA |
|---|--------|----------------|---------|-----|--------------|----------|

READI-CAT 2 SMOOTHIES

| | | | | | | |
|--|--------|----------------|---------|-----|--------------|----------|
| | BRACCO | 2% (9GM/450ML) | N208143 | 002 | Jan 15, 2016 | Jan NEWA |
|--|--------|----------------|---------|-----|--------------|----------|

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

| | | | | | | |
|---|---------------------|------|---------|-----|--------------|----------|
| @ | ACTAVIS LABS FL INC | 5MG | A076267 | 001 | Feb 11, 2004 | Jan DISC |
| @ | | 10MG | A076267 | 002 | Feb 11, 2004 | Jan DISC |
| @ | | 20MG | A076267 | 003 | Feb 11, 2004 | Jan DISC |
| @ | | 40MG | A076267 | 004 | Feb 11, 2004 | Jan DISC |

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

| | | | | | | |
|---|----------------------|-------------|---------|-----|--------------|----------|
| @ | ACTAVIS LABS FL INC | 5MG;6.25MG | A076342 | 001 | Feb 11, 2004 | Jan DISC |
| @ | | 10MG;12.5MG | A076342 | 002 | Feb 11, 2004 | Jan DISC |
| @ | | 20MG;12.5MG | A076342 | 003 | Feb 11, 2004 | Jan DISC |
| @ | | 20MG;25MG | A076342 | 004 | Feb 11, 2004 | Jan DISC |
| @ | IVAX SUB TEVA PHARMS | 5MG;6.25MG | A076348 | 001 | Feb 11, 2004 | Mar DISC |
| @ | | 10MG;12.5MG | A076348 | 002 | Feb 11, 2004 | Mar DISC |
| @ | | 20MG;12.5MG | A076348 | 003 | Feb 11, 2004 | Mar DISC |
| @ | | 20MG;25MG | A076348 | 004 | Feb 11, 2004 | Mar DISC |
| @ | SUN PHARM INDS LTD | 5MG;6.25MG | A077483 | 001 | Sep 08, 2005 | Mar DISC |
| @ | | 10MG;12.5MG | A077483 | 002 | Sep 08, 2005 | Mar DISC |
| @ | | 20MG;12.5MG | A077483 | 003 | Sep 08, 2005 | Mar DISC |
| @ | | 20MG;25MG | A077483 | 004 | Sep 08, 2005 | Mar DISC |

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

| | | | | | | | | |
|----|---|----------------------|------------|---------|-----|--------------|-----|------|
| AP | | GLENMARK PHARMS LTD | 25MG/VIAL | A204771 | 001 | Mar 24, 2016 | Mar | NEWA |
| AP | | | 100MG/VIAL | A204771 | 002 | Mar 24, 2016 | Mar | NEWA |
| AP | | INNOPHARMA LICENSING | 25MG/VIAL | A205476 | 001 | Mar 24, 2016 | Mar | NEWA |
| AP | | | 100MG/VIAL | A205476 | 002 | Mar 24, 2016 | Mar | NEWA |
| | | TREANDA | | | | | | |
| AP | + | CEPHALON | 25MG/VIAL | N022249 | 002 | May 01, 2009 | Mar | CFTG |
| AP | + | | 100MG/VIAL | N022249 | 001 | Mar 20, 2008 | Mar | CFTG |

BENZONATATE

CAPSULE; ORAL

BENZONATATE

| | | | | | | | | |
|----|--|----------------|-------|---------|-----|--------------|-----|------|
| AA | | BIONPHARMA INC | 100MG | A081297 | 001 | Jan 29, 1993 | Jan | CAHN |
| AA | | | 200MG | A081297 | 002 | Oct 30, 2007 | Jan | CAHN |

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN PAK

| | | | | | | | | |
|--|---|---------|--------|---------|-----|--------------|-----|------|
| | + | CUTANEA | 5%; 3% | N050769 | 001 | Nov 27, 2000 | Feb | CAHN |
|--|---|---------|--------|---------|-----|--------------|-----|------|

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

| | | | | | | | | |
|--|---|------------|------|---------|-----|--------------|-----|------|
| | @ | IMPAX LABS | 50MG | A040845 | 001 | Nov 18, 2008 | Mar | DISC |
|--|---|------------|------|---------|-----|--------------|-----|------|

BETAMETHASONE DIPROPIONATE

SPRAY; TOPICAL

SERNIVO

| | | | | | | | | |
|--|---|--------------------|---------------------|---------|-----|--------------|-----|------|
| | + | PROMIUS PHARMA LLC | EQ 0.05% BASE/SPRAY | N208079 | 001 | Feb 05, 2016 | Feb | NEWA |
|--|---|--------------------|---------------------|---------|-----|--------------|-----|------|

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

| | | | | | | | | |
|----|--|-----------------|-------------------|---------|-----|--------------|-----|------|
| AB | | GLENMARK PHARMS | EQ 0.05% BASE; 1% | A202894 | 001 | Oct 30, 2015 | Mar | CAHN |
|----|--|-----------------|-------------------|---------|-----|--------------|-----|------|

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

| | | | | | | | | |
|----|--|---------------------|--------------|---------|-----|--------------|-----|------|
| AT | | TELIGENT PHARMA INC | EQ 0.5% BASE | A075630 | 001 | Apr 12, 2001 | Jan | CAHN |
|----|--|---------------------|--------------|---------|-----|--------------|-----|------|

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

| | | | | | | | | |
|--|---|------------|------|---------|-----|--------------|-----|------|
| | @ | IMPAX LABS | 5MG | A040739 | 001 | Nov 01, 2006 | Mar | DISC |
| | @ | | 10MG | A040741 | 001 | Nov 01, 2006 | Mar | DISC |
| | @ | | 25MG | A040740 | 001 | Nov 01, 2006 | Mar | DISC |
| | @ | | 50MG | A040721 | 004 | Nov 01, 2006 | Mar | DISC |

BIMATOPROST

SOLUTION/DROPS; TOPICAL

BIMATOPROST

| | | | | | | | | |
|-----|----|------------|-------|---------|-----|--------------|-----|------|
| >A> | AT | SANDOZ INC | 0.03% | A202719 | 001 | Apr 19, 2016 | Apr | NEWA |
|-----|----|------------|-------|---------|-----|--------------|-----|------|

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL

HELIDAC

| | | | | | | | | |
|--|---|--------------------|---|---------|-----|--------------|-----|------|
| | @ | SEBELA IRELAND LTD | 262.4MG, N/A, N/A; N/A, 250MG, N/A; N/A, N/A, 500MG | N050719 | 001 | Aug 15, 1996 | Jan | CAHN |
|--|---|--------------------|---|---------|-----|--------------|-----|------|

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

| | | | | | | | | |
|--|---|----------------|------|---------|-----|--------------|-----|------|
| | @ | SUN PHARM INDS | 5MG | A075474 | 001 | Oct 25, 2002 | Mar | CAHN |
| | @ | | 10MG | A075474 | 002 | Oct 25, 2002 | Mar | CAHN |

BRIVARACETAM

SOLUTION;INTRAVENOUS

BRIVIACT

+ UBC INC 50MG/5ML (10MG/ML) N205837 001 Feb 18, 2016 Feb NEWA

SOLUTION;ORAL

BRIVIACT

+ UCB INC 10MG/ML N205838 001 Feb 18, 2016 Feb NEWA

TABLET;ORAL

BRIVIACT

UCB INC 10MG N205836 001 Feb 18, 2016 Feb NEWA
 25MG N205836 002 Feb 18, 2016 Feb NEWA
 50MG N205836 003 Feb 18, 2016 Feb NEWA
 75MG N205836 004 Feb 18, 2016 Feb NEWA
 + 100MG N205836 005 Feb 18, 2016 Feb NEWA

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC

BROMSITE

>A> + INSITE VISION INC EQ 0.075% ACID N206911 001 Apr 08, 2016 Apr NEWA

BROMOCRIPTINE MESYLATE

CAPSULE;ORAL

BROMOCRIPTINE MESYLATE

AB + MYLAN EQ 5MG BASE A077226 001 Apr 04, 2005 Jan CRLD

PARLODEL

@ US PHARMS HOLDINGS I EQ 5MG BASE N017962 002 Mar 01, 1982 Jan DISC

TABLET;ORAL

BROMOCRIPTINE MESYLATE

AB + PADDOCK LLC EQ 2.5MG BASE A077646 001 Oct 01, 2008 Jan CRLD

AB SANDOZ INC EQ 2.5MG BASE A074631 001 Jan 13, 1998 Feb CAHN

PARLODEL

>D> @ US PHARMS HOLDINGS I EQ 2.5MG BASE N017962 001 Apr CMFD

>A> AB EQ 2.5MG BASE N017962 001 Apr CMFD

@ EQ 2.5MG BASE N017962 001 Jan DISC

BUDESONIDE

CAPSULE;ORAL

BUDESONIDE

AB ACTAVIS ELIZABETH 3MG A206623 001 Apr 08, 2016 Mar NEWA

ENTOCORT EC

AB + ELAN PHARMA INTL LTD 3MG N021324 001 Oct 02, 2001 Jan CAHN

SUSPENSION;INHALATION

BUDESONIDE

AN TEVA PHARMS USA 1MG/2ML A204548 001 Mar 08, 2016 Feb NEWA

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

>D> AP + BEDFORD 0.25MG/ML A074441 001 Jan 27, 1995 Apr CAHN

>A> AP + EUROHLTH INTL SARL 0.25MG/ML A074441 001 Jan 27, 1995 Apr CAHN

BUPRENORPHINE HYDROCHLORIDE

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB SUN PHARM INDS LTD EQ 2MG BASE A201760 001 Jan 29, 2016 Jan NEWA

AB EQ 8MG BASE A201760 002 Jan 29, 2016 Jan NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1 INVAGEN PHARMS 100MG A206674 001 Feb 09, 2016 Jan NEWA

AB1 150MG A206674 002 Feb 09, 2016 Jan NEWA

AB1 200MG A206674 003 Feb 09, 2016 Jan NEWA

AB1 SCIEGEN PHARMS INC 100MG A205794 001 Mar 01, 2016 Feb NEWA

AB1 150MG A205794 002 Mar 01, 2016 Feb NEWA

AB1 200MG A205794 003 Mar 01, 2016 Feb NEWA

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL
CONTRAVE

| | | | | | | | | |
|-----|---|-------------------|----------|---------|-----|--------------|-----|------|
| >A> | + | OREXIGEN | 90MG;8MG | N200063 | 001 | Sep 10, 2014 | Apr | CAHN |
| >D> | + | TAKEDA PHARMS USA | 90MG;8MG | N200063 | 001 | Sep 10, 2014 | Apr | CAHN |

BUSULFAN

INJECTABLE; INJECTION
BUSULFAN

| | | | | | | | | |
|----|--|---------------------|--------|---------|-----|--------------|-----|------|
| AP | | LUITPOLD PHARMS INC | 6MG/ML | A202259 | 001 | Dec 22, 2015 | Mar | CAHN |
|----|--|---------------------|--------|---------|-----|--------------|-----|------|

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
BUTORPHANOL TARTRATE

| | | | | | | | | |
|-----|----|--|--------|---------|-----|--------------|-----|------|
| >D> | AP | BEDFORD | 2MG/ML | A075046 | 001 | Aug 12, 1998 | Apr | CAHN |
| | | @ CLARIS | 2MG/ML | A075697 | 001 | Oct 23, 2001 | Jan | CAHN |
| >A> | AP | EUROHLTH INTL SARL | 2MG/ML | A075046 | 001 | Aug 12, 1998 | Apr | CAHN |
| | | BUTORPHANOL TARTRATE PRESERVATIVE FREE | | | | | | |
| >D> | AP | BEDFORD | 1MG/ML | A075045 | 001 | Aug 12, 1998 | Apr | CAHN |
| >D> | AP | | 2MG/ML | A075045 | 002 | Aug 12, 1998 | Apr | CAHN |
| | | @ CLARIS | 1MG/ML | A075695 | 001 | Oct 23, 2001 | Mar | CAHN |
| | | @ | 2MG/ML | A075695 | 002 | Oct 23, 2001 | Mar | CAHN |
| >A> | AP | EUROHLTH INTL SARL | 1MG/ML | A075045 | 001 | Aug 12, 1998 | Apr | CAHN |
| >A> | AP | | 2MG/ML | A075045 | 002 | Aug 12, 1998 | Apr | CAHN |

CABERGOLINE

TABLET; ORAL
CABERGOLINE

| | | | | | | | | |
|--|--|------------------|-------|---------|-----|--------------|-----|------|
| | | @ IMPAX LABS INC | 0.5MG | A077843 | 001 | Jul 03, 2007 | Mar | DISC |
|--|--|------------------|-------|---------|-----|--------------|-----|------|

CABOZANTINIB S-MALATE

TABLET; ORAL
CABOMETYX

| | | | | | | | | |
|-----|---|--------------|--------------|---------|-----|--------------|-----|------|
| >A> | | EXELIXIS INC | EQ 20MG BASE | N208692 | 001 | Apr 25, 2016 | Apr | NEWA |
| >A> | | | EQ 40MG BASE | N208692 | 002 | Apr 25, 2016 | Apr | NEWA |
| >A> | + | | EQ 60MG BASE | N208692 | 003 | Apr 25, 2016 | Apr | NEWA |

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL
MIGERGOT

| | | | | | | | | |
|---|--|----------------|-----------|---------|-----|--------------|-----|------|
| + | | HORIZON PHARMA | 100MG;2MG | A086557 | 001 | Oct 04, 1983 | Jan | CAHN |
|---|--|----------------|-----------|---------|-----|--------------|-----|------|

CALCIPOTRIENE

CREAM; TOPICAL
CALCIPOTRIENE

| | | | | | | | | |
|----|--|-----------------|--------|---------|-----|--------------|-----|------|
| AB | | GLENMARK PHARMS | 0.005% | A205772 | 001 | Jun 09, 2015 | Mar | CAHN |
|----|--|-----------------|--------|---------|-----|--------------|-----|------|

CALCITRIOL

CAPSULE; ORAL
CALCITRIOL

| | | | | | | | | |
|----|--|----------------|---------|---------|-----|--------------|-----|------|
| AB | | BIONPHARMA INC | 0.25MCG | A091174 | 001 | May 24, 2013 | Jan | CAHN |
| AB | | | 0.5MCG | A091174 | 002 | May 24, 2013 | Jan | CAHN |

INJECTABLE; INJECTION
CALCITRIOL

| | | | | | | | | |
|--|--|------------------|------------|---------|-----|--------------|-----|------|
| | | AKORN | 0.001MG/ML | A078066 | 001 | Jan 29, 2008 | Feb | CTEC |
| | | @ ROCKWELL MEDCL | 0.001MG/ML | A076206 | 001 | Sep 17, 2003 | Feb | DISC |

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL

| | | | | | | | | |
|--|--|---|--|---------|-----|--------------|-----|------|
| | | DELFLX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER | | | | | | |
| | | @ FRESENIUS MEDCL | 25.7MG/100ML;1.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML | N018379 | 002 | | Feb | DISC |
| | | DELFLX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER | | | | | | |
| | | @ FRESENIUS MEDCL | 25.7MG/100ML;2.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML | N018379 | 003 | | Feb | DISC |
| | | DELFLX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER | | | | | | |
| | | @ FRESENIUS MEDCL | 25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML | N018379 | 007 | Jun 24, 1988 | Feb | DISC |
| | | DELFLX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER | | | | | | |
| | | @ FRESENIUS MEDCL | 25.7MG/100ML;4.25GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML | N018379 | 001 | | Feb | DISC |

SOLUTION;INTRAPERITONEAL

DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

| | | | | | |
|--------------------|---|---------|-----|--------------|----------|
| @ FRESSENIUS MEDCL | 25.7MG/100ML;1.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML | N018379 | 004 | Jul 07, 1982 | Feb DISC |
|--------------------|---|---------|-----|--------------|----------|

DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

| | | | | | |
|--------------------|---|---------|-----|--------------|----------|
| @ FRESSENIUS MEDCL | 25.7MG/100ML;2.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML | N018379 | 005 | Jul 07, 1982 | Feb DISC |
|--------------------|---|---------|-----|--------------|----------|

DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

| | | | | | |
|--------------------|---|---------|-----|--------------|----------|
| @ FRESSENIUS MEDCL | 25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML | N018379 | 008 | Jun 24, 1988 | Feb DISC |
|--------------------|---|---------|-----|--------------|----------|

DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

| | | | | | |
|--------------------|--|---------|-----|--------------|----------|
| @ FRESSENIUS MEDCL | 25.7MG/100ML;4.25GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML | N018379 | 006 | Jul 07, 1982 | Feb DISC |
|--------------------|--|---------|-----|--------------|----------|

DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

| | | | | | |
|-----------------|---|---------|-----|--------------|----------|
| BAXTER HLTHCARE | 25.7MG/100ML;3.5GM/100ML;15.2MG/100ML;567MG/100ML;392MG/100ML | N017512 | 010 | Nov 18, 1985 | Feb CTEC |
|-----------------|---|---------|-----|--------------|----------|

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

| | | | | | |
|-----------------|---|---------|-----|--------------|----------|
| BAXTER HLTHCARE | 25.7MG/100ML;3.5GM/100ML;5.08MG/100ML;538MG/100ML;448MG/100ML | N017512 | 011 | Nov 18, 1985 | Feb CTEC |
|-----------------|---|---------|-----|--------------|----------|

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

| | | | | | |
|----------|--------|---------|-----|--------------|----------|
| @ APOTEX | 12.5MG | A074737 | 001 | Oct 28, 1998 | Mar DISC |
| @ | 25MG | A074737 | 002 | Oct 28, 1998 | Mar DISC |
| @ | 50MG | A074737 | 003 | Oct 28, 1998 | Mar DISC |
| @ | 100MG | A074737 | 004 | Oct 28, 1998 | Mar DISC |
| @ SANDOZ | 12.5MG | A074363 | 001 | Nov 09, 1995 | Jan DISC |
| @ | 25MG | A074363 | 002 | Nov 09, 1995 | Jan DISC |
| @ | 50MG | A074363 | 003 | Nov 09, 1995 | Jan DISC |
| @ | 100MG | A074363 | 004 | Nov 09, 1995 | Jan DISC |
| @ STASON | 12.5MG | A074677 | 004 | May 30, 1997 | Mar DISC |
| @ | 25MG | A074677 | 002 | May 30, 1997 | Mar DISC |
| @ | 50MG | A074677 | 001 | May 30, 1997 | Mar DISC |
| @ | 100MG | A074677 | 003 | May 30, 1997 | Mar DISC |

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

| | | | | | | |
|----|-------------------|-------|---------|-----|--------------|----------|
| AB | MYLAN IRELAND LTD | 100MG | A076697 | 001 | May 20, 2011 | Jan CAHN |
| AB | | 200MG | A076697 | 002 | May 20, 2011 | Jan CAHN |
| AB | | 300MG | A076697 | 003 | May 20, 2011 | Jan CAHN |

CARBIDOPA

TABLET;ORAL

CARBIDOPA

| | | | | | | |
|----|-------------------|------|---------|-----|--------------|----------|
| AB | EDENBRIDGE PHARMS | 25MG | A205304 | 001 | Feb 17, 2016 | Feb NEWA |
|----|-------------------|------|---------|-----|--------------|----------|

CARBOPLATIN

INJECTABLE;IV (INFUSION)

CARBOPLATIN

| | | | | | | | |
|-----|----|-----------------|----------------------|---------|-----|--------------|----------|
| >D> | AP | ACTAVIS TOTOWA | 50MG/5ML (10MG/ML) | A078732 | 001 | Feb 06, 2012 | Apr DISC |
| >A> | @ | | 50MG/5ML (10MG/ML) | A078732 | 001 | Feb 06, 2012 | Apr DISC |
| >D> | AP | | 150MG/15ML (10MG/ML) | A078732 | 002 | Feb 06, 2012 | Apr DISC |
| >A> | @ | | 150MG/15ML (10MG/ML) | A078732 | 002 | Feb 06, 2012 | Apr DISC |
| >D> | AP | | 450MG/45ML (10MG/ML) | A078732 | 003 | Feb 06, 2012 | Apr DISC |
| >A> | @ | | 450MG/45ML (10MG/ML) | A078732 | 003 | Feb 06, 2012 | Apr DISC |
| >D> | AP | | 600MG/60ML (10MG/ML) | A078732 | 004 | Feb 06, 2012 | Apr DISC |
| >A> | @ | | 600MG/60ML (10MG/ML) | A078732 | 004 | Feb 06, 2012 | Apr DISC |
| | AP | SANDOZ INC | 50MG/5ML (10MG/ML) | A078280 | 001 | May 08, 2008 | Feb CAHN |
| | AP | | 150MG/15ML (10MG/ML) | A078280 | 002 | May 08, 2008 | Feb CAHN |
| | AP | | 450MG/45ML (10MG/ML) | A078280 | 003 | May 08, 2008 | Feb CAHN |
| | AP | SANJA PHARMS CO | 50MG/5ML (10MG/ML) | A205487 | 001 | Mar 28, 2016 | Mar NEWA |
| | AP | | 150MG/15ML (10MG/ML) | A205487 | 002 | Mar 28, 2016 | Mar NEWA |
| | AP | | 450MG/45ML (10MG/ML) | A205487 | 003 | Mar 28, 2016 | Mar NEWA |

CARFILZOMIB

POWDER;INTRAVENOUS

KYPROLIS

| | | | | | | |
|---|-------------|-----------|---------|-----|--------------|----------|
| + | ONYX THERAP | 60MG/VIAL | N202714 | 001 | Jul 20, 2012 | Feb CAHN |
|---|-------------|-----------|---------|-----|--------------|----------|

CARISOPRODOLTABLET; ORAL
CARISOPRODOL

| | | | | | | | |
|----|-------------------|-------|--|---------|-----|--------------|----------|
| AA | INGENUS PHARMS NJ | 350MG | | A040823 | 001 | Oct 22, 2008 | Jan CAHN |
|----|-------------------|-------|--|---------|-----|--------------|----------|

CEFADROXIL/CEFADROXIL HEMIHYDRATEFOR SUSPENSION; ORAL
CEFADROXIL

| | | | | | | | |
|--|----------------------|-------------------|--|---------|-----|--------------|----------|
| | @ SUN PHARM INDS LTD | EQ 125MG BASE/5ML | | A065115 | 001 | Mar 26, 2003 | Feb DISC |
| | @ | EQ 250MG BASE/5ML | | A065115 | 002 | Mar 26, 2003 | Feb DISC |
| | @ | EQ 500MG BASE/5ML | | A065115 | 003 | Mar 26, 2003 | Feb DISC |

CEFAZOLIN SODIUMINJECTABLE; INJECTION
CEFAZOLIN SODIUM

| | | | | | | | |
|----|-------------|------------------|--|---------|-----|--------------|----------|
| AP | HOSPIRA INC | EQ 1GM BASE/VIAL | | A201654 | 001 | Feb 03, 2016 | Jan NEWA |
|----|-------------|------------------|--|---------|-----|--------------|----------|

>D> CEFDITOREN PIVOXIL

>D> TABLET; ORAL

>D> SPECTRACEF

| | | | | | | | |
|-----|---------------|-------|--|---------|-----|--------------|----------|
| >D> | VANSEN PHARMA | 200MG | | N021222 | 001 | Aug 29, 2001 | Apr DISC |
| >A> | @ | 200MG | | N021222 | 001 | Aug 29, 2001 | Apr DISC |
| >D> | + | 400MG | | N021222 | 002 | Jul 21, 2008 | Apr DISC |
| >A> | @ | 400MG | | N021222 | 002 | Jul 21, 2008 | Apr DISC |

CEFEPIME HYDROCHLORIDEINJECTABLE; INJECTION
CEFEPIME HYDROCHLORIDE

| | | | | | | | |
|----|-------------------|--------------------|--|---------|-----|--------------|----------|
| AP | QILU PHARM CO LTD | EQ 500MG BASE/VIAL | | A203704 | 001 | Feb 01, 2016 | Jan NEWA |
| AP | | EQ 1GM BASE/VIAL | | A203704 | 002 | Feb 01, 2016 | Jan NEWA |
| AP | | EQ 2GM BASE/VIAL | | A203704 | 003 | Feb 01, 2016 | Jan NEWA |

CEFOTAXIME SODIUMINJECTABLE; INJECTION
CEFOTAXIME SODIUM

| | | | | | | | |
|---|-------------|-------------------|--------------------|---------|-----|--------------|----------|
| AP | HOSPIRA INC | EQ 1GM BASE/VIAL | | A203132 | 001 | Feb 19, 2016 | Feb NEWA |
| AP | | EQ 2GM BASE/VIAL | | A203132 | 002 | Feb 19, 2016 | Feb NEWA |
| CLAFORAN | | | | | | | |
| AP | + | US PHARM HOLDINGS | EQ 500MG BASE/VIAL | N050547 | 001 | | Jan CAHN |
| AP | + | | EQ 1GM BASE/VIAL | N050547 | 002 | | Jan CAHN |
| AP | + | | EQ 2GM BASE/VIAL | N050547 | 003 | | Jan CAHN |
| AP | + | | EQ 10GM BASE/VIAL | N050547 | 004 | Dec 29, 1983 | Jan CAHN |
| CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | | | | |
| | + | US PHARM HOLDINGS | EQ 20MG BASE/ML | N050596 | 002 | May 20, 1985 | Jan CAHN |
| | + | | EQ 40MG BASE/ML | N050596 | 004 | May 20, 1985 | Jan CAHN |
| CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | | | | |
| | @ | US PHARM HOLDINGS | EQ 20MG BASE/ML | N050596 | 001 | May 20, 1985 | Jan CAHN |
| | @ | | EQ 40MG BASE/ML | N050596 | 003 | May 20, 1985 | Jan CAHN |

CEFOTETAN DISODIUMINJECTABLE; INJECTION
CEFOTAN

| | | | | | | | |
|----|-----------------------|-------------------|--|---------|-----|--------------|----------|
| | @ TELIGENT PHARMA INC | EQ 1GM BASE/VIAL | | A063293 | 001 | Apr 29, 1993 | Jan CAHN |
| AP | | EQ 1GM BASE/VIAL | | N050588 | 001 | Dec 27, 1985 | Feb CMFD |
| | @ | EQ 1GM BASE/VIAL | | N050588 | 001 | Dec 27, 1985 | Jan CAHN |
| | @ | EQ 2GM BASE/VIAL | | A063293 | 002 | Apr 29, 1993 | Jan CAHN |
| AP | | EQ 2GM BASE/VIAL | | N050588 | 002 | Dec 27, 1985 | Feb CMFD |
| | @ | EQ 2GM BASE/VIAL | | N050588 | 002 | Dec 27, 1985 | Jan CAHN |
| | @ | EQ 10GM BASE/VIAL | | N050588 | 003 | Apr 25, 1988 | Jan CAHN |

CEFPODOXIME PROXETILFOR SUSPENSION; ORAL
CEFPODOXIME PROXETIL

| | | | | | | | |
|--|----------------------|-------------------|--|---------|-----|--------------|----------|
| | @ SUN PHARM INDS LTD | EQ 50MG BASE/5ML | | A065082 | 001 | May 31, 2002 | Feb DISC |
| | @ | EQ 100MG BASE/5ML | | A065082 | 002 | May 31, 2002 | Feb DISC |

TABLET; ORAL

CEFPODOXIME PROXETIL

| | | | | | | | |
|--|----------------------|---------------|--|---------|-----|--------------|----------|
| | @ SUN PHARM INDS LTD | EQ 100MG BASE | | A065083 | 001 | Aug 20, 2003 | Feb DISC |
| | @ | EQ 200MG BASE | | A065083 | 002 | Aug 20, 2003 | Feb DISC |

CEFTRIAZONE SODIUMINJECTABLE; INJECTION
CEFTRIAZONE

| | | | | | | | | |
|-----|----|---------------------|--------------------|----------|-----|--------------|-----|------|
| >D> | AP | HOSPIRA INC | EQ 1GM BASE/VIAL | A 065231 | 001 | Aug 02, 2005 | Apr | DISC |
| >A> | @ | | EQ 1GM BASE/VIAL | A 065231 | 001 | Aug 02, 2005 | Apr | DISC |
| >D> | AP | | EQ 1GM BASE/VIAL | A 202563 | 001 | Aug 20, 2012 | Apr | DISC |
| >A> | @ | | EQ 1GM BASE/VIAL | A 202563 | 001 | Aug 20, 2012 | Apr | DISC |
| >D> | AP | | EQ 2GM BASE/VIAL | A 065231 | 002 | Aug 02, 2005 | Apr | DISC |
| >A> | @ | | EQ 2GM BASE/VIAL | A 065231 | 002 | Aug 02, 2005 | Apr | DISC |
| >D> | AP | | EQ 2GM BASE/VIAL | A 202563 | 002 | Aug 20, 2012 | Apr | DISC |
| >A> | @ | | EQ 2GM BASE/VIAL | A 202563 | 002 | Aug 20, 2012 | Apr | DISC |
| >D> | | ROCEPHIN | | | | | | |
| >D> | AP | + HOFFMANN LA ROCHE | EQ 500MG BASE/VIAL | A 063239 | 002 | Aug 13, 1993 | Apr | DISC |
| >A> | @ | | EQ 500MG BASE/VIAL | A 063239 | 002 | Aug 13, 1993 | Apr | DISC |
| >D> | AP | + HOFFMANN LA ROCHE | EQ 1GM BASE/VIAL | A 063239 | 003 | Aug 13, 1993 | Apr | DISC |
| >A> | @ | | EQ 1GM BASE/VIAL | A 063239 | 003 | Aug 13, 1993 | Apr | DISC |

CEFUROXIME AXETILFOR SUSPENSION; ORAL
CEFTIN

GLAXOSMITHKLINE

EQ 125MG BASE/5ML

N 050672 001 Jun 30, 1994 Feb CTEC

+ EQ 250MG BASE/5ML

N 050672 002 Apr 29, 1997 Feb CTEC

CEFUROXIME AXETIL

@ SUN PHARM INDS LTD EQ 125MG BASE/5ML

A 065323 001 Feb 05, 2008 Feb DISC

@ EQ 250MG BASE/5ML

A 065323 002 Feb 05, 2008 Feb DISC

TABLET; ORAL

CEFUROXIME AXETIL

@ SUN PHARM INDS LTD EQ 125MG BASE

A 065118 001 Apr 25, 2003 Feb DISC

@ EQ 250MG BASE

A 065118 002 Apr 25, 2003 Feb DISC

@ EQ 500MG BASE

A 065118 003 Apr 25, 2003 Feb DISC

CEFUROXIME SODIUM

INJECTABLE; INJECTION

ZINACEF

AP + IGI LABS INC EQ 1.5GM BASE/VIAL

N 050558 003 Oct 19, 1983 Jan CAHN

AP + IGI LABS INC EQ 7.5GM BASE/VIAL

N 050558 004 Oct 23, 1986 Jan CAHN

ZINACEF IN PLASTIC CONTAINER

@ IGI LABS INC EQ 15MG BASE/ML

N 050643 001 Apr 28, 1989 Jan CAHN

+ EQ 30MG BASE/ML

N 050643 002 Apr 28, 1989 Jan CAHN

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

ZINACEF

AB + IGI LABS INC EQ 750MG BASE/VIAL

N 050558 002 Oct 19, 1983 Jan CAHN

CELECOXIB

CAPSULE; ORAL

CELECOXIB

AB AUROBINDO PHARMA LTD 50MG

A 206827 001 Feb 01, 2016 Jan NEWA

AB 100MG

A 206827 002 Feb 01, 2016 Jan NEWA

AB 200MG

A 206827 003 Feb 01, 2016 Jan NEWA

AB 400MG

A 206827 004 Feb 01, 2016 Jan NEWA

AB MACLEODS PHARMS LTD 50MG

A 204590 001 Mar 16, 2016 Feb NEWA

AB 100MG

A 204590 002 Mar 16, 2016 Feb NEWA

AB 200MG

A 204590 003 Mar 16, 2016 Feb NEWA

AB 400MG

A 204590 004 Mar 16, 2016 Feb NEWA

CEPHALEXIN

CAPSULE; ORAL

CEPHALEXIN

@ SUN PHARM INDS LTD EQ 250MG BASE

A 065007 001 Sep 16, 1999 Feb DISC

@ EQ 500MG BASE

A 065007 002 Sep 16, 1999 Feb DISC

FOR SUSPENSION; ORAL

KEFLEX

@ PRAGMA PHARMS LLC EQ 100MG BASE/ML

N 050406 003 Mar CAHN

@ EQ 125MG BASE/5ML

N 050406 001 Mar CAHN

@ EQ 250MG BASE/5ML

N 050406 002 Mar CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

| | | | | | | | |
|-----|------------------|-----------|---------|---------|--------------|--------------|----------|
| AA | NOSTRUM LABS INC | 5MG/5ML | A090191 | 001 | Nov 12, 2009 | Mar | CAHN |
| >D> | AA | WOCKHARDT | 5MG/5ML | A078757 | 001 | Aug 28, 2009 | Apr DISC |
| >A> | @ | | 5MG/5ML | A078757 | 001 | Aug 28, 2009 | Apr DISC |

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

PERIOGARD

| | | | | | | | |
|----|----------------------|-------|---------|-----|--------------|-----|------|
| AT | COLGATE-PALMOLIVE CO | 0.12% | A203212 | 001 | Jan 28, 2016 | Jan | NEWA |
|----|----------------------|-------|---------|-----|--------------|-----|------|

CHLOROQUINE PHOSPHATE

TABLET;ORAL

CHLOROQUINE PHOSPHATE

@ IMPAX LABS

EQ 150MG BASE

A080880 001

Mar DISC

@

EQ 300MG BASE

A040516 001 Aug 29, 2003

Mar DISC

CHLORPHENIRAMINE MALEATE

TABLET;ORAL

CHLORPHENIRAMINE MALEATE

@ AUROLIFE PHARMA LLC 4MG

A080961 001

Mar CAHN

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

| | | | | | | | |
|----|------------------|--------------------------|---------|-----|--------------|-----|------|
| AA | MAYNE PHARMA INC | 4MG/5ML;5MG/5ML;60MG/5ML | A205657 | 001 | Aug 03, 2015 | Feb | CAHN |
|----|------------------|--------------------------|---------|-----|--------------|-----|------|

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

@ AUROLIFE PHARMA LLC 100MG

A088725 001 Aug 31, 1984

Mar CAHN

@

250MG

A088726 001 Aug 31, 1984

Mar CAHN

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

| | | | | | | | |
|----|----------------|------|---------|-----|--------------|-----|------|
| AB | MYLAN | 25MG | A086831 | 002 | | Jan | CTEC |
| AB | SUN PHARM INDS | 25MG | A089286 | 002 | Jul 21, 1986 | Jan | NEWA |

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

@ AUROLIFE PHARMA LLC 250MG

A089852 001 May 04, 1988

Feb CAHN

@ 500MG

A089853 001 May 04, 1988

Feb CAHN

| | | | | | | | |
|-----|--|--------|-------|---------|-----|--------------|----------|
| >D> | | MIKART | 750MG | A040861 | 002 | Jun 01, 2010 | Apr CRLD |
|-----|--|--------|-------|---------|-----|--------------|----------|

| | | | | | | | |
|-----|---|--|-------|---------|-----|--------------|----------|
| >A> | + | | 750MG | A040861 | 002 | Jun 01, 2010 | Apr CRLD |
|-----|---|--|-------|---------|-----|--------------|----------|

@ SUN PHARM INDS 500MG

A089970 001 Sep 27, 1990

Mar CAHN

CICLESONIDE

AEROSOL, METERED;INHALATION

ALVESCO

| | | | | | | | |
|---|-------------|------------|---------|-----|--------------|-----|------|
| + | TAKEDA GMBH | 0.08MG/INH | N021658 | 002 | Jan 10, 2008 | Jan | CRLD |
|---|-------------|------------|---------|-----|--------------|-----|------|

CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

| | | | | | | | |
|-----|--|--|--|--|--|--|--|
| >A> | | | | | | | |
|-----|--|--|--|--|--|--|--|

| | | | | | | | |
|-----|--|--------|--|--|--|--|--|
| >A> | | OTOVEL | | | | | |
|-----|--|--------|--|--|--|--|--|

| | | | | | | | |
|-----|---|---------------------|---------------------|---------|-----|--------------|----------|
| >A> | + | LABORATORIOS SALVAT | EQ 0.3% BASE;0.025% | N208251 | 001 | Apr 29, 2016 | Apr NEWA |
|-----|---|---------------------|---------------------|---------|-----|--------------|----------|

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

CIPROFLOXACIN EXTENDED RELEASE

@ ACTAVIS LABS FL INC 212.6MG;EQ 287.5MG BASE

A077417 001 Nov 30, 2010

Jan DISC

@ 425.2MG;EQ 574.9MG BASE

A077809 001 Nov 30, 2010

Jan DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

@ SUN PHARM INDS EQ 10MG BASE
 @ EQ 20MG BASE
 @ EQ 40MG BASE

A077052 001 Jul 03, 2006 Mar CAHN
 A077052 002 Jul 03, 2006 Mar CAHN
 A077052 003 Jul 03, 2006 Mar CAHN

CLARITHROMYCIN

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

AB ALLIED PHARMA INC 500MG

A203243 001 Feb 29, 2016 Feb NEWA

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

>D> AP BEDFORD EQ 150MG BASE/ML
 >A> AP EUROHLTH INTL SARL EQ 150MG BASE/ML

A065206 001 Sep 24, 2004 Apr CAHN
 A065206 001 Sep 24, 2004 Apr CAHN

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

VELTIN

BX + AQUA PHARMS LLC 1.2%; 0.025%

N050803 001 Jul 16, 2010 Jan CAHN

CLOBETASOL PROPIONATE

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

AB + FOUGERA PHARMS 0.05%

A074407 001 Feb 23, 1996 Mar CRLD

TEMOVATE

@ FOUGERA PHARMS 0.05%

N019323 001 Dec 27, 1985 Mar DISC

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

ANAFRANIL

AB + MALLINCKRODT LLC 25MG
 AB 50MG

N019906 001 Dec 29, 1989 Jan CRLD
 N019906 002 Dec 29, 1989 Jan CRLD

CLONIDINE HYDROCHLORIDE

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC 0.1MG
 @ 0.2MG
 @ 0.3MG

A070887 001 Aug 31, 1988 Feb CAHN
 A070886 001 Aug 31, 1988 Feb CAHN
 A071294 001 Aug 31, 1988 Feb CAHN

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB SUN PHARM INDS EQ 75MG BASE

A078133 001 Jun 10, 2013 Mar CAHN

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

CLORAZEPATE DIPOTASSIUM

>A> @ AUROLIFE PHARMA LLC 3.75MG
 @ 7.5MG
 @ 15MG
 >D> @ SANDOZ 3.75MG

A072219 001 Aug 26, 1988 Apr CAHN
 A072220 001 Aug 26, 1988 Feb CAHN
 A072112 001 Aug 26, 1988 Feb CAHN
 A072219 001 Aug 26, 1988 Apr CAHN

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

@ AUROLIFE PHARMA LLC 3.75MG
 @ 7.5MG
 @ 15MG

A072512 001 May 11, 1990 Mar CAHN
 A072513 001 May 11, 1990 Mar CAHN
 A072514 001 May 11, 1990 Feb CAHN

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA NOSTRUM LABS INC 10MG/5ML; 6.25MG/5ML

A090180 001 Mar 17, 2010 Feb CAHN

COLCHICINECAPSULE;ORAL
MITTIGARE

+ HIKMA INTL PHARMS 0.6MG N204820 001 Sep 26, 2014 Mar CRLD

COLCHICINE; PROBENECIDTABLET;ORAL
PROBENECID AND COLCHICINE

AB INGENUS PHARMS NJ 0.5MG;500MG A040618 001 May 13, 2008 Jan CAHN

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDESUSPENSION/DROPS;OTIC
COLY-MYCIN S+ ENDO PHARMS INC EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG N050356 001 Feb CAHN
BASE/ML;0.5MG/MLCORTICOTROPININJECTABLE;INJECTION
PURIFIED CORTROPHIN GEL@ ANI PHARMS 40 UNITS/ML N008975 001 Feb CAHN
@ 80 UNITS/ML N008975 002 Feb CAHNCORTICOTROPIN-ZINC HYDROXIDEINJECTABLE;INJECTION
CORTROPHIN-ZINC

@ ANI PHARMS 40 UNITS/ML N009854 001 Feb CAHN

CYANOCOBALAMININJECTABLE;INJECTION
CYANOCOBALAMIN

AP SOMERSET THERAPS LLC 1MG/ML A206503 001 Dec 11, 2015 Mar CAHN

SPRAY, METERED;NASAL
NASCOBAL

+ ENDO PHARMS INC 0.5MG/SPRAY N021642 001 Jan 31, 2005 Feb CAHN

CYCLOPHOSPHAMIDEINJECTABLE;INJECTION
CYTOXAN (LYOPHILIZED)@ BAXTER HLTHCARE 500MG/VIAL N012142 003 Mar DISC
@ 1GM/VIAL N012142 004 Aug 30, 1982 Mar DISC
@ 2GM/VIAL N012142 005 Aug 30, 1982 Mar DISCCYPROHEPTADINE HYDROCHLORIDETABLET;ORAL
CYPROHEPTADINE HYDROCHLORIDE

AA INGENUS PHARMS NJ 4MG A205087 001 Sep 23, 2015 Jan CAHN

CYTARABINEINJECTABLE;INJECTION
CYTARABINE

AP MYLAN PHARMS INC 20MG/ML A200915 001 Dec 13, 2011 Mar CAHN

AP 20MG/ML A200916 001 Dec 13, 2011 Mar CAHN

DACLATASVIR DIHYDROCHLORIDETABLET;ORAL
DAKLINZA

>A> BRISTOL-MYERS SQUIBB EQ 90MG BASE N206843 003 Apr 13, 2016 Apr NEWA

DACTINOMYCININJECTABLE;INJECTION
DACTINOMYCIN

@ EUROHLTH INTL SARL 0.5MG/VIAL A090304 001 Mar 16, 2010 Feb DISC

DALBAVANCIN HYDROCHLORIDEPOWDER;IV (INFUSION)
DALVANCE

+ DURATA THERAPS INTL EQ 500MG BASE/VIAL N021883 001 May 23, 2014 Jan CDFR

DANTROLENE SODIUMINJECTABLE; INJECTION
DANTROLENE SODIUM

| | | | | | | | |
|----|---------------------|-----------|---------|-----|--------------|-----|------|
| AP | MYLAN INSTITUTIONAL | 20MG/VIAL | A205239 | 001 | Feb 18, 2016 | Feb | NEWA |
|----|---------------------|-----------|---------|-----|--------------|-----|------|

DAPSONEGEL; TOPICAL
ACZONE

+ ALLERGAN INC 7.5%

| | | | | |
|---------|-----|--------------|-----|------|
| N207154 | 001 | Feb 24, 2016 | Feb | NEWA |
|---------|-----|--------------|-----|------|

TABLET; ORAL
DAPSONE

| | | | | | | | | |
|-----|---------|--------------------|---------|---------|--------------|--------------|------|------|
| AB | ALVOGEN | 25MG | A205429 | 001 | Jan 07, 2016 | Mar | CAHN | |
| AB | | 100MG | A205429 | 002 | Jan 07, 2016 | Mar | CAHN | |
| >A> | AB | NORTH CREEK PHARMS | 25MG | A204074 | 001 | May 10, 2016 | Apr | NEWA |
| >A> | AB | | 100MG | A204074 | 002 | May 10, 2016 | Apr | NEWA |
| >A> | AB | NOSTRUM LABS INC | 25MG | A203887 | 001 | May 06, 2016 | Apr | NEWA |
| >A> | AB | | 100MG | A203887 | 002 | May 06, 2016 | Apr | NEWA |

DAPTOMYCINPOWDER; INTRAVENOUS
CUBICIN

| | | | | | | | |
|----|----------|------------|---------|-----|--------------|-----|------|
| AP | + CUBIST | 500MG/VIAL | N021572 | 002 | Sep 12, 2003 | Jan | CDFR |
|----|----------|------------|---------|-----|--------------|-----|------|

DAPTOMYCIN

| | | | | | | | |
|----|-------------|------------|---------|-----|--------------|-----|------|
| AP | HOSPIRA INC | 500MG/VIAL | A202857 | 001 | Sep 12, 2014 | Jan | CDFR |
|----|-------------|------------|---------|-----|--------------|-----|------|

| | | | | | | | |
|----|-----------------|------------|---------|-----|--------------|-----|------|
| AP | TEVA PARENTERAL | 500MG/VIAL | A091039 | 001 | Mar 25, 2016 | Mar | NEWA |
|----|-----------------|------------|---------|-----|--------------|-----|------|

POWDER; IV (INFUSION)
CUBICIN

@ CUBIST 250MG/VIAL

| | | | | |
|---------|-----|--------------|-----|------|
| N021572 | 001 | Sep 12, 2003 | Jan | CDFR |
|---------|-----|--------------|-----|------|

DARIFENACIN HYDROBROMIDETABLET, EXTENDED RELEASE; ORAL
ENABLEX

| | | | | | | | |
|----|------|---------------|---------|-----|--------------|-----|------|
| AB | APIL | EQ 7.5MG BASE | N021513 | 001 | Dec 22, 2004 | Jan | CAHN |
|----|------|---------------|---------|-----|--------------|-----|------|

| | | | | | | | |
|----|---|--------------|---------|-----|--------------|-----|------|
| AB | + | EQ 15MG BASE | N021513 | 002 | Dec 22, 2004 | Jan | CAHN |
|----|---|--------------|---------|-----|--------------|-----|------|

DEFERASIROX

TABLET, FOR SUSPENSION; ORAL

DEFERASIROX

| | | | | | | | |
|----|-------------------|-------|---------|-----|--------------|-----|------|
| AB | ACTAVIS ELIZABETH | 125MG | A203560 | 001 | Jan 26, 2016 | Jan | NEWA |
|----|-------------------|-------|---------|-----|--------------|-----|------|

| | | | | | | | |
|----|--|-------|---------|-----|--------------|-----|------|
| AB | | 250MG | A203560 | 002 | Jan 26, 2016 | Jan | NEWA |
|----|--|-------|---------|-----|--------------|-----|------|

| | | | | | | | |
|----|--|-------|---------|-----|--------------|-----|------|
| AB | | 500MG | A203560 | 003 | Jan 26, 2016 | Jan | NEWA |
|----|--|-------|---------|-----|--------------|-----|------|

EXJADE

| | | | | | | | |
|----|----------|-------|---------|-----|--------------|-----|------|
| AB | NOVARTIS | 125MG | N021882 | 001 | Nov 02, 2005 | Jan | CFTG |
|----|----------|-------|---------|-----|--------------|-----|------|

| | | | | | | | |
|----|--|-------|---------|-----|--------------|-----|------|
| AB | | 250MG | N021882 | 002 | Nov 02, 2005 | Jan | CFTG |
|----|--|-------|---------|-----|--------------|-----|------|

| | | | | | | | |
|----|---|-------|---------|-----|--------------|-----|------|
| AB | + | 500MG | N021882 | 003 | Nov 02, 2005 | Jan | CFTG |
|----|---|-------|---------|-----|--------------|-----|------|

DEFIBROTIDE SODIUMSOLUTION; IV (INFUSION)
DEFITELIO

+ GENTIUM SPA 200MG/2.5ML (80MG/ML)

| | | | | |
|---------|-----|--------------|-----|------|
| N208114 | 001 | Mar 30, 2016 | Mar | NEWA |
|---------|-----|--------------|-----|------|

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DEMECLOCYCLINE HYDROCHLORIDE

@ IMPAX LABS 150MG

| | | | | |
|---------|-----|--------------|-----|------|
| A065094 | 001 | Mar 22, 2004 | Mar | DISC |
|---------|-----|--------------|-----|------|

@ 300MG

| | | | | |
|---------|-----|--------------|-----|------|
| A065094 | 002 | Mar 22, 2004 | Mar | DISC |
|---------|-----|--------------|-----|------|

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

DESIPRAMINE HYDROCHLORIDE

| | | | | | | | | |
|-----|------------------|----------------|---------|---------|--------------|--------------|------|------|
| AB | AMNEAL PHARMS CO | 10MG | A208105 | 001 | Mar 17, 2016 | Mar | NEWA | |
| AB | | 25MG | A208105 | 002 | Mar 17, 2016 | Mar | NEWA | |
| AB | | 50MG | A208105 | 003 | Mar 17, 2016 | Mar | NEWA | |
| AB | | 75MG | A208105 | 004 | Mar 17, 2016 | Mar | NEWA | |
| AB | | 100MG | A208105 | 005 | Mar 17, 2016 | Mar | NEWA | |
| AB | | 150MG | A208105 | 006 | Mar 17, 2016 | Mar | NEWA | |
| >A> | AB | INDICUS PHARMA | 10MG | A207433 | 001 | May 05, 2016 | Apr | NEWA |
| >A> | AB | | 25MG | A207433 | 002 | May 05, 2016 | Apr | NEWA |
| >A> | AB | | 50MG | A207433 | 003 | May 05, 2016 | Apr | NEWA |
| >A> | AB | | 75MG | A207433 | 004 | May 05, 2016 | Apr | NEWA |
| >A> | AB | | 100MG | A207433 | 005 | May 05, 2016 | Apr | NEWA |

TABLET;ORAL

DESIPRAMINE HYDROCHLORIDE

| | | | | | | | | |
|-----|----|-------------------|-------|---------|-----|--------------|-----|------|
| >A> | AB | | 150MG | A207433 | 006 | May 05, 2016 | Apr | NEWA |
| | | NORPRAMIN | | | | | | |
| | AB | US PHARM HOLDINGS | 10MG | N014399 | 007 | Feb 11, 1982 | Jan | CAHN |
| | AB | | 25MG | N014399 | 001 | | Jan | CAHN |
| | AB | | 50MG | N014399 | 003 | | Jan | CAHN |
| | AB | | 75MG | N014399 | 004 | | Jan | CAHN |
| | AB | + | 100MG | N014399 | 005 | | Jan | CAHN |
| | AB | | 150MG | N014399 | 006 | | Jan | CAHN |

DESONIDE

CREAM;TOPICAL

DESONIDE

| | | | | | | | | |
|--|----|------------------|-------|---------|-----|--------------|-----|------|
| | AB | G AND W LABS INC | 0.05% | A074027 | 001 | Sep 28, 1992 | Jan | CAHN |
|--|----|------------------|-------|---------|-----|--------------|-----|------|

DESOXIMETASONE

OINTMENT;TOPICAL

DESOXIMETASONE

| | | | | | | | | |
|-----|----|---------------------|-------|---------|-----|--------------|-----|------|
| >A> | AB | NOVEL LABS INC | 0.25% | A206792 | 001 | May 10, 2016 | Apr | NEWA |
| | AB | TELIGENT PHARMA INC | 0.25% | A208101 | 001 | Feb 25, 2016 | Feb | NEWA |

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DESVENLAFAXINE SUCCINATE

| | | | | | | | | |
|--|----|--------|---------------|---------|-----|--------------|-----|------|
| | AB | ROXANE | EQ 50MG BASE | A204082 | 001 | Feb 16, 2016 | Feb | NEWA |
| | AB | | EQ 100MG BASE | A204083 | 001 | Feb 16, 2016 | Feb | NEWA |

DEXAMETHASONE

TABLET;ORAL

DEXAMETHASONE

| | | | | | | | | |
|--|--|------------------|--------|---------|-----|--|-----|------|
| | | @ SUN PHARM INDS | 0.25MG | A084013 | 001 | | Mar | CAHN |
| | | @ | 0.25MG | A084764 | 001 | | Mar | CAHN |
| | | @ | 0.5MG | A084084 | 001 | | Mar | CAHN |
| | | @ | 0.5MG | A084766 | 001 | | Mar | CAHN |
| | | @ | 0.75MG | A084081 | 001 | | Mar | CAHN |
| | | @ | 0.75MG | A084765 | 001 | | Mar | CAHN |
| | | @ | 1.5MG | A084086 | 001 | | Mar | CAHN |
| | | @ | 1.5MG | A084763 | 001 | | Mar | CAHN |

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE

| | | | | | | | | |
|----|---|--------------------|----------------------|---------|-----|--------------|-----|------|
| AP | + | FRESENIUS KABI USA | EQ 10MG PHOSPHATE/ML | A040491 | 001 | Apr 11, 2003 | Mar | CTNA |
|----|---|--------------------|----------------------|---------|-----|--------------|-----|------|

DEXLANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

DEXILANT SOLUTAB

| | | | | | | | | |
|--|---|-------------------|------|---------|-----|--------------|-----|------|
| | + | TAKEDA PHARMS USA | 30MG | N208056 | 001 | Jan 26, 2016 | Jan | NEWA |
|--|---|-------------------|------|---------|-----|--------------|-----|------|

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

DEXMEDETOMIDINE HYDROCHLORIDE

| | | | | | | | | |
|----|---|----------------------|--|---------|-----|--------------|-----|------|
| AP | | ACCORD HLTHCARE INC | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | A204023 | 001 | Feb 09, 2016 | Jan | NEWA |
| AP | | AUROBINDO PHARMA LTD | EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) | A205867 | 001 | Mar 17, 2016 | Mar | NEWA |
| | | PRECEDEX | | | | | | |
| | + | HOSPIRA | EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) | N021038 | 004 | Nov 14, 2014 | Feb | CRLD |

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

| | | | | | | | | |
|--|----|----------------|-------|---------|-----|--------------|-----|------|
| | AB | SUN PHARM INDS | 2.5MG | A201231 | 001 | Sep 24, 2015 | Feb | CAHN |
| | AB | | 5MG | A201231 | 002 | Sep 24, 2015 | Feb | CAHN |
| | AB | | 10MG | A201231 | 003 | Sep 24, 2015 | Feb | CAHN |

DEXRAZOXANE HYDROCHLORIDEINJECTABLE; INJECTION
TOTECT

+ CLINIGEN HLTHCARE EQ 500MG BASE/VIAL N022025 001 Sep 06, 2007 Mar CAHN

DEXTROAMPHETAMINE SULFATECAPSULE, EXTENDED RELEASE; ORAL
DEXTROAMPHETAMINE SULFATE

| | | | | | | | |
|----|------------------|------|---------|-----|--------------|-----|------|
| AB | MYLAN PHARMS INC | 5MG | A206735 | 001 | Jan 27, 2016 | Jan | NEWA |
| AB | | 10MG | A206735 | 002 | Jan 27, 2016 | Jan | NEWA |
| AB | | 15MG | A206735 | 003 | Jan 27, 2016 | Jan | NEWA |

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

| | | | | | | | |
|----|----------------|------|---------|-----|--------------|-----|------|
| AA | NESHER PHARMS | 5MG | A206588 | 001 | Mar 28, 2016 | Mar | NEWA |
| AA | | 10MG | A206588 | 002 | Mar 28, 2016 | Mar | NEWA |
| AA | NOVEL LABS INC | 5MG | A204330 | 001 | Mar 16, 2016 | Feb | NEWA |
| AA | | 10MG | A204330 | 002 | Mar 16, 2016 | Feb | NEWA |

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

@ ANI PHARMS 15MG/5ML; 6.25MG/5ML N011265 002 Apr 02, 1984 Feb CMS1

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

BAXTER HLTHCARE 5GM/100ML; 31MG/100ML; 141MG/100ML; 2 N017484 001 Feb CMS1
0MG/100ML; 12MG/100ML; 260MG/100MLDEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 5GM/100ML; 205MG/100ML; 100MG/100ML; N018840 001 Jun 29, 1983 Feb CMS1
120MG/100ML; 220MG/100MLDIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

@ EUROHLTH INTL SARL 5MG/ML A070313 001 Dec 16, 1985 Jan CAHN

TABLET; ORAL

DIAZEPAM

DAVA PHARMS INC 2MG A070228 002 Sep 26, 1985 Jan NEWA
5MG A070228 003 Sep 26, 1985 Jan NEWADICLOFENAC POTASSIUM

CAPSULE; ORAL

DICLOFENAC POTASSIUM

AB BIONPHARMA INC 25MG A204648 001 Feb 23, 2016 Feb NEWA
ZIPSOR

AB + DEPOMED INC 25MG N022202 001 Jun 16, 2009 Feb CFTG

FOR SOLUTION; ORAL

CAMBIA

>D> + DEPOMED INC 50MG N022165 001 Jun 17, 2009 Apr CFTG

>A> AB + 50MG N022165 001 Jun 17, 2009 Apr CFTG

DICLOFENAC POTASSIUM

>A> AB PAR FORM 50MG A202964 001 May 02, 2016 Apr NEWA

TABLET; ORAL

CATAFLAM

@ NOVARTIS 50MG N020142 002 Nov 24, 1993 Mar DISC

DICLOFENAC POTASSIUM

AB + MYLAN 50MG A075463 001 Jul 26, 1999 Mar CRLD

DICLOFENAC SODIUM

GEL; TOPICAL

DICLOFENAC SODIUM

AB AMNEAL PHARMS 1% A208077 001 Mar 18, 2016 Mar NEWA

>A> AB TARO 3% A206298 001 Apr 28, 2016 Apr NEWA

VOLTAREN

AB + GLAXOSMITHKLINE CONS 1% N022122 001 Oct 17, 2007 Mar CFTG

| | | | | | | | | | |
|---------------------------------------|----|---|--|----------|---------|--------------|--------------|------|------|
| | | SOLUTION/DROPS;OPHTHALMIC | | | | | | | |
| | | DICLOFENAC SODIUM | | | | | | | |
| AT | | RISING PHARMS INC | 0.1% | A078553 | 001 | Dec 28, 2007 | Jan | CAHN | |
| | | TABLET, EXTENDED RELEASE;ORAL | | | | | | | |
| | | DICLOFENAC SODIUM | | | | | | | |
| AB | + | ACTAVIS ELIZABETH | 100MG | A075910 | 001 | Jan 07, 2002 | Feb | CRLD | |
| | | VOLTAREN-XR | | | | | | | |
| | | @ NOVARTIS | | 100MG | N020254 | 001 | Mar 08, 1996 | Feb | DISC |
| <u>DICLOFENAC SODIUM; MISOPROSTOL</u> | | | | | | | | | |
| | | TABLET, DELAYED RELEASE;ORAL | | | | | | | |
| | | DICLOFENAC SODIUM AND MISOPROSTOL | | | | | | | |
| AB | | EXELA PHARMA SCS LLC | 50MG;0.2MG | A200540 | 001 | Mar 14, 2014 | Mar | CAHN | |
| AB | | | 75MG;0.2MG | A200540 | 002 | Mar 14, 2014 | Mar | CAHN | |
| <u>DICYCLOMINE HYDROCHLORIDE</u> | | | | | | | | | |
| | | CAPSULE;ORAL | | | | | | | |
| | | DICYCLOMINE HYDROCHLORIDE | | | | | | | |
| | | @ SUN PHARM INDS | | 10MG | A084505 | 001 | Oct 21, 1986 | Mar | CAHN |
| | | INJECTABLE;INJECTION | | | | | | | |
| | | DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE) | | | | | | | |
| AP | | EUROHLTH INTL SARL | 10MG/ML | A040465 | 001 | Jun 30, 2003 | Mar | CMS1 | |
| | | SYRUP;ORAL | | | | | | | |
| | | BENTYL | | | | | | | |
| | | @ APTALIS PHARMA US | | 10MG/5ML | N007961 | 002 | Oct 15, 1984 | Jan | DISC |
| | | DICYCLOMINE HYDROCHLORIDE | | | | | | | |
| | + | MIKART | 10MG/5ML | A040169 | 001 | Mar 24, 2005 | Jan | CRLD | |
| | | TABLET;ORAL | | | | | | | |
| | | DICYCLOMINE HYDROCHLORIDE | | | | | | | |
| | | @ SUN PHARM INDS | | 20MG | A084600 | 001 | Jul 29, 1985 | Mar | CAHN |
| <u>DIENOGEST; ESTRADIOL VALERATE</u> | | | | | | | | | |
| | | TABLET;ORAL | | | | | | | |
| | | ESTRADIOL VALERATE AND DIENOGEST | | | | | | | |
| >A> | AB | WATSON LABS INC | N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M | A202349 | 001 | May 06, 2016 | Apr | NEWA | |
| | | G, N/A | | | | | | | |
| | | NATAZIA | | | | | | | |
| >D> | + | BAYER HLTHCARE | N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M | N022252 | 001 | May 06, 2010 | Apr | CFTG | |
| | | G, N/A | | | | | | | |
| >A> | AB | + | N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M | N022252 | 001 | May 06, 2010 | Apr | CFTG | |
| | | G, N/A | | | | | | | |
| <u>DIETHYLPROPION HYDROCHLORIDE</u> | | | | | | | | | |
| | | TABLET;ORAL | | | | | | | |
| | | DIETHYLPROPION HYDROCHLORIDE | | | | | | | |
| | | @ COREPHARMA | | 25MG | A040828 | 001 | Nov 05, 2008 | Mar | DISC |
| | | TENUATE | | | | | | | |
| >A> | AA | + | ACTAVIS LABS UT INC | 25MG | N011722 | 002 | | Apr | CAHN |
| >D> | AA | + | ALLERGAN SALES LLC | 25MG | N011722 | 002 | | Apr | CAHN |
| | AA | + | | 25MG | N011722 | 002 | | Mar | CAHN |
| | | TABLET, EXTENDED RELEASE;ORAL | | | | | | | |
| | | TENUATE DOSPAN | | | | | | | |
| >A> | AB | + | ACTAVIS LABS UT INC | 75MG | N012546 | 001 | | Apr | CAHN |
| >D> | AB | + | ALLERGAN SALES LLC | 75MG | N012546 | 001 | | Apr | CAHN |
| | AB | + | | 75MG | N012546 | 001 | | Mar | CAHN |
| <u>DIHYDROERGOTAMINE MESYLATE</u> | | | | | | | | | |
| | | INJECTABLE;INJECTION | | | | | | | |
| | | DIHYDROERGOTAMINE MESYLATE | | | | | | | |
| >D> | AP | | BEDFORD LABS | 1MG/ML | A040453 | 001 | Jun 09, 2003 | Apr | CAHN |
| >A> | AP | | EUROHLTH INTL SARL | 1MG/ML | A040453 | 001 | Jun 09, 2003 | Apr | CAHN |
| <u>DILTIAZEM HYDROCHLORIDE</u> | | | | | | | | | |
| | | CAPSULE, EXTENDED RELEASE;ORAL | | | | | | | |
| | | DILTIAZEM HYDROCHLORIDE | | | | | | | |
| | | @ ACTAVIS LABS FL INC | | 120MG | A074852 | 001 | Oct 10, 1997 | Jan | DISC |
| | | @ | | 180MG | A074852 | 002 | Oct 10, 1997 | Jan | DISC |
| | | @ | | 240MG | A074852 | 003 | Oct 10, 1997 | Jan | DISC |
| AB3 | | VALEANT PHARMS NORTH | 120MG | A075116 | 001 | Dec 23, 1999 | Jan | CAHN | |
| AB3 | | | 180MG | A075116 | 002 | Dec 23, 1999 | Jan | CAHN | |
| AB3 | | | 240MG | A075116 | 003 | Dec 23, 1999 | Jan | CAHN | |
| AB3 | | | 300MG | A075116 | 004 | Dec 23, 1999 | Jan | CAHN | |

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

| | | | | | | | | | |
|-----|----|---|--------------------|--------|---------|-----|--------------|-----|------|
| >D> | AP | + | BEDFORD | 5MG/ML | A074617 | 001 | Feb 28, 1996 | Apr | CAHN |
| >A> | AP | + | EUROHLTH INTL SARL | 5MG/ML | A074617 | 001 | Feb 28, 1996 | Apr | CAHN |

DINOPROSTONEINSERT, EXTENDED RELEASE; VAGINAL
CERVIDIL

| | | | | | | | | | |
|--|--|---|--------------------|------|---------|-----|--------------|-----|------|
| | | + | FERRING PHARMS INC | 10MG | N020411 | 001 | Mar 30, 1995 | Jan | CAHN |
|--|--|---|--------------------|------|---------|-----|--------------|-----|------|

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

| | | | | | | | | | |
|--|--|---|----------------|------|---------|-----|--------------|-----|------|
| | | @ | HIKMA PHARMS | 50MG | A083567 | 001 | | Feb | CAHN |
| | | @ | SUN PHARM INDS | 25MG | A089488 | 001 | Jan 02, 1987 | Mar | CAHN |

DIPYRIDAMOLE

INJECTABLE; INJECTION

DIPYRIDAMOLE

| | | | | | | | | | |
|-----|----|---|--------------------|--------|---------|-----|--------------|-----|------|
| >D> | AP | + | BEDFORD | 5MG/ML | A074939 | 001 | Apr 13, 1998 | Apr | CAHN |
| >A> | AP | + | EUROHLTH INTL SARL | 5MG/ML | A074939 | 001 | Apr 13, 1998 | Apr | CAHN |

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

| | | | | | | | | | |
|--|--|---|---------------------|---------------|---------|-----|--------------|-----|------|
| | | @ | AUROLIFE PHARMA LLC | EQ 100MG BASE | A070470 | 001 | Dec 10, 1985 | Feb | CAHN |
| | | @ | | EQ 150MG BASE | A070471 | 001 | Dec 10, 1985 | Feb | CAHN |
| | | @ | SUN PHARM INDS | EQ 100MG BASE | A070351 | 001 | Dec 17, 1985 | Mar | CAHN |
| | | @ | | EQ 150MG BASE | A070352 | 001 | Dec 17, 1985 | Mar | CAHN |

DISULFIRAM

TABLET; ORAL

DISULFIRAM

| | | | | | | | | | |
|----|--|--|---------------|-------|---------|-----|--------------|-----|------|
| AB | | | ALVOGEN MALTA | 250MG | A091681 | 001 | Aug 08, 2013 | Jan | CAHN |
|----|--|--|---------------|-------|---------|-----|--------------|-----|------|

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

| | | | | | | | | | |
|--|--|---|------------|------------------------|---------|-----|--------------|-----|------|
| | | @ | IMPAX LABS | EQ 250MG VALPROIC ACID | A078791 | 001 | May 06, 2009 | Feb | DISC |
| | | @ | | EQ 500MG VALPROIC ACID | A078791 | 002 | Aug 04, 2009 | Feb | DISC |

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

| | | | | | | | | | |
|--|--|---|---------------------|-------------------|---------|-----|--------------|-----|------|
| | | @ | TELIGENT PHARMA INC | EQ 12.5MG BASE/ML | A074098 | 001 | Feb 21, 1995 | Jan | CAHN |
|--|--|---|---------------------|-------------------|---------|-----|--------------|-----|------|

DOCETAXEL

SOLUTION; IV (INFUSION)

DOCETAXEL

| | | | | | | | | | |
|--|--|--|--------------|---------------------|---------|-----|--------------|-----|------|
| | | | EAGLE PHARMS | 20MG/ML (20MG/ML) | N205934 | 001 | Dec 22, 2015 | Jan | CAHN |
| | | | | 80MG/4ML (20MG/ML) | N205934 | 002 | Dec 22, 2015 | Jan | CAHN |
| | | | | 160MG/8ML (20MG/ML) | N205934 | 003 | Dec 22, 2015 | Jan | CAHN |

DOLASETRON MESYLATE

INJECTABLE; INJECTION

ANZEMET

| | | | | | | | | | |
|--|--|---|-------------------|--------------------------|---------|-----|--------------|-----|------|
| | | + | US PHARM HOLDINGS | 12.5MG/0.625ML (20MG/ML) | N020624 | 002 | Sep 11, 1997 | Jan | CAHN |
| | | + | | 100MG/5ML (20MG/ML) | N020624 | 001 | Sep 11, 1997 | Jan | CAHN |
| | | + | | 500MG/25ML (20MG/ML) | N020624 | 003 | Dec 11, 2001 | Jan | CAHN |

TABLET; ORAL

ANZEMET

| | | | | | | | | | |
|--|--|---|-------------------|-------|---------|-----|--------------|-----|------|
| | | | US PHARM HOLDINGS | 50MG | N020623 | 001 | Sep 11, 1997 | Jan | CAHN |
| | | + | | 100MG | N020623 | 002 | Sep 11, 1997 | Jan | CAHN |

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

| | | | | | | | | | |
|----|--|--|---------------------|------|---------|-----|--------------|-----|------|
| AB | | | DEXCEL PHARMA | 23MG | A203713 | 001 | Feb 19, 2016 | Feb | NEWA |
| AB | | | INDICUS PHARMA | 23MG | A203419 | 001 | Apr 12, 2016 | Mar | NEWA |
| AB | | | OSMOTICA PHARM CORP | 23MG | A203114 | 001 | Jan 26, 2016 | Jan | NEWA |

TABLET, ORALLY DISINTEGRATING;ORAL
DONEPEZIL HYDROCHLORIDE

@ SUN PHARM INDS 5MG A077975 002 Dec 11, 2009 Mar CAHN
@ 10MG A077975 001 Dec 11, 2009 Mar CAHN

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION
DOXAPRAM HYDROCHLORIDE

>D> AP BEDFORD 20MG/ML A076266 001 Jan 10, 2003 Apr CAHN
>A> AP EUROHLTH INTL SARL 20MG/ML A076266 001 Jan 10, 2003 Apr CAHN

DOXAZOSIN MESYLATE

TABLET;ORAL

DOXAZOSIN MESYLATE

@ IDT AUSTRALIA LTD EQ 1MG BASE A075432 001 Oct 18, 2000 Mar CAHN
@ EQ 2MG BASE A075432 002 Oct 18, 2000 Mar CAHN
@ EQ 4MG BASE A075432 003 Oct 18, 2000 Mar CAHN
@ EQ 8MG BASE A075432 004 Oct 18, 2000 Mar CAHN

DOXEPIIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIIN HYDROCHLORIDE

@ SUN PHARM INDS EQ 25MG BASE A071502 001 Feb 18, 1988 Mar CAHN
@ EQ 50MG BASE A071653 001 Feb 18, 1988 Mar CAHN
@ EQ 75MG BASE A071654 001 Feb 18, 1988 Mar CAHN
@ EQ 100MG BASE A071521 001 Feb 18, 1988 Mar CAHN

TABLET;ORAL

DOXEPIIN HYDROCHLORIDE

AB MYLAN PHARMS INC EQ 3MG BASE A202337 001 Jan 20, 2016 Jan NEWA
AB EQ 6MG BASE A202337 002 Jan 20, 2016 Jan NEWA

DOXERCALCIFEROL

INJECTABLE; INJECTION

DOXERCALCIFEROL

AP AKORN INC 2MCG/ML (2MCG/ML) A203929 002 Mar 28, 2016 Mar NEWA
HECTOROL
AP GENZYME CORP 2MCG/ML (2MCG/ML) N021027 002 Apr 06, 2000 Mar CFTG

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB G AND W LABS INC EQ 50MG BASE A204446 001 May 28, 2015 Mar CAHN
AB EQ 75MG BASE A204446 002 May 28, 2015 Mar CAHN
AB EQ 100MG BASE A204446 003 May 28, 2015 Mar CAHN
AB ZYDUS PHARMS USA INC EQ 50MG BASE A205115 001 Feb 18, 2016 Feb NEWA
AB EQ 75MG BASE A205115 002 Feb 18, 2016 Feb NEWA
AB EQ 100MG BASE A205115 003 Feb 18, 2016 Feb NEWA

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

ACTICLATE CAP

>A> + AQUA PHARMS EQ 75MG BASE N208253 001 Apr 26, 2016 Apr NEWA

DOXYCYCLINE HYCLATE

AB SUN PHARM INDS EQ 100MG BASE A062676 001 Jul 10, 1986 Mar CAHN

TABLET;ORAL

DOXYCYCLINE HYCLATE

@ COREPHARMA EQ 20MG BASE A065182 001 May 13, 2005 Mar DISC
AB SUN PHARM INDS EQ 20MG BASE A065134 001 May 13, 2005 Mar CAHN
AB EQ 100MG BASE A062677 001 Jul 10, 1986 Mar CAHN
@ VINTAGE PHARMS EQ 100MG BASE A062538 001 Apr 07, 1986 Mar DISC

TABLET, DELAYED RELEASE;ORAL

DORYX

>D> MAYNE PHARMA EQ 80MG BASE N050795 004 Apr 11, 2013 Apr CFTG
>A> AB EQ 80MG BASE N050795 004 Apr 11, 2013 Apr CFTG

DOXYCYCLINE HYCLATE

@ IMPAX LABS INC EQ 75MG BASE A090505 001 Dec 28, 2010 Mar DISC
@ EQ 100MG BASE A090505 002 Dec 28, 2010 Mar DISC
>A> AB MYLAN EQ 80MG BASE A090431 004 Apr 29, 2016 Apr NEWA

DROSPIRENONE; ETHINYL ESTRADIOLTABLET; ORAL
MELAMISA

| | | | | | | | |
|----|-----------------|------------|---------|-----|--------------|-----|------|
| AB | NOVAST LABS LTD | 3MG;0.02MG | A202016 | 001 | Jan 26, 2016 | Jan | NEWA |
|----|-----------------|------------|---------|-----|--------------|-----|------|

TABLET; ORAL-28

DROSPIRENONE AND ETHINYL ESTRADIOL

| | | | | | | | |
|----|---------------------|------------|---------|-----|--------------|-----|------|
| AB | GLENMARK PHARMS LTD | 3MG;0.03MG | A204848 | 001 | Mar 25, 2016 | Mar | NEWA |
|----|---------------------|------------|---------|-----|--------------|-----|------|

DUTASTERIDECAPSULE; ORAL
DUTASTERIDE

| | | | | | | | | |
|-----|----|---------------------|-------|---------|-----|--------------|-----|------|
| >A> | AB | AUROLIFE PHARMA LLC | 0.5MG | A202660 | 001 | Nov 20, 2015 | Apr | CAHN |
| | AB | BIONPHARMA INC | 0.5MG | A200899 | 001 | Nov 20, 2015 | Jan | CAHN |
| | AB | INTERGEL PHARMS INC | 0.5MG | A206373 | 001 | Mar 17, 2016 | Feb | NEWA |
| >D> | AB | SANDOZ INC | 0.5MG | A202660 | 001 | Nov 20, 2015 | Apr | CAHN |
| | AB | STRIDES PHARMA | 0.5MG | A204262 | 001 | Nov 20, 2015 | Mar | CAHN |

EDROPHONIUM CHLORIDEINJECTABLE; INJECTION
TENSILON

@ TELIGENT PHARMA INC 10MG/ML

N007959 001 Jan CAHN

TENSILON PRESERVATIVE FREE

@ TELIGENT PHARMA INC 10MG/ML

N007959 002 Jan CAHN

EFAVIRENZTABLET; ORAL
EFAVIRENZ

| | | | | | | | |
|----|----------------|-------|---------|-----|--------------|-----|------|
| AB | MYLAN LABS LTD | 600MG | A091471 | 001 | Feb 17, 2016 | Feb | NEWA |
|----|----------------|-------|---------|-----|--------------|-----|------|

SUSTIVA

| | | | | | | | | |
|----|---|----------------------|-------|---------|-----|--------------|-----|------|
| AB | + | BRISTOL MYERS SQUIBB | 600MG | N021360 | 002 | Feb 01, 2002 | Feb | CFTG |
|----|---|----------------------|-------|---------|-----|--------------|-----|------|

ELBASVIR; GRAZOPREVRTABLET; ORAL
ZEPATIER

+ MERCK SHARP DOHME 50MG;100MG

N208261 001 Jan 28, 2016 Jan NEWA

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

| | | | | | | | | |
|-----|---|---------------------|---------------------------------|---------|-----|--------------|-----|------|
| >A> | | TABLET; ORAL | | | | | | |
| >A> | | ODEFSEY | | | | | | |
| >A> | + | GILEAD SCIENCES INC | 200MG;EQ 25MG BASE;EQ 25MG BASE | N208351 | 001 | Mar 01, 2016 | Apr | CAIN |

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

| | | | | | | | | |
|-----|---|---------------------|---------------------------------|---------|-----|--------------|-----|------|
| >D> | | TABLET; ORAL | | | | | | |
| >D> | | ODEFSEY | | | | | | |
| >D> | + | GILEAD SCIENCES INC | 200MG;EQ 25MG BASE;EQ 25MG BASE | N208351 | 001 | Mar 01, 2016 | Apr | CAIN |
| | + | | 200MG;EQ 25MG BASE;EQ 25MG BASE | N208351 | 001 | Mar 01, 2016 | Mar | NEWA |

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

| | | | | | | | | |
|-----|---|---------------------|--------------------|---------|-----|--------------|-----|------|
| >A> | | TABLET; ORAL | | | | | | |
| >A> | | DESCOVY | | | | | | |
| >A> | + | GILEAD SCIENCES INC | 200MG;EQ 25MG BASE | N208215 | 001 | Apr 04, 2016 | Apr | NEWA |

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATETABLET; ORAL
TRUVADAGILEAD
100MG;150MG
133MG;200MG
167MG;250MG

| | | | | |
|---------|-----|--------------|-----|------|
| N021752 | 002 | Mar 10, 2016 | Mar | NEWA |
| N021752 | 003 | Mar 10, 2016 | Mar | NEWA |
| N021752 | 004 | Mar 10, 2016 | Mar | NEWA |

ENALAPRILATINJECTABLE; INJECTION
ENALAPRILAT

| | | | | | | | | | |
|-----|----|---|--------------------|-----------|---------|-----|--------------|-----|------|
| >D> | AP | + | BEDFORD | 1.25MG/ML | A075634 | 001 | Aug 22, 2000 | Apr | CAHN |
| >A> | AP | + | EUROHLTH INTL SARL | 1.25MG/ML | A075634 | 001 | Aug 22, 2000 | Apr | CAHN |

| | | | | | | | | |
|-----|--------------------------|--|---------------------------------|---------|-----|--------------|-----|------|
| >A> | <u>EPHEDRINE SULFATE</u> | | | | | | | |
| >A> | SOLUTION;INTRAVENOUS | | | | | | | |
| >A> | AKOVAZ | | | | | | | |
| >A> | + | FLAMEL IRELAND LTD | 50MG/ML | N208289 | 001 | Apr 29, 2016 | Apr | NEWA |
| | | <u>EPINASTINE HYDROCHLORIDE</u> | | | | | | |
| | | SOLUTION/DROPS;OPHTHALMIC | | | | | | |
| | | EPINASTINE HYDROCHLORIDE | | | | | | |
| AT | | SOMERSET THERAPS LLC | 0.05% | A090951 | 001 | Oct 31, 2011 | Mar | CAHN |
| | | <u>EPINEPHRINE</u> | | | | | | |
| | | INJECTABLE;INJECTION | | | | | | |
| | | SUS-PHRINE SULFITE FREE | | | | | | |
| | | @ FOREST LABS | 1.5MG/AMP | N007942 | 003 | Feb 05, 1999 | Mar | CMS1 |
| | | @ | 5MG/ML | N007942 | 001 | | Mar | CMS1 |
| | | INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS | | | | | | |
| | | AUVI-Q | | | | | | |
| BX | + | KALEO INC | EQ 0.15MG/DELIVERY | N201739 | 002 | Aug 10, 2012 | Mar | CAHN |
| BX | | | EQ 0.3MG/DELIVERY | N201739 | 001 | Aug 10, 2012 | Mar | CAHN |
| | | <u>EPINEPHRINE HYDROCHLORIDE</u> | | | | | | |
| | | SOLUTION;IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS | | | | | | |
| | | EPINEPHRINE | | | | | | |
| | | BELCHER PHARMS LLC | EQ 1MG BASE/ML (EQ 1MG BASE/ML) | N205029 | 001 | Jul 29, 2014 | Feb | CDFR |
| | | <u>ERGOCALCIFEROL</u> | | | | | | |
| | | CAPSULE;ORAL | | | | | | |
| | | DRISDOL | | | | | | |
| AA | + | US PHARM HOLDINGS | 50,000 IU | N003444 | 001 | | Jan | CAHN |
| | | VITAMIN D | | | | | | |
| AA | | BIONPHARMA INC | 50,000 IU | A080704 | 001 | | Jan | CAHN |
| | | <u>ERGOLOID MESYLATES</u> | | | | | | |
| | | TABLET;ORAL | | | | | | |
| | | ERGOLOID MESYLATES | | | | | | |
| AB | | SUN PHARM INDS | 1MG | A081113 | 001 | Oct 31, 1991 | Mar | CAHN |
| | | <u>ERYTHROMYCIN</u> | | | | | | |
| | | SOLUTION;TOPICAL | | | | | | |
| | | C-SOLVE-2 | | | | | | |
| | | @ FOUGERA PHARMS | 2% | A062468 | 001 | Jul 03, 1985 | Feb | DISC |
| | | ERYTHRO-STATIN | | | | | | |
| | | @ HI TECH PHARMA | 2% | A064101 | 001 | Oct 22, 1996 | Feb | DISC |
| | | ERYTHROMYCIN | | | | | | |
| AT | + | FOUGERA PHARMS | 2% | A064187 | 001 | Sep 30, 1997 | Jan | CRLD |
| AT | | PERRIGO NEW YORK | 2% | A063038 | 001 | Jan 11, 1991 | Jan | CRLD |
| | | <u>ESCITALOPRAM OXALATE</u> | | | | | | |
| | | SOLUTION;ORAL | | | | | | |
| | | ESCITALOPRAM OXALATE | | | | | | |
| AA | | MACLEODS PHARMS LTD | EQ 5MG BASE/5ML | A202754 | 001 | Mar 31, 2016 | Mar | NEWA |
| | | <u>ESMOLOL HYDROCHLORIDE</u> | | | | | | |
| >A> | | SOLUTION;INTRAVENOUS | | | | | | |
| >A> | | ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER | | | | | | |
| >A> | + | HQ SPCLT PHARMA | 2GM/100ML (20MG/ML) | N205703 | 002 | Apr 07, 2016 | Apr | NEWA |
| >A> | | ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER | | | | | | |
| >A> | | HQ SPCLT PHARMA | 2.5GM/250ML (10MG/ML) | N205703 | 001 | Apr 07, 2016 | Apr | NEWA |
| | | <u>ESOMEPRAZOLE MAGNESIUM</u> | | | | | | |
| | | CAPSULE, DELAYED REL PELLETS;ORAL | | | | | | |
| | | ESOMEPRAZOLE MAGNESIUM | | | | | | |
| >A> | AB | AUROBINDO PHARMA LTD | EQ 20MG BASE | A205606 | 001 | Apr 21, 2016 | Apr | NEWA |
| >A> | AB | | EQ 40MG BASE | A205606 | 002 | Apr 21, 2016 | Apr | NEWA |
| >D> | AB | HETERO LABS LTD III | EQ 20MG BASE | A202784 | 001 | Sep 21, 2015 | Apr | CTEC |
| >A> | BX | | EQ 20MG BASE | A202784 | 001 | Sep 21, 2015 | Apr | CTEC |
| >D> | AB | | EQ 40MG BASE | A202784 | 002 | Sep 21, 2015 | Apr | CTEC |
| >A> | BX | | EQ 40MG BASE | A202784 | 002 | Sep 21, 2015 | Apr | CTEC |

ESTRADIOL

CREAM;VAGINAL

ESTRACE

| | | | | | | | | |
|-----|---|--------------------|-------|---------|-----|--------------|-----|------|
| >A> | + | ALLERGAN SALES LLC | 0.01% | A086069 | 001 | Jan 31, 1984 | Apr | CAHN |
| >D> | + | WARNER CHILCOTT US | 0.01% | A086069 | 001 | Jan 31, 1984 | Apr | CAHN |

FILM, EXTENDED RELEASE;TRANSDERMAL

ALORA

| | | | | | | | | |
|----|--|--------------------|--------------|---------|-----|--------------|-----|------|
| BX | | ALLERGAN SALES LLC | 0.025MG/24HR | N020655 | 004 | Apr 05, 2002 | Mar | CAHN |
| BX | | | 0.05MG/24HR | N020655 | 001 | Dec 20, 1996 | Mar | CAHN |
| BX | | | 0.075MG/24HR | N020655 | 002 | Dec 20, 1996 | Mar | CAHN |
| BX | | | 0.1MG/24HR | N020655 | 003 | Dec 20, 1996 | Mar | CAHN |

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL

FEMRING

| | | | | | | | | |
|--|---|------|---------------------|---------|-----|--------------|-----|------|
| | | APIL | EQ 0.05MG BASE/24HR | N021367 | 001 | Mar 20, 2003 | Jan | CAHN |
| | + | | EQ 0.1MG BASE/24HR | N021367 | 002 | Mar 20, 2003 | Jan | CAHN |

TABLET;ORAL

FEMTRACE

| | | | | | | | | |
|--|---|------|--------|---------|-----|--------------|-----|------|
| | | APIL | 0.45MG | N021633 | 001 | Aug 20, 2004 | Jan | CAHN |
| | | | 0.9MG | N021633 | 002 | Aug 20, 2004 | Jan | CAHN |
| | + | | 1.8MG | N021633 | 003 | Aug 20, 2004 | Jan | CAHN |

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

| | | | | | | | | |
|----|---|----------------|------------|---------|-----|--------------|-----|------|
| AB | | JAI PHARMA LTD | 0.05MG;1MG | A204704 | 001 | Feb 09, 2016 | Jan | NEWA |
| | | ZOVIA 1/50E-28 | | | | | | |
| AB | + | WATSON LABS | 0.05MG;1MG | A072723 | 001 | Dec 30, 1991 | Jan | CTEC |

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

FAYOSIM

| | | | | | | | | |
|----|--|-----------|---|---------|-----|--------------|-----|------|
| AB | | LUPIN LTD | 0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A | A205943 | 001 | Mar 29, 2016 | Mar | NEWA |
|----|--|-----------|---|---------|-----|--------------|-----|------|

QUARTETTE

| | | | | | | | | |
|----|---|--------------------|---|---------|-----|--------------|-----|------|
| AB | + | TEVA BRANDED PHARM | 0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A | N204061 | 001 | Mar 28, 2013 | Mar | CFTG |
|----|---|--------------------|---|---------|-----|--------------|-----|------|

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

BREVICON 21-DAY

| | | | | | | | | |
|-----|--|-----------------------|---------------|---------|-----|--|-----|------|
| >D> | | @ ACTAVIS LABS UT INC | 0.035MG;0.5MG | N017566 | 001 | | Apr | CAHN |
| >A> | | @ ALLERGAN SALES LLC | 0.035MG;0.5MG | N017566 | 001 | | Apr | CAHN |

NORINYL 1+35 21-DAY

| | | | | | | | | |
|----|--|--------------------|-------------|---------|-----|--|-----|------|
| AB | | ALLERGAN SALES LLC | 0.035MG;1MG | N017565 | 001 | | Mar | CAHN |
|----|--|--------------------|-------------|---------|-----|--|-----|------|

TABLET;ORAL-28

BREVICON 28-DAY

| | | | | | | | | |
|----|--|--------------------|---------------|---------|-----|--|-----|------|
| AB | | ALLERGAN SALES LLC | 0.035MG;0.5MG | N017743 | 001 | | Mar | CAHN |
|----|--|--------------------|---------------|---------|-----|--|-----|------|

NORINYL 1+35 28-DAY

| | | | | | | | | |
|----|--|--------------------|-------------|---------|-----|--|-----|------|
| AB | | ALLERGAN SALES LLC | 0.035MG;1MG | N017565 | 002 | | Mar | CAHN |
|----|--|--------------------|-------------|---------|-----|--|-----|------|

TABLET, CHEWABLE;ORAL

FEMCON FE

| | | | | | | | | |
|----|---|------|---------------|---------|-----|--------------|-----|------|
| AB | + | APIL | 0.035MG;0.4MG | N021490 | 001 | Nov 14, 2003 | Jan | CAHN |
|----|---|------|---------------|---------|-----|--------------|-----|------|

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

| | | | | | | | | |
|----|---|-----------|---------------|---------|-----|--------------|-----|------|
| AB | + | APIL | 0.025MG;0.8MG | N022573 | 001 | Dec 22, 2010 | Jan | CAHN |
| AB | | LUPIN LTD | 0.035MG;0.4MG | A091332 | 001 | Mar 23, 2016 | Mar | NEWA |

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

| | | | | | | | | |
|-----|--|-------------------|------------|---------|-----|--------------|-----|------|
| >A> | | @ APIL | 0.02MG;1MG | N204426 | 001 | Apr 19, 2013 | Apr | CAHN |
| >D> | | @ WARNER CHILCOTT | 0.02MG;1MG | N204426 | 001 | Apr 19, 2013 | Apr | CAHN |

TABLET;ORAL

FEMHRT

| | | | | | | | | |
|----|--|------|----------------|---------|-----|--------------|-----|------|
| AB | | APIL | 0.0025MG;0.5MG | N021065 | 001 | Jan 14, 2005 | Jan | CAHN |
| | | @ | 0.005MG;1MG | N021065 | 002 | Oct 15, 1999 | Jan | CAHN |

LO LOESTRIN FE

| | | | | | | | | |
|--|---|------|-----------------------|---------|-----|--------------|-----|------|
| | + | APIL | 0.01MG,0.01MG;1MG,N/A | N022501 | 001 | Oct 21, 2010 | Jan | CAHN |
|--|---|------|-----------------------|---------|-----|--------------|-----|------|

| | | | | | | | | | |
|-----|----|---|---|---------|-----|--------------|-----|------|--|
| | | TABLET;ORAL-21 | | | | | | | |
| | | ESTROSTEP 21 | | | | | | | |
| | | @ APIL | 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG | N020130 | 001 | Oct 09, 1996 | Jan | CAHN | |
| | | LOESTRIN 21 1.5/30 | | | | | | | |
| >A> | AB | APIL | 0.03MG;1.5MG | N017875 | 001 | | Apr | CAHN | |
| >D> | AB | WARNER CHILCOTT LLC | 0.03MG;1.5MG | N017875 | 001 | | Apr | CAHN | |
| | | LOESTRIN 21 1/20 | | | | | | | |
| >A> | AB | APIL | 0.02MG;1MG | N017876 | 001 | | Apr | CAHN | |
| >D> | AB | WARNER CHILCOTT LLC | 0.02MG;1MG | N017876 | 001 | | Apr | CAHN | |
| | | NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL | | | | | | | |
| | AB | GLENMARK PHARMS LTD | 0.02MG;1MG | A206969 | 001 | Jan 20, 2016 | Jan | NEWA | |
| | | TABLET;ORAL-28 | | | | | | | |
| | | ESTROSTEP FE | | | | | | | |
| | AB | + APIL | 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG | N020130 | 002 | Oct 09, 1996 | Jan | CAHN | |
| | | LOESTRIN FE 1.5/30 | | | | | | | |
| >A> | AB | + APIL | 0.03MG;1.5MG | N017355 | 001 | | Apr | CAHN | |
| >D> | AB | + WARNER CHILCOTT LLC | 0.03MG;1.5MG | N017355 | 001 | | Apr | CAHN | |
| | | LOESTRIN FE 1/20 | | | | | | | |
| >A> | AB | APIL | 0.02MG;1MG | N017354 | 001 | | Apr | CAHN | |
| >D> | AB | WARNER CHILCOTT | 0.02MG;1MG | N017354 | 001 | | Apr | CAHN | |
| | | TABLET, CHEWABLE;ORAL | | | | | | | |
| | | MINASTRIN 24 FE | | | | | | | |
| | | + APIL | 0.02MG;1MG | N203667 | 001 | May 08, 2013 | Jan | CAHN | |
| | | TABLET, CHEWABLE, TABLET;ORAL | | | | | | | |
| | | LO MINASTRIN FE | | | | | | | |
| | | + APIL | 0.01MG,0.01MG,N/A;1MG,N/A,N/A | N204654 | 001 | Jul 24, 2013 | Jan | CAHN | |
| | | <u>ETHINYL ESTRADIOL; NORGESTIMATE</u> | | | | | | | |
| | | TABLET;ORAL-28 | | | | | | | |
| | | NORGESTIMATE AND ETHINYL ESTRADIOL | | | | | | | |
| | AB | GLENMARK PHARMS LTD | 0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG | A204057 | 001 | Feb 23, 2016 | Feb | NEWA | |
| | AB | JAI PHARMA LTD | 0.035MG, 0.035MG, 0.035MG;0.18MG, 0.215MG, 0.25MG | A201897 | 001 | Jan 27, 2016 | Jan | NEWA | |
| | AB | | 0.035MG;0.25MG | A201896 | 001 | Jan 27, 2016 | Jan | NEWA | |
| >A> | AB | LUPIN LTD | 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG | A205588 | 001 | Apr 26, 2016 | Apr | NEWA | |
| | | <u>ETHOSUXIMIDE</u> | | | | | | | |
| | | CAPSULE;ORAL | | | | | | | |
| | | ETHOSUXIMIDE | | | | | | | |
| | AB | BIONPHARMA INC | 250MG | A040430 | 001 | Oct 28, 2002 | Jan | CAHN | |
| | | <u>ETIDRONATE DISODIUM</u> | | | | | | | |
| | | TABLET;ORAL | | | | | | | |
| | | DIDRONEL | | | | | | | |
| >A> | AB | APIL | 200MG | N017831 | 001 | | Apr | CAHN | |
| >A> | AB | + | 400MG | N017831 | 002 | | Apr | CAHN | |
| >D> | AB | PROCTER AND GAMBLE | 200MG | N017831 | 001 | | Apr | CAHN | |
| >D> | AB | + | 400MG | N017831 | 002 | | Apr | CAHN | |
| | | <u>ETODOLAC</u> | | | | | | | |
| | | CAPSULE;ORAL | | | | | | | |
| | | ETODOLAC | | | | | | | |
| | | @ LEHIGH VALLEY | 300MG | A074929 | 001 | Jan 30, 1998 | Feb | CAHN | |
| | | <u>ETOMIDATE</u> | | | | | | | |
| | | INJECTABLE; INJECTION | | | | | | | |
| | | ETOMIDATE | | | | | | | |
| >D> | AP | BEDFORD | 2MG/ML | A074593 | 001 | Nov 04, 1996 | Apr | CAHN | |
| >A> | AP | EUROHLTH INTL SARL | 2MG/ML | A074593 | 001 | Nov 04, 1996 | Apr | CAHN | |
| | AP | HIKMA FARMACEUTICA | 2MG/ML | A202354 | 001 | Feb 25, 2016 | Feb | NEWA | |
| | | <u>EXEMESTANE</u> | | | | | | | |
| | | TABLET;ORAL | | | | | | | |
| | | EXEMESTANE | | | | | | | |
| | AB | ALVOGEN MALTA | 25MG | A200898 | 001 | Jul 28, 2014 | Jan | CAHN | |

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS
BYDUREON PEN

| | | | | | | |
|---|----------------|-----|---------|-----|--------------|----------|
| + | ASTRAZENECA AB | 2MG | N022200 | 002 | Feb 28, 2014 | Feb NEWA |
|---|----------------|-----|---------|-----|--------------|----------|

FAMOTIDINE

INJECTABLE; INJECTION
FAMOTIDINE

| | | | | | | | |
|-----|----|------------------------------|---------|---------|-----|--------------|----------|
| >D> | AP | BEDFORD | 10MG/ML | A075651 | 001 | Apr 16, 2001 | Apr CAHN |
| >D> | AP | | 10MG/ML | A075684 | 001 | Apr 16, 2001 | Apr CAHN |
| >A> | AP | EUROHLTH INTL SARL | 10MG/ML | A075651 | 001 | Apr 16, 2001 | Apr CAHN |
| >A> | AP | | 10MG/ML | A075684 | 001 | Apr 16, 2001 | Apr CAHN |
| | | FAMOTIDINE PRESERVATIVE FREE | | | | | |
| >D> | AP | BEDFORD | 10MG/ML | A075622 | 001 | Apr 16, 2001 | Apr CAHN |
| >D> | AP | BEDFORD LABS | 10MG/ML | A075825 | 001 | Apr 17, 2001 | Apr CAHN |
| >A> | AP | EUROHLTH INTL SARL | 10MG/ML | A075622 | 001 | Apr 16, 2001 | Apr CAHN |
| >A> | AP | | 10MG/ML | A075825 | 001 | Apr 17, 2001 | Apr CAHN |

TABLET; ORAL

FAMOTIDINE

| | | | | | | |
|---|----------------|------|---------|-----|--------------|----------|
| @ | SUN PHARM INDS | 20MG | A075639 | 002 | Dec 12, 2001 | Mar CAHN |
| @ | | 40MG | A075639 | 001 | Dec 12, 2001 | Mar CAHN |

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL
FELODIPINE

| | | | | | | |
|----|----------------|-------|---------|-----|--------------|----------|
| AB | SUN PHARM INDS | 2.5MG | A075896 | 001 | Nov 02, 2004 | Mar CAHN |
| AB | | 5MG | A075896 | 002 | Nov 02, 2004 | Mar CAHN |
| AB | | 10MG | A075896 | 003 | Nov 02, 2004 | Mar CAHN |

FENOFIBRATE

TABLET; ORAL
FENOFIBRATE

| | | | | | | | |
|-----|----|----------------------|-------|---------|-----|--------------|----------|
| >A> | AB | AUROBINDO PHARMA LTD | 48MG | A205118 | 001 | May 05, 2016 | Apr NEWA |
| >A> | AB | | 145MG | A205118 | 002 | May 05, 2016 | Apr NEWA |

FENOFIBRIC ACID

TABLET; ORAL
FIBRICOR

| | | | | | | | |
|-----|---|---------------------|-------|---------|-----|--------------|----------|
| >A> | | ARALENZ PHARMS | 35MG | N022418 | 001 | Aug 14, 2009 | Apr CAHN |
| >A> | + | | 105MG | N022418 | 002 | Aug 14, 2009 | Apr CAHN |
| >D> | | TRIBUTE PHARMS INTL | 35MG | N022418 | 001 | Aug 14, 2009 | Apr CAHN |
| >D> | + | | 105MG | N022418 | 002 | Aug 14, 2009 | Apr CAHN |

FENOPROFEN CALCIUM

CAPSULE; ORAL
FENOPROFEN CALCIUM

| | | | | | | |
|---|---------------------|---------------|---------|-----|--------------|----------|
| @ | AUROLIFE PHARMA LLC | EQ 200MG BASE | A072394 | 001 | Oct 17, 1988 | Mar CAHN |
| @ | | EQ 300MG BASE | A072395 | 001 | Oct 17, 1988 | Feb CAHN |

TABLET; ORAL
FENOPROFEN CALCIUM

| | | | | | | |
|---|---------------------|---------------|---------|-----|--------------|----------|
| @ | AUROLIFE PHARMA LLC | EQ 600MG BASE | A072396 | 001 | Oct 17, 1988 | Feb CAHN |
| @ | SUN PHARM INDS | EQ 600MG BASE | A072902 | 001 | Dec 21, 1990 | Mar CAHN |

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL
FENTANYL-12

| | | | | | | |
|----|-------|------------|---------|-----|--------------|----------|
| AB | AVEVA | 12.5MCG/HR | A077449 | 005 | Sep 11, 2015 | Jan NEWA |
|----|-------|------------|---------|-----|--------------|----------|

FERRIC PYROPHOSPHATE CITRATE

FOR SOLUTION; INTRAVENOUS
TRIFERIC

| | | | | | | | |
|-----|---|----------------------|-------------------|---------|-----|--------------|----------|
| >A> | + | ROCKWELL MEDICAL INC | 272MG IRON/PACKET | N208551 | 001 | Apr 25, 2016 | Apr NEWA |
|-----|---|----------------------|-------------------|---------|-----|--------------|----------|

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE; ORAL
FESOTERODINE FUMARATE

| | | | | | | |
|---|----------------|-----|---------|-----|--------------|----------|
| @ | ALKEM LABS LTD | 4MG | A204827 | 001 | Dec 10, 2015 | Jan DISC |
| @ | | 8MG | A204827 | 002 | Dec 10, 2015 | Jan DISC |

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

| | | | | | |
|----------------|------------|----------|-----|--------------|----------|
| @ BARR | 60MG;120MG | A 076236 | 001 | Apr 14, 2005 | Mar DISC |
| @ IMPAX PHARMS | 60MG;120MG | A 076298 | 001 | Nov 12, 2010 | Mar DISC |

FLAVOXATE HYDROCHLORIDE

TABLET;ORAL

FLAVOXATE HYDROCHLORIDE

| | | | | | |
|----------------|-------|----------|-----|--------------|----------|
| @ IMPAX PHARMS | 100MG | A 076234 | 001 | Aug 28, 2003 | Mar DISC |
|----------------|-------|----------|-----|--------------|----------|

FLUCONAZOLE

FOR SUSPENSION;ORAL

FLUCONAZOLE

| | | | | | |
|----------------------|-----------|----------|-----|--------------|----------|
| @ SUN PHARM INDS LTD | 50MG/5ML | A 076332 | 001 | Jul 29, 2004 | Feb DISC |
| @ | 200MG/5ML | A 076332 | 002 | Jul 29, 2004 | Feb DISC |

INJECTABLE;INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

| | | | | | | |
|--------|--|----------------------|----------|-----|--------------|----------|
| >D> | BEDFORD | 100MG/50ML (2MG/ML) | A 076087 | 002 | Sep 26, 2008 | Apr CAHN |
| >D> AP | | 200MG/100ML (2MG/ML) | A 076087 | 001 | Jul 29, 2004 | Apr CAHN |
| >D> AP | | 400MG/200ML (2MG/ML) | A 076087 | 003 | Jul 29, 2004 | Apr CAHN |
| >A> | EUROHLTH INTL SARL | 100MG/50ML (2MG/ML) | A 076087 | 002 | Sep 26, 2008 | Apr CAHN |
| >A> AP | | 200MG/100ML (2MG/ML) | A 076087 | 001 | Jul 29, 2004 | Apr CAHN |
| >A> AP | | 400MG/200ML (2MG/ML) | A 076087 | 003 | Jul 29, 2004 | Apr CAHN |
| | @ TEVA PHARMS USA | 200MG/100ML (2MG/ML) | A 076653 | 001 | Jul 29, 2004 | Jan DISC |
| | @ | 400MG/200ML (2MG/ML) | A 076653 | 002 | Jul 29, 2004 | Jan DISC |
| | FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | | | | | |
| AP | ACS DOBFAR INFO SA | 200MG/100ML (2MG/ML) | A 079104 | 001 | Jul 30, 2009 | Mar CMS1 |
| AP | | 400MG/200ML (2MG/ML) | A 079104 | 002 | Jul 30, 2009 | Mar CMS1 |

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS

FLUDEOXYGLUCOSE F18

| | | | | | | |
|----|-----------------------|--------------|----------|-----|--------------|----------|
| AP | KREITCHMAN PET CTR | 10-100mCi/ML | A 203942 | 001 | Apr 11, 2016 | Mar NEWA |
| AP | + QUEEN HAMAMATSU PET | 10-100mCi/ML | A 203771 | 001 | Aug 31, 2015 | Mar CTEC |
| AP | ZEVACOR PHARMA INC | 20-300mCi/ML | A 203591 | 001 | Aug 31, 2015 | Feb CAHN |

FLUMAZENIL

INJECTABLE;INJECTION

FLUMAZENIL

| | | | | | | |
|--------|--------------------|----------------------|----------|-----|--------------|----------|
| >D> AP | BEDFORD LABS | 0.5MG/5ML (0.1MG/ML) | A 076256 | 002 | Oct 12, 2004 | Apr CAHN |
| >D> AP | | 1MG/10ML (0.1MG/ML) | A 076256 | 001 | Oct 12, 2004 | Apr CAHN |
| >A> AP | EUROHLTH INTL SARL | 0.5MG/5ML (0.1MG/ML) | A 076256 | 002 | Oct 12, 2004 | Apr CAHN |
| >A> AP | | 1MG/10ML (0.1MG/ML) | A 076256 | 001 | Oct 12, 2004 | Apr CAHN |

FLUOCINOLONE ACETONIDE

OIL;TOPICAL

FLUOCINOLONE ACETONIDE

| | | | | | | |
|--------|------|-------|----------|-----|--------------|----------|
| >A> AT | LYNE | 0.01% | A 090982 | 001 | Apr 25, 2016 | Apr NEWA |
| >A> AT | | 0.01% | A 203377 | 001 | Apr 25, 2016 | Apr NEWA |

OIL/DROPS;OTIC

FLUOCINOLONE ACETONIDE

| | | | | | | |
|--------|------|-------|----------|-----|--------------|----------|
| >A> AT | LYNE | 0.01% | A 203378 | 001 | Apr 25, 2016 | Apr NEWA |
|--------|------|-------|----------|-----|--------------|----------|

FLUOROURACIL

INJECTABLE;INJECTION

FLUOROURACIL

| | | | | | | |
|----|-------------------|----------------------|----------|-----|--------------|----------|
| AP | SAGENT PHARMS | 2.5GM/50ML (50MG/ML) | A 203609 | 001 | Feb 17, 2016 | Feb NEWA |
| AP | | 5GM/100ML (50MG/ML) | A 203609 | 002 | Feb 17, 2016 | Feb NEWA |
| | @ SPECTRUM PHARMS | 500MG/10ML (50MG/ML) | N 012209 | 001 | | Jan CAHN |

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE

| | | | | | |
|------------------|--------------|----------|-----|--------------|----------|
| @ SUN PHARM INDS | EQ 10MG BASE | A 075787 | 001 | Jan 29, 2002 | Mar CAHN |
| @ | EQ 20MG BASE | A 075787 | 002 | Jan 29, 2002 | Mar CAHN |

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

| | | | | | | |
|---|---------------------|--------------|----------|-----|--------------|----------|
| + | EDGEMONT PHARMS LLC | EQ 60MG BASE | N 202133 | 001 | Oct 06, 2011 | Mar CRLD |
|---|---------------------|--------------|----------|-----|--------------|----------|

| | | | | | | | |
|--|--|---------------------|-------------------------------|---------|--------------|--------------|----------|
| <u>TABLET; ORAL</u> | | | | | | | |
| SARAFEM | | | | | | | |
| AB1 | APIL | EQ 10MG BASE | N021860 | 001 | May 19, 2006 | Jan | CAHN |
| AB1 | | EQ 15MG BASE | N021860 | 002 | May 19, 2006 | Jan | CAHN |
| AB1 | + | EQ 20MG BASE | N021860 | 003 | May 19, 2006 | Jan | CAHN |
| <u>FLURANDRENOLIDE</u> | | | | | | | |
| CREAM; TOPICAL | | | | | | | |
| CORDRAN SP | | | | | | | |
| AT | + | AQUA PHARMS | 0.05% | N012806 | 002 | | Mar CFTG |
| FLURANDRENOLIDE | | | | | | | |
| AT | | TELIGENT PHARMA INC | 0.05% | A205342 | 001 | Apr 13, 2016 | Mar NEWA |
| TAPE; TOPICAL | | | | | | | |
| CORDRAN | | | | | | | |
| >D> | + | ACTAVIS LABS UT INC | 0.004MG/SQ CM | N016455 | 001 | | Apr CAHN |
| >A> | + | ALLERGAN SALES LLC | 0.004MG/SQ CM | N016455 | 001 | | Apr CAHN |
| <u>FLURANDRENOLIDE; NEOMYCIN SULFATE</u> | | | | | | | |
| CREAM; TOPICAL | | | | | | | |
| CORDRAN N | | | | | | | |
| | @ | LILLY | 0.05%;EQ 3.5MG BASE/GM | N050346 | 001 | | Mar CMS1 |
| OINTMENT; TOPICAL | | | | | | | |
| CORDRAN N | | | | | | | |
| | @ | LILLY | 0.05%;EQ 3.5MG BASE/GM | N050345 | 001 | | Mar CMS1 |
| <u>FLURAZEPAM HYDROCHLORIDE</u> | | | | | | | |
| CAPSULE; ORAL | | | | | | | |
| FLURAZEPAM HYDROCHLORIDE | | | | | | | |
| | @ | AUROLIFE PHARMA LLC | 15MG | A071716 | 001 | Jul 31, 1991 | Feb CAHN |
| | @ | | 30MG | A071717 | 001 | Jul 31, 1991 | Feb CAHN |
| | @ | SUN PHARM INDS | 15MG | A070454 | 001 | Aug 04, 1986 | Mar CAHN |
| | @ | | 30MG | A070455 | 001 | Aug 04, 1986 | Mar CAHN |
| <u>FLURBIPROFEN</u> | | | | | | | |
| TABLET; ORAL | | | | | | | |
| FLURBIPROFEN | | | | | | | |
| | @ | AUROLIFE PHARMA LLC | 50MG | A074448 | 001 | Jul 28, 1995 | Feb CAHN |
| | @ | | 100MG | A074448 | 002 | Jul 28, 1995 | Feb CAHN |
| <u>FLUTICASONE FUROATE</u> | | | | | | | |
| POWDER; INHALATION | | | | | | | |
| ARNUITY ELLIPTA | | | | | | | |
| + | | GLAXOSMITHKLINE | 0.1MG/INH | N205625 | 001 | Aug 20, 2014 | Mar CRLD |
| <u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE</u> | | | | | | | |
| POWDER; INHALATION | | | | | | | |
| BREQ ELLIPTA | | | | | | | |
| + | | GLAXO GRP LTD | 0.2MG/INH;EQ 0.025MG BASE/INH | N204275 | 002 | Apr 30, 2015 | Mar CRLD |
| <u>FLUVOXAMINE MALEATE</u> | | | | | | | |
| TABLET; ORAL | | | | | | | |
| FLUVOXAMINE MALEATE | | | | | | | |
| | @ | NOSTRUM LABS INC | 25MG | A075900 | 001 | Feb 23, 2006 | Feb CAHN |
| | @ | | 50MG | A075900 | 002 | Feb 23, 2006 | Feb CAHN |
| | @ | | 100MG | A075900 | 003 | Feb 23, 2006 | Feb CAHN |
| | @ | SUN PHARM INDS | 25MG | A076125 | 001 | Apr 29, 2002 | Mar CAHN |
| | @ | | 50MG | A076125 | 002 | Apr 29, 2002 | Mar CAHN |
| | @ | | 100MG | A076125 | 003 | Apr 29, 2002 | Mar CAHN |
| <u>FOLIC ACID</u> | | | | | | | |
| TABLET; ORAL | | | | | | | |
| FOLIC ACID | | | | | | | |
| | @ | SUN PHARM INDS | 1MG | A040582 | 001 | Jul 18, 2005 | Mar CAHN |
| >A> | <u>FORMOTEROL FUMARATE; GLYCOPYRROLATE</u> | | | | | | |
| >A> | AEROSOL, METERED; INHALATION | | | | | | |
| >A> | BEVESPI AEROSPHERE | | | | | | |
| >A> | + | PEARL THERAPS INC | 0.0048MG/INH;0.0090MG/INH | N208294 | 001 | Apr 25, 2016 | Apr NEWA |

FOSAMPRENAVIR CALCIUM

TABLET;ORAL

| | | | | | | | | |
|--------|-----------------------|---------------|---------|-----|--------------|-----|------|--|
| >A> | FOSAMPRENAVIR CALCIUM | | | | | | | |
| >A> AB | MYLAN PHARMS INC | EQ 700MG BASE | A204060 | 001 | Apr 15, 2016 | Apr | NEWA | |
| | LEXIVA | | | | | | | |
| >D> | + VIIV HLTHCARE | EQ 700MG BASE | N021548 | 001 | Oct 20, 2003 | Apr | CFTG | |
| >A> AB | + | EQ 700MG BASE | N021548 | 001 | Oct 20, 2003 | Apr | CFTG | |

FOSINOPRIL SODIUM

TABLET;ORAL

FOSINOPRIL SODIUM

| | | | | | | | | |
|---|---------------------|------|---------|-----|--------------|-----|------|--|
| @ | ACTAVIS LABS FL INC | 10MG | A076620 | 001 | Oct 15, 2004 | Jan | DISC | |
| @ | | 20MG | A076620 | 002 | Oct 15, 2004 | Jan | DISC | |
| @ | | 40MG | A076620 | 003 | Oct 15, 2004 | Jan | DISC | |

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

| | | | | | | | | |
|---|---------------------|-------------|---------|-----|--------------|-----|------|--|
| @ | ACTAVIS LABS FL INC | 10MG;12.5MG | A076608 | 001 | Dec 03, 2004 | Jan | DISC | |
| @ | | 20MG;12.5MG | A076608 | 002 | Dec 03, 2004 | Jan | DISC | |
| @ | SUN PHARM INDS LTD | 10MG;12.5MG | A076739 | 001 | Dec 17, 2004 | Feb | DISC | |
| @ | | 20MG;12.5MG | A076739 | 002 | Dec 17, 2004 | Feb | DISC | |

FROVATRIPTAN SUCCINATE

TABLET;ORAL

FROVATRIPTAN SUCCINATE

| | | | | | | | | |
|----|---------------------|---------------|---------|-----|--------------|-----|------|--|
| AB | GLENMARK PHARMS LTD | EQ 2.5MG BASE | A204730 | 001 | Mar 11, 2016 | Feb | NEWA | |
|----|---------------------|---------------|---------|-----|--------------|-----|------|--|

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

| | | | | | | | | |
|---|--------------------|---------|---------|-----|--------------|-----|------|--|
| @ | EUROHLTH INTL SARL | 10MG/ML | A071439 | 001 | Sep 14, 1990 | Jan | CAHN | |
| @ | LUITPOLD | 10MG/ML | N018579 | 001 | Nov 30, 1983 | Feb | DISC | |

TABLET;ORAL

FUROSEMIDE

| | | | | | | | | |
|----|-------------------|------|---------|-----|--------------|-----|------|--|
| @ | SUN PHARM INDS | 20MG | A070043 | 001 | Sep 26, 1985 | Mar | CAHN | |
| @ | | 80MG | A070100 | 001 | Jan 26, 1988 | Mar | CAHN | |
| | LASIX | | | | | | | |
| AB | US PHARM HOLDINGS | 20MG | N016273 | 002 | | Jan | CAHN | |
| AB | | 40MG | N016273 | 001 | | Jan | CAHN | |
| AB | + | 80MG | N016273 | 003 | | Jan | CAHN | |

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

| | | | | | | | | |
|----|--------------------|-------|---------|-----|--------------|-----|------|--|
| AB | SCIEGEN PHARMS INC | 100MG | A204989 | 001 | Feb 18, 2016 | Feb | NEWA | |
| AB | | 300MG | A204989 | 002 | Feb 18, 2016 | Feb | NEWA | |
| AB | | 400MG | A204989 | 003 | Feb 18, 2016 | Feb | NEWA | |
| @ | SUN PHARM INDS | 100MG | A076537 | 001 | Jun 30, 2005 | Mar | CAHN | |
| @ | | 300MG | A076537 | 002 | Jun 30, 2005 | Mar | CAHN | |
| @ | | 400MG | A076537 | 003 | Jun 30, 2005 | Mar | CAHN | |

SOLUTION;ORAL

GABAPENTIN

| | | | | | | | | |
|----|-----------------|-----------|---------|-----|--------------|-----|------|--|
| AA | TRIS PHARMA INC | 250MG/5ML | A091286 | 001 | Mar 14, 2016 | Feb | NEWA | |
|----|-----------------|-----------|---------|-----|--------------|-----|------|--|

TABLET;ORAL

GABAPENTIN

| | | | | | | | | |
|----|--------------------|-------|---------|-----|--------------|-----|------|--|
| AB | SCIEGEN PHARMS INC | 600MG | A205101 | 001 | Feb 04, 2016 | Jan | NEWA | |
| AB | | 800MG | A205101 | 002 | Feb 04, 2016 | Jan | NEWA | |

GALANTAMINE HYDROBROMIDE

CAPSULE, EXTENDED RELEASE;ORAL

GALANTAMINE HYDROBROMIDE

| | | | | | | | | |
|---|------------|--------------|---------|-----|--------------|-----|------|--|
| @ | IMPAX LABS | EQ 8MG BASE | A078484 | 001 | May 27, 2009 | Feb | DISC | |
| @ | | EQ 16MG BASE | A078484 | 002 | May 27, 2009 | Feb | DISC | |
| @ | | EQ 24MG BASE | A078484 | 003 | May 27, 2009 | Feb | DISC | |

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

| | | | | | | | |
|----|---------------|------------------------|---------|-----|--------------|-----|------|
| AP | ACTAVIS INC | 200MG/5.26ML (38MG/ML) | A204549 | 001 | Apr 11, 2016 | Mar | NEWA |
| AP | | 1GM/26.3ML (38MG/ML) | A204549 | 002 | Apr 11, 2016 | Mar | NEWA |
| AP | | 2GM/52.6ML (38MG/ML) | A204549 | 003 | Apr 11, 2016 | Mar | NEWA |
| AP | + HOSPIRA INC | 200MG/5.26ML (38MG/ML) | N200795 | 001 | Aug 04, 2011 | Mar | CFTG |
| AP | + | 1GM/26.3ML (38MG/ML) | N200795 | 002 | Aug 04, 2011 | Mar | CFTG |
| AP | + | 2GM/52.6ML (38MG/ML) | N200795 | 003 | Aug 04, 2011 | Mar | CFTG |

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

@ ACTAVIS LABS FL INC 1MG
 @ 2MG
 @ 4MG

A076995 001 Apr 27, 2010 Jan DISC
 A076995 002 Apr 27, 2010 Jan DISC
 A076995 003 Apr 27, 2010 Jan DISC

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

ROSIGLITAZONE MALEATE AND GLIMEPIRIDE

+ TEVA PHARMS USA 1MG; 4MG
 2MG; 4MG
 2MG; 8MG
 4MG; 4MG
 4MG; 8MG

A078709 001 Apr 01, 2016 Mar NEWA
 A078709 002 Apr 01, 2016 Mar NEWA
 A078709 004 Apr 01, 2016 Mar NEWA
 A078709 003 Apr 01, 2016 Mar NEWA
 A078709 005 Apr 01, 2016 Mar NEWA

GLYBURIDE

TABLET; ORAL

GLYBURIDE

>A> AB1 PHARMADAX INC 1.25MG
 >A> AB1 2.5MG
 >A> AB1 5MG
 >A> AB1 ZYDUS PHARMS USA INC 1.25mg
 >A> AB1 2.5mg
 >A> AB1 5MG

A203581 001 Apr 14, 2016 Apr NEWA
 A203581 002 Apr 14, 2016 Apr NEWA
 A203581 003 Apr 14, 2016 Apr NEWA
 A206749 001 May 10, 2016 Apr NEWA
 A206749 002 May 10, 2016 Apr NEWA
 A206749 003 May 10, 2016 Apr NEWA

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

@ COREPHARMA 1.25MG; 250MG
 @ 2.5MG; 500MG
 @ 5MG; 500MG

AB ZYDUS PHARMS USA INC 1.25MG; 250MG
 AB 2.5MG; 500MG
 AB 5MG; 500MG

A076731 001 Nov 19, 2004 Jan DISC
 A076731 002 Nov 19, 2004 Jan DISC
 A076731 003 Nov 19, 2004 Jan DISC
 A206748 001 Feb 29, 2016 Feb NEWA
 A206748 002 Feb 29, 2016 Feb NEWA
 A206748 003 Feb 29, 2016 Feb NEWA

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

AP + HIKMA FARMACEUTICA 0.2MG/ML
 ROBINUL
 @ EUROHLTH INTL SARL 0.2MG/ML

A090963 001 Sep 21, 2011 Feb CRDL
 N017558 001 Feb DISC

TABLET; ORAL

GLYCOPYRROLATE

AA RISING PHARMS INC 1MG
 AA 2MG
 ROBINUL
 AA + CASPER PHARMA LLC 1MG
 ROBINUL FORTE
 AA + CASPER PHARMA LLC 2MG

A040821 001 Dec 29, 2008 Jan CAHN
 A040821 002 Dec 29, 2008 Jan CAHN
 N012827 001 Jan CAHN
 N012827 002 Jan CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP BIONPHARMA INC EQ 0.1MG BASE/ML (EQ 0.1MG
 BASE/ML)
 AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML)
 AP HIKMA FARMACEUTICA EQ 1MG BASE/ML (EQ 1MG BASE/ML)
 AP EQ 4MG BASE/4ML (EQ 1MG BASE/ML)
 GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE
 AP BIONPHARMA INC EQ 1MG BASE/ML (EQ 1MG BASE/ML)

A078863 001 Jun 30, 2008 Jan CAHN
 A078880 001 Jun 30, 2008 Jan CAHN
 A078629 001 Dec 23, 2009 Jan CMS1
 A078629 002 Dec 23, 2009 Jan CMS1
 A078863 002 Jun 30, 2008 Jan CAHN

TABLET;ORAL

GRANISETRON HYDROCHLORIDE

| | | | | | |
|--------------|-------------|---------|-----|--------------|----------|
| @ COREPHARMA | EQ 1MG BASE | A078260 | 001 | Dec 31, 2007 | Mar DISC |
|--------------|-------------|---------|-----|--------------|----------|

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYCOFENIX

| | | | | | | | |
|-----|---|----------------------|------------------------------|---------|-----|--------------|----------|
| >D> | + | MIKART INC | 200MG/5ML;2.5MG/5ML;30MG/5ML | N022279 | 001 | May 14, 2015 | Apr CAHN |
| >A> | + | MISSION PHARMACAL CO | 200MG/5ML;2.5MG/5ML;30MG/5ML | N022279 | 001 | May 14, 2015 | Apr CAHN |

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

| | | | | | |
|------------------|-------------|---------|-----|--------------|----------|
| @ IMPAX LABS INC | EQ 1MG BASE | A202238 | 001 | Oct 20, 2015 | Mar DISC |
| @ | EQ 2MG BASE | A202238 | 002 | Oct 20, 2015 | Mar DISC |
| @ | EQ 3MG BASE | A202238 | 003 | Oct 20, 2015 | Mar DISC |
| @ | EQ 4MG BASE | A202238 | 004 | Oct 20, 2015 | Mar DISC |

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

| | | | | | |
|--------------------|-------|---------|-----|--------------|----------|
| @ CYCLE PHARMS LTD | 2MG | A071130 | 001 | Feb 17, 1987 | Jan CAHN |
| @ SUN PHARM INDS | 2MG | A071172 | 001 | Jan 02, 1987 | Mar CAHN |
| @ | 5MG | A071212 | 001 | Jan 07, 1988 | Mar CAHN |
| @ | 10MG | A071173 | 001 | Jan 07, 1988 | Mar CAHN |
| @ | 20MG | A071177 | 001 | Jan 07, 1988 | Mar CAHN |
| @ VINTAGE | 0.5MG | A071235 | 002 | Nov 03, 1986 | Jan CMS1 |
| @ | 1MG | A071235 | 003 | Nov 03, 1986 | Jan CMS1 |
| @ | 5MG | A071235 | 004 | Nov 03, 1986 | Jan CMS1 |
| @ | 10MG | A071235 | 005 | Jul 20, 1987 | Jan CMS1 |

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

TABLET;ORAL

HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

| | | | | | |
|---------------------|-----------|---------|-----|--------------|----------|
| @ ACTAVIS ELIZABETH | 1.5MG;5MG | A040295 | 001 | Dec 01, 2000 | Jan CMS1 |
|---------------------|-----------|---------|-----|--------------|----------|

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDRALAZINE HYDROCHLORIDE

| | | | | | | | |
|--------|--|---------------------|---------|---------|-----|--------------|----------|
| >A> AP | | MYLAN INSTITUTIONAL | 20MG/ML | A204680 | 001 | Apr 28, 2016 | Apr NEWA |
|--------|--|---------------------|---------|---------|-----|--------------|----------|

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

| | | | | | | | |
|--------|--|------------------|-------|---------|-----|--------------|----------|
| >D> AA | | ACTAVIS GRP PTC | 10MG | A091679 | 001 | Mar 04, 2013 | Apr DISC |
| >A> | | @ | 10MG | A091679 | 001 | Mar 04, 2013 | Apr DISC |
| >D> AA | | | 25MG | A091679 | 002 | Mar 04, 2013 | Apr DISC |
| >A> | | @ | 25MG | A091679 | 002 | Mar 04, 2013 | Apr DISC |
| >D> AA | | | 50MG | A091679 | 003 | Mar 04, 2013 | Apr DISC |
| >A> | | @ | 50MG | A091679 | 003 | Mar 04, 2013 | Apr DISC |
| >D> AA | | | 100MG | A091679 | 004 | Mar 04, 2013 | Apr DISC |
| >A> | | @ | 100MG | A091679 | 004 | Mar 04, 2013 | Apr DISC |
| | | @ SUN PHARM INDS | 10MG | A089359 | 001 | Jul 25, 1986 | Mar CAHN |
| | | @ | 25MG | A089258 | 001 | May 05, 1986 | Mar CAHN |
| | | @ | 50MG | A089259 | 001 | May 05, 1986 | Mar CAHN |

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

HYDRALAZINE AND HYDROCHLOROTHIAZIDE

| | | | | | |
|---------------|-----------|---------|-----|--|----------|
| @ WATSON LABS | 25MG;15MG | A085827 | 001 | | Feb CMS1 |
|---------------|-----------|---------|-----|--|----------|

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET;ORAL

RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

| | | | | | |
|------------------|-----------------|---------|-----|--------------|----------|
| @ SUN PHARM INDS | 25MG;15MG;0.1MG | A088570 | 001 | Apr 10, 1984 | Mar CAHN |
|------------------|-----------------|---------|-----|--------------|----------|

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

MICROZIDE

| | | | | | | | |
|--------|---|---------------------|--------|---------|-----|--------------|----------|
| >D> AB | + | ACTAVIS LABS UT INC | 12.5MG | N020504 | 001 | Dec 27, 1996 | Apr CAHN |
| >A> AB | + | ALLERGAN SALES LLC | 12.5MG | N020504 | 001 | Dec 27, 1996 | Apr CAHN |

TABLET;ORAL

HYDROCHLOROTHIAZIDE

| | | | | | | |
|-----------------------|-------|---------|-----|--|-----|------|
| @ AUROLIFE PHARMA LLC | 25MG | A083899 | 001 | | Feb | CAHN |
| @ | 50MG | A085219 | 001 | | Feb | CAHN |
| @ SUN PHARM INDS | 25MG | A083972 | 001 | | Mar | CAHN |
| @ | 50MG | A083972 | 002 | | Mar | CAHN |
| @ | 100MG | A083972 | 003 | | Mar | CAHN |
| ORETIC | | | | | | |
| @ ABBVIE | 50MG | N011971 | 002 | | Jan | DISC |

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET;ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

| | | | | | | | |
|----|----------------------|--------------|---------|-----|--------------|-----|------|
| AB | AUROBINDO PHARMA LTD | 25MG;300MG | A203630 | 003 | Mar 31, 2016 | Mar | NEWA |
| AB | INTL SPECLT CHEMS | 12.5MG;150MG | A203036 | 001 | Jan 15, 2016 | Jan | NEWA |
| AB | | 12.5MG;300MG | A203036 | 002 | Jan 15, 2016 | Jan | NEWA |
| AB | | 25MG;300MG | A203036 | 003 | Jan 15, 2016 | Mar | CTEC |
| | | 25MG;300MG | A203036 | 003 | Jan 15, 2016 | Jan | NEWA |

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

ZESTORETIC

| | | | | | | | |
|----|---------------|-------------|---------|-----|--------------|-----|------|
| AB | ALVOGEN MALTA | 12.5MG;10MG | N019888 | 003 | Nov 18, 1993 | Jan | CAHN |
| AB | + | 12.5MG;20MG | N019888 | 001 | Sep 20, 1990 | Jan | CAHN |
| AB | + | 25MG;20MG | N019888 | 002 | Jul 20, 1989 | Jan | CAHN |

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET;ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

| | | | | | | | |
|----|----------------|-----------|---------|-----|--------------|-----|------|
| AB | SUN PHARM INDS | 25MG;25MG | A089534 | 001 | Jul 02, 1987 | Mar | CAHN |
|----|----------------|-----------|---------|-----|--------------|-----|------|

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

| | | | | | | | |
|----|--------------|--------------|---------|-----|--------------|-----|------|
| AB | PRINSTON INC | 12.5MG;80MG | A206083 | 001 | Feb 08, 2016 | Jan | NEWA |
| AB | | 12.5MG;160MG | A206083 | 002 | Feb 08, 2016 | Jan | NEWA |
| AB | | 12.5MG;320MG | A206083 | 003 | Feb 08, 2016 | Jan | NEWA |
| AB | | 25MG;160MG | A206083 | 004 | Feb 08, 2016 | Jan | NEWA |
| AB | | 25MG;320MG | A206083 | 005 | Feb 08, 2016 | Jan | NEWA |

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET;ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

| | | | | | | |
|-----------------------|-----------|---------|-----|--------------|-----|------|
| @ ACTAVIS LABS FL INC | 5MG;200MG | A077454 | 001 | Jun 23, 2010 | Jan | DISC |
|-----------------------|-----------|---------|-----|--------------|-----|------|

HYDROCORTISONE

TABLET;ORAL

HYDROCORTISONE

| | | | | | | | | |
|-----|----|--------------------|------|---------|-----|--------------|-----|------|
| >A> | AB | PHARMACEUTICS INTL | 5MG | A207029 | 001 | Apr 26, 2016 | Apr | NEWA |
| >A> | AB | | 10MG | A207029 | 002 | Apr 26, 2016 | Apr | NEWA |
| >A> | AB | | 20MG | A207029 | 003 | Apr 26, 2016 | Apr | NEWA |

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS;OTIC

PEDIOTIC

| | | | | | | |
|------------------|-------------------------------------|---------|-----|--------------|-----|------|
| @ MONARCH PHARMS | 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML | A062822 | 001 | Sep 29, 1987 | Jan | DISC |
|------------------|-------------------------------------|---------|-----|--------------|-----|------|

HYDROXOCOBALAMIN

INJECTABLE;INJECTION

CYANOKIT

| | | | | | | |
|-----------|----------------------|---------|-----|--------------|-----|------|
| @ SERB SA | 2.5GM/VIAL (5GM/KIT) | N022041 | 002 | Dec 15, 2006 | Jan | CAHN |
| + | 5GM/VIAL (5GM/KIT) | N022041 | 001 | Apr 08, 2011 | Jan | CAHN |

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL

HYDROXYCHLOROQUINE SULFATE

| | | | | | | | |
|----|-------------|-------|---------|-----|--------------|-----|------|
| AB | WATSON LABS | 200MG | A040133 | 001 | Nov 30, 1995 | Feb | CMFD |
|----|-------------|-------|---------|-----|--------------|-----|------|

HYDROXYPROGESTERONE CAPROATE

INJECTABLE; INJECTION

HYDROXYPROGESTERONE CAPROATE

| | | | | | | | |
|---|-------------------------|---------------------|---------|-----|--------------|-----|------|
| + | ASPEN GLOBAL INC | 250MG/ML | A200271 | 001 | Aug 24, 2015 | Jan | CAHN |
| | SOLUTION; INTRAMUSCULAR | | | | | | |
| | MAKENA | | | | | | |
| + | LUMARA HEALTH INC | 250MG/ML (250MG/ML) | N021945 | 002 | Feb 19, 2016 | Feb | NEWA |

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

| | | | | | | | |
|---|---------------------|-------|---------|-----|--------------|-----|------|
| @ | AUROLIFE PHARMA LLC | 10MG | A087869 | 001 | Dec 20, 1982 | Feb | CAHN |
| @ | | 25MG | A087870 | 001 | Dec 20, 1982 | Feb | CAHN |
| @ | | 50MG | A087871 | 001 | Dec 20, 1982 | Feb | CAHN |
| @ | SUN PHARM INDS | 10MG | A089381 | 001 | May 19, 1986 | Mar | CAHN |
| @ | | 25MG | A089382 | 001 | May 19, 1986 | Mar | CAHN |
| @ | | 50MG | A089383 | 001 | May 19, 1986 | Mar | CAHN |
| @ | | 100MG | A087862 | 001 | Apr 18, 1983 | Mar | CAHN |

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS

IBANDRONATE SODIUM

| | | | | | | | |
|----|----------------------|-----------------|---------|-----|--------------|-----|------|
| AP | ACCORD HLTHCARE | EQ 3MG BASE/3ML | A206058 | 001 | Feb 05, 2016 | Jan | NEWA |
| | TABLET; ORAL | | | | | | |
| | IBANDRONATE SODIUM | | | | | | |
| AB | AUROBINDO PHARMA LTD | EQ 150MG BASE | A204502 | 001 | Mar 11, 2016 | Feb | NEWA |
| AB | SUN PHARM INDS | EQ 150MG BASE | A078996 | 001 | Aug 15, 2012 | Mar | CAHN |

IBUPROFEN

TABLET; ORAL

IBUPROFEN

| | | | | | | | |
|---|---------------------|-------|---------|-----|--------------|-----|------|
| @ | AUROLIFE PHARMA LLC | 300MG | A070734 | 001 | Jun 12, 1986 | Feb | CAHN |
| @ | | 400MG | A070735 | 001 | Jun 12, 1986 | Feb | CAHN |
| @ | | 600MG | A070736 | 001 | Jun 12, 1986 | Feb | CAHN |
| @ | | 800MG | A071938 | 001 | Jan 14, 1988 | Mar | CAHN |
| @ | SUN PHARM INDS | 400MG | A070079 | 001 | Jul 24, 1985 | Mar | CAHN |
| @ | | 600MG | A070080 | 001 | Jul 24, 1985 | Mar | CAHN |
| @ | | 800MG | A071448 | 001 | Feb 18, 1987 | Mar | CAHN |

IBUPROFEN LYISINE

INJECTABLE; INTRAVENOUS

IBUPROFEN LYISINE

| | | | | | | | |
|----|----------------------|------------------------------------|---------|-----|--------------|-----|------|
| AP | EXELA PHARMA SCIENCE | EQ 20MG BASE/2ML (EQ 10MG BASE/ML) | A202402 | 001 | Mar 30, 2016 | Mar | NEWA |
| | NEOPROFEN | | | | | | |
| AP | + RECORDATI RARE | EQ 20MG BASE/2ML (EQ 10MG BASE/ML) | N021903 | 001 | Apr 13, 2006 | Mar | CFTG |

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

| | | | | | | | |
|----|----------------|------|---------|-----|--------------|-----|------|
| AB | SUN PHARM INDS | 10MG | A081048 | 001 | Jun 05, 1990 | Mar | CAHN |
| AB | | 25MG | A081049 | 001 | Jun 05, 1990 | Mar | CAHN |
| AB | | 50MG | A081050 | 001 | Jun 05, 1990 | Mar | CAHN |

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

| | | | | | | | |
|----|--------------------|--------------|---------|-----|--------------|-----|------|
| AB | + ROXANE | EQ 75MG HCL | A091099 | 001 | Apr 16, 2010 | Feb | CRLD |
| | TOFRANIL-PM | | | | | | |
| | @ MALLINCKRODT INC | EQ 75MG HCL | N017090 | 001 | | Feb | DISC |
| | @ | EQ 100MG HCL | N017090 | 004 | | Feb | DISC |
| | @ | EQ 125MG HCL | N017090 | 003 | | Feb | DISC |
| | @ | EQ 150MG HCL | N017090 | 002 | | Feb | DISC |

INDIUM IN-111 CHLORIDE

INJECTABLE; INJECTION

INDIUM IN 111 CHLORIDE

| | | | | | | | |
|---|---------------------|------------|---------|-----|--------------|-----|------|
| + | MALLINKRODT NUCLEAR | 5mCi/0.5ML | N019841 | 001 | Sep 27, 1994 | Jan | CAHN |
|---|---------------------|------------|---------|-----|--------------|-----|------|

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION
INDIUM IN 111 OXYQUINOLINE

+ GE HEALTHCARE 1mCi/ML N019044 001 Dec 24, 1985 Mar CMS1

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION
OCTREOSCAN

+ MALLINKRODT NUCLEAR 3mCi/ML N020314 001 Jun 02, 1994 Jan CAHN

INDOCYANINE GREEN

INJECTABLE; INJECTION
INDOCYANINE GREEN

AP DIAGNOSTIC GREEN 25MG/VIAL A040811 001 Nov 21, 2007 Jan CAHN

INDOMETHACIN SODIUM

INJECTABLE; INJECTION
INDOMETHACIN SODIUM

>A> AP HOSPIRA INC EQ 1MG BASE/VIAL A204118 001 Apr 19, 2016 Apr NEWA

INSULIN DETEMIR RECOMBINANT

INJECTABLE; SUBCUTANEOUS
LEVEMIR FLEXPEN

@ NOVO NORDISK INC 300 UNITS/3ML (100 UNITS/ML) N021536 002 Jun 16, 2005 Feb DISC

INSULIN HUMAN

SOLUTION; SUBCUTANEOUS
HUMULIN R

+ LILLY 10000 UNITS/20ML (500 UNITS/ML) N018780 004 Mar 31, 1994 Jan CAIN

+ HUMULIN R KWIKPEN 1500 UNITS/3ML (500 UNITS/ML) N018780 002 Dec 29, 2015 Jan NEWA

INSULIN RECOMBINANT HUMAN

POWDER; INHALATION
AFREZZA

+ MANNKIND 4 UNITS/INH N022472 001 Jun 27, 2014 Mar CAHN

+ 8 UNITS/INH N022472 002 Jun 27, 2014 Mar CAHN

+ 12 UNITS/INH N022472 003 Apr 17, 2015 Mar CAHN

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION
CAMPTOSAR

>D> + PFIZER INC 300MG/15ML (20MG/ML) N020571 003 Aug 05, 2010 Apr CTEC

>A> AP + 300MG/15ML (20MG/ML) N020571 003 Aug 05, 2010 Apr CTEC

IRINOTECAN HYDROCHLORIDE

>A> AP QILU PHARM CO LTD 40MG/2ML (20MG/ML) A203380 001 May 03, 2016 Apr NEWA

>A> AP 100MG/5ML (20MG/ML) A203380 002 May 03, 2016 Apr NEWA

>A> AP 300MG/15ML (20MG/ML) A203380 003 May 03, 2016 Apr NEWA

AP SANDOZ INC 40MG/2ML (20MG/ML) A090137 001 Nov 12, 2009 Jan CAHN

AP 100MG/5ML (20MG/ML) A090137 002 Nov 12, 2009 Jan CAHN

IRON DEXTRAN

INJECTABLE; INJECTION
INFED

>D> BP + ACTAVIS LABS UT INC EQ 50MG IRON/ML N017441 001 Apr CAHN

>A> BP + ALLERGAN SALES LLC EQ 50MG IRON/ML N017441 001 Apr CAHN

ISONIAZID

TABLET; ORAL
ISONIAZID

@ SUN PHARM INDS 100MG A080136 001 Mar CAHN

@ 300MG A083633 001 Mar CAHN

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL
DILATRATE-SR

+ AUXILIUM PHARMS INC 40MG N019790 001 Sep 02, 1988 Mar CAHN

TABLET; ORAL

ISOSORBIDE DINITRATE

@ SUN PHARM INDS 5MG A086166 002 Sep 19, 1986 Mar CAHN

TABLET, EXTENDED RELEASE;ORAL
ISOSORBIDE DINITRATE

@ COREPHARMA 40MG A040723 001 Mar 17, 2008 Mar DISC
+ SUN PHARM INDS INC 40MG A040009 001 Dec 30, 1998 Mar CTEC

ISOSULFAN BLUE

INJECTABLE;INJECTION
ISOSULFAN BLUE

AP AUROBINDO PHARMA LTD 1% A206831 001 Feb 02, 2016 Jan NEWA
AP + MYLAN INSTITUTIONAL 1% A090874 001 Jul 20, 2010 Jan CTEC

ITRACONAZOLE

SOLUTION;ORAL

>D> ITRACONAZOLE
>D> AA AMNEAL PHARMS 10MG/ML A205573 001 Oct 30, 2015 Apr DISC
>A> @ 10MG/ML A205573 001 Oct 30, 2015 Apr DISC
SPORANOX
>D> AA + JANSSEN PHARMS 10MG/ML N020657 001 Feb 21, 1997 Apr CTEC
>A> + 10MG/ML N020657 001 Feb 21, 1997 Apr CTEC

KETOCONAZOLE

TABLET;ORAL

KETOCONAZOLE
@ SUN PHARM INDS 200MG A075314 001 Jun 15, 1999 Jan CAHN

KETOPROFEN

CAPSULE;ORAL

KETOPROFEN
@ AUROLIFE PHARMA LLC 50MG A074024 001 Dec 29, 1995 Feb CAHN
@ 75MG A074024 002 Dec 29, 1995 Feb CAHN

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION

KETOROLAC TROMETHAMINE

>D> @ BEDFORD 15MG/ML A075222 001 Apr 26, 1999 Apr CAHN
>D> @ 30MG/ML A075222 002 Apr 26, 1999 Apr CAHN
>A> @ EUROHLTH INTL SARL 15MG/ML A075222 001 Apr 26, 1999 Apr CAHN
>A> @ 30MG/ML A075222 002 Apr 26, 1999 Apr CAHN

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION

LABETALOL HYDROCHLORIDE

AP SAGENT STRIDES 5MG/ML A079134 001 Feb 03, 2010 Jan CTNA
TRANDATE
@ SEBELA IRELAND LTD 5MG/ML N019425 001 Dec 31, 1985 Jan CAHN

TABLET;ORAL

LABETALOL HYDROCHLORIDE

AB NOSTRUM LABS INC 100MG A075215 001 Jul 29, 1999 Jan CAHN
AB 200MG A075215 002 Jul 29, 1999 Jan CAHN
AB 300MG A075215 003 Jul 29, 1999 Jan CAHN

LACOSAMIDE

SOLUTION;ORAL

LACOSAMIDE

>A> AA AMNEAL PHARMS 10MG/ML A204839 001 Apr 28, 2016 Apr NEWA
VIMPAT
>D> + UCB INC 10MG/ML N022255 001 Apr 20, 2010 Apr CFTG
>A> AA + 10MG/ML N022255 001 Apr 20, 2010 Apr CFTG

TABLET;ORAL

LACOSAMIDE

>A> AB ACTAVIS LABS FL INC 50MG A204855 001 Apr 28, 2016 Apr NEWA
>A> AB 100MG A204855 002 Apr 28, 2016 Apr NEWA
>A> AB 150MG A204855 003 Apr 28, 2016 Apr NEWA
>A> AB 200MG A204855 004 Apr 28, 2016 Apr NEWA
>A> AB ALEMBIC PHARMS LTD 50MG A204974 001 Apr 28, 2016 Apr NEWA
>A> AB 100MG A204974 002 Apr 28, 2016 Apr NEWA
>A> AB 150MG A204974 003 Apr 28, 2016 Apr NEWA
>A> AB 200MG A204974 004 Apr 28, 2016 Apr NEWA
>A> AB AUROBINDO PHARMA LTD 50MG A204994 001 Apr 28, 2016 Apr NEWA
>A> AB 100MG A204994 002 Apr 28, 2016 Apr NEWA
>A> AB 150MG A204994 003 Apr 28, 2016 Apr NEWA
>A> AB 200MG A204994 004 Apr 28, 2016 Apr NEWA

TABLET;ORAL

LACOSAMIDE

| | | | | | | | | |
|---------------|----|-------------------|-------|---------|-----|--------------|-----|------|
| >A> | AB | MSN LABS PVT LTD | 50MG | A204921 | 001 | Apr 28, 2016 | Apr | NEWA |
| >A> | AB | | 100MG | A204921 | 002 | Apr 28, 2016 | Apr | NEWA |
| >A> | AB | | 150MG | A204921 | 003 | Apr 28, 2016 | Apr | NEWA |
| >A> | AB | | 200MG | A204921 | 004 | Apr 28, 2016 | Apr | NEWA |
| >A> | AB | MYLAN PHARMS INC | 50MG | A205026 | 001 | Apr 28, 2016 | Apr | NEWA |
| >A> | AB | | 100MG | A205026 | 002 | Apr 28, 2016 | Apr | NEWA |
| >A> | AB | | 150MG | A205026 | 003 | Apr 28, 2016 | Apr | NEWA |
| >A> | AB | | 200MG | A205026 | 004 | Apr 28, 2016 | Apr | NEWA |
| >A> | AB | SUN PHARMA GLOBAL | 50MG | A205031 | 001 | Apr 28, 2016 | Apr | NEWA |
| >A> | AB | | 100MG | A205031 | 002 | Apr 28, 2016 | Apr | NEWA |
| >A> | AB | | 150MG | A205031 | 003 | Apr 28, 2016 | Apr | NEWA |
| >A> | AB | | 200MG | A205031 | 004 | Apr 28, 2016 | Apr | NEWA |
| <u>VIMPAT</u> | | | | | | | | |
| >D> | | UCB INC | 50MG | N022253 | 001 | Oct 28, 2008 | Apr | CFTG |
| >A> | AB | | 50MG | N022253 | 001 | Oct 28, 2008 | Apr | CFTG |
| >D> | | | 100MG | N022253 | 002 | Oct 28, 2008 | Apr | CFTG |
| >A> | AB | | 100MG | N022253 | 002 | Oct 28, 2008 | Apr | CFTG |
| >D> | | | 150MG | N022253 | 003 | Oct 28, 2008 | Apr | CFTG |
| >A> | AB | | 150MG | N022253 | 003 | Oct 28, 2008 | Apr | CFTG |
| >D> | | + | 200MG | N022253 | 004 | Oct 28, 2008 | Apr | CFTG |
| >A> | AB | + | 200MG | N022253 | 004 | Oct 28, 2008 | Apr | CFTG |

LAMIVUDINE

TABLET;ORAL

LAMIVUDINE

| | | | | | | | | |
|----|--|------------------|-------|---------|-----|--------------|-----|------|
| AB | | MYLAN PHARMS INC | 150MG | A204528 | 001 | Mar 04, 2016 | Feb | NEWA |
| AB | | | 300MG | A204528 | 002 | Mar 04, 2016 | Feb | NEWA |

LAMOTRIGINE

TABLET, EXTENDED RELEASE;ORAL

LAMICTAL XR

| | | | | | | | | |
|----|---|---------------------|-------|---------|-----|--------------|-----|------|
| AB | + | GLAXOSMITHKLINE LLC | 200MG | N022115 | 004 | May 29, 2009 | Jan | CRLD |
|----|---|---------------------|-------|---------|-----|--------------|-----|------|

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC

LATANOPROST

| | | | | | | | | |
|-----|----|---------|--------|---------|-----|--------------|-----|------|
| >A> | AT | FDC LTD | 0.005% | A202442 | 001 | Apr 22, 2016 | Apr | NEWA |
|-----|----|---------|--------|---------|-----|--------------|-----|------|

LETROZOLE

TABLET;ORAL

LETROZOLE

| | | | | | | | | |
|----|--|----------------------|-------|---------|-----|--------------|-----|------|
| AB | | KREMERS URBAN PHARMS | 2.5MG | A091098 | 001 | Jun 03, 2011 | Jan | CAHN |
|----|--|----------------------|-------|---------|-----|--------------|-----|------|

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION

LEVALBUTEROL HYDROCHLORIDE

| | | | | | | | | |
|----|--|---------------|-----------------|---------|-----|--------------|-----|------|
| AN | | RITEDOSE CORP | EQ 0.0103% BASE | A203653 | 001 | Mar 22, 2016 | Mar | NEWA |
| AN | | | EQ 0.021% BASE | A203653 | 002 | Mar 22, 2016 | Mar | NEWA |
| AN | | | EQ 0.042% BASE | A203653 | 003 | Mar 22, 2016 | Mar | NEWA |

LEVETIRACETAM

INJECTABLE;IV (INFUSION)

LEVETIRACETAM

| | | | | | | | | |
|----|--|----------------------|----------------------|---------|-----|--------------|-----|------|
| AP | | AUROBINDO PHARMA LTD | 500MG/5ML (100MG/ML) | A204312 | 001 | Feb 01, 2016 | Jan | NEWA |
|----|--|----------------------|----------------------|---------|-----|--------------|-----|------|

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

| | | | | | | | | |
|----|--|----------------------|-------|---------|-----|--------------|-----|------|
| AB | | INTELLIPHARMACEUTICS | 500MG | A204511 | 001 | Feb 23, 2016 | Feb | NEWA |
| AB | | | 750MG | A204511 | 002 | Feb 23, 2016 | Feb | NEWA |
| AB | | SUN PHARM INDS | 500MG | A091285 | 001 | Sep 12, 2011 | Mar | CAHN |
| AB | | | 750MG | A091285 | 002 | Sep 12, 2011 | Mar | CAHN |

TABLET, FOR SUSPENSION;ORAL

SPRITAM

| | | | | | | | | |
|--|--|-------------------|-------|---------|-----|--------------|-----|------|
| | | APRECIA PHARMS CO | 250MG | N207958 | 001 | Jul 31, 2015 | Feb | CDFR |
| | | | 500MG | N207958 | 002 | Jul 31, 2015 | Feb | CDFR |
| | | | 750MG | N207958 | 003 | Jul 31, 2015 | Feb | CDFR |
| | | + | 1GM | N207958 | 004 | Jul 31, 2015 | Mar | CRLD |
| | | | 1GM | N207958 | 004 | Jul 31, 2015 | Feb | CDFR |

LEVOFLOXACIN

INJECTABLE; INJECTION

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | | | | |
|----|----------------------|----------------------------|---------|-----|--------------|-----|------|
| AP | AUROBINDO PHARMA LTD | EQ 250MG/50ML (EQ 5MG/ML) | A206919 | 001 | Feb 10, 2016 | Jan | NEWA |
| AP | | EQ 500MG/100ML (EQ 5MG/ML) | A206919 | 002 | Feb 10, 2016 | Jan | NEWA |
| AP | | EQ 750MG/150ML (EQ 5MG/ML) | A206919 | 003 | Feb 10, 2016 | Jan | NEWA |

SOLUTION/DROPS; OPHTHALMIC

LEVOFLOXACIN

| | | | | | | | |
|----|---------------------|------|---------|-----|--------------|-----|------|
| AT | + RISING PHARMS INC | 0.5% | A077700 | 001 | Dec 20, 2010 | Jan | CAHN |
|----|---------------------|------|---------|-----|--------------|-----|------|

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

| | | | | | | | | |
|-----|----|----------------------|--------|---------|-----|--------------|-----|------|
| >D> | AB | PERRIGO R AND D | 0.75MG | A090740 | 001 | Dec 30, 2010 | Apr | CRLD |
| >A> | | + | 0.75MG | A090740 | 001 | Dec 30, 2010 | Apr | CRLD |
| >D> | AB | + WATSON LABS | 0.75MG | A078665 | 001 | Aug 28, 2009 | Apr | DISC |
| >A> | | @ | 0.75MG | A078665 | 001 | Aug 28, 2009 | Apr | DISC |
| >D> | | PLAN B | | | | | | |
| >D> | AB | + TEVA BRANDED PHARM | 0.75MG | N021045 | 002 | Aug 24, 2006 | Apr | DISC |
| >A> | | @ | 0.75MG | N021045 | 002 | Aug 24, 2006 | Apr | DISC |

LIDOCAINE

OINTMENT; TOPICAL

LIDOCAINE

| | | | | | | | |
|----|----------------------|----|---------|-----|--------------|-----|------|
| AT | TELISTENT PHARMA INC | 5% | A205318 | 001 | Feb 01, 2016 | Jan | NEWA |
|----|----------------------|----|---------|-----|--------------|-----|------|

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA 400MG/100ML

N018388 002

Feb DISC

LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER

@ HOSPIRA 800MG/100ML

N018388 003

Nov 05, 1982

Feb DISC

JELLY; TOPICAL

ANESTACON

@ BIONPHARMA INC

2%

A080429 001

Jan CAHN

LINEZOLID

SOLUTION; IV (INFUSION)

LINEZOLID

| | | | | | | | |
|----|--------------------|----------------------|---------|-----|--------------|-----|------|
| AP | FRESENIUS KABI USA | 600MG/300ML (2MG/ML) | A204764 | 001 | Mar 15, 2016 | Feb | NEWA |
|----|--------------------|----------------------|---------|-----|--------------|-----|------|

TABLET; ORAL

LINEZOLID

| | | | | | | | |
|----|-----------------|-------|---------|-----|--------------|-----|------|
| AB | GATE PHARMS | 600MG | A091210 | 001 | Feb 05, 2016 | Jan | NEWA |
| AB | GLENMARK PHARMS | 600MG | A078987 | 001 | Dec 21, 2015 | Mar | CAHN |

LIOTHYRONINE SODIUM

TABLET; ORAL

LIOTHYRONINE SODIUM

| | | | | | | | | |
|-----|------------------|--------------------|-----------------|---------|--------------|--------------|------|------|
| AB | MAYNE PHARMA INC | EQ 0.005MG BASE | A090097 | 001 | Mar 20, 2009 | Mar | CAHN | |
| AB | | EQ 0.025MG BASE | A090097 | 002 | Mar 20, 2009 | Mar | CAHN | |
| AB | | EQ 0.05MG BASE | A090097 | 003 | Mar 20, 2009 | Mar | CAHN | |
| >A> | AB | SUN PHARM INDS LTD | EQ 0.005MG BASE | A091382 | 001 | Apr 20, 2016 | Apr | NEWA |
| >A> | AB | | EQ 0.025MG BASE | A091382 | 002 | Apr 20, 2016 | Apr | NEWA |
| >A> | AB | | EQ 0.05MG BASE | A091382 | 003 | Apr 20, 2016 | Apr | NEWA |

LISINAPRIL

TABLET; ORAL

ZESTRIL

| | | | | | | | |
|----|---------------|-------|---------|-----|--------------|-----|------|
| AB | ALVOGEN MALTA | 2.5MG | N019777 | 005 | Apr 29, 1993 | Jan | CAHN |
| AB | | 5MG | N019777 | 001 | May 19, 1988 | Jan | CAHN |
| AB | | 10MG | N019777 | 002 | May 19, 1988 | Jan | CAHN |
| AB | | 20MG | N019777 | 003 | May 19, 1988 | Jan | CAHN |
| AB | | 30MG | N019777 | 006 | Jan 20, 1999 | Jan | CAHN |
| AB | + | 40MG | N019777 | 004 | May 19, 1988 | Jan | CAHN |

LITHIUM CARBONATE

CAPSULE;ORAL

LITHIUM CARBONATE

| | | | | | | |
|----|-------------------|-------|---------|-----|--------------|----------|
| AB | DELCOR ASSET CORP | 150MG | A076243 | 002 | Feb 24, 2003 | Feb CAHN |
| AB | | 300MG | A076243 | 001 | Jun 27, 2002 | Feb CAHN |
| AB | | 600MG | A078763 | 001 | Apr 15, 2008 | Feb CAHN |
| AB | HIKMA PHARMS | 600MG | A078763 | 001 | Apr 15, 2008 | Jan CMFD |

LOMITAPIDE MESYLATE

CAPSULE;ORAL

JUXTAPID

| | | | | | | |
|---|----------|--------------|---------|-----|--------------|----------|
| | AEGERION | EQ 20MG BASE | N203858 | 003 | Dec 21, 2012 | Jan CRLD |
| + | | EQ 60MG BASE | N203858 | 006 | Apr 23, 2015 | Jan CRLD |

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

IMODIUM

@ J AND J CONSUMER INC 2MG

LOPERAMIDE HYDROCHLORIDE

| | | | | | | |
|----|---------|-----|---------|-----|--------------|----------|
| AB | + MYLAN | 2MG | A072741 | 001 | Sep 18, 1991 | Feb CRLD |
|----|---------|-----|---------|-----|--------------|----------|

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

| | | | | | | | |
|-----|----|-------------------|-------|---------|-----|--------------|----------|
| >D> | AB | HETERO LABS LTD V | 25MG | A203835 | 001 | Aug 12, 2015 | Apr CTEC |
| >A> | BX | | 25MG | A203835 | 001 | Aug 12, 2015 | Apr CTEC |
| >D> | AB | | 50MG | A203835 | 002 | Aug 12, 2015 | Apr CTEC |
| >A> | BX | | 50MG | A203835 | 002 | Aug 12, 2015 | Apr CTEC |
| >D> | AB | | 100MG | A203835 | 003 | Aug 12, 2015 | Apr CTEC |
| >A> | BX | | 100MG | A203835 | 003 | Aug 12, 2015 | Apr CTEC |
| >D> | AB | LUPIN LTD | 25MG | A078232 | 001 | Oct 06, 2010 | Apr CTEC |
| >A> | BX | | 25MG | A078232 | 001 | Oct 06, 2010 | Apr CTEC |
| >D> | AB | | 50MG | A078232 | 002 | Oct 06, 2010 | Apr CTEC |
| >A> | BX | | 50MG | A078232 | 002 | Oct 06, 2010 | Apr CTEC |
| >D> | AB | | 100MG | A078232 | 003 | Oct 06, 2010 | Apr CTEC |
| >A> | BX | | 100MG | A078232 | 003 | Oct 06, 2010 | Apr CTEC |

LOVASTATIN

TABLET;ORAL

LOVASTATIN

| | | | | | | |
|----|----------------|------|---------|-----|--------------|----------|
| AB | SUN PHARM INDS | 10MG | A077520 | 001 | Apr 14, 2006 | Mar CAHN |
| AB | | 20MG | A077520 | 002 | Apr 14, 2006 | Mar CAHN |
| AB | | 40MG | A077520 | 003 | Apr 14, 2006 | Mar CAHN |

LOXAPINE

POWDER;INHALATION

ADASUVE

+ ALEXZA PHARMS 10MG

| | | | |
|---------|-----|--------------|----------|
| N022549 | 001 | Dec 21, 2012 | Feb CAHN |
|---------|-----|--------------|----------|

MAGNESIUM SULFATE

INJECTABLE;INJECTION

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

| | | | | | | |
|--|--------------------|-----------------------|---------|-----|--------------|----------|
| AP | FRESENIUS KABI USA | 1GM/100ML | A206486 | 001 | Mar 07, 2016 | Feb NEWA |
| AP | + HOSPIRA | 1GM/100ML | N020488 | 001 | Jul 11, 1995 | Feb CFTG |
| AP | HQ SPCLT PHARMA | 1GM/100ML | A207349 | 001 | Mar 02, 2016 | Feb NEWA |
| MAGNESIUM SULFATE IN PLASTIC CONTAINER | | | | | | |
| AP | FRESENIUS KABI USA | 4GM/100ML (40MG/ML) | A206485 | 001 | Mar 15, 2016 | Feb NEWA |
| AP | | 4GM/50ML (80MG/ML) | A206485 | 002 | Mar 15, 2016 | Feb NEWA |
| AP | | 2GM/50ML (40MG/ML) | A206485 | 003 | Mar 15, 2016 | Mar NEWA |
| AP | | 20GM/500ML (40MG/ML) | A206485 | 004 | Mar 15, 2016 | Mar NEWA |
| AP | | 40GM/1000ML (40MG/ML) | A206485 | 005 | Mar 15, 2016 | Mar NEWA |
| AP | HOSPIRA | 2GM/50ML (40MG/ML) | N020309 | 003 | Jan 26, 2007 | Mar CFTG |
| AP | + | 4GM/100ML (40MG/ML) | N020309 | 001 | Jun 24, 1994 | Feb CFTG |
| AP | + | 4GM/50ML (80MG/ML) | N020309 | 002 | Jun 24, 1994 | Feb CFTG |
| AP | | 20GM/500ML (40MG/ML) | N020309 | 004 | Jan 18, 1995 | Mar CFTG |
| AP | | 40GM/1000ML (40MG/ML) | N020309 | 005 | Jan 18, 1995 | Mar CFTG |

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

| | | | | | | |
|---|--------------------|----------------------|---------|-----|--------------|----------|
| + | FRESENIUS KABI USA | 10GM/20ML (500MG/ML) | N019316 | 003 | Jan 29, 2016 | Jan NEWA |
| + | | 25GM/50ML (500MG/ML) | N019316 | 004 | Jan 29, 2016 | Jan NEWA |

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

@ RISING PHARMS INC

12.5MG

A 040179 001 Jan 30, 1997 Jan CAHN

@

25MG

A 040179 002 Jan 30, 1997 Jan CAHN

MEGESTROL ACETATE

SUSPENSION; ORAL

MEGACE ES

AB + ENDO PHARMS INC

125MG/ML

N 021778 001 Jul 05, 2005 Feb CAHN

MELOXICAM

TABLET; ORAL

MELOXICAM

@ SUN PHARM INDS

7.5MG

A 077935 001 Jul 19, 2006 Jan CAHN

@

15MG

A 077935 002 Jul 19, 2006 Jan CAHN

MELPHALAN

TABLET; ORAL

ALKERAN

+ APOTEX INC

2MG

N 014691 002

Jan CAHN

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERAN

AP + APOTEX INC

EQ 50MG BASE/VIAL

N 020207 001 Nov 18, 1992 Jan CAHN

POWDER; IV (INFUSION)

EVOVELA

SPECTRUM PHARMS

EQ 50MG BASE/VIAL

N 207155 001 Mar 10, 2016 Mar NEWA

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

@ US PHARM HOLDINGS

25MG/ML

N 005010 007

Jan CAHN

@

50MG/ML

N 005010 002

Jan CAHN

@

75MG/ML

N 005010 009

Jan CAHN

@

100MG/ML

N 005010 003

Jan CAHN

SYRUP; ORAL

DEMEROL

@ US PHARM HOLDINGS

50MG/5ML

N 005010 005

Jan CAHN

TABLET; ORAL

DEMEROL

AA + US PHARM HOLDINGS

50MG

N 005010 001

Jan CAHN

AA +

100MG

N 005010 004

Jan CAHN

MEPERIDINE HYDROCHLORIDE

@ SUN PHARM INDS

50MG

A 080448 001

Mar CAHN

@

100MG

A 080448 002

Mar CAHN

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE

@ AUROLIFE PHARMA LLC

400MG

A 080655 001

Feb CAHN

@ SUN PHARM INDS

200MG

A 080699 001

Mar CAHN

@

400MG

A 080699 002

Mar CAHN

MERCAPTOPYRINE

TABLET; ORAL

MERCAPTOPYRINE

>A> AB DR REDDYS LABS INTL

50MG

A 040461 001 Feb 11, 2004 Apr CAHN

>D> AB PROMETHEUS LABS

50MG

A 040461 001 Feb 11, 2004 Apr CAHN

PURINETHOL

@ STASON PHARMS

50MG

N 009053 002

Jan CAHN

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

AP ANNEAL PHARMS

500MG/VIAL

A 205883 001 Apr 12, 2016 Mar NEWA

AP

1GM/VIAL

A 205883 002 Apr 12, 2016 Mar NEWA

>A> AP SAVIOR LIFETEC CORP

500MG/VIAL

A 206086 001 Apr 19, 2016 Apr NEWA

>A> AP

1GM/VIAL

A 206086 002 Apr 19, 2016 Apr NEWA

MESALAMINECAPSULE, DELAYED RELEASE;ORAL
DELZICOL

+ APIL 400MG

N204412 001 Feb 01, 2013 Jan CAHN

TABLET, DELAYED RELEASE;ORAL

ASACOL

@ APIL 400MG

N019651 001 Jan 31, 1992 Jan CAHN

ASACOL HD

+ APIL 800MG

N021830 001 May 29, 2008 Jan CAHN

METFORMIN HYDROCHLORIDE

TABLET;ORAL

METFORMIN HYDROCHLORIDE

AB SUN PHARM INDS 500MG

A076038 001 Feb 21, 2002 Mar CAHN

AB 850MG

A076038 002 Feb 21, 2002 Mar CAHN

AB 1GM

A076038 003 Feb 21, 2002 Mar CAHN

TABLET, EXTENDED RELEASE;ORAL

GLUMETZA

AB3 SANTARUS INC 500MG

N021748 001 Jun 03, 2005 Jan CTEC

AB3 + 1GM

N021748 002 Jun 03, 2005 Jan CTEC

METFORMIN HYDROCHLORIDE

@ IMPAX LABS 500MG

A076249 001 Jul 30, 2004 Mar DISC

@ 750MG

A076985 001 Sep 13, 2005 Mar DISC

>A> AB1 MARKSANS PHARMA 500MG

A090295 001 Apr 29, 2016 Apr NEWA

>A> AB 750MG

A090295 002 Apr 29, 2016 Apr NEWA

@ SUN PHARM INDS 500MG

A077124 001 Dec 21, 2005 Mar CAHN

METHENAMINE HIPPURATE

TABLET;ORAL

HIPREX

AB + US PHARM HOLDINGS 1GM

N017681 001 Jan CAHN

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

AB RISING PHARMS INC 5MG

A202068 001 Mar 07, 2012 Jan CAHN

AB 10MG

A202068 002 Mar 07, 2012 Jan CAHN

METHOCARBAMOL

TABLET;ORAL

METHOCARBAMOL

@ SANDOZ 500MG

A084616 001 Feb DISC

@ 750MG

A084615 001 Feb DISC

@ SUN PHARM INDS 500MG

A084488 001 Mar CAHN

@ 750MG

A084486 001 Mar CAHN

ROBAXIN

AA + AUXILIUM PHARMS INC 500MG

N011011 004 Mar CAHN

ROBAXIN-750

AA + AUXILIUM PHARMS INC 750MG

N011011 006 Mar CAHN

METHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE SODIUM PRESERVATIVE FREE

AP SANDOZ INC EQ 50MG BASE/2ML (EQ 25MG BASE/ML)

A090039 001 Mar 31, 2009 Jan CAHN

AP EQ 250MG BASE/10ML (EQ 25MG
BASE/ML)

A090039 002 Mar 31, 2009 Jan CAHN

AP EQ 1GM BASE/40ML (EQ 25MG BASE/ML)

A090029 001 Mar 31, 2009 Jan CAHN

METHOXSALEN

INJECTABLE;INJECTION

UVADEX

>A> + MALLINCKRODT HOSP 0.02MG/ML

N020969 001 Feb 25, 1999 Apr CAHN

>D> + THERAKOS 0.02MG/ML

N020969 001 Feb 25, 1999 Apr CAHN

METHYLDOPA

TABLET;ORAL

METHYLDOPA

@ SUN PHARM INDS 125MG

A070073 001 Oct 09, 1986 Mar CAHN

@ 250MG

A070060 001 Oct 09, 1986 Mar CAHN

@ 500MG

A070074 001 Oct 09, 1986 Mar CAHN

| | | | | | | | | | |
|-----|--|--------------------|--|--|---------|-----|--------------|-----|------|
| >A> | <u>METHYLENE BLUE</u> | | | | | | | | |
| >A> | SOLUTION;INTRAVENOUS | | | | | | | | |
| >A> | PROVAYBLUE | | | | | | | | |
| >A> | + PROVEPHARM SAS | 50MG/10ML (5MG/ML) | | | N204630 | 001 | Apr 08, 2016 | Apr | NEWA |
| | <u>METHYLERGONOVINE MALEATE</u> | | | | | | | | |
| | TABLET;ORAL | | | | | | | | |
| | METHERGINE | | | | | | | | |
| | @ EDISON THERAPS LLC | 0.2MG | | | N006035 | 003 | | Jan | DISC |
| | METHYLERGONOVINE MALEATE | | | | | | | | |
| | + NOVEL LABS INC | 0.2MG | | | A091577 | 001 | May 02, 2011 | Jan | CRLD |
| | <u>METHYLPHENIDATE HYDROCHLORIDE</u> | | | | | | | | |
| | SOLUTION;ORAL | | | | | | | | |
| | METHYLPHENIDATE HYDROCHLORIDE | | | | | | | | |
| AA | NOSTRUM LABS INC | 5MG/5ML | | | A201466 | 001 | Nov 12, 2013 | Feb | CAHN |
| AA | | 10MG/5ML | | | A201466 | 002 | Nov 12, 2013 | Feb | CAHN |
| | TABLET, EXTENDED RELEASE;ORAL | | | | | | | | |
| | METHYLPHENIDATE HYDROCHLORIDE | | | | | | | | |
| AB | TEDOR PHARMA INC | 10MG | | | A204772 | 001 | Feb 29, 2016 | Feb | NEWA |
| AB | | 20MG | | | A204772 | 002 | Feb 29, 2016 | Feb | NEWA |
| | <u>METHYLPREDNISOLONE SODIUM SUCCINATE</u> | | | | | | | | |
| | INJECTABLE;INJECTION | | | | | | | | |
| | METHYLPREDNISOLONE SODIUM SUCCINATE | | | | | | | | |
| AP | HIKMA FARMACEUTICA | EQ 500MG BASE/VIAL | | | A202691 | 001 | Feb 16, 2016 | Feb | NEWA |
| AP | | EQ 1GM BASE/VIAL | | | A202691 | 002 | Feb 16, 2016 | Feb | NEWA |
| AP | SAGENT PHARMS | EQ 40MG BASE/VIAL | | | A040888 | 001 | Jul 18, 2011 | Jan | CAHN |
| AP | | EQ 125MG BASE/VIAL | | | A040888 | 002 | Jul 18, 2011 | Jan | CAHN |
| AP | | EQ 500MG BASE/VIAL | | | A040888 | 003 | Jul 18, 2011 | Jan | CAHN |
| AP | | EQ 1GM BASE/VIAL | | | A040888 | 004 | Jul 18, 2011 | Jan | CAHN |
| AP | | EQ 2GM BASE/VIAL | | | A040888 | 005 | Jul 18, 2011 | Jan | CAHN |
| | <u>METHYLTESTOSTERONE</u> | | | | | | | | |
| | TABLET;ORAL | | | | | | | | |
| >D> | ANDROID 10 | | | | | | | | |
| >D> | BP VALEANT PHARM INTL | 10MG | | | A086450 | 001 | | Apr | DISC |
| >A> | @ | 10MG | | | A086450 | 001 | | Apr | DISC |
| | METHYLTESTOSTERONE | | | | | | | | |
| | @ IMPAX LABS | 25MG | | | A084310 | 001 | | Mar | DISC |
| | <u>METOCLOPRAMIDE HYDROCHLORIDE</u> | | | | | | | | |
| | TABLET;ORAL | | | | | | | | |
| | METOCLOPRAMIDE HYDROCHLORIDE | | | | | | | | |
| AB | SUN PHARM INDS | EQ 5MG BASE | | | A071536 | 002 | Jan 16, 1997 | Mar | CAHN |
| | @ | EQ 10MG BASE | | | A071536 | 001 | Apr 28, 1993 | Mar | CAHN |
| | <u>METOPROLOL TARTRATE</u> | | | | | | | | |
| | INJECTABLE;INJECTION | | | | | | | | |
| | METOPROLOL TARTRATE | | | | | | | | |
| >D> | AP BEDFORD LABS | 1MG/ML | | | A076495 | 001 | Jul 07, 2003 | Apr | CAHN |
| >A> | AP EUROHLTH INTL SARL | 1MG/ML | | | A076495 | 001 | Jul 07, 2003 | Apr | CAHN |
| | TABLET;ORAL | | | | | | | | |
| | METOPROLOL TARTRATE | | | | | | | | |
| AB | SUN PHARM INDS | 25MG | | | A073654 | 002 | Jul 15, 2009 | Mar | CAHN |
| AB | | 100MG | | | A073654 | 001 | Dec 21, 1993 | Mar | CAHN |
| | <u>METRONIDAZOLE</u> | | | | | | | | |
| | GEL;VAGINAL | | | | | | | | |
| | NUVESSA | | | | | | | | |
| >D> | + ACTAVIS LABS UT INC | 1.3% | | | N205223 | 001 | Mar 24, 2014 | Apr | CAHN |
| >A> | + ALLERGAN SALES LLC | 1.3% | | | N205223 | 001 | Mar 24, 2014 | Apr | CAHN |
| | TABLET;ORAL | | | | | | | | |
| | METRONIDAZOLE | | | | | | | | |
| AB | NOSTRUM LABS INC | 250MG | | | A070772 | 001 | Jul 16, 1986 | Jan | CAHN |
| AB | | 500MG | | | A070773 | 001 | Jul 16, 1986 | Jan | CAHN |

MICONAZOLETABLET;BUCCAL
ORAVIG

+ MIDATECH PHARMA US 50MG N022404 001 Apr 16, 2010 Jan CAHN

MIDAZOLAM HYDROCHLORIDEINJECTABLE;INJECTION
MIDAZOLAM HYDROCHLORIDE

| | | | | | | | |
|-----|----|--------------------|----------------|----------|-----|--------------|----------|
| >D> | AP | BEDFORD LABS | EQ 1MG BASE/ML | A 075421 | 002 | Jun 20, 2000 | Apr CAHN |
| >D> | AP | | EQ 5MG BASE/ML | A 075421 | 001 | Jun 20, 2000 | Apr CAHN |
| >A> | AP | EUROHLTH INTL SARL | EQ 1MG BASE/ML | A 075421 | 002 | Jun 20, 2000 | Apr CAHN |
| >A> | AP | | EQ 5MG BASE/ML | A 075421 | 001 | Jun 20, 2000 | Apr CAHN |

MIGLITOLTABLET;ORAL
GLYSET

| | | | | | | | |
|----|---|----------------------|-------|---------|-----|--------------|----------|
| AB | + | PHARMACIA AND UPJOHN | 25MG | N020682 | 001 | Dec 18, 1996 | Feb CRLD |
| AB | | | 100MG | N020682 | 003 | Dec 18, 1996 | Feb CRLD |

MILNACIPRAN HYDROCHLORIDETABLET;ORAL
MILNACIPRAN HYDROCHLORIDE

| | | | | | | | |
|-----|----|----------------------|--------|----------|-----|--------------|----------|
| >A> | AB | AMNEAL PHARMS | 12.5MG | A 205081 | 001 | Apr 22, 2016 | Apr NEWA |
| >A> | AB | | 25MG | A 205081 | 002 | Apr 22, 2016 | Apr NEWA |
| >A> | AB | | 50MG | A 205081 | 003 | Apr 22, 2016 | Apr NEWA |
| >A> | AB | | 100MG | A 205081 | 004 | Apr 22, 2016 | Apr NEWA |
| | | @ LIBERTY PHARMA INC | 12.5MG | A 205071 | 001 | Jan 27, 2016 | Jan DISC |
| | | | 12.5MG | A 205071 | 001 | Jan 27, 2016 | Jan NEWA |
| | | @ | 25MG | A 205071 | 002 | Jan 27, 2016 | Jan DISC |
| | | | 25MG | A 205071 | 002 | Jan 27, 2016 | Jan NEWA |
| | | @ | 50MG | A 205071 | 003 | Jan 27, 2016 | Jan DISC |
| | | | 50MG | A 205071 | 003 | Jan 27, 2016 | Jan NEWA |
| | | @ | 100MG | A 205071 | 004 | Jan 27, 2016 | Jan DISC |
| | | | 100MG | A 205071 | 004 | Jan 27, 2016 | Jan NEWA |
| | | SAVELLA | | | | | |
| >D> | | CYPRESS BIOSCIENCE | 12.5MG | N022256 | 001 | Jan 14, 2009 | Apr CFTG |
| >A> | AB | | 12.5MG | N022256 | 001 | Jan 14, 2009 | Apr CFTG |
| >D> | | | 25MG | N022256 | 002 | Jan 14, 2009 | Apr CFTG |
| >A> | AB | | 25MG | N022256 | 002 | Jan 14, 2009 | Apr CFTG |
| >D> | | + | 50MG | N022256 | 003 | Jan 14, 2009 | Apr CFTG |
| >A> | AB | + | 50MG | N022256 | 003 | Jan 14, 2009 | Apr CFTG |
| >D> | | | 100MG | N022256 | 004 | Jan 14, 2009 | Apr CFTG |
| >A> | AB | | 100MG | N022256 | 004 | Jan 14, 2009 | Apr CFTG |

MILRINONE LACTATEINJECTABLE;INJECTION
MILRINONE LACTATE

| | | | | | | | |
|-----|----|---|---------------------------------------|----------|-----|--------------|----------|
| >D> | AP | BEDFORD | EQ 1MG BASE/ML | A 075660 | 001 | May 28, 2002 | Apr CAHN |
| >A> | AP | EUROHLTH INTL SARL | EQ 1MG BASE/ML | A 075660 | 001 | May 28, 2002 | Apr CAHN |
| | | MILRINONE LACTATE IN DEXTROSE 5% | | | | | |
| | AP | CLARIS | EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML) | A 077151 | 002 | Jul 20, 2005 | Mar CAHN |
| | | MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER | | | | | |
| | | @ CLARIS | EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML) | A 077151 | 001 | Jul 20, 2005 | Mar CAHN |

MINOCYCLINE HYDROCHLORIDETABLET;ORAL
MINOCYCLINE HYDROCHLORIDE

| | | | | | | | |
|----|--|----------------|---------------|----------|-----|--------------|----------|
| AB | | SUN PHARM INDS | EQ 50MG BASE | A 090217 | 001 | Jan 29, 2016 | Jan NEWA |
| AB | | | EQ 75MG BASE | A 090217 | 002 | Jan 29, 2016 | Jan NEWA |
| AB | | | EQ 100MG BASE | A 090217 | 003 | Jan 29, 2016 | Jan NEWA |

TABLET, EXTENDED RELEASE;ORAL
MINOCYCLINE HYDROCHLORIDE

| | | | | | | | |
|--|--|------------------|---------------|----------|-----|--------------|----------|
| | | @ IMPAX LABS INC | EQ 45MG BASE | A 090024 | 001 | Feb 03, 2009 | Mar DISC |
| | | @ | EQ 90MG BASE | A 090024 | 002 | Feb 03, 2009 | Mar DISC |
| | | @ | EQ 135MG BASE | A 090024 | 003 | Feb 03, 2009 | Mar DISC |

MINOXIDILTABLET;ORAL
MINOXIDIL

| | | | | | | | |
|----|----------------|------|---------|-----|--------------|-----|------|
| AB | SUN PHARM INDS | 10MG | A072709 | 001 | Dec 14, 1995 | Mar | CAHN |
|----|----------------|------|---------|-----|--------------|-----|------|

MIRTAZAPINETABLET;ORAL
MIRTAZAPINE

| | | | | | | | |
|---|---------------------|------|---------|-----|--------------|-----|------|
| @ | ACTAVIS LABS FL INC | 15MG | A076336 | 001 | Jun 20, 2003 | Jan | DISC |
| @ | | 30MG | A076336 | 002 | Jun 20, 2003 | Jan | DISC |
| @ | | 45MG | A076336 | 003 | Jun 20, 2003 | Jan | DISC |

MITOMYCININJECTABLE; INJECTION
MITOMYCIN

| | | | | | | | | |
|-----|----|--------------------|-----------|---------|-----|--------------|-----|------|
| >D> | AP | BEDFORD | 5MG/VIAL | A064117 | 001 | Apr 19, 1995 | Apr | CAHN |
| >D> | AP | | 20MG/VIAL | A064117 | 002 | Apr 19, 1995 | Apr | CAHN |
| >A> | AP | EUROHLTH INTL SARL | 5MG/VIAL | A064117 | 001 | Apr 19, 1995 | Apr | CAHN |
| | AP | | 5MG/VIAL | A064180 | 001 | Dec 23, 1999 | Jan | CAHN |
| >A> | AP | | 20MG/VIAL | A064117 | 002 | Apr 19, 1995 | Apr | CAHN |
| | AP | | 20MG/VIAL | A064180 | 002 | Dec 23, 1999 | Jan | CAHN |

MODAFINILTABLET;ORAL
MODAFINIL

| | | | | | | | |
|----|-----------------|-------|---------|-----|--------------|-----|------|
| AB | WATSON LABS INC | 100MG | A076715 | 001 | Nov 01, 2012 | Jan | CAHN |
| AB | | 200MG | A076715 | 002 | Nov 01, 2012 | Jan | CAHN |

MOMETASONE FUROATESPRAY, METERED;NASAL
MOMETASONE FUROATE

| | | | | | | | |
|----|---------------------|----------------------|---------|-----|--------------|-----|------|
| AB | APOTEX INC | EQ 0.05MG BASE/SPRAY | A091161 | 001 | Mar 22, 2016 | Mar | NEWA |
| AB | + MERCK SHARP DOHME | EQ 0.05MG BASE/SPRAY | N020762 | 001 | Oct 01, 1997 | Mar | CFTG |

MORPHINE SULFATECAPSULE, EXTENDED RELEASE;ORAL
KADIAN

| | | | | | | | | |
|-----|----|-----------------------|-------|---------|-----|--------------|-----|------|
| >D> | AB | + ACTAVIS LABS UT INC | 10MG | N020616 | 008 | Apr 20, 2007 | Apr | CAHN |
| | AB | + | 10MG | N020616 | 008 | Apr 20, 2007 | Feb | CTEC |
| >D> | AB | | 20MG | N020616 | 001 | Jul 03, 1996 | Apr | CAHN |
| | AB | | 20MG | N020616 | 001 | Jul 03, 1996 | Feb | CTEC |
| >D> | AB | | 30MG | N020616 | 004 | Mar 09, 2001 | Apr | CAHN |
| | AB | | 30MG | N020616 | 004 | Mar 09, 2001 | Feb | CTEC |
| >D> | AB | | 40MG | N020616 | 009 | Jul 09, 2012 | Apr | CAHN |
| | AB | | 40MG | N020616 | 009 | Jul 09, 2012 | Feb | CTEC |
| >D> | AB | | 50MG | N020616 | 002 | Jul 03, 1996 | Apr | CAHN |
| | AB | | 50MG | N020616 | 002 | Jul 03, 1996 | Feb | CTEC |
| >D> | AB | | 60MG | N020616 | 005 | Mar 09, 2001 | Apr | CAHN |
| | AB | | 60MG | N020616 | 005 | Mar 09, 2001 | Feb | CTEC |
| >D> | AB | | 70MG | N020616 | 010 | Jul 09, 2012 | Apr | CAHN |
| | AB | | 70MG | N020616 | 010 | Jul 09, 2012 | Feb | CTEC |
| >D> | AB | | 80MG | N020616 | 006 | Oct 27, 2006 | Apr | CAHN |
| | AB | | 80MG | N020616 | 006 | Oct 27, 2006 | Feb | CTEC |
| >D> | AB | + | 100MG | N020616 | 003 | Jul 03, 1996 | Apr | CAHN |
| | AB | + | 100MG | N020616 | 003 | Jul 03, 1996 | Feb | CTEC |
| >D> | | | 130MG | N020616 | 011 | Jul 09, 2012 | Apr | CAHN |
| >D> | | | 150MG | N020616 | 012 | Jul 09, 2012 | Apr | CAHN |
| >D> | | + | 200MG | N020616 | 007 | Feb 27, 2007 | Apr | CAHN |
| | | + | 200MG | N020616 | 007 | Feb 27, 2007 | Feb | CTEC |
| >A> | AB | + ALLERGAN SALES LLC | 10MG | N020616 | 008 | Apr 20, 2007 | Apr | CAHN |
| >A> | AB | | 20MG | N020616 | 001 | Jul 03, 1996 | Apr | CAHN |
| >A> | AB | | 30MG | N020616 | 004 | Mar 09, 2001 | Apr | CAHN |
| >A> | AB | | 40MG | N020616 | 009 | Jul 09, 2012 | Apr | CAHN |
| >A> | AB | | 50MG | N020616 | 002 | Jul 03, 1996 | Apr | CAHN |
| >A> | AB | | 60MG | N020616 | 005 | Mar 09, 2001 | Apr | CAHN |
| >A> | AB | | 70MG | N020616 | 010 | Jul 09, 2012 | Apr | CAHN |
| >A> | AB | | 80MG | N020616 | 006 | Oct 27, 2006 | Apr | CAHN |
| >A> | AB | + | 100MG | N020616 | 003 | Jul 03, 1996 | Apr | CAHN |
| >A> | | | 130MG | N020616 | 011 | Jul 09, 2012 | Apr | CAHN |
| >A> | | | 150MG | N020616 | 012 | Jul 09, 2012 | Apr | CAHN |
| >A> | | + | 200MG | N020616 | 007 | Feb 27, 2007 | Apr | CAHN |

| | | | | | | | | |
|---------------------------------------|------------------|------------------|---------------|---------|--------------|--------------|------|------|
| <u>CAPSULE, EXTENDED RELEASE;ORAL</u> | | | | | | | | |
| <u>MORPHINE SULFATE</u> | | | | | | | | |
| AB | IMPAX LABS INC | 20MG | A200411 | 001 | Apr 12, 2016 | Mar | NEWA | |
| AB | | 30MG | A200411 | 002 | Apr 12, 2016 | Mar | NEWA | |
| AB | | 50MG | A200411 | 003 | Apr 12, 2016 | Mar | NEWA | |
| AB | | 60MG | A200411 | 004 | Apr 12, 2016 | Mar | NEWA | |
| AB | | 80MG | A200411 | 005 | Apr 12, 2016 | Mar | NEWA | |
| AB | | 100MG | A200411 | 006 | Apr 12, 2016 | Mar | NEWA | |
| AB | PAR PHARM INC | 20MG | A200812 | 001 | Nov 10, 2011 | Feb | CTEC | |
| AB | | 30MG | A200812 | 002 | Nov 10, 2011 | Feb | CTEC | |
| AB | | 50MG | A200812 | 003 | Nov 10, 2011 | Feb | CTEC | |
| AB | | 60MG | A200812 | 004 | Nov 10, 2011 | Feb | CTEC | |
| AB | | 80MG | A200812 | 005 | Nov 10, 2011 | Feb | CTEC | |
| AB | | 100MG | A200812 | 006 | Nov 10, 2011 | Feb | CTEC | |
| AB | TEVA PHARMS USA | 20MG | A202718 | 001 | Dec 29, 2014 | Feb | CTEC | |
| AB | | 30MG | A202718 | 002 | Dec 29, 2014 | Feb | CTEC | |
| AB | | 40MG | A202718 | 007 | Jun 03, 2015 | Feb | CTEC | |
| AB | | 50MG | A202718 | 003 | Dec 29, 2014 | Feb | CTEC | |
| AB | | 60MG | A202718 | 004 | Dec 29, 2014 | Feb | CTEC | |
| AB | | 70MG | A202718 | 008 | Jun 03, 2015 | Feb | CTEC | |
| AB | | 80MG | A202718 | 005 | Dec 29, 2014 | Feb | CTEC | |
| AB | | 100MG | A202718 | 006 | Dec 29, 2014 | Feb | CTEC | |
| AB | UPSHER SMITH | 10MG | A202104 | 001 | Jun 03, 2013 | Feb | CTEC | |
| AB | | 20MG | A202104 | 002 | Jun 03, 2013 | Feb | CTEC | |
| AB | | 30MG | A202104 | 003 | Jun 03, 2013 | Feb | CTEC | |
| AB | | 50MG | A202104 | 004 | Jun 03, 2013 | Feb | CTEC | |
| AB | | 60MG | A202104 | 005 | Jun 03, 2013 | Feb | CTEC | |
| AB | | 80MG | A202104 | 006 | Jun 03, 2013 | Feb | CTEC | |
| AB | | 100MG | A202104 | 007 | Jun 03, 2013 | Feb | CTEC | |
| <u>SOLUTION;ORAL</u> | | | | | | | | |
| <u>MORPHINE SULFATE</u> | | | | | | | | |
| AA | NOSTRUM LABS INC | 10MG/5ML | A201011 | 001 | Feb 05, 2014 | Mar | CAHN | |
| AA | | 20MG/5ML | A201011 | 002 | Feb 05, 2014 | Mar | CAHN | |
| <u>MOXIFLOXACIN HYDROCHLORIDE</u> | | | | | | | | |
| <u>TABLET;ORAL</u> | | | | | | | | |
| <u>MOXIFLOXACIN HYDROCHLORIDE</u> | | | | | | | | |
| AB | CROSSMEDIKA SA | EQ 400MG BASE | A205348 | 001 | Jan 14, 2016 | Jan | NEWA | |
| <u>NALIDIXIC ACID</u> | | | | | | | | |
| <u>TABLET;ORAL</u> | | | | | | | | |
| <u>NALIDIXIC ACID</u> | | | | | | | | |
| | @ SUN PHARM INDS | 250MG | A070270 | 001 | Jun 29, 1988 | Mar | CAHN | |
| | @ | 1GM | A070272 | 001 | Jun 29, 1988 | Mar | CAHN | |
| <u>NAPROXEN</u> | | | | | | | | |
| <u>TABLET;ORAL</u> | | | | | | | | |
| <u>NAPROSYN</u> | | | | | | | | |
| AB | ATNAHS PHARMA US | 250MG | N017581 | 002 | | Feb | CAHN | |
| AB | | 375MG | N017581 | 003 | | Feb | CAHN | |
| AB | + | 500MG | N017581 | 004 | Apr 15, 1982 | Feb | CAHN | |
| <u>NAPROXEN</u> | | | | | | | | |
| | @ SANDOZ | 250MG | A074140 | 001 | Dec 21, 1993 | Feb | DISC | |
| | @ | 375MG | A074140 | 002 | Dec 21, 1993 | Feb | DISC | |
| | @ | 500MG | A074140 | 003 | Dec 21, 1993 | Feb | DISC | |
| <u>TABLET, DELAYED RELEASE;ORAL</u> | | | | | | | | |
| <u>EC-NAPROSYN</u> | | | | | | | | |
| AB | + | ATNAHS PHARMA US | 375MG | N020067 | 002 | Oct 14, 1994 | Feb | CAHN |
| AB | + | | 500MG | N020067 | 003 | Oct 14, 1994 | Feb | CAHN |
| <u>NAPROXEN</u> | | | | | | | | |
| | @ SANDOZ | 375MG | A075061 | 001 | Feb 18, 1998 | Feb | DISC | |
| | @ | 500MG | A075061 | 002 | Feb 18, 1998 | Feb | DISC | |
| <u>NAPROXEN SODIUM</u> | | | | | | | | |
| <u>TABLET;ORAL</u> | | | | | | | | |
| <u>ANAPROX</u> | | | | | | | | |
| AB | ATNAHS PHARMA US | EQ 250MG BASE | N018164 | 001 | | Feb | CAHN | |
| <u>ANAPROX DS</u> | | | | | | | | |
| AB | + | ATNAHS PHARMA US | EQ 500MG BASE | N018164 | 003 | Sep 30, 1987 | Feb | CAHN |

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

NEFAZODONE HYDROCHLORIDE

@ SUN PHARM INDS LTD 50MG
 @ 100MG
 @ 150MG
 @ 200MG
 @ 250MG

A076409 001 Sep 16, 2003 Feb DISC
 A076409 002 Sep 16, 2003 Feb DISC
 A076409 003 Sep 16, 2003 Feb DISC
 A076409 004 Sep 16, 2003 Feb DISC
 A076409 005 Sep 16, 2003 Feb DISC

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

@ VALIDUS PHARMS 10MG
 @ 20MG

A073250 001 Oct 08, 1991 Mar CAHN
 A074045 001 Apr 30, 1992 Mar CAHN

TABLET, EXTENDED RELEASE; ORAL

ADALAT CC

AB1 ALVOGEN 30MG
 AB1 + 60MG
 AB1 + 90MG

N020198 001 Apr 21, 1993 Feb CAHN
 N020198 002 Apr 21, 1993 Feb CAHN
 N020198 003 Apr 21, 1993 Feb CAHN

NIFEDIPINE

AB1 VALEANT PHARMS NORTH 30MG
 AB1 60MG
 AB1 90MG

A075269 001 Dec 04, 2000 Jan CAHN
 A075269 002 Dec 04, 2000 Jan CAHN
 A076070 001 Aug 16, 2002 Jan CAHN

NIMODIPINE

CAPSULE; ORAL

NIMODIPINE

AB + BIONPHARMA INC 30MG

A076740 001 Jan 17, 2008 Jan CAHN

NITISINONE

>A> SUSPENSION; ORAL

>A> ORFADIN

>A> + SOBI 4MG/ML

N206356 001 Apr 22, 2016 Apr NEWA

NITRIC OXIDE

GAS; INHALATION

INOMAX

+ MALLINCKRODT HOSP 800PPM

N020845 003 Dec 23, 1999 Jan CAHN

NITROFURANTOIN

SUSPENSION; ORAL

NITROFURANTOIN

>A> AB ACTAVIS MID ATLANTIC 25MG/5ML
 AB NOSTRUM LABS INC 25MG/5ML

A205180 001 May 03, 2016 Apr NEWA
 A201355 001 Aug 14, 2013 Feb CAHN

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

NITROFURANTOIN

AB SUN PHARM INDS 25MG
 AB 50MG
 AB 100MG

A201722 001 Feb 16, 2016 Feb NEWA
 A201722 002 Feb 16, 2016 Feb NEWA
 A201722 003 Feb 16, 2016 Feb NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACROBID

AB + ALVOGEN MALTA 75MG; 25MG

N020064 001 Dec 24, 1991 Jan CAHN

NIZATIDINE

SOLUTION; ORAL

AXID

@ BRAINTREE 15MG/ML

N021494 001 May 25, 2004 Feb DISC

NIZATIDINE

+ AMNEAL PHARMS 15MG/ML

A090576 001 Nov 18, 2009 Feb CRLD

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

>D> AP BEDFORD EQ 1MG BASE/ML
 AP CLARIS EQ 1MG BASE/ML
 >A> AP EUROHLTH INTL SARL EQ 1MG BASE/ML

A040462 001 Oct 31, 2003 Apr CAHN
 A040859 001 Mar 27, 2012 Jan CAHN
 A040462 001 Oct 31, 2003 Apr CAHN

NORETHINDRONETABLET; ORAL-28
NOR-QD

| | | | | | | | | | | |
|-----|---|------|--------|--|---------|-----|--|--|-----|------|
| AB1 | + | APIL | 0.35MG | | N017060 | 001 | | | Jan | CAHN |
|-----|---|------|--------|--|---------|-----|--|--|-----|------|

NORTRIPTYLINE HYDROCHLORIDECAPSULE; ORAL
NORTRIPTYLINE HYDROCHLORIDE

| | | | | | | | | | |
|--|---|---------------------|--------------|--|---------|-----|--------------|-----|------|
| | @ | AUROLIFE PHARMA LLC | EQ 10MG BASE | | A074835 | 001 | Jun 30, 1997 | Feb | CAHN |
| | @ | | EQ 25MG BASE | | A074835 | 002 | Jun 30, 1997 | Feb | CAHN |
| | @ | | EQ 50MG BASE | | A074835 | 003 | Jun 30, 1997 | Feb | CAHN |
| | @ | | EQ 75MG BASE | | A074835 | 004 | Jun 30, 1997 | Feb | CAHN |

NYSTATINTABLET; ORAL
NYSTATIN

| | | | | | | | | | |
|----|--|----------------|---------------|--|---------|-----|--------------|-----|------|
| AA | | SUN PHARM INDS | 500,000 UNITS | | A062838 | 001 | Dec 22, 1988 | Mar | CAHN |
|----|--|----------------|---------------|--|---------|-----|--------------|-----|------|

NYSTATIN; TRIAMCINOLONE ACETONIDECREAM; TOPICAL
NYSTATIN TRIAMCINOLONE ACETONIDE

| | | | | | | | | | |
|--|---|------------|------------------------|--|---------|-----|--------------|-----|------|
| | @ | PHARMADERM | 100,000 UNITS/GM; 0.1% | | A062596 | 001 | Oct 08, 1985 | Mar | CMS1 |
|--|---|------------|------------------------|--|---------|-----|--------------|-----|------|

OCTREOTIDE ACETATEINJECTABLE; INJECTION
OCTREOTIDE ACETATE

| | | | | | | | | | |
|--|---|---------------|--|--|---------|-----|--------------|-----|------|
| | @ | WOCKHARDT USA | EQ 0.2MG BASE/ML | | A090986 | 001 | May 11, 2011 | Jan | DISC |
| | @ | | EQ 1MG BASE/ML | | A090986 | 002 | May 11, 2011 | Jan | DISC |
| | | | OCTREOTIDE ACETATE (PRESERVATIVE FREE) | | | | | | |
| | @ | WOCKHARDT USA | EQ 0.05MG BASE/ML | | A090985 | 001 | May 11, 2011 | Jan | DISC |
| | @ | | EQ 0.1MG BASE/ML | | A090985 | 002 | May 11, 2011 | Jan | DISC |
| | @ | | EQ 0.5MG BASE/ML | | A090985 | 003 | May 11, 2011 | Jan | DISC |
| | | | OCTREOTIDE ACETATE PRESERVATIVE FREE | | | | | | |
| | @ | WOCKHARDT USA | EQ 0.05MG BASE/ML | | A090985 | 001 | May 11, 2011 | Feb | CMS1 |
| | @ | | EQ 0.1MG BASE/ML | | A090985 | 002 | May 11, 2011 | Feb | CMS1 |
| | @ | | EQ 0.5MG BASE/ML | | A090985 | 003 | May 11, 2011 | Feb | CMS1 |

OFLOXACINSOLUTION/DROPS; OPHTHALMIC
OFLOXACIN

| | | | | | | | | | |
|----|--|---------|------|--|---------|-----|--------------|-----|------|
| AT | | ALVOGEN | 0.3% | | A076830 | 001 | Aug 31, 2004 | Mar | CAHN |
|----|--|---------|------|--|---------|-----|--------------|-----|------|

SOLUTION/DROPS; OTIC
FLOXIN OTIC

| | | | | | | | | | |
|--|---|---------|------|--|---------|-----|--------------|-----|------|
| | @ | DAIICHI | 0.3% | | N020799 | 001 | Dec 16, 1997 | Feb | DISC |
|--|---|---------|------|--|---------|-----|--------------|-----|------|

| | | | | | | | | | |
|----|---|-----------------|------|--|---------|-----|--------------|-----|------|
| AT | | ALVOGEN | 0.3% | | A090395 | 001 | Aug 11, 2009 | Mar | CAHN |
| AT | + | BAUSCH AND LOMB | 0.3% | | A076128 | 001 | Mar 17, 2008 | Feb | CRLD |

OLANZAPINETABLET; ORAL
OLANZAPINE

| | | | | | | | | | |
|----|--|-------------------|-------|--|---------|-----|--------------|-----|------|
| AB | | INVAGEN PHARMS | 2.5MG | | A203333 | 001 | Mar 15, 2016 | Feb | NEWA |
| AB | | | 5MG | | A203333 | 002 | Mar 15, 2016 | Feb | NEWA |
| AB | | | 7.5MG | | A203333 | 003 | Mar 15, 2016 | Feb | NEWA |
| AB | | | 10MG | | A203333 | 004 | Mar 15, 2016 | Feb | NEWA |
| AB | | | 15MG | | A203333 | 005 | Mar 15, 2016 | Feb | NEWA |
| AB | | | 20MG | | A203333 | 006 | Mar 15, 2016 | Feb | NEWA |
| AB | | QILU PHARM CO LTD | 2.5MG | | A204319 | 001 | Jan 27, 2016 | Jan | NEWA |
| AB | | | 5MG | | A204319 | 002 | Jan 27, 2016 | Jan | NEWA |
| AB | | | 7.5MG | | A204319 | 003 | Jan 27, 2016 | Jan | NEWA |
| AB | | | 10MG | | A204319 | 004 | Jan 27, 2016 | Jan | NEWA |
| AB | | | 15MG | | A204319 | 005 | Jan 27, 2016 | Jan | NEWA |
| AB | | | 20MG | | A204319 | 006 | Jan 27, 2016 | Jan | NEWA |

TABLET, ORALLY DISINTEGRATING; ORAL
OLANZAPINE

| | | | | | | | | | |
|----|--|----------------|------|--|---------|-----|--------------|-----|------|
| AB | | INVAGEN PHARMS | 5MG | | A203456 | 001 | Mar 16, 2016 | Feb | NEWA |
| AB | | | 10MG | | A203456 | 002 | Mar 16, 2016 | Feb | NEWA |
| AB | | | 15MG | | A203456 | 003 | Mar 16, 2016 | Feb | NEWA |
| AB | | | 20MG | | A203456 | 004 | Mar 16, 2016 | Feb | NEWA |

OLOPATADINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC
OLOPATADINE HYDROCHLORIDE

| | | | | | | | |
|----|----------------------|--------------|---------|-----|--------------|-----|------|
| AT | SOMERSET THERAPS LLC | EQ 0.1% BASE | A206306 | 001 | Dec 07, 2015 | Mar | CAHN |
|----|----------------------|--------------|---------|-----|--------------|-----|------|

OMEGA-3-ACID ETHYL ESTERSCAPSULE;ORAL
OMEGA-3-ACID ETHYL ESTERS

| | | | | | | | |
|----|---------------|--|---------|-----|--------------|-----|------|
| AB | AMNEAL PHARMS | 1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS | A204940 | 001 | Nov 27, 2015 | Jan | CMS1 |
|----|---------------|--|---------|-----|--------------|-----|------|

OMEGA-3-ACID ETHYL ESTERS TYPE ACAPSULE;ORAL
OMTRYG

+ TRYGG

1.2GM CONTAINS AT LEAST 900MG OF
THE ETHYL ESTERS OF OMEGA-3 FATTY
ACIDS

| | | | | |
|---------|-----|--------------|-----|------|
| N204977 | 001 | Apr 23, 2014 | Mar | CAIN |
|---------|-----|--------------|-----|------|

OMEPRAZOLECAPSULE, DELAYED REL PELLETS;ORAL
OMEPRAZOLE

| | | | | | | | |
|----|----------|------|---------|-----|--------------|-----|------|
| AB | + SANDOZ | 20MG | A075757 | 002 | Jan 28, 2003 | Mar | CRLD |
| AB | + | 40MG | A076515 | 001 | Jan 21, 2009 | Mar | CRLD |

ONDANSETRON HYDROCHLORIDEINJECTABLE;INJECTION
ONDANSETRON HYDROCHLORIDE

| | | | | | | | | |
|-----|----|---|----------------|---------|-----|--------------|-----|------|
| >D> | AP | BEDFORD | EQ 2MG BASE/ML | A076967 | 001 | Dec 26, 2006 | Apr | CAHN |
| >A> | AP | EUROHLTH INTL SARL | EQ 2MG BASE/ML | A076967 | 001 | Dec 26, 2006 | Apr | CAHN |
| | | ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE | | | | | | |
| | AP | ACCORD HLTHCARE | EQ 2MG BASE/ML | A206845 | 001 | Mar 10, 2016 | Feb | NEWA |
| >D> | AP | BEDFORD LABS | EQ 2MG BASE/ML | A077011 | 001 | Dec 26, 2006 | Apr | CAHN |
| >A> | AP | EUROHLTH INTL SARL | EQ 2MG BASE/ML | A077011 | 001 | Dec 26, 2006 | Apr | CAHN |

OXALIPLATININJECTABLE;IV (INFUSION)
OXALIPLATIN

| | | | | | | | | |
|-----|----|-------------------|---------------------|---------|-----|--------------|-----|------|
| >A> | AP | QILU PHARM CO LTD | 50MG/VIAL | A204616 | 001 | May 11, 2016 | Apr | NEWA |
| >A> | AP | | 100MG/VIAL | A204616 | 002 | May 11, 2016 | Apr | NEWA |
| | AP | SANDOZ INC | 50MG/10ML (5MG/ML) | A078812 | 001 | Aug 07, 2009 | Jan | CAHN |
| | AP | | 100MG/20ML (5MG/ML) | A078812 | 002 | Aug 07, 2009 | Jan | CAHN |

OXAZEPAMCAPSULE;ORAL
OXAZEPAM@ SUN PHARM INDS
@
@10MG
15MG
30MG

| | | | | |
|---------|-----|--------------|-----|------|
| A071026 | 002 | Aug 10, 1987 | Mar | CAHN |
| A071026 | 003 | Aug 10, 1987 | Mar | CAHN |
| A071026 | 001 | Aug 10, 1987 | Mar | CAHN |

OXICONAZOLE NITRATECREAM;TOPICAL
OXICONAZOLE NITRATE

| | | | | | | | |
|----|------------------|------------|---------|-----|--------------|-----|------|
| AB | TARO | EQ 1% BASE | A205076 | 001 | Mar 07, 2016 | Feb | NEWA |
| | OXISTAT | | | | | | |
| AB | + FOUGERA PHARMS | EQ 1% BASE | N019828 | 001 | Dec 30, 1988 | Feb | CFTG |

OXYBUTYNINFILM, EXTENDED RELEASE;TRANSDERMAL
OXYTROL

| | | | | | | | | |
|-----|----|--------------------------|------------|---------|-----|--------------|-----|------|
| >D> | AB | + ACTAVIS LABS UT INC | 3.9MG/24HR | N021351 | 002 | Feb 26, 2003 | Apr | CAHN |
| >A> | AB | + ALLERGAN SALES LLC | 3.9MG/24HR | N021351 | 002 | Feb 26, 2003 | Apr | CAHN |
| | | GEL, METERED;TRANSDERMAL | | | | | | |
| | | GELNIQUE 3% | | | | | | |
| >D> | | + ACTAVIS LABS UT INC | 3% | N202513 | 001 | Dec 07, 2011 | Apr | CAHN |
| >A> | | + ALLERGAN SALES LLC | 3% | N202513 | 001 | Dec 07, 2011 | Apr | CAHN |

OXYBUTYNIN CHLORIDEGEL; TRANSDERMAL
GELNIQUE

| | | | | | | | |
|-----|---|---------------------|--------------------|---------|-----|--------------|----------|
| >D> | + | ACTAVIS LABS UT INC | 10% (100MG/PACKET) | N022204 | 001 | Jan 27, 2009 | Apr CAHN |
| >A> | + | ALLERGAN SALES LLC | 10% (100MG/PACKET) | N022204 | 001 | Jan 27, 2009 | Apr CAHN |

TABLET, EXTENDED RELEASE; ORAL
OXYBUTYNIN CHLORIDE

| | | | | | | | |
|----|--|-----------------|------|---------|-----|--------------|----------|
| AB | | ACCORD HLTHCARE | 5MG | A207138 | 001 | Feb 29, 2016 | Feb NEWA |
| AB | | | 10MG | A207138 | 002 | Feb 29, 2016 | Feb NEWA |
| AB | | | 15MG | A207138 | 003 | Feb 29, 2016 | Feb NEWA |

OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE HYDROCHLORIDE

| | | | | | | | |
|----|--|----------------|-----|---------|-----|--------------|----------|
| AB | | ANI PHARMS INC | 5MG | A205177 | 001 | Mar 31, 2016 | Mar NEWA |
|----|--|----------------|-----|---------|-----|--------------|----------|

>A> CAPSULE, EXTENDED RELEASE; ORAL

>A> XTAMPZA ER

| | | | | | | | |
|-----|--|---------------------|----------------|---------|-----|--------------|----------|
| >A> | | COLLEGIUM PHARM INC | EQ 9MG BASE | N208090 | 001 | Apr 26, 2016 | Apr NEWA |
| >A> | | | EQ 13.5MG BASE | N208090 | 002 | Apr 26, 2016 | Apr NEWA |
| >A> | | | EQ 18MG BASE | N208090 | 003 | Apr 26, 2016 | Apr NEWA |
| >A> | | | EQ 27MG BASE | N208090 | 004 | Apr 26, 2016 | Apr NEWA |
| >A> | | | EQ 36MG BASE | N208090 | 005 | Apr 26, 2016 | Apr NEWA |

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

| | | | | | | | |
|-----|----|-----------------|------|---------|-----|--------------|----------|
| AB | | ALVOGEN MALTA | 5MG | A202116 | 001 | Dec 30, 2011 | Jan CAHN |
| AB | | | 15MG | A202116 | 002 | Dec 30, 2011 | Jan CAHN |
| AB | | | 30MG | A202116 | 003 | Dec 30, 2011 | Jan CAHN |
| >A> | AB | COASTAL PHARMS | 10MG | A091313 | 004 | Apr 29, 2016 | Apr NEWA |
| >A> | AB | | 20MG | A091313 | 005 | Apr 29, 2016 | Apr NEWA |
| AB | | KEN LIFESCIENCE | 5MG | A207119 | 001 | Apr 12, 2016 | Mar NEWA |
| AB | | | 10MG | A207119 | 002 | Apr 12, 2016 | Mar NEWA |
| AB | | | 15MG | A207119 | 003 | Apr 12, 2016 | Mar NEWA |
| AB | | | 20MG | A207119 | 004 | Apr 12, 2016 | Mar NEWA |
| AB | | | 30MG | A207119 | 005 | Apr 12, 2016 | Mar NEWA |

OXYMORPHONE HYDROCHLORIDE

TABLET; ORAL

OXYMORPHONE HYDROCHLORIDE

| | | | | | | | |
|-----|----|---------------------|------|---------|-----|--------------|----------|
| >A> | AB | AUROLIFE PHARMA LLC | 5MG | A204459 | 001 | Apr 26, 2016 | Apr NEWA |
| >A> | AB | | 10MG | A204459 | 002 | Apr 26, 2016 | Apr NEWA |

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

| | | | | | | | |
|----|--|------------|--------|---------|-----|--------------|----------|
| AP | | SANDOZ INC | 6MG/ML | A078167 | 001 | Dec 26, 2007 | Jan CAHN |
|----|--|------------|--------|---------|-----|--------------|----------|

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR

INVEGA SUSTENNA

| | | | | | | | |
|--|---|----------------|-----------------------------|---------|-----|--------------|----------|
| | | JANSSEN PHARMS | 117MG/0.75ML (117MG/0.75ML) | N022264 | 003 | Jul 31, 2009 | Mar CRLD |
| | + | | 156MG/ML (156MG/ML) | N022264 | 004 | Jul 31, 2009 | Mar CRLD |

PALONOSETRON HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

| | | | | | | | |
|-----|----|--------------------|---|---------|-----|--------------|----------|
| >A> | AP | DR REDDYS LABS LTD | EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) | A201533 | 001 | Apr 21, 2016 | Apr NEWA |
| >A> | AP | | EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) | A201533 | 002 | Apr 21, 2016 | Apr NEWA |

SOLUTION; INTRAVENOUS

PALONOSETRON HYDROCHLORIDE

| | | | | | | | |
|--|--|--------------------|---|---------|-----|--------------|----------|
| | | DR REDDYS LABS LTD | EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) | N203050 | 001 | Mar 01, 2016 | Mar NEWA |
| | | | EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) | N203050 | 002 | Mar 01, 2016 | Mar NEWA |

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION
PAMIDRONATE DISODIUM

| | | | | | | | |
|----|---------------|--------------------|----------|-----|--------------|-----|------|
| AP | SAGENT PHARMS | 30MG/10ML (3MG/ML) | A 078373 | 001 | Dec 23, 2008 | Jan | CAHN |
| AP | | 90MG/10ML (9MG/ML) | A 078373 | 002 | Dec 23, 2008 | Jan | CAHN |

PANTOPRAZOLE SODIUM

INJECTABLE; IV (INFUSION)
PANTOPRAZOLE SODIUM

| | | | | | | | |
|----|-------------------------------|-------------------|----------|-----|--------------|-----|------|
| AP | AUROBINDO PHARMA LTD | EQ 40MG BASE/VIAL | A 205675 | 001 | Mar 30, 2016 | Mar | NEWA |
| | TABLET, DELAYED RELEASE; ORAL | | | | | | |
| | PANTOPRAZOLE SODIUM | | | | | | |
| AB | AMNEAL PHARMS | EQ 20MG BASE | A 205119 | 001 | Jan 26, 2016 | Jan | NEWA |
| AB | | EQ 40MG BASE | A 205119 | 002 | Jan 26, 2016 | Jan | NEWA |

PARICALCITOL

CAPSULE; ORAL
PARICALCITOL

| | | | | | | | |
|----|--------------------|------|----------|-----|--------------|-----|------|
| AB | BIONPHARMA INC | 1MCG | A 202539 | 001 | Mar 27, 2014 | Jan | CAHN |
| AB | | 2MCG | A 202539 | 002 | Mar 27, 2014 | Jan | CAHN |
| AB | | 4MCG | A 202539 | 003 | Mar 27, 2014 | Jan | CAHN |
| AB | LOTUS PHARM CO LTD | 1MCG | A 206710 | 001 | Feb 24, 2016 | Feb | NEWA |
| AB | | 2MCG | A 206710 | 002 | Feb 24, 2016 | Feb | NEWA |
| AB | | 4MCG | A 206710 | 003 | Feb 24, 2016 | Feb | NEWA |

SOLUTION; INTRAVENOUS
PARICALCITOL

| | | | | | | | |
|----|-----------------|-------------------------|----------|-----|--------------|-----|------|
| AP | ACCORD HLTHCARE | 0.002MG/ML (0.002MG/ML) | N 207174 | 001 | Feb 04, 2016 | Feb | NEWA |
| AP | | 0.005MG/ML (0.005MG/ML) | N 207174 | 002 | Feb 04, 2016 | Feb | NEWA |
| AP | | 0.01MG/2ML (0.005MG/ML) | N 207174 | 003 | Feb 04, 2016 | Feb | NEWA |

PENBUTOLOL SULFATE

TABLET; ORAL
LEVATOL

| | | | | | | | |
|---|---------------------|------|----------|-----|--------------|-----|------|
| @ | AUXILIUM PHARMS INC | 10MG | N 018976 | 001 | Dec 30, 1987 | Mar | CAHN |
| @ | | 20MG | N 018976 | 004 | Jan 05, 1989 | Mar | CAHN |

>A> PENCICLOVIR

>A> CREAM; TOPICAL
>A> DENAVIR

| | | | | | | | | |
|-----|---|-------------|----|----------|-----|--------------|-----|------|
| >A> | + | DENCO ASSET | 1% | N 020629 | 001 | Sep 24, 1996 | Apr | CAIN |
|-----|---|-------------|----|----------|-----|--------------|-----|------|

>D> PENCICLOVIR SODIUM

>D> CREAM; TOPICAL
>D> DENAVIR

| | | | | | | | | |
|-----|---|-------------|----|----------|-----|--------------|-----|------|
| >D> | + | DENCO ASSET | 1% | N 020629 | 001 | Sep 24, 1996 | Apr | CAIN |
|-----|---|-------------|----|----------|-----|--------------|-----|------|

PENTETATE CALCIUM TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS
PENTETATE CALCIUM TRISODIUM

| | | | | | | | | |
|-----|---|--------------------|------------------------------------|----------|-----|--------------|-----|------|
| >D> | @ | HAMELN PHARMA PLUS | EQ 1GM BASE/5ML (EQ 200MG BASE/ML) | N 021749 | 001 | Aug 11, 2004 | Apr | CMFD |
| >A> | + | | EQ 1GM BASE/5ML (EQ 200MG BASE/ML) | N 021749 | 001 | Aug 11, 2004 | Apr | CMFD |
| | @ | | EQ 1GM BASE/5ML (EQ 200MG BASE/ML) | N 021749 | 001 | Aug 11, 2004 | Feb | CAHN |

PENTETATE ZINC TRISODIUM

SOLUTION; INHALATION, INTRAVENOUS
PENTETATE ZINC TRISODIUM

| | | | | | | | | |
|-----|---|--------------------|------------------------------------|----------|-----|--------------|-----|------|
| >D> | @ | HAMELN PHARMA PLUS | EQ 1GM BASE/5ML (EQ 200MG BASE/ML) | N 021751 | 001 | Aug 11, 2004 | Apr | CMFD |
| >A> | + | | EQ 1GM BASE/5ML (EQ 200MG BASE/ML) | N 021751 | 001 | Aug 11, 2004 | Apr | CMFD |
| | @ | | EQ 1GM BASE/5ML (EQ 200MG BASE/ML) | N 021751 | 001 | Aug 11, 2004 | Feb | CAHN |

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE; ORAL
PENTOXIFYLLINE

| | | | | | | | | |
|----|--------|-------------------|-------|----------|-----|--------------|-----|------|
| AB | + | APOTEX | 400MG | A 075191 | 001 | Jun 09, 1999 | Mar | CRLD |
| | @ | IMPAX LABS | 400MG | A 075093 | 001 | Aug 10, 1999 | Mar | DISC |
| | @ | PLIVA | 400MG | A 074874 | 001 | May 25, 1999 | Mar | DISC |
| | TRENAL | | | | | | | |
| | @ | US PHARM HOLDINGS | 400MG | N 018631 | 001 | Aug 30, 1984 | Jan | CAHN |

PERAMPANEL

>A> SUSPENSION;ORAL
 >A> FYCOMPA
 >A> + EISAI INC 0.5MG/ML N208277 001 Apr 29, 2016 Apr NEWA

PERPHENAZINE

TABLET;ORAL
 PERPHENAZINE
 AB WILSHIRE PHARMS INC 2MG A205973 001 Dec 17, 2015 Jan CAHN
 AB 4MG A205973 002 Dec 17, 2015 Jan CAHN
 AB 8MG A205973 003 Dec 17, 2015 Jan CAHN
 AB 16MG A205973 004 Dec 17, 2015 Jan CAHN

PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM

TABLET;ORAL
 SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE
 @ ABLE 200MG,N/A,N/A;N/A,800MG,160MG N021105 001 Jun 26, 2001 Jan CMS1

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL
 PHENTERMINE HYDROCHLORIDE
 AA SUN PHARM INDS 30MG A040525 001 Oct 23, 2003 Mar CAHN
 @ 37.5MG A040527 001 Oct 23, 2003 Mar CAHN
 TABLET;ORAL
 PHENTERMINE HYDROCHLORIDE
 AA INGENUS PHARMS NJ 37.5MG A091451 001 Sep 21, 2012 Jan CAHN
 AA SUN PHARM INDS 37.5MG A040526 001 Oct 23, 2003 Mar CAHN

PHENYLBUZAZONE

CAPSULE;ORAL
 PHENYLBUZAZONE
 @ SUN PHARM INDS 100MG A088994 001 Dec 04, 1985 Mar CAHN
 TABLET;ORAL
 PHENYLBUZAZONE
 @ SUN PHARM INDS 100MG A088863 001 Dec 04, 1985 Mar CAHN

PHYTONADIONE

INJECTABLE;INJECTION
 AQUAMEPHYTON
 @ TELIGENT PHARMA INC 1MG/0.5ML N012223 002 Jan CAHN
 @ 10MG/ML N012223 001 Jan CAHN

>A> PIMAVANSERIN TARTRATE
 >A> TABLET;ORAL
 >A> NUPLAZID
 >A> + ACADIA PHARMS INC EQ 17MG BASE N207318 001 Apr 29, 2016 Apr NEWA

PINDOLOL

TABLET;ORAL
 PINDOLOL
 AB SUN PHARM INDS 5MG A074063 001 Jan 27, 1994 Mar CAHN
 AB 10MG A074063 002 Jan 27, 1994 Mar CAHN

PIROXICAM

CAPSULE;ORAL
 PIROXICAM
 AB MYLAN PHARMS INC 20MG A074118 001 Jun 15, 1993 Jan CAHN
 @ SUN PHARM INDS 20MG A073536 001 Mar 12, 1993 Mar CAHN

PODOFILOX

GEL;TOPICAL
 CONDYLOX
 + ALLERGAN SALES LLC 0.5% N020529 001 Mar 13, 1997 Mar CAHN
 SOLUTION;TOPICAL
 CONDYLOX
 AT + ALLERGAN SALES LLC 0.5% N019795 001 Dec 13, 1990 Mar CAHN

POLYMYXIN B SULFATEINJECTABLE; INJECTION
POLYMYXIN B SULFATE

| | | | | | | | |
|-----|----------------------|----------------------------|---------|-----|--------------|-----|------|
| AP | AUROBINDO PHARMA LTD | EQ 500,000 UNITS BASE/VIAL | A206589 | 001 | Apr 04, 2016 | Mar | NEWA |
| >A> | GLAND PHARMA LTD | EQ 500,000 UNITS BASE/VIAL | A207322 | 001 | Apr 14, 2016 | Apr | NEWA |

POTASSIUM CHLORIDECAPSULE, EXTENDED RELEASE; ORAL
POTASSIUM CHLORIDE

| | | | | | | | |
|----|----------------------|-------|---------|-----|--------------|-----|------|
| AB | GLENMARK PHARMS LTD | 10MEQ | A202868 | 001 | Jan 19, 2016 | Jan | NEWA |
| AB | KREMERS URBAN PHARMS | 8MEQ | A204210 | 001 | Mar 28, 2016 | Mar | NEWA |
| AB | | 10MEQ | A204210 | 002 | Mar 28, 2016 | Mar | NEWA |
| AB | TRIS PHARMA INC | 8MEQ | A201944 | 001 | Mar 04, 2016 | Feb | NEWA |
| AB | | 10MEQ | A201944 | 002 | Mar 04, 2016 | Feb | NEWA |

TABLET, EXTENDED RELEASE; ORAL
POTASSIUM CHLORIDE

| | | | | | | | |
|-----|----------------|-------|---------|-----|--------------|-----|------|
| AB1 | NOVEL LABS INC | 10MEQ | A206347 | 001 | Jan 21, 2016 | Jan | NEWA |
| AB1 | | 20MEQ | A206347 | 002 | Jan 21, 2016 | Jan | NEWA |

PRAMIPEXOLE DIHYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL
PRAMIPEXOLE DIHYDROCHLORIDE

| | | | | | | | | |
|-----|----|-------------------|---------|---------|-----|--------------|-----|------|
| >A> | AB | ACTAVIS ELIZABETH | 0.375MG | A201963 | 001 | Apr 21, 2016 | Apr | NEWA |
| >A> | AB | | 0.75MG | A201963 | 002 | Apr 21, 2016 | Apr | NEWA |
| >A> | AB | | 1.5MG | A201963 | 003 | Apr 21, 2016 | Apr | NEWA |
| >A> | AB | | 3MG | A201963 | 004 | Apr 21, 2016 | Apr | NEWA |
| >A> | AB | | 4.5MG | A201963 | 005 | Apr 21, 2016 | Apr | NEWA |

PRAVASTATIN SODIUMTABLET; ORAL
PRAVASTATIN SODIUM

| | | | | | | | |
|----|-----------|------|---------|-----|--------------|-----|------|
| AB | CIPLA LTD | 80MG | A077904 | 004 | Mar 22, 2016 | Mar | NEWA |
| | @ MYLAN | 10MG | A077013 | 001 | Oct 23, 2006 | Mar | DISC |
| | @ | 20MG | A077013 | 002 | Oct 23, 2006 | Mar | DISC |
| | @ | 40MG | A077013 | 003 | Oct 23, 2006 | Mar | DISC |
| | @ | 80MG | A077013 | 004 | Dec 28, 2007 | Mar | DISC |

PREDNISOLONETABLET; ORAL
PREDNISOLONE

| | | | | | | | |
|---|---------------------|-----|---------|-----|--|-----|------|
| @ | AUROLIFE PHARMA LLC | 5MG | A084773 | 001 | | Feb | CAHN |
|---|---------------------|-----|---------|-----|--|-----|------|

PREDNISOLONE SODIUM PHOSPHATESOLUTION; ORAL
ORAPRED

| | | | | | | | |
|----|----------------------|------------------|---------|-----|--------------|-----|------|
| @ | CONCORDIA PHARMS INC | EQ 15MG BASE/5ML | A075117 | 001 | Dec 14, 2000 | Mar | DISC |
| AA | + WOCHKHARDT | EQ 15MG BASE/5ML | A076895 | 001 | Oct 04, 2004 | Mar | CRLD |

PREDNISONETABLET; ORAL
PREDNISONE

| | | | | | | | |
|----|---------------------|------|---------|-----|--------------|-----|------|
| @ | AUROLIFE PHARMA LLC | 5MG | A084774 | 001 | | Mar | CAHN |
| @ | | 10MG | A089983 | 001 | Jan 12, 1989 | Mar | CAHN |
| @ | | 20MG | A085813 | 001 | | Mar | CAHN |
| @ | | 50MG | A089984 | 001 | Jan 12, 1989 | Mar | CAHN |
| AB | DELCOR ASSET CORP | 5MG | A080292 | 001 | | Mar | CAHN |
| AB | | 10MG | A088832 | 001 | Dec 04, 1985 | Mar | CAHN |
| AB | | 20MG | A083677 | 001 | | Mar | CAHN |
| AB | SUN PHARM INDS | 20MG | A089247 | 001 | Dec 04, 1985 | Mar | CAHN |

PRIMIDONETABLET; ORAL
PRIMIDONE

| | | | | | | | |
|----|----------------|-------|---------|-----|--------------|-----|------|
| @ | IMPAX LABS | 50MG | A040717 | 001 | Feb 12, 2008 | Mar | DISC |
| @ | | 250MG | A040717 | 002 | Feb 12, 2008 | Mar | DISC |
| AB | SUN PHARM INDS | 50MG | A040626 | 001 | Sep 29, 2005 | Mar | CAHN |
| AB | | 250MG | A040626 | 002 | Sep 29, 2005 | Mar | CAHN |

PROCHLORPERAZINE EDISYLATEINJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

| | | | | | | | | |
|-----|----|--------------------|----------------|----------|-----|--------------|-----|------|
| >D> | AP | BEDFORD | EQ 5MG BASE/ML | A 040540 | 001 | May 28, 2004 | Apr | CAHN |
| >A> | AP | EUROHLTH INTL SARL | EQ 5MG BASE/ML | A 040540 | 001 | May 28, 2004 | Apr | CAHN |

PROGESTERONECAPSULE; ORAL
PROGESTERONE

| | | | | | | | |
|----|----------------|-------|----------|-----|--------------|-----|------|
| AB | BIONPHARMA INC | 100MG | A 200900 | 001 | Aug 16, 2013 | Jan | CAHN |
| AB | | 200MG | A 200900 | 002 | Aug 16, 2013 | Jan | CAHN |

GEL; VAGINAL

CRINONE

| | | | | | | | | |
|-----|---|---------------------|----|----------|-----|--------------|-----|------|
| >D> | + | ACTAVIS LABS UT INC | 4% | N 020701 | 001 | Jul 31, 1997 | Apr | CAHN |
| >D> | + | | 8% | N 020701 | 002 | Jul 31, 1997 | Apr | CAHN |
| >A> | + | ALLERGAN SALES LLC | 4% | N 020701 | 001 | Jul 31, 1997 | Apr | CAHN |
| >A> | + | | 8% | N 020701 | 002 | Jul 31, 1997 | Apr | CAHN |

INJECTABLE; INJECTION
PROGESTERONE

| | | | | | | | | |
|-----|----|-----------------------|---------|----------|-----|--|-----|------|
| >D> | AO | + ACTAVIS LABS UT INC | 50MG/ML | N 017362 | 002 | | Apr | CAHN |
| >A> | AO | + ALLERGAN SALES LLC | 50MG/ML | N 017362 | 002 | | Apr | CAHN |

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

| | | | | | | | |
|----|------------------|------------|----------|-----|--------------|-----|------|
| AA | NOSTRUM LABS INC | 6.25MG/5ML | A 040891 | 001 | Mar 13, 2009 | Feb | CAHN |
|----|------------------|------------|----------|-----|--------------|-----|------|

TABLET; ORAL

PROMETHAZINE HYDROCHLORIDE

| | | | | | | | |
|---|----------------|--------|----------|-----|--------------|-----|------|
| @ | IMPAX LABS | 12.5MG | A 040724 | 001 | Feb 12, 2008 | Mar | DISC |
| @ | | 25MG | A 040724 | 002 | Feb 12, 2008 | Mar | DISC |
| @ | | 50MG | A 040791 | 001 | May 20, 2008 | Mar | DISC |
| @ | SUN PHARM INDS | 12.5MG | A 084555 | 001 | | Mar | CAHN |
| @ | | 25MG | A 084554 | 001 | | Mar | CAHN |
| @ | | 50MG | A 084557 | 001 | | Jan | CAHN |

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPAFENONE HYDROCHLORIDE

| | | | | | | | | |
|-----|----|------------------|-------|----------|-----|--------------|-----|------|
| >A> | AB | MYLAN PHARMS INC | 225MG | A 203803 | 001 | Apr 29, 2016 | Apr | NEWA |
| >A> | AB | | 325MG | A 203803 | 002 | Apr 29, 2016 | Apr | NEWA |
| >A> | AB | | 425MG | A 203803 | 003 | Apr 29, 2016 | Apr | NEWA |

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

| | | | | | | | | |
|-----|----|------------------|-------|----------|-----|--------------|-----|------|
| >A> | AB | ORION CORP ORION | 150MG | A 202445 | 001 | May 11, 2016 | Apr | NEWA |
| >A> | AB | | 225MG | A 202445 | 002 | May 11, 2016 | Apr | NEWA |
| >A> | AB | | 300MG | A 202445 | 003 | May 11, 2016 | Apr | NEWA |
| | AB | SUN PHARM INDS | 150MG | A 075998 | 001 | Nov 29, 2001 | Mar | CAHN |
| | AB | | 225MG | A 075998 | 002 | Nov 29, 2001 | Mar | CAHN |
| | AB | | 300MG | A 075998 | 003 | Nov 29, 2001 | Mar | CAHN |

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

INDERAL LA

| | | | | | | | | |
|-----|----|---------------------|-------|----------|-----|--------------|-----|------|
| >A> | AB | ANI PHARMS INC | 60MG | N 018553 | 004 | Mar 18, 1987 | Apr | CAHN |
| >A> | AB | | 80MG | N 018553 | 002 | Apr 19, 1983 | Apr | CAHN |
| >A> | AB | | 120MG | N 018553 | 003 | Apr 19, 1983 | Apr | CAHN |
| >A> | AB | + | 160MG | N 018553 | 001 | Apr 19, 1983 | Apr | CAHN |
| >D> | AB | CRANFORD PHARMS LLC | 60MG | N 018553 | 004 | Mar 18, 1987 | Apr | CAHN |
| >D> | AB | | 80MG | N 018553 | 002 | Apr 19, 1983 | Apr | CAHN |
| >D> | AB | | 120MG | N 018553 | 003 | Apr 19, 1983 | Apr | CAHN |
| >D> | AB | + | 160MG | N 018553 | 001 | Apr 19, 1983 | Apr | CAHN |

PROPRANOLOL HYDROCHLORIDE

| | | | | | | | |
|----|--------------|-------|----------|-----|--------------|-----|------|
| BX | UPSHER SMITH | 60MG | A 078311 | 001 | Mar 06, 2009 | Mar | CTEC |
| BX | | 80MG | A 078311 | 002 | Mar 06, 2009 | Mar | CTEC |
| BX | | 120MG | A 078311 | 003 | Mar 06, 2009 | Mar | CTEC |
| BX | | 160MG | A 078311 | 004 | Mar 06, 2009 | Mar | CTEC |

INJECTABLE; INJECTION

PROPRANOLOL HYDROCHLORIDE

| | | | | | | | | |
|-----|----|--------------------|--------|----------|-----|--------------|-----|------|
| >D> | AP | BEDFORD | 1MG/ML | A 075792 | 001 | Aug 29, 2000 | Apr | CAHN |
| >A> | AP | EUROHLTH INTL SARL | 1MG/ML | A 075792 | 001 | Aug 29, 2000 | Apr | CAHN |
| | | @ SANDOZ | 1MG/ML | A 076400 | 001 | Feb 26, 2003 | Mar | DISC |

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

| | | | | | | | |
|---|----------------|------|---------|-----|--------------|-----|------|
| @ | SUN PHARM INDS | 10MG | A070319 | 001 | Oct 22, 1985 | Mar | CAHN |
| @ | | 20MG | A070320 | 001 | Oct 22, 1985 | Mar | CAHN |
| @ | | 40MG | A070103 | 001 | Oct 22, 1985 | Mar | CAHN |
| @ | | 80MG | A070322 | 001 | Aug 04, 1986 | Mar | CAHN |

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

| | | | | | | | |
|---|----------------|------|---------|-----|--|-----|------|
| @ | SUN PHARM INDS | 50MG | A083982 | 001 | | Mar | CAHN |
|---|----------------|------|---------|-----|--|-----|------|

PYRIDOSTIGMINE BROMIDE

TABLET, EXTENDED RELEASE;ORAL

PYRIDOSTIGMINE BROMIDE

| | | | | | | | |
|----|---------------|-------|---------|-----|--------------|-----|------|
| AB | ALVOGEN MALTA | 180MG | A204737 | 001 | Jun 26, 2015 | Jan | CAHN |
|----|---------------|-------|---------|-----|--------------|-----|------|

QUAZEPAM

TABLET;ORAL

DORAL

| | | | | | | | | |
|-----|---|------------------|-------|---------|-----|--------------|-----|------|
| | @ | CUTIS HEALTH LLC | 7.5MG | N018708 | 003 | Feb 26, 1987 | Mar | CAHN |
| >D> | @ | | 15MG | N018708 | 001 | Dec 27, 1985 | Apr | CMFD |
| >A> | + | | 15MG | N018708 | 001 | Dec 27, 1985 | Apr | CMFD |
| | @ | | 15MG | N018708 | 001 | Dec 27, 1985 | Mar | CAHN |

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

| | | | | | | | | |
|-----|----|------------------|---------------|---------|-----|--------------|-----|------|
| >D> | AB | ACTAVIS GRP PTC | EQ 25MG BASE | A201762 | 001 | Feb 27, 2013 | Apr | DISC |
| >A> | @ | | EQ 25MG BASE | A201762 | 001 | Feb 27, 2013 | Apr | DISC |
| >D> | AB | | EQ 50MG BASE | A201762 | 002 | Feb 27, 2013 | Apr | DISC |
| >A> | @ | | EQ 50MG BASE | A201762 | 002 | Feb 27, 2013 | Apr | DISC |
| >D> | AB | | EQ 100MG BASE | A201762 | 003 | Feb 27, 2013 | Apr | DISC |
| >A> | @ | | EQ 100MG BASE | A201762 | 003 | Feb 27, 2013 | Apr | DISC |
| >D> | AB | | EQ 150MG BASE | A201762 | 004 | Feb 27, 2013 | Apr | DISC |
| >A> | @ | | EQ 150MG BASE | A201762 | 004 | Feb 27, 2013 | Apr | DISC |
| >D> | AB | | EQ 200MG BASE | A201762 | 005 | Feb 27, 2013 | Apr | DISC |
| >A> | @ | | EQ 200MG BASE | A201762 | 005 | Feb 27, 2013 | Apr | DISC |
| >D> | AB | | EQ 300MG BASE | A201762 | 006 | Feb 27, 2013 | Apr | DISC |
| >A> | @ | | EQ 300MG BASE | A201762 | 006 | Feb 27, 2013 | Apr | DISC |
| >D> | AB | | EQ 400MG BASE | A201762 | 007 | Feb 27, 2013 | Apr | DISC |
| >A> | @ | | EQ 400MG BASE | A201762 | 007 | Feb 27, 2013 | Apr | DISC |
| | AB | UNICHEM LABS LTD | EQ 25MG BASE | A202674 | 001 | Mar 08, 2016 | Feb | NEWA |
| | AB | | EQ 50MG BASE | A202674 | 002 | Mar 08, 2016 | Feb | NEWA |
| | AB | | EQ 100MG BASE | A202674 | 003 | Mar 08, 2016 | Feb | NEWA |
| | AB | | EQ 200MG BASE | A202674 | 004 | Mar 08, 2016 | Feb | NEWA |
| | AB | | EQ 300MG BASE | A202674 | 005 | Mar 08, 2016 | Feb | NEWA |
| | AB | | EQ 400MG BASE | A202674 | 006 | Mar 08, 2016 | Feb | NEWA |

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

| | | | | | | | |
|---|---------------------|--------------|---------|-----|--------------|-----|------|
| @ | ACTAVIS LABS FL INC | EQ 5MG BASE | A076049 | 001 | Jan 14, 2005 | Jan | DISC |
| @ | | EQ 10MG BASE | A076049 | 002 | Jan 14, 2005 | Jan | DISC |
| @ | | EQ 20MG BASE | A076049 | 003 | Jan 14, 2005 | Jan | DISC |
| @ | | EQ 40MG BASE | A076049 | 004 | Jan 14, 2005 | Jan | DISC |

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

| | | | | | | | | |
|----|---|---------------------|-------|---------|-----|--------------|-----|------|
| | @ | AUROLIFE PHARMA LLC | 324MG | A089894 | 001 | Dec 15, 1988 | Mar | CAHN |
| BX | + | SUN PHARM INDS | 324MG | A089338 | 001 | Feb 11, 1987 | Mar | CAHN |

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

| | | | | | | | |
|----|----------------|-------|---------|-----|--------------|-----|------|
| AB | SUN PHARM INDS | 200MG | A081030 | 001 | Apr 14, 1989 | Mar | CAHN |
| AB | | 300MG | A081031 | 001 | Apr 14, 1989 | Mar | CAHN |

RALOXIFENE HYDROCHLORIDE

TABLET; ORAL

RALOXIFENE HYDROCHLORIDE

| | | | | | | | |
|----|---------------------|------|---------|-----|--------------|-----|------|
| AB | AMNEAL PHARMS | 60MG | A208206 | 001 | Apr 08, 2016 | Mar | NEWA |
| AB | GLENMARK PHARMS LTD | 60MG | A204491 | 001 | Mar 22, 2016 | Mar | NEWA |

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ZANTAC

| | | | | | | | |
|----|-----------------------------|--------------------|---------|-----|--------------|-----|------|
| AP | + IGI LABS INC | EQ 25MG BASE/ML | N019090 | 001 | Oct 19, 1984 | Jan | CAHN |
| | ZANTAC IN PLASTIC CONTAINER | | | | | | |
| | @ IGI LABS INC | EQ 1MG BASE/ML | N019593 | 002 | Sep 27, 1991 | Jan | CAHN |
| | @ | EQ 50MG BASE/100ML | N019593 | 001 | Dec 17, 1986 | Jan | CAHN |

SYRUP; ORAL

RANITIDINE HYDROCHLORIDE

| | | | | | | | |
|-----|------------------|-----------------|---------|-----|--------------|-----|------|
| AA | NOSTRUM LABS INC | EQ 15MG BASE/ML | A091091 | 001 | Sep 20, 2011 | Mar | CAHN |
| >D> | AA | WOCKHARDT | A079211 | 001 | May 26, 2009 | Apr | DISC |
| >A> | @ | EQ 15MG BASE/ML | A079211 | 001 | May 26, 2009 | Apr | DISC |
| >D> | AA | EQ 15MG BASE/ML | A079212 | 001 | Feb 23, 2009 | Apr | DISC |
| >A> | @ | EQ 15MG BASE/ML | A079212 | 001 | Feb 23, 2009 | Apr | DISC |

RASAGILINE MESYLATE

TABLET; ORAL

RASAGILINE MESYLATE

| | | | | | | | |
|----|-----------------|---------------|---------|-----|--------------|-----|------|
| AB | ORCHID HLTHCARE | EQ 0.5MG BASE | A201970 | 001 | Mar 15, 2016 | Feb | NEWA |
| AB | | EQ 1MG BASE | A201970 | 002 | Mar 15, 2016 | Feb | NEWA |

RESERPINE

TABLET; ORAL

RESERPINE

@ HIKMA INTL PHARMS

0.1MG

A080975 001

Feb CAHN

@

0.25MG

A080975 002

Feb CAHN

@

1MG

A080975 003

Feb CAHN

RETAPAMULIN

OINTMENT; TOPICAL

ALTABAX

+ AQUA PHARMS LLC 1%

N022055 001 Apr 12, 2007 Jan CAHN

RIBOFLAVIN 5'-PHOSPHATE SODIUM

>A> SOLUTION/DROPS; OPHTHALMIC

>A> PHOTREXA

| | | | | | | | |
|-----|--------------|--------|---------|-----|--------------|-----|------|
| >A> | + AVEDRO INC | 0.146% | N203324 | 001 | Apr 15, 2016 | Apr | NEWA |
|-----|--------------|--------|---------|-----|--------------|-----|------|

>A> PHOTREXA VISCOUS IN DEXTROSE 20%

| | | | | | | | |
|-----|--------------|--------|---------|-----|--------------|-----|------|
| >A> | + AVEDRO INC | 0.146% | N203324 | 002 | Apr 15, 2016 | Apr | NEWA |
|-----|--------------|--------|---------|-----|--------------|-----|------|

RIFAMPIN

INJECTABLE; INJECTION

RIFAMPIN

| | | | | | | | | |
|-----|-------------------|--------------------|------------|---------|--------------|--------------|------|------|
| >D> | AP | BEDFORD | 600MG/VIAL | A064217 | 001 | Oct 29, 1999 | Apr | CAHN |
| >A> | AP | EUROHLTH INTL SARL | 600MG/VIAL | A064217 | 001 | Oct 29, 1999 | Apr | CAHN |
| AP | HIKMA PHARMS | 600MG/VIAL | A205039 | 001 | Mar 03, 2016 | Feb | NEWA | |
| AP | WATSON PHARMS INC | 600MG/VIAL | A206736 | 001 | Jan 19, 2016 | Jan | NEWA | |

RILUZOLE

TABLET; ORAL

RILUZOLE

| | | | | | | | |
|----|----------------|------|---------|-----|--------------|-----|------|
| AB | ALKEM LABS LTD | 50MG | A204048 | 001 | Mar 30, 2016 | Mar | NEWA |
|----|----------------|------|---------|-----|--------------|-----|------|

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

| | | | | | | | |
|----|------|-------|---------|-----|--------------|-----|------|
| AB | APIL | 5MG | N020835 | 002 | Apr 14, 2000 | Jan | CAHN |
| AB | | 30MG | N020835 | 001 | Mar 27, 1998 | Jan | CAHN |
| AB | + | 35MG | N020835 | 003 | May 25, 2002 | Jan | CAHN |
| | @ | 75MG | N020835 | 004 | Apr 16, 2007 | Jan | CAHN |
| AB | + | 150MG | N020835 | 005 | Apr 22, 2008 | Jan | CAHN |

TABLET, DELAYED RELEASE; ORAL

ATELVIA

| | | | | | | | |
|----|--------|------|---------|-----|--------------|-----|------|
| AB | + APIL | 35MG | N022560 | 001 | Oct 08, 2010 | Jan | CAHN |
|----|--------|------|---------|-----|--------------|-----|------|

RISPERIDONESOLUTION;ORAL
RISPERIDONE

| | | | | | | | | |
|-----|----|-----------|--------|---------|-----|--------------|-----|------|
| >D> | AA | WOCKHARDT | 1MG/ML | A078744 | 001 | Oct 08, 2009 | Apr | DISC |
| >A> | | @ | 1MG/ML | A078744 | 001 | Oct 08, 2009 | Apr | DISC |

RIVASTIGMINEFILM, EXTENDED RELEASE;TRANSDERMAL
RIVASTIGMINE

| | | | | | | | | |
|----|--|---------------|-------------|---------|-----|--------------|-----|------|
| AB | | ALVOGEN MALTA | 4.6MG/24HR | A204403 | 001 | Sep 03, 2015 | Jan | CAHN |
| AB | | | 9.5MG/24HR | A204403 | 002 | Sep 03, 2015 | Jan | CAHN |
| AB | | | 13.3MG/24HR | A204403 | 003 | Aug 31, 2015 | Jan | CAHN |

RIVASTIGMINE TARTRATECAPSULE;ORAL
EXELON

| | | | | | | | | |
|----|---|-----------------------|---------------|---------|-----|--------------|-----|------|
| AB | + | NOVARTIS | EQ 6MG BASE | N020823 | 006 | Apr 21, 2000 | Jan | CRLD |
| | | RIVASTIGMINE TARTRATE | | | | | | |
| AB | | AUROBINDO PHARMA LTD | EQ 1.5MG BASE | A204572 | 001 | Mar 25, 2016 | Mar | NEWA |
| AB | | | EQ 3MG BASE | A204572 | 002 | Mar 25, 2016 | Mar | NEWA |
| AB | | | EQ 4.5MG BASE | A204572 | 003 | Mar 25, 2016 | Mar | NEWA |
| AB | | | EQ 6MG BASE | A204572 | 004 | Mar 25, 2016 | Mar | NEWA |

RIZATRIPTAN BENZOATETABLET;ORAL
RIZATRIPTAN BENZOATE

| | | | | | | | | |
|----|--|------------------|--------------|---------|-----|--------------|-----|------|
| AB | | ALKEM LABS LTD | EQ 5MG BASE | A203269 | 001 | Feb 18, 2016 | Feb | NEWA |
| AB | | | EQ 10MG BASE | A203269 | 002 | Feb 18, 2016 | Feb | NEWA |
| AB | | NOSTRUM LABS INC | EQ 5MG BASE | A202047 | 001 | Dec 31, 2012 | Jan | CAHN |
| AB | | | EQ 10MG BASE | A202047 | 002 | Dec 31, 2012 | Jan | CAHN |

ROPIVACAINE HYDROCHLORIDEINJECTABLE;INJECTION
ROPIVACAINE HYDROCHLORIDE

| | | | | | | | | |
|----|--|-----------|--------|---------|-----|--------------|-----|------|
| AP | | AKORN INC | 5MG/ML | A203955 | 001 | Apr 11, 2016 | Mar | NEWA |
|----|--|-----------|--------|---------|-----|--------------|-----|------|

SOLUTION;INJECTION
NAROPIN

| | | | | | | | | |
|-----|---|--------------------|-----------------------|---------|-----|--------------|-----|------|
| AP | | FRESENIUS KABI USA | 20MG/10ML (2MG/ML) | N020533 | 001 | Sep 24, 1996 | Mar | CDFR |
| AP | | | 40MG/20ML (2MG/ML) | N020533 | 002 | Sep 24, 1996 | Mar | NEWA |
| >A> | | @ | 75MG/10ML (7.5MG/ML) | N020533 | 012 | Sep 24, 1996 | Apr | DISC |
| >A> | | | 75MG/10ML (7.5MG/ML) | N020533 | 012 | Sep 24, 1996 | Apr | NEWA |
| | | | 100MG/20ML (5MG/ML) | N020533 | 003 | Sep 24, 1996 | Mar | CDFR |
| AP | | | 100MG/10ML (10MG/ML) | N020533 | 005 | Sep 24, 1996 | Mar | NEWA |
| AP | | | 150MG/20ML (7.5MG/ML) | N020533 | 004 | Sep 24, 1996 | Mar | CDFR |
| AP | | | 150MG/30ML (5MG/ML) | N020533 | 008 | Sep 24, 1996 | Mar | NEWA |
| | | | 200MG/100ML (2MG/ML) | N020533 | 006 | Sep 24, 1996 | Mar | NEWA |
| AP | + | | 200MG/20ML (10MG/ML) | N020533 | 011 | Sep 24, 1996 | Mar | NEWA |
| | | | 400MG/200ML (2MG/ML) | N020533 | 007 | Sep 24, 1996 | Mar | NEWA |
| >D> | | | 500MG/100ML (5MG/ML) | N020533 | 009 | Sep 24, 1996 | Apr | CMS1 |
| >A> | | | 500MG/100ML (5MG/ML) | N020533 | 009 | Jan 04, 2011 | Apr | CMS1 |
| | | | 500MG/100ML (5MG/ML) | N020533 | 009 | Sep 24, 1996 | Mar | NEWA |
| >D> | | | 1GM/200ML (5MG/ML) | N020533 | 010 | Sep 24, 1996 | Apr | CMS1 |
| >A> | | | 1GM/200ML (5MG/ML) | N020533 | 010 | Jan 04, 2011 | Apr | CMS1 |
| | | | 1GM/200ML (5MG/ML) | N020533 | 010 | Sep 24, 1996 | Mar | NEWA |

ROPIVACAINE HYDROCHLORIDE

| | | | | | | | | |
|----|--|----------------|-----------------------|---------|-----|--------------|-----|------|
| AP | | HOSPIRA | 20MG/10ML (2MG/ML) | A090194 | 001 | Sep 23, 2014 | Mar | CDFR |
| AP | | | 40MG/20ML (2MG/ML) | A090194 | 005 | Sep 23, 2014 | Mar | NEWA |
| AP | | | 100MG/10ML (10MG/ML) | A090194 | 004 | Sep 23, 2014 | Mar | CDFR |
| AP | | | 150MG/30ML (5MG/ML) | A090194 | 002 | Sep 23, 2014 | Mar | CDFR |
| AP | | | 150MG/20ML (7.5MG/ML) | A090194 | 003 | Sep 23, 2014 | Mar | CDFR |
| AP | | | 200MG/20ML (10MG/ML) | A090194 | 006 | Sep 23, 2014 | Mar | NEWA |
| AP | | NAVINTA LLC | 150MG/30ML (5MG/ML) | A078601 | 002 | Jul 17, 2014 | Mar | CDFR |
| AP | | | 200MG/20ML (10MG/ML) | A078601 | 003 | Jul 17, 2014 | Mar | CDFR |
| AP | | SAGENT STRIDES | 40MG/20ML (2MG/ML) | A090318 | 001 | Sep 23, 2014 | Mar | CDFR |
| AP | | | 150MG/30ML (5MG/ML) | A090318 | 002 | Sep 23, 2014 | Mar | CDFR |
| AP | | | 150MG/20ML (7.5MG/ML) | A090318 | 003 | Sep 23, 2014 | Mar | CDFR |
| AP | | | 200MG/20ML (10MG/ML) | A090318 | 004 | Sep 23, 2014 | Mar | CDFR |

ROSUVASTATIN CALCIUMTABLET;ORAL
CRESTOR

| | | | | | | | | |
|-----|----------------------|-----------------|------|---------|-----|--------------|-----|------|
| >D> | IPR | 5MG | | N021366 | 002 | Aug 12, 2003 | Apr | CFTG |
| >A> | AB | 5MG | | N021366 | 002 | Aug 12, 2003 | Apr | CFTG |
| >D> | | 10MG | | N021366 | 003 | Aug 12, 2003 | Apr | CFTG |
| >A> | AB | 10MG | | N021366 | 003 | Aug 12, 2003 | Apr | CFTG |
| >D> | | 20MG | | N021366 | 004 | Aug 12, 2003 | Apr | CFTG |
| >A> | AB | 20MG | | N021366 | 004 | Aug 12, 2003 | Apr | CFTG |
| >D> | + | 40MG | | N021366 | 005 | Aug 12, 2003 | Apr | CFTG |
| >A> | AB | 40MG | | N021366 | 005 | Aug 12, 2003 | Apr | CFTG |
| >A> | ROSUVASTATIN CALCIUM | | | | | | | |
| >A> | AB | WATSON LABS INC | 5MG | A079167 | 001 | Apr 29, 2016 | Apr | NEWA |
| >A> | AB | | 10MG | A079167 | 002 | Apr 29, 2016 | Apr | NEWA |
| >A> | AB | | 20MG | A079167 | 003 | Apr 29, 2016 | Apr | NEWA |
| >A> | AB | | 40MG | A079167 | 004 | Apr 29, 2016 | Apr | NEWA |

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

| | | | | | | | | |
|---|----------------|---------------|--|---------|-----|--------------|-----|------|
| @ | SUN PHARM INDS | EQ 25MG BASE | | A077818 | 001 | Feb 06, 2007 | Mar | CAHN |
| @ | | EQ 50MG BASE | | A077818 | 002 | Feb 06, 2007 | Mar | CAHN |
| @ | | EQ 100MG BASE | | A077818 | 003 | Feb 06, 2007 | Mar | CAHN |

SILDENAFIL CITRATE

TABLET;ORAL

SILDENAFIL CITRATE

| | | | | | | | | | |
|-----|----|-----------------|---------------|--------------|---------|--------------|--------------|------|------|
| >D> | AB | ACTAVIS GRP PTC | EQ 20MG BASE | A200149 | 001 | Feb 25, 2013 | Apr | DISC | |
| >A> | | @ | EQ 20MG BASE | A200149 | 001 | Feb 25, 2013 | Apr | DISC | |
| | | @ | TEVA | EQ 25MG BASE | A077342 | 001 | Mar 09, 2016 | Feb | DISC |
| | | | EQ 25MG BASE | A077342 | 001 | Mar 09, 2016 | Feb | NEWA | |
| | | @ | EQ 50MG BASE | A077342 | 002 | Mar 09, 2016 | Feb | DISC | |
| | | | EQ 50MG BASE | A077342 | 002 | Mar 09, 2016 | Feb | NEWA | |
| | | @ | EQ 100MG BASE | A077342 | 003 | Mar 09, 2016 | Feb | DISC | |
| | | | EQ 100MG BASE | A077342 | 003 | Mar 09, 2016 | Feb | NEWA | |

SILODOSIN

CAPSULE;ORAL

RAPAFLO

| | | | | | | | | |
|-----|---|---------------------|-----|---------|-----|--------------|-----|------|
| >D> | + | ACTAVIS LABS UT INC | 4MG | N022206 | 001 | Oct 08, 2008 | Apr | CAHN |
| >D> | | | 8MG | N022206 | 002 | Oct 08, 2008 | Apr | CAHN |
| >A> | + | ALLERGAN SALES LLC | 4MG | N022206 | 001 | Oct 08, 2008 | Apr | CAHN |
| >A> | | | 8MG | N022206 | 002 | Oct 08, 2008 | Apr | CAHN |

SIMVASTATIN

| | | | | | | | | |
|-----|---------------------|--------------------|------|---------|-----|--------------|-----|------|
| >A> | SUSPENSION;ORAL | | | | | | | |
| >A> | SIMVASTATIN | | | | | | | |
| >A> | ROSEMONT PHARMS LTD | 20MG/5ML | | N206679 | 001 | Apr 21, 2016 | Apr | NEWA |
| >A> | + | 40MG/5ML | | N206679 | 002 | Apr 21, 2016 | Apr | NEWA |
| | TABLET;ORAL | | | | | | | |
| | SIMVASTATIN | | | | | | | |
| | @ | SUN PHARM INDS LTD | 5MG | A076285 | 001 | Dec 20, 2006 | Feb | DISC |
| | @ | | 10MG | A076285 | 002 | Dec 20, 2006 | Feb | DISC |
| | @ | | 20MG | A076285 | 003 | Dec 20, 2006 | Feb | DISC |
| | @ | | 40MG | A076285 | 004 | Dec 20, 2006 | Feb | DISC |
| | @ | | 80MG | A076285 | 005 | Jun 23, 2006 | Feb | DISC |

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION;IV (INFUSION)

AMMONUL

| | | | | | | | | |
|----|---|--|-----------------------------|---------|-----|--------------|-----|------|
| AP | + | MEDICIS | 10%;10% (5GM/50ML;5GM/50ML) | N020645 | 001 | Feb 17, 2005 | Feb | CFTG |
| AP | | SODIUM PHENYLACETATE AND SODIUM BENZOATE | | | | | | |
| AP | | AILEX PHARMS PVT LTD | 10%;10% (5GM/50ML;5GM/50ML) | A207096 | 001 | Feb 24, 2016 | Feb | NEWA |

SODIUM BICARBONATE

INJECTABLE;INJECTION

SODIUM BICARBONATE

| | | | | | | | | |
|--|-------------|-----------|--|---------|-----|--------------|-----|------|
| | HOSPIRA INC | 0.5MEQ/ML | | A202981 | 001 | Mar 04, 2016 | Feb | NEWA |
|--|-------------|-----------|--|---------|-----|--------------|-----|------|

SODIUM FLUORIDE F-18

| | | | | | | | |
|----|------------------------|--------------|---------|-----|--------------|-----|------|
| | INJECTABLE;INTRAVENOUS | | | | | | |
| | SODIUM FLUORIDE F-18 | | | | | | |
| AP | ZEVACOR PHARMA INC | 10-200mCi/ML | A203592 | 001 | Aug 18, 2015 | Feb | CAHN |

SODIUM IODIDE I-131

| | | | | | | | |
|--|---------------------|--------------|---------|-----|--------------|-----|------|
| | CAPSULE;ORAL | | | | | | |
| | SODIUM IODIDE I 131 | | | | | | |
| | JUBILANT DRAXIMAGE | 0.009-0.1mCi | N021305 | 006 | May 19, 2005 | Mar | CMS1 |
| | @ | 2-200mCi | N021305 | 004 | Nov 18, 2004 | Mar | CMS1 |

SODIUM PHENYL BUTYRATE

| | | | | | | | |
|--------|------------------------|-----------------|---------|-----|--------------|-----|------|
| | POWDER;ORAL | | | | | | |
| | BUPHENYL | | | | | | |
| AB | + HORIZON PHARMA INC | 3GM/TEASPOONFUL | N020573 | 001 | Apr 30, 1996 | Mar | CAHN |
| | TABLET;ORAL | | | | | | |
| | BUPHENYL | | | | | | |
| AB | + HORIZON PHARMA USA | 500MG | N020572 | 001 | May 13, 1996 | Mar | CAHN |
| | SODIUM PHENYL BUTYRATE | | | | | | |
| >A> AB | PAR PHARM | 500MG | A204395 | 001 | Apr 15, 2016 | Apr | NEWA |

SODIUM POLYSTYRENE SULFONATE

| | | | | | | | |
|----|------------------------------|-----------|---------|-----|--------------|-----|------|
| | POWDER;ORAL, RECTAL | | | | | | |
| | SODIUM POLYSTYRENE SULFONATE | | | | | | |
| AA | BELCHER PHARMS LLC | 454GM/BOT | A205727 | 001 | Feb 23, 2016 | Feb | NEWA |
| AA | INVATECH PHARMA | 454GM/BOT | A206815 | 001 | Feb 18, 2016 | Feb | NEWA |

SOTALOL HYDROCHLORIDE

| | | | | | | | |
|--|-----------------------|-------|---------|-----|--------------|-----|------|
| | TABLET;ORAL | | | | | | |
| | SOTALOL HYDROCHLORIDE | | | | | | |
| | @ IMPAX PHARMS | 80MG | A075663 | 001 | Nov 07, 2000 | Mar | DISC |
| | @ | 120MG | A075663 | 002 | Nov 07, 2000 | Mar | DISC |
| | @ | 160MG | A075663 | 003 | Nov 07, 2000 | Mar | DISC |
| | @ | 240MG | A075663 | 004 | Nov 07, 2000 | Mar | DISC |
| | @ SUN PHARM INDS | 80MG | A075515 | 001 | Oct 15, 2001 | Mar | CAHN |
| | @ | 80MG | A076576 | 001 | Apr 08, 2004 | Mar | CAHN |
| | @ | 120MG | A075515 | 004 | Oct 15, 2001 | Mar | CAHN |
| | @ | 120MG | A076576 | 002 | Apr 08, 2004 | Mar | CAHN |
| | @ | 160MG | A075515 | 002 | Oct 15, 2001 | Mar | CAHN |
| | @ | 160MG | A076576 | 003 | Apr 08, 2004 | Mar | CAHN |
| | @ | 240MG | A075515 | 003 | Oct 15, 2001 | Mar | CAHN |

SPIRONOLACTONE

| | | | | | | | |
|----|----------------|-------|---------|-----|--------------|-----|------|
| | TABLET;ORAL | | | | | | |
| | SPIRONOLACTONE | | | | | | |
| AB | SUN PHARM INDS | 25MG | A089424 | 001 | Jul 23, 1986 | Mar | CAHN |
| AB | | 50MG | A089424 | 002 | Aug 11, 1999 | Mar | CAHN |
| AB | | 100MG | A089424 | 003 | Aug 11, 1999 | Mar | CAHN |

SUCRALFATE

| | | | | | | | |
|----|-------------------|-----|---------|-----|--------------|-----|------|
| | TABLET;ORAL | | | | | | |
| | SUCRALFATE | | | | | | |
| AB | MYLAN IRELAND LTD | 1GM | A074415 | 001 | Jun 08, 1998 | Jan | CAHN |

SUGAMMADEX SODIUM

| | | | | | | | |
|--|----------------------|-----------------------------|---------|-----|--------------|-----|------|
| | SOLUTION;INTRAVENOUS | | | | | | |
| | BRIDION | | | | | | |
| | ORGANON SUB MERCK | EQ 200MG BASE/2ML (EQ 100MG | N022225 | 002 | Dec 15, 2015 | Jan | CPOT |
| | | BASE/ML) | | | | | |
| | + | EQ 500MG BASE/5ML (EQ 100MG | N022225 | 001 | Dec 15, 2015 | Jan | CPOT |
| | | BASE/ML) | | | | | |

SULFAMETHOXAZOLE

| | | | | | | | |
|--|-----------------------|-------|---------|-----|--|-----|------|
| | TABLET;ORAL | | | | | | |
| | SULFAMETHOXAZOLE | | | | | | |
| | @ AUROLIFE PHARMA LLC | 500MG | A085844 | 001 | | Feb | CAHN |

SULFAMETHOXAZOLE; TRIMETHOPRIM

| TABLET; ORAL | | BACTRIM | | | | | | | |
|-----------------------------------|------------------|-------------|---------|-----|--------------|--|--|-----|------|
| AB | SUN PHARM INDS | 400MG;80MG | N017377 | 001 | | | | Mar | CAHN |
| BACTRIM DS | | | | | | | | | |
| AB | + SUN PHARM INDS | 800MG;160MG | N017377 | 002 | | | | Mar | CAHN |
| SULFAMETHOXAZOLE AND TRIMETHOPRIM | | | | | | | | | |
| AB | SUN PHARM INDS | 800MG;160MG | A071017 | 001 | Aug 25, 1986 | | | Mar | CAHN |

SULFASALAZINE

| TABLET; ORAL | | SULFASALAZINE | | | | | | | |
|--------------|------------------|---------------|---------|-----|--------------|--|--|-----|------|
| | @ SUN PHARM INDS | 500MG | A089590 | 001 | Oct 19, 1987 | | | Mar | CAHN |

SULFISOXAZOLE

| TABLET; ORAL | | SULFISOXAZOLE | | | | | | | |
|--------------|-----------------------|---------------|---------|-----|--|--|--|-----|------|
| | @ AUROLIFE PHARMA LLC | 500MG | A085628 | 001 | | | | Feb | CAHN |

SULINDAC

| TABLET; ORAL | | SULINDAC | | | | | | | |
|--------------|----------------|----------|---------|-----|--------------|--|--|-----|------|
| AB | SUN PHARM INDS | 150MG | A072050 | 001 | Apr 17, 1991 | | | Mar | CAHN |
| AB | | 200MG | A072051 | 001 | Apr 17, 1991 | | | Mar | CAHN |

SUMATRIPTAN

| SPRAY; NASAL | | IMITREX | | | | | | | |
|--------------|-------------------|------------|---------|-----|--------------|--|--|-----|------|
| AB | + GLAXOSMITHKLINE | 5MG/SPRAY | N020626 | 001 | Aug 26, 1997 | | | Feb | CFTG |
| AB | + SUMATRIPTAN | 20MG/SPRAY | N020626 | 003 | Aug 26, 1997 | | | Feb | CFTG |
| SUMATRIPTAN | | | | | | | | | |
| AB | LANNETT | 5MG/SPRAY | A204841 | 001 | Feb 19, 2016 | | | Feb | NEWA |
| AB | | 20MG/SPRAY | A204841 | 002 | Feb 19, 2016 | | | Feb | NEWA |

SUMATRIPTAN SUCCINATE

| POWDER; INHALATION | | ONZETRA XSAIL | | | | | | | |
|------------------------|--------------------|---------------------------------------|---------|-----|--------------|--|--|-----|------|
| | + AVANIR PHARMS | EQ 11MG BASE | N206099 | 001 | Jan 27, 2016 | | | Jan | NEWA |
| SOLUTION; SUBCUTANEOUS | | | | | | | | | |
| ZEMBRACE SYMTOUCH | | | | | | | | | |
| | DR REDDYS LABS LTD | EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) | N208223 | 001 | Jan 28, 2016 | | | Jan | NEWA |

TAMOXIFEN CITRATE

| SOLUTION; ORAL | | SOLTAMOX | | | | | | | |
|-------------------|-----------------------|------------------|---------|-----|--------------|--|--|-----|------|
| | MIDATECH PHARMA US | EQ 10MG BASE/5ML | N021807 | 001 | Oct 29, 2005 | | | Jan | CAHN |
| TABLET; ORAL | | | | | | | | | |
| TAMOXIFEN CITRATE | | | | | | | | | |
| | @ ACTAVIS LABS FL INC | EQ 10MG BASE | A076179 | 001 | Feb 20, 2003 | | | Jan | DISC |
| | @ | EQ 20MG BASE | A076179 | 002 | Feb 20, 2003 | | | Jan | DISC |

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

| SOLUTION; INTRAVENOUS | | ULTRA-TECHNEKOW FM | | | | | | | |
|-----------------------|-----------------------|---------------------|---------|-----|--------------|--|--|-----|------|
| | + MALLINKRODT NUCLEAR | 1-19 CI/GENERATOR | N017243 | 003 | Feb 18, 2014 | | | Jan | CAHN |
| | @ | 0.25-3 CI/GENERATOR | N017243 | 002 | | | | Jan | CAHN |

TEGASEROD MALEATE

| TABLET; ORAL | | ZELNORM | | | | | | | |
|--------------|--------------------|-------------|---------|-----|--------------|--|--|-----|------|
| | @ US WORLDMEDS LLC | EQ 2MG BASE | N021200 | 001 | Jul 24, 2002 | | | Jan | CAHN |
| | @ | EQ 6MG BASE | N021200 | 002 | Jul 24, 2002 | | | Jan | CAHN |

TELITHROMYCIN

| TABLET; ORAL | | KETEK | | | | | | | |
|--------------|---------------------|-------|---------|-----|--------------|--|--|-----|------|
| | @ SANOFI AVENTIS US | 300MG | N021144 | 002 | Feb 09, 2005 | | | Mar | DISC |
| | @ | 400MG | N021144 | 001 | Apr 01, 2004 | | | Mar | DISC |

TELMISARTAN

TABLET; ORAL

TELMISARTAN

| | | | | | | | | |
|-----|----|-------------------|------|---------|-----|--------------|-----|------|
| >A> | AB | HETERO LABS LTD V | 20MG | A205901 | 001 | Apr 22, 2016 | Apr | NEWA |
| >A> | AB | | 40MG | A205901 | 002 | Apr 22, 2016 | Apr | NEWA |
| >A> | AB | | 80MG | A205901 | 003 | Apr 22, 2016 | Apr | NEWA |

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

| | | | | | | | | |
|----|--|----------------|--------|---------|-----|--------------|-----|------|
| AB | | SUN PHARM INDS | 7.5MG | A078581 | 001 | Sep 08, 2009 | Mar | CAHN |
| | | @ | 15MG | A071174 | 001 | Jul 10, 1986 | Mar | CAHN |
| AB | | | 22.5MG | A071175 | 002 | Sep 14, 2009 | Mar | CAHN |
| | | @ | 30MG | A071175 | 001 | Jul 10, 1986 | Mar | CAHN |

TEMOZOLOMIDE

CAPSULE; ORAL

TEMOZOLOMIDE

| | | | | | | | | |
|-----|----|----------------------|-------|---------|-----|--------------|-----|------|
| AB | | IDT AUSTRALIA LTD | 5MG | A206413 | 001 | Apr 12, 2016 | Mar | NEWA |
| AB | | | 20MG | A206413 | 002 | Apr 12, 2016 | Mar | NEWA |
| AB | | | 100MG | A206413 | 003 | Apr 12, 2016 | Mar | NEWA |
| AB | | | 140MG | A206413 | 004 | Apr 12, 2016 | Mar | NEWA |
| AB | | | 180MG | A206413 | 005 | Apr 12, 2016 | Mar | NEWA |
| AB | | | 250MG | A206413 | 006 | Apr 12, 2016 | Mar | NEWA |
| AB | | KREMERS URBAN PHARMS | 5MG | A203898 | 001 | Feb 10, 2016 | Jan | NEWA |
| AB | | | 20MG | A203898 | 002 | Feb 10, 2016 | Jan | NEWA |
| AB | | | 100MG | A203898 | 003 | Feb 10, 2016 | Jan | NEWA |
| AB | | | 140MG | A203898 | 004 | Feb 10, 2016 | Jan | NEWA |
| AB | | | 180MG | A203898 | 005 | Feb 10, 2016 | Jan | NEWA |
| AB | | | 250MG | A203898 | 006 | Feb 10, 2016 | Jan | NEWA |
| AB | | LANNETT HOLDINGS INC | 5MG | A202750 | 001 | Mar 23, 2016 | Mar | NEWA |
| AB | | | 20MG | A202750 | 002 | Mar 23, 2016 | Mar | NEWA |
| AB | | | 100MG | A202750 | 003 | Mar 23, 2016 | Mar | NEWA |
| AB | | | 140MG | A202750 | 004 | Mar 23, 2016 | Mar | NEWA |
| AB | | | 180MG | A202750 | 005 | Mar 23, 2016 | Mar | NEWA |
| AB | | | 250MG | A202750 | 006 | Mar 23, 2016 | Mar | NEWA |
| >A> | AB | LOTUS PHARM CO LTD | 5MG | A206309 | 001 | Apr 27, 2016 | Apr | NEWA |
| >A> | AB | | 20MG | A206309 | 002 | Apr 27, 2016 | Apr | NEWA |
| >A> | AB | | 100MG | A206309 | 003 | Apr 27, 2016 | Apr | NEWA |
| >A> | AB | | 140MG | A206309 | 004 | Apr 27, 2016 | Apr | NEWA |
| >A> | AB | | 180MG | A206309 | 005 | Apr 27, 2016 | Apr | NEWA |
| >A> | AB | | 250MG | A206309 | 006 | Apr 27, 2016 | Apr | NEWA |

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

| | | | | | | | | | |
|-----|----|---|--------------------|--------|---------|-----|--------------|-----|------|
| >D> | AP | + | BEDFORD | 1MG/ML | A076770 | 001 | Apr 23, 2004 | Apr | CAHN |
| >A> | AP | + | EUROHLTH INTL SARL | 1MG/ML | A076770 | 001 | Apr 23, 2004 | Apr | CAHN |

TABLET; ORAL

TERBUTALINE SULFATE

@ IMPAX LABS

@

LANNETT

2.5MG

5MG

2.5MG

5MG

| | | | | |
|---------|-----|--------------|-----|------|
| A075877 | 001 | Jun 26, 2001 | Mar | DISC |
| A075877 | 002 | Jun 26, 2001 | Mar | DISC |
| A077152 | 001 | Mar 25, 2005 | Mar | CTEC |
| A077152 | 002 | Mar 25, 2005 | Mar | CTEC |

TESTOSTERONE

FILM, EXTENDED RELEASE; TRANSDERMAL

ANDRODERM

| | | | | | | | |
|---|--------------------|------------|---------|-----|--------------|-----|------|
| + | ALLERGAN SALES LLC | 2MG/24HR | N020489 | 003 | Oct 20, 2011 | Mar | CAHN |
| @ | | 2.5MG/24HR | N020489 | 001 | Sep 29, 1995 | Mar | CAHN |
| + | | 4MG/24HR | N020489 | 004 | Oct 20, 2011 | Mar | CAHN |
| @ | | 5MG/24HR | N020489 | 002 | May 02, 1997 | Mar | CAHN |

PELLET; IMPLANTATION

TESTOPEL

+ AUXILIUM PHARMS INC 75MG

A080911 001 Mar CAHN

TABLET, EXTENDED RELEASE; BUCCAL

STRIANT

+ AUXILIUM PHARMS INC 30MG

N021543 001 Jun 19, 2003 Mar CAHN

TETRABENAZINE

TABLET; ORAL

TETRABENAZINE

| | | | | | | |
|----|-------------------|--------|---------|-----|--------------|----------|
| AB | HETERO LABS LTD V | 12.5MG | A204574 | 001 | Feb 03, 2016 | Jan NEWA |
| AB | | 25MG | A204574 | 002 | Feb 03, 2016 | Jan NEWA |

TETRACAINE HYDROCHLORIDE

SOLUTION; OPHTHALMIC

TETRACAINE HYDROCHLORIDE

| | | | | | | |
|---|---------------|------|---------|-----|--------------|----------|
| + | ALCON RES LTD | 0.5% | N208135 | 001 | Feb 29, 2016 | Feb NEWA |
|---|---------------|------|---------|-----|--------------|----------|

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

TETRACYCLINE HYDROCHLORIDE

| | | | | | | |
|--------|--------------------|-------|---------|-----|--------------|----------|
| >D> | @ CHARTWELL CIENCA | 250MG | A062752 | 001 | Aug 12, 1988 | Apr CMFD |
| >A> AB | | 250MG | A062752 | 001 | Aug 12, 1988 | Apr CMFD |
| >D> | @ | 500MG | A062752 | 002 | Aug 12, 1988 | Apr CMFD |
| >A> AB | | 500MG | A062752 | 002 | Aug 12, 1988 | Apr CMFD |
| | @ SUN PHARM INDS | 250MG | A060736 | 001 | | Mar CAHN |
| | @ | 500MG | A060736 | 002 | | Mar CAHN |

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

| | | | | | | |
|---|---------------------|-------|---------|-----|--------------|----------|
| | AUXILIUM PHARMS INC | 200MG | A087943 | 001 | Aug 22, 1983 | Mar CAHN |
| | | 300MG | A087944 | 001 | Aug 22, 1983 | Mar CAHN |
| + | | 400MG | A081034 | 001 | Feb 28, 1992 | Mar CAHN |

SOLUTION, ELIXIR; ORAL

ELIXOPHYLLIN

| | | | | | | |
|---|------------------|-----------|---------|-----|--|----------|
| + | NOSTRUM LABS INC | 80MG/15ML | A085186 | 001 | | Jan CAHN |
|---|------------------|-----------|---------|-----|--|----------|

TABLET, EXTENDED RELEASE; ORAL

THEOCHRON

| | | | | | | |
|----|------------------|-------|---------|-----|--------------|----------|
| AB | NOSTRUM LABS INC | 100MG | A088320 | 001 | Feb 21, 1985 | Jan CAHN |
| AB | | 200MG | A088321 | 001 | Feb 21, 1985 | Jan CAHN |
| | @ | 300MG | A087400 | 002 | Jan 11, 1983 | Jan CAHN |

THEOPHYLLINE

| | | | | | | |
|----|-------------------|-------|---------|-----|--------------|----------|
| AB | MYLAN IRELAND LTD | 400MG | A040560 | 003 | Apr 21, 2006 | Jan CAHN |
| AB | + | 600MG | A040560 | 002 | Apr 21, 2006 | Jan CAHN |

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

| | | | | | | |
|----|----------------|-------|---------|-----|--------------|----------|
| AB | SUN PHARM INDS | 10MG | A089953 | 004 | Aug 01, 1986 | Mar CAHN |
| | @ | 15MG | A088461 | 001 | Nov 18, 1983 | Mar CAHN |
| AB | | 25MG | A089953 | 003 | Aug 01, 1986 | Mar CAHN |
| AB | | 50MG | A089953 | 002 | Aug 01, 1986 | Mar CAHN |
| AB | | 100MG | A089953 | 001 | Oct 07, 1988 | Mar CAHN |
| | @ | 150MG | A088737 | 001 | Sep 26, 1984 | Mar CAHN |
| | @ | 200MG | A088738 | 001 | Oct 16, 1984 | Mar CAHN |

THIOTHIXENE

CAPSULE; ORAL

THIOTHIXENE

| | | | | | | |
|---|--------|------|---------|-----|--------------|----------|
| @ | SANDOZ | 1MG | A071610 | 001 | Jun 24, 1987 | Mar DISC |
| @ | | 2MG | A071570 | 001 | Jun 24, 1987 | Mar DISC |
| @ | | 5MG | A071529 | 001 | Jun 24, 1987 | Mar DISC |
| @ | | 10MG | A071530 | 001 | Jun 24, 1987 | Mar DISC |

TINIDAZOLE

TABLET; ORAL

TINIDAZOLE

| | | | | | | |
|--------|-------------------|-------|---------|-----|--------------|----------|
| >D> AB | UNIQUE PHARM LABS | 250MG | A202489 | 001 | Oct 09, 2013 | Apr CTEC |
| >A> BX | | 250MG | A202489 | 001 | Oct 09, 2013 | Apr CTEC |
| >D> AB | | 500MG | A202489 | 002 | Oct 09, 2013 | Apr CTEC |
| >A> BX | | 500MG | A202489 | 002 | Oct 09, 2013 | Apr CTEC |

TOFACITINIB CITRATE

TABLET, EXTENDED RELEASE;ORAL
XELJANZ XR

+ PFIZER INC EQ 11MG BASE N208246 001 Feb 23, 2016 Feb NEWA

TOLAZAMIDE

TABLET;ORAL
TOLAZAMIDE

@ SUN PHARM INDS 100MG A071357 001 Jul 16, 1987 Mar CAHN
@ 250MG A071358 001 Jul 16, 1987 Mar CAHN
@ 500MG A071359 001 Jul 16, 1987 Mar CAHN

TOLMETIN SODIUM

CAPSULE;ORAL
TOLMETIN SODIUM

@ SUN PHARM INDS EQ 400MG BASE A073311 001 Nov 27, 1991 Mar CAHN

TABLET;ORAL
TOLMETIN SODIUM

AB SUN PHARM INDS EQ 200MG BASE A073310 001 Nov 27, 1991 Mar CAHN

TOPIRAMATE

TABLET;ORAL
TOPIRAMATE

>D> AB ACTAVIS TOTOWA 25MG A078637 001 Feb 27, 2013 Apr DISC
>A> @ 25MG A078637 001 Feb 27, 2013 Apr DISC
AB 25MG A078637 001 Feb 27, 2013 Jan CAHN
>D> AB 50MG A078637 002 Feb 27, 2013 Apr DISC
>A> @ 50MG A078637 002 Feb 27, 2013 Apr DISC
AB 50MG A078637 002 Feb 27, 2013 Jan CAHN
>D> AB 100MG A078637 003 Feb 27, 2013 Apr DISC
>A> @ 100MG A078637 003 Feb 27, 2013 Apr DISC
AB 100MG A078637 003 Feb 27, 2013 Jan CAHN
>D> AB 200MG A078637 004 Feb 27, 2013 Apr DISC
>A> @ 200MG A078637 004 Feb 27, 2013 Apr DISC
AB 200MG A078637 004 Feb 27, 2013 Jan CAHN

TRAMADOL HYDROCHLORIDE

TABLET;ORAL
TRAMADOL HYDROCHLORIDE

AB ACI HEALTHCARE LTD 50MG A202075 001 Nov 28, 2011 Mar CAHN
AB SUN PHARM INDS 50MG A076100 001 Jun 20, 2002 Mar CAHN

TABLET, EXTENDED RELEASE;ORAL
ULTRAM ER

AB1 + VALEANT PHARMS 100MG N021692 001 Sep 08, 2005 Mar CAHN
AB1 200MG N021692 002 Sep 08, 2005 Mar CAHN
AB1 300MG N021692 003 Sep 08, 2005 Mar CAHN

TRANEXAMIC ACID

INJECTABLE;INJECTION
TRANEXAMIC ACID

AP AUROBINDO PHARMA LTD 100MG/ML A205035 001 Jan 14, 2016 Jan NEWA
AP NORTH CREEK PHARMS 100MG/ML A202755 001 Feb 25, 2016 Feb NEWA

TRAZODONE HYDROCHLORIDE

TABLET;ORAL
TRAZODONE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC 50MG A072484 001 Apr 30, 1990 Feb CAHN
AB SUN PHARM INDS 50MG A073137 002 Mar 24, 1993 Mar CAHN
AB 100MG A073137 001 Mar 24, 1993 Mar CAHN
AB 150MG A073137 003 Dec 22, 1995 Mar CAHN

TRETINOIN

CREAM;TOPICAL
TRETINOIN

AB ELAN PHARMA INTL LTD 0.025% A075264 001 Dec 24, 1998 Feb CAHN
AB1 0.05% A075265 001 Dec 24, 1998 Feb CAHN
AB 0.1% A075213 001 Dec 24, 1998 Feb CAHN

GEL;TOPICAL
TRETINOIN

AB ELAN PHARMA INTL LTD 0.01% A075589 001 Jun 11, 2002 Feb CAHN
AB 0.025% A075529 001 Feb 22, 2000 Feb CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE

| | | | | | | | |
|----|---------------------------------|-------|---------|-----|--------------|-----|------|
| | CAPSULE;ORAL | | | | | | |
| | TRIMETHOBENZAMIDE HYDROCHLORIDE | | | | | | |
| AB | SUN PHARM INDS | 300MG | A076570 | 001 | Aug 28, 2003 | Mar | CAHN |

TRIMETHOPRIM

| | | | | | | | |
|--|------------------|-------|---------|-----|--------------|-----|------|
| | TABLET;ORAL | | | | | | |
| | TRIMETHOPRIM | | | | | | |
| | @ SUN PHARM INDS | 200MG | A070495 | 001 | Sep 24, 1986 | Mar | CAHN |

TRIMETHOPRIM HYDROCHLORIDE

| | | | | | | | |
|--|---------------|------------------|---------|-----|--------------|-----|------|
| | SOLUTION;ORAL | | | | | | |
| | PRIMSOL | | | | | | |
| | @ AYTU PHARMS | EQ 25MG BASE/5ML | A074374 | 001 | Jun 23, 1995 | Jan | CAHN |
| | + | EQ 50MG BASE/5ML | N074973 | 001 | Jan 24, 2000 | Jan | CAHN |

TRIMIPRAMINE MALEATE

| | | | | | | | | |
|-----|----------------------|----------------|---------------|---------|-----|--------------|-----|------|
| | CAPSULE;ORAL | | | | | | | |
| | TRIMIPRAMINE MALEATE | | | | | | | |
| >A> | AB | CROSSMEDIKA SA | EQ 25MG BASE | A208127 | 001 | Apr 15, 2016 | Apr | NEWA |
| >A> | AB | | EQ 50MG BASE | A208127 | 002 | Apr 15, 2016 | Apr | NEWA |
| >A> | AB | | EQ 100MG BASE | A208127 | 003 | Apr 15, 2016 | Apr | NEWA |

TRIPTORELIN PAMOATE

| | | | | | | | | |
|-----|--------------------------|---------------------|----------------------|---------|-----|--------------|-----|------|
| | INJECTABLE;INTRAMUSCULAR | | | | | | | |
| | TRELSTAR | | | | | | | |
| >D> | + | ACTAVIS LABS UT INC | EQ 3.75MG BASE/VIAL | N020715 | 001 | Jun 15, 2000 | Apr | CAHN |
| >D> | + | | EQ 11.25MG BASE/VIAL | N021288 | 001 | Jun 29, 2001 | Apr | CAHN |
| >D> | + | | EQ 22.5MG BASE/VIAL | N022437 | 001 | Mar 10, 2010 | Apr | CAHN |
| >A> | + | ALLERGAN SALES LLC | EQ 3.75MG BASE/VIAL | N020715 | 001 | Jun 15, 2000 | Apr | CAHN |
| >A> | + | | EQ 11.25MG BASE/VIAL | N021288 | 001 | Jun 29, 2001 | Apr | CAHN |
| >A> | + | | EQ 22.5MG BASE/VIAL | N022437 | 001 | Mar 10, 2010 | Apr | CAHN |

TROSPIUM CHLORIDE

| | | | | | | | | |
|-----|--------------------------------|------------|------|---------|-----|--------------|-----|------|
| | CAPSULE, EXTENDED RELEASE;ORAL | | | | | | | |
| | TROSPIUM CHLORIDE | | | | | | | |
| >D> | AB | SANDOZ INC | 60MG | A091635 | 001 | Apr 29, 2015 | Apr | DISC |
| >A> | | @ | 60MG | A091635 | 001 | Apr 29, 2015 | Apr | DISC |

UNOPROSTONE ISOPROPYL

| | | | | | | | |
|--|---------------------------|-------|---------|-----|--------------|-----|------|
| | SOLUTION/DROPS;OPHTHALMIC | | | | | | |
| | RESCULA | | | | | | |
| | @ R-TECH UENO LTD | 0.15% | N021214 | 001 | Aug 03, 2000 | Mar | DISC |
| | @ SUCAMPO PHARMA LLC | 0.15% | N021214 | 001 | Aug 03, 2000 | Mar | CAHN |

URSODIOL

| | | | | | | | |
|----|----------------------|-------|---------|-----|--------------|-----|------|
| | CAPSULE;ORAL | | | | | | |
| | ACTIGALL | | | | | | |
| | @ ALLERGAN SALES LLC | 150MG | N019594 | 001 | Dec 31, 1987 | Mar | CAHN |
| AB | + | 300MG | N019594 | 002 | Dec 31, 1987 | Mar | CAHN |

VALGANCICLOVIR HYDROCHLORIDE

| | | | | | | | |
|----|------------------------------|---------------|---------|-----|--------------|-----|------|
| | TABLET;ORAL | | | | | | |
| | VALGANCICLOVIR HYDROCHLORIDE | | | | | | |
| AB | AUROBINDO PHARMA LTD | EQ 450MG BASE | A204750 | 001 | Mar 31, 2016 | Mar | NEWA |
| AB | HETERO LABS LTD V | EQ 450MG BASE | A205166 | 001 | Mar 18, 2016 | Mar | NEWA |

VALPROATE SODIUM

| | | | | | | | | |
|-----|----------------------|--------------------|------------------|---------|-----|--------------|-----|------|
| | INJECTABLE;INJECTION | | | | | | | |
| | VALPROATE SODIUM | | | | | | | |
| >D> | AP | BEDFORD | EQ 100MG BASE/ML | A076295 | 001 | Nov 14, 2002 | Apr | CAHN |
| >A> | AP | EUROHLTH INTL SARL | EQ 100MG BASE/ML | A076295 | 001 | Nov 14, 2002 | Apr | CAHN |

VALPROIC ACID

| | | | | | | | |
|----|------------------|-----------|---------|-----|--------------|-----|------|
| | CAPSULE;ORAL | | | | | | |
| | VALPROIC ACID | | | | | | |
| AB | BIONPHARMA INC | 250MG | A073484 | 001 | Jun 29, 1993 | Jan | CAHN |
| | SYRUP;ORAL | | | | | | |
| | VALPROIC ACID | | | | | | |
| AA | NOSTRUM LABS INC | 250MG/5ML | A090517 | 001 | May 28, 2010 | Mar | CAHN |

VANCOMYCIN HYDROCHLORIDEINJECTABLE; INJECTION
VANCOMYCIN HYDROCHLORIDE

| | | | | | | | |
|----|----------------------|--------------------|---------|-----|--------------|-----|------|
| AP | AUROBINDO PHARMA LTD | EQ 500MG BASE/VIAL | A205780 | 001 | Mar 31, 2016 | Mar | NEWA |
| AP | | EQ 1GM BASE/VIAL | A205780 | 002 | Mar 31, 2016 | Mar | NEWA |
| AP | | EQ 5GM BASE/VIAL | A205779 | 001 | Mar 29, 2016 | Mar | NEWA |
| AP | | EQ 10GM BASE/VIAL | A205779 | 002 | Mar 29, 2016 | Mar | NEWA |
| AP | GLAND PHARMA LTD | EQ 500MG BASE/VIAL | A205694 | 001 | Jan 21, 2016 | Jan | NEWA |
| AP | | EQ 1GM BASE/VIAL | A205694 | 002 | Jan 21, 2016 | Jan | NEWA |

VECURONIUM BROMIDEINJECTABLE; INJECTION
VECURONIUM BROMIDE

| | | | | | | | | |
|-----|----|--------------------|-----------|---------|-----|--------------|-----|------|
| >D> | AP | BEDFORD | 10MG/VIAL | A075549 | 001 | Jun 13, 2000 | Apr | CAHN |
| >D> | AP | | 20MG/VIAL | A075549 | 002 | Jun 13, 2000 | Apr | CAHN |
| >A> | AP | EUROHLTH INTL SARL | 10MG/VIAL | A075549 | 001 | Jun 13, 2000 | Apr | CAHN |
| >A> | AP | | 20MG/VIAL | A075549 | 002 | Jun 13, 2000 | Apr | CAHN |
| | AP | SAGENT PHARMS | 10MG/VIAL | A078274 | 001 | Dec 29, 2008 | Jan | CAHN |
| | AP | | 20MG/VIAL | A078274 | 002 | Dec 29, 2008 | Jan | CAHN |

>A> VENETOCLAX

>A> TABLET; ORAL

>A> VENCLEXTA

| | | | | | | | | |
|-----|--|------------|-------|---------|-----|--------------|-----|------|
| >A> | | ABBVIE INC | 10MG | N208573 | 001 | Apr 11, 2016 | Apr | NEWA |
| >A> | | | 50MG | N208573 | 002 | Apr 11, 2016 | Apr | NEWA |
| >A> | | + | 100MG | N208573 | 003 | Apr 11, 2016 | Apr | NEWA |

VERAPAMIL HYDROCHLORIDEINJECTABLE; INJECTION
CALAN

| | | | | | | | | |
|-----|----|--------------------------------|--------------------|---------|-----|--------------|-----|------|
| >D> | | @ EXELA PHARMA SCS LLC | 2.5MG/ML | N018925 | 001 | Mar 30, 1984 | Apr | CMFD |
| | | SOLUTION; INTRAVENOUS | | | | | | |
| | | VERAPAMIL HYDROCHLORIDE | | | | | | |
| >A> | AP | EXELA PHARMA SCS LLC | 5MG/2ML (2.5MG/ML) | N018925 | 001 | Mar 30, 1984 | Apr | CMFD |
| | | TABLET, EXTENDED RELEASE; ORAL | | | | | | |
| | | CALAN SR | | | | | | |
| | | @ PFIZER | 180MG | N019152 | 002 | Dec 15, 1989 | Feb | DISC |

VINORELBINE TARTRATEINJECTABLE; INJECTION
VINORELBINE TARTRATE

| | | | | | | | | |
|-----|----|--------------------|-----------------|---------|-----|--------------|-----|------|
| >D> | AP | BEDFORD | EQ 10MG BASE/ML | A076461 | 001 | Dec 11, 2003 | Apr | CAHN |
| >A> | AP | EUROHLTH INTL SARL | EQ 10MG BASE/ML | A076461 | 001 | Dec 11, 2003 | Apr | CAHN |

VORICONAZOLEFOR SUSPENSION; ORAL
VORICONAZOLE

| | | | | | | | |
|----|---------------|-----------|---------|-----|--------------|-----|------|
| AB | AMNEAL PHARMS | 200MG/5ML | A205034 | 001 | Apr 13, 2016 | Mar | NEWA |
|----|---------------|-----------|---------|-----|--------------|-----|------|

INJECTABLE; IV (INFUSION)
VORICONAZOLE

| | | | | | | | |
|----|-------------|------------|---------|-----|--------------|-----|------|
| AP | ALVOGEN INC | 200MG/VIAL | A206398 | 001 | Mar 23, 2016 | Mar | NEWA |
|----|-------------|------------|---------|-----|--------------|-----|------|

TABLET; ORAL
VORICONAZOLE

| | | | | | | | |
|----|----------------------|-------|---------|-----|--------------|-----|------|
| AB | AUROBINDO PHARMA LTD | 50MG | A206837 | 001 | Jan 22, 2016 | Jan | NEWA |
| AB | | 200MG | A206837 | 002 | Jan 22, 2016 | Jan | NEWA |

XENON XE-133GAS; INHALATION
XENON XE 133

| | | | | | | | |
|--|----------------|------------|---------|-----|--|-----|------|
| | LANTHEUS MEDCL | 20mCi/VIAL | N017284 | 002 | | Feb | CTEC |
|--|----------------|------------|---------|-----|--|-----|------|

| | | | | | | | |
|--|---------------------|------------|---------|-----|--------------|-----|------|
| | MALLINKRODT NUCLEAR | 10mCi/VIAL | N018327 | 001 | Mar 09, 1982 | Feb | CMFD |
|--|---------------------|------------|---------|-----|--------------|-----|------|

| | | | | | | | |
|--|--|------------|---------|-----|--------------|-----|------|
| | | 20mCi/VIAL | N018327 | 002 | Mar 09, 1982 | Feb | CMFD |
|--|--|------------|---------|-----|--------------|-----|------|

ZOLMITRIPTAN

TABLET; ORAL

ZOLMITRIPTAN

| | | | | | | | | |
|-----|----|----------------------|-------|---------|-----|--------------|-----|------|
| >A> | AB | AUROBINDO PHARMA LTD | 2.5MG | A207021 | 001 | May 11, 2016 | Apr | NEWA |
| >A> | AB | | 5MG | A207021 | 002 | May 11, 2016 | Apr | NEWA |

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

| | | | | | |
|------------------|------|---------|-----|--------------|----------|
| @ SUN PHARM INDS | 5MG | A077288 | 001 | Apr 23, 2007 | Mar CAHN |
| @ | 10MG | A077288 | 002 | Apr 23, 2007 | Mar CAHN |

ZONISAMIDE

CAPSULE; ORAL

ZONEGRAN

| | | | | | | |
|----|---------------------|-------|---------|-----|--------------|----------|
| AB | SUNOVION PHARMS INC | 25MG | N020789 | 003 | Aug 22, 2003 | Feb CAHN |
| AB | | 50MG | N020789 | 002 | Aug 22, 2003 | Feb CAHN |
| AB | + | 100MG | N020789 | 001 | Mar 27, 2000 | Feb CAHN |
| | ZONISAMIDE | | | | | |
| AB | BIONPHARMA INC | 25MG | A077813 | 001 | Aug 16, 2006 | Jan CAHN |
| AB | | 50MG | A077813 | 002 | Aug 16, 2006 | Jan CAHN |
| AB | | 100MG | A077813 | 003 | Aug 16, 2006 | Jan CAHN |
| | @ SUN PHARM INDS | 25MG | A077635 | 001 | Dec 22, 2005 | Mar CAHN |
| | @ | 50MG | A077635 | 002 | Dec 22, 2005 | Mar CAHN |
| | @ | 100MG | A077635 | 003 | Dec 22, 2005 | Mar CAHN |

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL

EXCEDRIN (MIGRAINE)

+ GLAXOSMITHKLINE CONS 250MG;250MG;65MG N020802 001 Jan 14, 1998 Feb CAHN

BUDESONIDE

SPRAY, METERED;NASAL

BUDESONIDE

>A> APOTEX INC 0.032MG/SPRAY A078949 002 Nov 20, 2015 Apr NEWA

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

BIONPHARMA INC 5MG N022429 001 Jul 23, 2009 Jan CAHN

+ 10MG N022429 004 Jul 23, 2009 Jan CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

BIONPHARMA INC 5MG N022429 003 Jul 23, 2009 Jan CAHN

+ 10MG N022429 002 Jul 23, 2009 Jan CAHN

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

>D> CYPRESS PHARM 5MG/5ML A090300 001 Oct 10, 2008 Apr DISC

>A> @ 5MG/5ML A090300 001 Oct 10, 2008 Apr DISC

NOSTRUM LABS INC 5MG/5ML A091327 001 Oct 17, 2011 Mar CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

>D> CYPRESS PHARM 5MG/5ML A090300 002 Oct 10, 2008 Apr DISC

>A> @ 5MG/5ML A090300 002 Oct 10, 2008 Apr DISC

NOSTRUM LABS INC 5MG/5ML A091327 002 Oct 17, 2011 Mar CAHN

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

NOVEL LABS INC 5MG A206793 001 Mar 08, 2016 Feb NEWA

10MG A206793 002 Mar 08, 2016 Feb NEWA

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

CHLORPHENIRAMINE MALEATE

@ AUROLIFE PHARMA LLC 12MG A070797 001 Aug 12, 1988 Feb CAHN

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

BIONPHARMA INC 25MG;EQ 200MG FREE ACID AND A090397 001 Nov 22, 2010 Jan CAHN

POTASSIUM SALT

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

>A> AUROBINDO PHARMA LTD 10MG A206531 001 Apr 26, 2016 Apr NEWA

>A> 20MG A206531 002 Apr 26, 2016 Apr NEWA

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

APOTEX TECHNOLOGIES 0.05MG/SPRAY A208150 001 Feb 29, 2016 Feb NEWA

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

BIONPHARMA INC EQ 200MG FREE ACID AND POTASSIUM A078682 001 Mar 24, 2009 Jan CAHN

SALT

MIDOL LIQUID GELS

+ BIONPHARMA INC 200MG N021472 001 Oct 18, 2002 Jan CAHN

TABLET;ORAL

IBUPROFEN

@ SUN PHARM INDS 200MG A070493 001 Dec 24, 1985 Mar CAHN

@ 200MG A070908 001 Sep 26, 1986 Mar CAHN

@ 200MG A071462 001 Oct 02, 1986 Mar CAHN

LEVONORGESTREL

TABLET;ORAL

HER STYLE

| | | | | | | | |
|-----|----------------------|--------|---------|-----|--------------|-----|------|
| | NOVAST LABS LTD | 1.5MG | A207976 | 001 | Mar 11, 2016 | Feb | NEWA |
| | LEVONORGESTREL | | | | | | |
| | GLENMARK PHARMS LTD | 1.5MG | A207044 | 001 | Mar 25, 2016 | Mar | NEWA |
| >A> | + PERRIGO R AND D | 0.75MG | A090740 | 001 | Dec 30, 2010 | Apr | CRLD |
| >A> | @ WATSON LABS | 0.75MG | A078665 | 001 | Aug 28, 2009 | Apr | DISC |
| | PLAN B | | | | | | |
| >A> | @ TEVA BRANDED PHARM | 0.75MG | N021045 | 002 | Aug 24, 2006 | Apr | DISC |

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

| | | | | | | | |
|--|----------------|-----|---------|-----|--------------|-----|------|
| | BIONPHARMA INC | 1MG | N021855 | 001 | Aug 04, 2005 | Jan | CAHN |
| | + | 2MG | N021855 | 002 | Aug 04, 2005 | Jan | CAHN |

MICONAZOLE NITRATE

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

MONISTAT 3 COMBINATION PACK

| | | | | | | | |
|--|--------------------|----------|---------|-----|--------------|-----|------|
| | + MEDTECH PRODUCTS | 2%,200MG | N020670 | 002 | Apr 16, 1996 | Mar | CMS1 |
|--|--------------------|----------|---------|-----|--------------|-----|------|

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

| | | | | | | | |
|--|------------------|---------------|---------|-----|--------------|-----|------|
| | + BIONPHARMA INC | EQ 200MG BASE | N021920 | 001 | Feb 17, 2006 | Mar | CAHN |
|--|------------------|---------------|---------|-----|--------------|-----|------|

TABLET;ORAL

NAPROXEN SODIUM

| | | | | | | | |
|--|----------------------|---------------|---------|-----|--------------|-----|------|
| | AUROBINDO PHARMA LTD | EQ 200MG BASE | A205497 | 001 | Mar 18, 2016 | Mar | NEWA |
|--|----------------------|---------------|---------|-----|--------------|-----|------|

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

| | | | | | | | |
|-----|---------------------|-------------|---------|-----|--------------|-----|------|
| >A> | ACTAVIS LABS NY INC | EQ 2MG BASE | A204794 | 001 | May 10, 2016 | Apr | NEWA |
| | | EQ 4MG BASE | A204833 | 001 | Feb 26, 2016 | Feb | NEWA |

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL FOR WOMEN

| | | | | | | | |
|--|----------------------|------------|---------|-----|--------------|-----|------|
| | + ALLERGAN SALES LLC | 3.9MG/24HR | N202211 | 001 | Jan 25, 2013 | Jan | CAHN |
|--|----------------------|------------|---------|-----|--------------|-----|------|

POTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

| | | | | | | | |
|--|----------------------|---------|---------|-----|--------------|-----|------|
| | MISSION PHARMACAL CO | 65MG/ML | A206211 | 001 | Mar 24, 2016 | Mar | NEWA |
|--|----------------------|---------|---------|-----|--------------|-----|------|

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 04 APRIL 2016

NO APRIL 2016 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO APRIL 2016 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--|-----------|------------------------|--------------|-------------------------|----------------------|-----------------------------|
| <u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEO</u> | | | | | | |
| N 205551 001 | 9242986 | Dec 08, 2029 | DS DP | | | |
| <u>ACETYLCYSTEINE - CETYLEV</u> | | | | | | |
| N 207916 001 | 8747894 | May 08, 2032 | DP U-1373 | | | |
| <u>ACETYLCYSTEINE - CETYLEV</u> | | | | | | |
| N 207916 002 | 8747894 | May 08, 2032 | DP U-1373 | | | |
| <u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u> | | | | | | |
| N 207917 001 | 8809305 | Dec 23, 2022 | U-1078 | | | |
| <u>AFATINIB DIMALEATE - GILOTRIF</u> | | | | | | |
| N 201292 003 | | | | | >A> I-730 | Apr 15, 2019 |
| <u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u> | | | | | | |
| N 205636 001 | 8978966 | Jan 13, 2032 | DP | | >A> NPP | Apr 28, 2019 |
| | 9216260 | Jun 28, 2031 | DP | | | |
| <u>ALECTINIB HYDROCHLORIDE - ALECENSA</u> | | | | | | |
| N 208434 001 | | | | | ODE | Dec 11, 2022 |
| <u>ALOGLIPTIN BENZOATE - NESINA</u> | | | | | | |
| N 022271 001 | | | | | >A> M-177 | Apr 05, 2019 |
| <u>ALOGLIPTIN BENZOATE - NESINA</u> | | | | | | |
| N 022271 002 | | | | | >A> M-177 | Apr 05, 2019 |
| <u>ALOGLIPTIN BENZOATE - NESINA</u> | | | | | | |
| N 022271 003 | | | | | >A> M-177 | Apr 05, 2019 |
| <u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u> | | | | | | |
| N 203414 001 | | | | | >A> M-177 | Apr 05, 2019 |
| <u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u> | | | | | | |
| N 203414 002 | | | | | >A> M-177 | Apr 05, 2019 |
| <u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u> | | | | | | |
| N 022426 001 | | | | | >A> M-177 | Apr 05, 2019 |
| <u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u> | | | | | | |
| N 022426 002 | | | | | >A> M-177 | Apr 05, 2019 |
| <u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u> | | | | | | |
| N 022426 003 | | | | | >A> M-177 | Apr 05, 2019 |
| <u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u> | | | | | | |
| N 022426 004 | | | | | >A> M-177 | Apr 05, 2019 |
| <u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u> | | | | | | |
| N 022426 005 | | | | | >A> M-177 | Apr 05, 2019 |
| <u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u> | | | | | | |
| N 022426 006 | | | | | >A> M-177 | Apr 05, 2019 |
| <u>AMPHETAMINE - ADZENYS XR-ODT</u> | | | | | | |
| N 204326 001 | 8709491 | Jun 28, 2032 | DP | | | |
| | 8840924 | Jun 05, 2026 | DP | | | |
| | 9017731 | Jun 28, 2032 | DP | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|---|-------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>AMPHETAMINE - ADZENYS XR-ODT</u> | | | | | | |
| N 204326 001 | 9265737 | Jun 28, 2032 | DP | | | |
| <u>AMPHETAMINE - ADZENYS XR-ODT</u> | | | | | | |
| N 204326 002 | 8709491 | Jun 28, 2032 | DP | | | |
| | 8840924 | Jun 05, 2026 | DP | | | |
| | 9017731 | Jun 28, 2032 | DP | | | |
| | 9265737 | Jun 28, 2032 | DP | | | |
| <u>AMPHETAMINE - ADZENYS XR-ODT</u> | | | | | | |
| N 204326 003 | 8709491 | Jun 28, 2032 | DP | | | |
| | 8840924 | Jun 05, 2026 | DP | | | |
| | 9017731 | Jun 28, 2032 | DP | | | |
| | 9265737 | Jun 28, 2032 | DP | | | |
| <u>AMPHETAMINE - ADZENYS XR-ODT</u> | | | | | | |
| N 204326 004 | 8709491 | Jun 28, 2032 | DP | | | |
| | 8840924 | Jun 05, 2026 | DP | | | |
| | 9017731 | Jun 28, 2032 | DP | | | |
| | 9265737 | Jun 28, 2032 | DP | | | |
| <u>AMPHETAMINE - ADZENYS XR-ODT</u> | | | | | | |
| N 204326 005 | 8709491 | Jun 28, 2032 | DP | | | |
| | 8840924 | Jun 05, 2026 | DP | | | |
| | 9017731 | Jun 28, 2032 | DP | | | |
| | 9265737 | Jun 28, 2032 | DP | | | |
| <u>AMPHETAMINE - ADZENYS XR-ODT</u> | | | | | | |
| N 204326 006 | 8709491 | Jun 28, 2032 | DP | | | |
| | 8840924 | Jun 05, 2026 | DP | | | |
| | 9017731 | Jun 28, 2032 | DP | | | |
| | 9265737 | Jun 28, 2032 | DP | | | |
| <u>ASPIRIN - ASPIRIN</u> | | | | | | |
| N 203697 001 | >A> 9216150 | Sep 29, 2032 | DP | | | |
| | >A> 9226892 | Sep 29, 2032 | | | U-1731 | |
| | >A> 9226892 | Sep 29, 2032 | | | U-1732 | |
| | >A> 9226892 | Sep 29, 2032 | | | U-1733 | |
| <u>AVANAFIL - STENDRA</u> | | | | | | |
| N 202276 001 | 6656935 | Apr 27, 2025 | DS DP | | U-155 | |
| <u>AVANAFIL - STENDRA</u> | | | | | | |
| N 202276 002 | 6656935 | Apr 27, 2025 | DS DP | | U-155 | |
| <u>AVANAFIL - STENDRA</u> | | | | | | |
| N 202276 003 | 6656935 | Apr 27, 2025 | DS DP | | U-155 | |
| <u>AXITINIB - INLYTA</u> | | | | | | |
| N 202324 001 | >A> 6534524 | Apr 29, 2025 | DS DP | | | |
| <u>AXITINIB - INLYTA</u> | | | | | | |
| N 202324 002 | >A> 6534524 | Apr 29, 2025 | DS DP | | | |
| <u>AZELAIC ACID - FINACEA</u> | | | | | | |
| N 207071 001 | 9265725 | Dec 08, 2027 | DP | | | |
| <u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u> | | | | | | |
| N 202236 001 | 9259428 | Jun 13, 2023 | | | U-644 | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--|-----------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u> | | | | | | |
| N 202331 001 | 9169238 | Feb 04, 2030 | DP | | | |
| <u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u> | | | | | | |
| N 202331 002 | 9169238 | Feb 04, 2030 | DP | | | |
| <u>BALSALAZIDE DISODIUM - GIAZO</u> | | | | | | |
| N 022205 001 | 9192616 | Aug 02, 2026 | U-1229 | | | |
| <u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u> | | | | | | |
| N 208194 001 | 9265831 | Jan 28, 2031 | DP | | | |
| <u>BETAMETHASONE DIPROPIONATE - SERNIVO</u> | | | | | | |
| N 208079 001 | | | | | NDF | Feb 05, 2019 |
| <u>BIMATOPROST - LUMIGAN</u> | | | | | | |
| N 022184 001 | 9241918 | Mar 16, 2025 | DP U-1814 | | | |
| <u>BIMATOPROST - LATISSE</u> | | | | | | |
| N 022369 001 | 9216183 | Jan 15, 2023 | U-1487 | | | |
| | 9226931 | Jan 15, 2023 | U-1799 | | | |
| <u>BRIMONIDINE TARTRATE - ALPHAGAN P</u> | | | | | | |
| N 021262 001 >A> | 9295641 | Jul 10, 2021 | U-1833 | | | |
| <u>BRIMONIDINE TARTRATE - ALPHAGAN P</u> | | | | | | |
| N 021770 001 >A> | 9295641 | Jul 10, 2021 | U-1833 | | | |
| <u>BRIVARACETAM - BRIVIACT</u> | | | | | | |
| N 205836 001 | 6784197 | Feb 21, 2021 | DS DP U-1815 | | NCE | Feb 18, 2021 |
| | 6911461 | Feb 21, 2021 | DS DP U-1815 | | | |
| | 8492416 | Feb 21, 2021 | U-1815 | | | |
| <u>BRIVARACETAM - BRIVIACT</u> | | | | | | |
| N 205836 002 | 6784197 | Feb 21, 2021 | DS DP U-1815 | | NCE | Feb 18, 2021 |
| | 6911461 | Feb 21, 2021 | DS DP U-1815 | | | |
| | 8492416 | Feb 21, 2021 | U-1815 | | | |
| <u>BRIVARACETAM - BRIVIACT</u> | | | | | | |
| N 205836 003 | 6784197 | Feb 21, 2021 | DS DP U-1815 | | NCE | Feb 18, 2021 |
| | 6911461 | Feb 21, 2021 | DS DP U-1815 | | | |
| | 8492416 | Feb 21, 2021 | U-1815 | | | |
| <u>BRIVARACETAM - BRIVIACT</u> | | | | | | |
| N 205836 004 | 6784197 | Feb 21, 2021 | DS DP U-1815 | | NCE | Feb 18, 2021 |
| | 6911461 | Feb 21, 2021 | DS DP U-1815 | | | |
| | 8492416 | Feb 21, 2021 | U-1815 | | | |
| <u>BRIVARACETAM - BRIVIACT</u> | | | | | | |
| N 205836 005 | 6784197 | Feb 21, 2021 | DS DP U-1815 | | NCE | Feb 18, 2021 |
| | 6911461 | Feb 21, 2021 | DS DP U-1815 | | | |
| | 8492416 | Feb 21, 2021 | U-1815 | | | |
| <u>BRIVARACETAM - BRIVIACT</u> | | | | | | |
| N 205837 001 | 6784197 | Feb 21, 2021 | DS DP U-1815 | | NCE | Feb 18, 2021 |
| | 6911461 | Feb 21, 2021 | DS DP U-1815 | | | |
| | 8492416 | Feb 21, 2021 | U-1815 | | | |
| <u>BRIVARACETAM - BRIVIACT</u> | | | | | | |
| N 205838 001 | 6784197 | Feb 21, 2021 | DS DP U-1815 | | NCE | Feb 18, 2021 |
| | 6911461 | Feb 21, 2021 | DS DP U-1815 | | | |
| | 8492416 | Feb 21, 2021 | U-1815 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>BRIVARACETAM - BRIVIACT</u> | | | | | | |
| N 205838 001 | 6784197 | Feb 21, 2021 | DS DP U-1815 | | NCE | Feb 18, 2021 |
| | 6911461 | Feb 21, 2021 | DS DP U-1815 | | | |
| | 8492416 | Feb 21, 2021 | U-1815 | | | |
| <u>BROMFENAC SODIUM - BROMSITE</u> | | | | | | |
| N 206911 001 | >A> 8778999 | Sep 03, 2029 | DP U-1834 | | >A> NP | Apr 08, 2019 |
| <u>BROMOCRIPTINE MESYLATE - CYCLOSET</u> | | | | | | |
| N 020866 001 | 9192576 | Apr 30, 2032 | DP U-976 | | | |
| <u>BUDESONIDE - ENTOCORT EC</u> | | | | | | |
| N 021324 001 | | | | | >A> M-178 >A> NPP | Apr 29, 2019 Apr 29, 2019 |
| <u>BUDESONIDE - UCERIS</u> | | | | | | |
| N 203634 001 | >A> 9320716 | Jun 09, 2020 | DP U-1325 | | | |
| <u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u> | | | | | | |
| N 204242 001 | 9259421 | Sep 18, 2032 | DP | | | |
| <u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u> | | | | | | |
| N 204242 002 | 9259421 | Sep 18, 2032 | DP | | | |
| <u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u> | | | | | | |
| N 204242 003 | 9259421 | Sep 18, 2032 | DP | | | |
| <u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u> | | | | | | |
| N 204242 004 | 9259421 | Sep 18, 2032 | DP | | | |
| <u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u> | | | | | | |
| N 204242 005 | 9259421 | Sep 18, 2032 | DP | | | |
| <u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u> | | | | | | |
| N 200063 001 | 9248123 | Jan 13, 2032 | U-1808 | | | |
| <u>CABOZANTINIB S-MALATE - CABOMETYX</u> | | | | | | |
| N 208692 001 | | | | | >A> NCE >A> NP | Nov 29, 2017 Apr 25, 2019 |
| <u>CABOZANTINIB S-MALATE - CABOMETYX</u> | | | | | | |
| N 208692 002 | | | | | >A> NCE >A> NP | Nov 29, 2017 Apr 25, 2019 |
| <u>CABOZANTINIB S-MALATE - CABOMETYX</u> | | | | | | |
| N 208692 003 | | | | | >A> NCE >A> NP | Nov 29, 2017 Apr 25, 2019 |
| <u>CANGRELOR - KENGREAL</u> | | | | | | |
| N 204958 001 | 9295687 | Jul 10, 2035 | DP | | | |
| <u>CAREFILZOMIB - KYPROLIS</u> | | | | | | |
| N 202714 001 | | | | | I-722 I-723 | Jan 21, 2019 Jan 21, 2019 |
| <u>CEFIXIME - SUPRAX</u> | | | | | | |
| N 202091 001 | 9233112 | Dec 14, 2028 | DP U-1676 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>CERTINIB - ZYKADIA</u> | | | | | | |
| N 205755 001 | >A> 9309229 | Jan 18, 2032 | DS DP | | | |
| <u>CIPROFLOXACIN - OTIPRIO</u> | | | | | | |
| N 207986 001 | 9233068 | Dec 11, 2029 | DP | | NP | Dec 10, 2018 |
| <u>CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - OTOVEL</u> | | | | | | |
| N 208251 001 | >A> 8932610 | Mar 24, 2030 | DP U-1578 | | >A> NC | Apr 29, 2019 |
| <u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u> | | | | | | |
| N 207561 001 | 5814639 | Sep 29, 2015 | DS DP | | | |
| | 5814639*PED | Mar 29, 2016 | | | | |
| | 6703396 | Mar 09, 2021 | DS DP | | | |
| | 6703396*PED | Sep 09, 2021 | | | | |
| | 7803788 | Feb 02, 2022 | | U-257 | | |
| | >A> 9296769 | Aug 15, 2032 | DS DP | U-257 | | |
| <u>COBIMETINIB FUMARATE - COTELLIC</u> | | | | | | |
| N 206192 001 | | | | | ODE | Nov 10, 2022 |
| <u>CRIZOTINIB - XALKORI</u> | | | | | | |
| N 202570 001 | | | | | ODE | Mar 11, 2023 |
| <u>CRIZOTINIB - XALKORI</u> | | | | | | |
| N 202570 002 | | | | | ODE | Mar 11, 2023 |
| <u>CYCLOSPORINE - RESTASIS</u> | | | | | | |
| N 050790 001 | 9248191 | Aug 27, 2024 | | U-1479 | | |
| <u>CYSTEAMINE BITARTRATE - PROCYSBI</u> | | | | | | |
| N 203389 001 | 9233077 | Jun 17, 2034 | DP | | | |
| <u>CYSTEAMINE BITARTRATE - PROCYSBI</u> | | | | | | |
| N 203389 002 | 9233077 | Jun 17, 2034 | DP | | | |
| <u>DABRAFENIB MESYLATE - TAFINLAR</u> | | | | | | |
| N 202806 001 | 9233956 | May 04, 2029 | | U-1811 | M-170 | Nov 20, 2018 |
| <u>DABRAFENIB MESYLATE - TAFINLAR</u> | | | | | | |
| N 202806 002 | 9233956 | May 04, 2029 | | U-1811 | M-170 | Nov 20, 2018 |
| <u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u> | | | | | | |
| N 206843 001 | | | | | D-161 | Feb 05, 2019 |
| | | | | | D-162 | Feb 05, 2019 |
| | | | | | I-726 | Feb 05, 2019 |
| | | | | | I-727 | Feb 05, 2019 |
| <u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u> | | | | | | |
| N 206843 002 | | | | | D-161 | Feb 05, 2019 |
| | | | | | D-162 | Feb 05, 2019 |
| | | | | | I-726 | Feb 05, 2019 |
| | | | | | I-727 | Feb 05, 2019 |
| <u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u> | | | | | | |
| N 021883 001 | | | | | D-154 | Jan 20, 2019 |
| <u>DAPSONE - ACZONE</u> | | | | | | |
| N 207154 001 | 5863560 | Sep 11, 2016 | DP | | NS | Feb 24, 2019 |
| | 6060085 | Sep 11, 2016 | | U-124 | | |
| | 6620435 | Sep 11, 2016 | DP | | | |
| | 9161926 | Nov 18, 2033 | DP | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>DAPSONE - ACZONE</u> | | | | | | |
| N 207154 001 | 5863560 | Sep 11, 2016 | DP | | NS | Feb 24, 2019 |
| | 6060085 | Sep 11, 2016 | U-124 | | | |
| | 6620435 | Sep 11, 2016 | DP | | | |
| | 9161926 | Nov 18, 2033 | DP | | | |
| <u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u> | | | | | | |
| N 206619 001 | | | | | >A> D-163 | Apr 22, 2019 |
| <u>DEFERASIROX - JADENU</u> | | | | | | |
| N 206910 001 | 9283209 | Nov 21, 2034 | DS DP | | ODE | Jan 23, 2020 |
| <u>DEFERASIROX - JADENU</u> | | | | | | |
| N 206910 002 | 9283209 | Nov 21, 2034 | DS DP | | ODE | Jan 23, 2020 |
| <u>DEFERASIROX - JADENU</u> | | | | | | |
| N 206910 003 | 9283209 | Nov 21, 2034 | DS DP | | ODE | Jan 23, 2020 |
| <u>DEFIBROTIDE SODIUM - DEFITELIO</u> | | | | | | |
| N 208114 001 | | | | | NCE >A> ODE | Mar 30, 2021 Mar 30, 2023 |
| <u>DEXAMETHASONE - OZURDEX</u> | | | | | | |
| N 022315 001 | 9283178 | Oct 20, 2020 | U-1205 | | | |
| <u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u> | | | | | | |
| N 050818 001 | 8450287 | Dec 19, 2027 | DP | | | |
| <u>DEXLANSOPRAZOLE - DEXILANT</u> | | | | | | |
| N 022287 001 | 9233103 | Mar 05, 2032 | U-1805 | | | |
| | 9238029 | Jan 17, 2026 | DP | | | |
| <u>DEXLANSOPRAZOLE - DEXILANT</u> | | | | | | |
| N 022287 002 | 9233103 | Mar 05, 2032 | U-1805 | | | |
| | 9238029 | Jan 17, 2026 | DP | | | |
| <u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u> | | | | | | |
| N 208056 001 | 6238994 | May 17, 2019 | DP | | | |
| | 6238994*PED | Nov 17, 2019 | | | | |
| | 6462058 | Jun 15, 2020 | DS DP U-950 | | | |
| | 6462058 | Jun 15, 2020 | DS DP U-951 | | | |
| | 6462058*PED | Dec 15, 2020 | | | | |
| | 6664276 | Jan 30, 2023 | DS DP U-950 | | | |
| | 6664276 | Jan 30, 2023 | DS DP U-951 | | | |
| | 6664276*PED | Jul 30, 2023 | | | | |
| | 6939971 | Jun 15, 2020 | U-950 | | | |
| | 6939971 | Jun 15, 2020 | U-951 | | | |
| | 6939971*PED | Dec 15, 2020 | | | | |
| | 7285668 | Jun 15, 2020 | DS | | | |
| | 7285668*PED | Dec 15, 2020 | | | | |
| | 7399485 | May 26, 2018 | DP | | | |
| | 7399485*PED | Nov 26, 2018 | | | | |
| | 7431942 | May 17, 2019 | DP | | | |
| | 7431942*PED | Nov 17, 2019 | | | | |
| | 7875292 | May 17, 2019 | DP | | | |
| | 7875292*PED | Nov 17, 2019 | | | | |
| | 8461187 | Jan 17, 2026 | DP | | | |
| | 8461187*PED | Jul 17, 2026 | | | | |
| | 8784885 | Oct 15, 2023 | DP | | | |
| | 8784885*PED | Apr 15, 2024 | | | | |
| | 8871273 | Jan 11, 2028 | DP | | | |
| | 8871273*PED | Jul 11, 2028 | | | | |
| | 9011926 | Feb 24, 2026 | DP | | | |
| | 9145389 | Jun 15, 2020 | DS DP | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|---|-------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u> | | | | | | |
| N 208056 001 | 9238029 | Jan 17, 2026 | DP | | | |
| | 9241910 | Mar 10, 2029 | DP | | | |
| <u>DICLOFENAC SODIUM - PENNSAID</u> | | | | | | |
| N 204623 001 | 9220784 | Oct 17, 2027 | U-1488 | | | |
| <u>DOCETAXEL - DOCETAXEL</u> | | | | | | |
| N 205934 001 >A> | 9308195 | Sep 30, 2033 | DP | | | |
| <u>DOCETAXEL - DOCETAXEL</u> | | | | | | |
| N 205934 002 >A> | 9308195 | Sep 30, 2033 | DP | | | |
| <u>DOCETAXEL - DOCETAXEL</u> | | | | | | |
| N 205934 003 >A> | 9308195 | Sep 30, 2033 | DP | | | |
| <u>DOLUTEGRAVIR SODIUM - TIVICAY</u> | | | | | | |
| N 204790 001 | 9242986 | Dec 08, 2029 | DS DP | | | |
| <u>DOXEPIH HYDROCHLORIDE - SILENOR</u> | | | | | | |
| N 022036 001 | 8513299 | Sep 07, 2030 | U-620 | | | |
| | 9107898 | May 01, 2028 | U-620 | | | |
| <u>DOXEPIH HYDROCHLORIDE - SILENOR</u> | | | | | | |
| N 022036 002 | 8513299 | Sep 07, 2030 | U-620 | | | |
| | 9107898 | May 01, 2028 | U-620 | | | |
| <u>DOXYCYCLINE - ORACEA</u> | | | | | | |
| N 050805 001 | 9241946 | Apr 05, 2022 | U-1063 | | | |
| <u>EFINACONAZOLE - JUBLIA</u> | | | | | | |
| N 203567 001 >A> | 9302009 | Oct 24, 2030 | DP | | | |
| <u>ELBASVIR; GRAZOPREVR - ZEPATIER</u> | | | | | | |
| N 208261 001 | 7973040 | Jul 24, 2029 | DS DP U-1813 | | NCE | Jan 28, 2021 |
| | 8871759 | May 04, 2031 | DS DP U-1813 | | | |
| <u>EMPAGLIFLOZIN - JARDIANCE</u> | | | | | | |
| N 204629 001 | 8551957 | Oct 19, 2029 | DP U-1651 | | M-174 | Mar 18, 2019 |
| <u>EMPAGLIFLOZIN - JARDIANCE</u> | | | | | | |
| N 204629 002 | 8551957 | Oct 19, 2029 | DP U-1651 | | M-174 | Mar 18, 2019 |
| <u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u> | | | | | | |
| N 206073 001 | 7407955 | May 02, 2025 | DS DP | | | |
| <u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u> | | | | | | |
| N 206073 002 | 7407955 | May 02, 2025 | DS DP | | | |
| <u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u> | | | | | | |
| N 208351 001 | 5814639 | Sep 29, 2015 | DS DP | | NCE | Nov 05, 2020 |
| | 5814639*PED | Mar 29, 2016 | | | | |
| | 5914331 | Jul 02, 2017 | DS | | | |
| | 5914331*PED | Jan 02, 2018 | | | | |
| | 6642245 | Nov 04, 2020 | U-257 | | | |
| | 6642245*PED | May 04, 2021 | | | | |
| | 6703396 | Mar 09, 2021 | DS DP | | | |
| | 6703396*PED | Sep 09, 2021 | | | | |
| | 6838464 | Feb 26, 2021 | DS DP | | | |
| | 7067522 | Dec 20, 2019 | DS DP | | | |
| | 7125879 | Aug 09, 2022 | DS DP U-257 | | | |
| | 7390791 | May 07, 2022 | DS DP | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|---|-----------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u> | | | | | | |
| N 208351 001 | 7803788 | Feb 02, 2022 | | | U-257 | |
| | 8080551 | Apr 11, 2023 | DS DP | | | |
| | 8101629 | Aug 09, 2022 | | | DP | |
| | 8754065 | Aug 15, 2032 | DS DP | | U-257 | |
| | >A> 9296769 | Aug 15, 2032 | DS DP | | U-257 | |
| <u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u> | | | | | | |
| N 208215 001 | >A> 5814639 | Sep 29, 2015 | DS DP | Y | >A> NCE | Nov 05, 2020 |
| | >A> 5814639*PED | Mar 29, 2016 | | | | |
| | >A> 5914331 | Jul 02, 2017 | DS | | | |
| | >A> 5914331*PED | Jan 02, 2018 | | | | |
| | >A> 6642245 | Nov 04, 2020 | | | U-257 | |
| | >A> 6703396 | Mar 09, 2021 | DS DP | | | |
| | >A> 6703396*PED | Sep 09, 2021 | | | | |
| | >A> 7390791 | May 07, 2022 | DS DP | | | |
| | >A> 7803788 | Feb 02, 2022 | | | U-257 | |
| | >A> 8754065 | Aug 15, 2032 | DS DP | | U-257 | |
| | >A> 9296769 | Aug 15, 2032 | DS DP | | U-257 | |
| <u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u> | | | | | | |
| N 021752 001 | 5914331 | Jul 02, 2017 | DS | | | |
| | 5914331*PED | Jan 02, 2018 | | | | |
| | 6043230 | Jul 25, 2017 | | | U-248 | |
| | 6043230 | Jul 25, 2017 | | | U-541 | |
| | 6043230 | Jul 25, 2017 | | | U-1170 | |
| | 6043230 | Jul 25, 2017 | | | U-1259 | |
| | 6043230*PED | Jan 25, 2018 | | | | |
| <u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u> | | | | | | |
| N 021752 002 | 5814639 | Sep 29, 2015 | DS DP | | | |
| | 5814639*PED | Mar 29, 2016 | | | | |
| | 5914331 | Jun 02, 2017 | DS | | | |
| | 5914331*PED | Dec 02, 2017 | | | | |
| | 5922695 | Jul 25, 2017 | DS | | U-248 | |
| | 5922695 | Jul 25, 2017 | DS | | U-541 | |
| | 5922695 | Jul 25, 2017 | DS | | U-1170 | |
| | 5922695 | Jul 25, 2017 | DS | | U-1259 | |
| | 5935946 | Jul 25, 2017 | DS DP | | U-248 | |
| | 5935946 | Jul 25, 2017 | DS DP | | U-541 | |
| | 5935946 | Jul 25, 2017 | DS DP | | U-1170 | |
| | 5935946 | Jul 25, 2017 | DS DP | | U-1259 | |
| | 5935946*PED | Jan 25, 2018 | | | | |
| | 5977089 | Jul 25, 2017 | DS DP | | U-248 | |
| | 5977089 | Jul 25, 2017 | DS DP | | U-541 | |
| | 5977089 | Jul 25, 2017 | DS DP | | U-1170 | |
| | 5977089 | Jul 25, 2017 | DS DP | | U-1259 | |
| | 5977089*PED | Jan 25, 2018 | | | | |
| | 6043230 | Jul 25, 2017 | | | U-248 | |
| | 6043230 | Jul 25, 2017 | | | U-541 | |
| | 6043230 | Jul 25, 2017 | | | U-1170 | |
| | 6043230 | Jul 25, 2017 | | | U-1259 | |
| | 6043230*PED | Jan 25, 2018 | | | | |
| | 6642245 | Nov 04, 2020 | | | U-248 | |
| | 6642245 | Nov 04, 2020 | | | U-541 | |
| | 6642245 | Nov 04, 2020 | | | U-1170 | |
| | 6642245 | Nov 04, 2020 | | | U-1259 | |
| | 6642245*PED | May 04, 2021 | | | | |
| | 6703396 | Mar 09, 2021 | DS DP | | | |
| | 6703396*PED | Sep 09, 2021 | | | | |
| <u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u> | | | | | | |
| N 021752 003 | 5814639 | Sep 29, 2015 | DS DP | | | |
| | 5814639*PED | Mar 29, 2016 | | | | |
| | 5914331 | Jun 02, 2017 | DS | | | |
| | 5914331*PED | Dec 02, 2017 | | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|---|-------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u> | | | | | | |
| N 021752 003 | 5922695 | Jul 25, 2017 | DS U-248 | | | |
| | 5922695 | Jul 25, 2017 | DS U-541 | | | |
| | 5922695 | Jul 25, 2017 | DS U-1170 | | | |
| | 5922695 | Jul 25, 2017 | DS U-1259 | | | |
| | 5935946 | Jul 25, 2017 | DS DP U-248 | | | |
| | 5935946 | Jul 25, 2017 | DS DP U-541 | | | |
| | 5935946 | Jul 25, 2017 | DS DP U-1170 | | | |
| | 5935946 | Jul 25, 2017 | DS DP U-1259 | | | |
| | 5935946*PED | Jan 25, 2018 | | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-248 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-541 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-1170 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-1259 | | | |
| | 5977089*PED | Jan 25, 2018 | | | | |
| | 6043230 | Jul 25, 2017 | U-248 | | | |
| | 6043230 | Jul 25, 2017 | U-541 | | | |
| | 6043230 | Jul 25, 2017 | U-1170 | | | |
| | 6043230 | Jul 25, 2017 | U-1259 | | | |
| | 6043230*PED | Jan 25, 2018 | | | | |
| | 6642245 | Nov 04, 2020 | U-248 | | | |
| | 6642245 | Nov 04, 2020 | U-541 | | | |
| | 6642245 | Nov 04, 2020 | U-1170 | | | |
| | 6642245 | Nov 04, 2020 | U-1259 | | | |
| | 6642245*PED | May 04, 2021 | | | | |
| | 6703396 | Mar 09, 2021 | DS DP | | | |
| | 6703396*PED | Sep 09, 2021 | | | | |
| <u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u> | | | | | | |
| N 021752 004 | 5814639 | Sep 29, 2015 | DS DP | | | |
| | 5814639*PED | Mar 29, 2016 | | | | |
| | 5914331 | Jun 02, 2017 | DS | | | |
| | 5914331*PED | Dec 02, 2017 | | | | |
| | 5922695 | Jul 25, 2017 | DS U-248 | | | |
| | 5922695 | Jul 25, 2017 | DS U-541 | | | |
| | 5922695 | Jul 25, 2017 | DS U-1170 | | | |
| | 5922695 | Jul 25, 2017 | DS U-1259 | | | |
| | 5935946 | Jul 25, 2017 | DS DP U-248 | | | |
| | 5935946 | Jul 25, 2017 | DS DP U-541 | | | |
| | 5935946 | Jul 25, 2017 | DS DP U-1170 | | | |
| | 5935946 | Jul 25, 2017 | DS DP U-1259 | | | |
| | 5935946*PED | Jan 25, 2018 | | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-248 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-541 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-1170 | | | |
| | 5977089 | Jul 25, 2017 | DS DP U-1259 | | | |
| | 5977089*PED | Jan 25, 2018 | | | | |
| | 6043230 | Jul 25, 2017 | U-248 | | | |
| | 6043230 | Jul 25, 2017 | U-541 | | | |
| | 6043230 | Jul 25, 2017 | U-1170 | | | |
| | 6043230 | Jul 25, 2017 | U-1259 | | | |
| | 6043230*PED | Jan 25, 2018 | | | | |
| | 6642245 | Nov 04, 2020 | U-248 | | | |
| | 6642245 | Nov 04, 2020 | U-541 | | | |
| | 6642245 | Nov 04, 2020 | U-1170 | | | |
| | 6642245 | Nov 04, 2020 | U-1259 | | | |
| | 6642245*PED | May 04, 2021 | | | | |
| | 6703396 | Mar 09, 2021 | DS DP | | | |
| | 6703396*PED | Sep 09, 2021 | | | | |
| <u>EPINEPHRINE - AUVI-O</u> | | | | | | |
| N 201739 001 | 9238108 | Jan 22, 2027 | DP | | | |
| | 9259539 | Feb 01, 2026 | DP | | | |
| | 9278182 | Feb 01, 2026 | DP | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>EPINEPHRINE - AUVI-Q</u> | | | | | | |
| N 201739 002 | 9238108 | Jan 22, 2027 | DP | | | |
| | 9259539 | Feb 01, 2026 | DP | | | |
| | 9278182 | Feb 01, 2026 | DP | | | |
| <u>EPINEPHRINE - ADRENALIN</u> | | | | | | |
| N 204200 001 | 9119876 | Mar 13, 2035 | DP | | | |
| | 9295657 | Mar 13, 2035 | U-1829 | | | |
| | 9295657 | Mar 13, 2035 | U-1830 | | | |
| <u>EPINEPHRINE - ADRENALIN</u> | | | | | | |
| N 204640 001 | 9295657 | Mar 13, 2035 | | | U-1829 | |
| <u>EPINEPHRINE HYDROCHLORIDE - EPINEPHRINE</u> | | | | | | |
| N 205029 001 | 9283197 | Aug 15, 2034 | DP U-1828 | | | |
| | 9283197 | Aug 15, 2034 | DP U-1829 | | | |
| | 9283197 | Aug 15, 2034 | DP U-1830 | | | |
| <u>ERIBULIN MESYLATE - HALAVEN</u> | | | | | | |
| N 201532 001 | 6469182 | Jun 16, 2019 | U-1096 | | I-721 | Jan 28, 2019 |
| | 6469182 | Jun 16, 2019 | U-1812 | | ODE | Jan 28, 2023 |
| <u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u> | | | | | | |
| N 022511 001 | 9220698 | Mar 10, 2031 | U-1781 | | | |
| <u>EVEROLIMUS - AFINITOR</u> | | | | | | |
| N 022334 001 | 8410131 | Nov 01, 2025 | U-1368 | | I-724 | Feb 26, 2019 |
| | 8410131*PED | May 01, 2026 | | | | |
| | 8436010 | Feb 22, 2022 | U-1396 | | | |
| | 8436010*PED | Aug 22, 2022 | | | | |
| <u>EVEROLIMUS - AFINITOR</u> | | | | | | |
| N 022334 002 | 8410131 | Nov 01, 2025 | U-1368 | | I-724 | Feb 26, 2019 |
| | 8410131*PED | May 01, 2026 | | | | |
| | 8436010 | Feb 22, 2022 | U-1396 | | | |
| | 8436010*PED | Aug 22, 2022 | | | | |
| <u>EVEROLIMUS - AFINITOR</u> | | | | | | |
| N 022334 003 | 8410131 | Nov 01, 2025 | U-1368 | | I-724 | Feb 26, 2019 |
| | 8410131*PED | May 01, 2026 | | | | |
| | 8436010 | Feb 22, 2022 | U-1396 | | | |
| | 8436010*PED | Aug 22, 2022 | | | | |
| <u>EVEROLIMUS - AFINITOR</u> | | | | | | |
| N 022334 004 | 8410131 | Nov 01, 2025 | U-1368 | | I-724 | Feb 26, 2019 |
| | 8410131*PED | May 01, 2026 | | | | |
| | 8436010 | Feb 22, 2022 | U-1396 | | | |
| | 8436010*PED | Aug 22, 2022 | | | | |
| <u>EXENATIDE SYNTHETIC - BYDUREON</u> | | | | | | |
| N 022200 001 | 9238076 | Apr 15, 2024 | DP U-412 | | | |
| <u>EXENATIDE SYNTHETIC - BYDUREON PEN</u> | | | | | | |
| N 022200 002 | >A> 5424286 | Dec 01, 2016 | U-1108 | | | |
| | >A> 6479065 | Aug 10, 2020 | DP | | | |
| | >A> 6495164 | May 25, 2020 | DP | | | |
| | >A> 6667061 | May 25, 2020 | DP | | | |
| | >A> 6824822 | Oct 09, 2022 | DP | | | |
| | >A> 6858576 | Jan 06, 2017 | U-656 | | | |
| | >A> 6872700 | Jan 14, 2020 | U-654 | | | |
| | >A> 6956026 | Jan 07, 2018 | U-687 | | | |
| | >A> 7223440 | Aug 31, 2021 | DP | | | |
| | >A> 7456254 | Jun 30, 2025 | DP U-1223 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|---|-------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>EXENATIDE SYNTHETIC - BYDUREON PEN</u> | | | | | | |
| N 022200 002 | >A> 7563871 | Apr 15, 2024 | DP | | | |
| | >A> 7612176 | Apr 13, 2025 | DP U-1223 | | | |
| | >A> 7741269 | Jan 07, 2018 | U-1224 | | | |
| | >A> 8216180 | Jan 12, 2028 | DP | Y | | |
| | >A> 8329648 | Aug 18, 2026 | U-1313 | | | |
| | >A> 8431685 | Apr 13, 2025 | DP U-412 | | | |
| | >A> 8439864 | Mar 25, 2028 | DP | Y | | |
| | >A> 8461105 | Apr 13, 2025 | DP U-412 | | | |
| | >A> 8906851 | Aug 18, 2026 | U-1313 | | | |
| | 9238076 | Apr 15, 2024 | DP U-412 | | | |
| <u>FENOFIBRATE - ANTARA (MICRONIZED)</u> | | | | | | |
| N 021695 005 | >A> 9314447 | May 31, 2033 | DP U-1447 | | | |
| | >A> 9314447 | May 31, 2033 | DP U-1448 | | | |
| <u>FENTANYL - SUBSYS</u> | | | | | | |
| N 202788 001 | 9241935 | Jan 25, 2027 | DP | | | |
| <u>FENTANYL - SUBSYS</u> | | | | | | |
| N 202788 002 | 9241935 | Jan 25, 2027 | DP | | | |
| <u>FENTANYL - SUBSYS</u> | | | | | | |
| N 202788 003 | 9241935 | Jan 25, 2027 | DP | | | |
| <u>FENTANYL - SUBSYS</u> | | | | | | |
| N 202788 004 | 9241935 | Jan 25, 2027 | DP | | | |
| <u>FENTANYL - SUBSYS</u> | | | | | | |
| N 202788 005 | 9241935 | Jan 25, 2027 | DP | | | |
| <u>FENTANYL - SUBSYS</u> | | | | | | |
| N 202788 006 | 9241935 | Jan 25, 2027 | DP | | | |
| <u>FENTANYL - SUBSYS</u> | | | | | | |
| N 202788 007 | 9241935 | Jan 25, 2027 | DP | | | |
| <u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u> | | | | | | |
| N 208294 001 | | | | >A> NP | | Apr 25, 2019 |
| <u>FOSAPREPITANT DIMEGLUMINE - EMEND</u> | | | | | | |
| N 022023 002 | | | | | D-155 | Feb 01, 2019 |
| <u>FULVESTRANT - FASLODEX</u> | | | | | | |
| N 021344 001 | 8329680 | Jan 09, 2021 | U-596 | | I-725 | Feb 19, 2019 |
| | 8329680 | Jan 09, 2021 | U-1826 | | | |
| | 8329680*PED | Jul 09, 2021 | | | | |
| <u>GADOBUTROL - GADAVIST</u> | | | | | | |
| N 201277 002 | | | | >A> I-731 | | Apr 27, 2019 |
| <u>GADOBUTROL - GADAVIST</u> | | | | | | |
| N 201277 006 | 5980864 | Nov 09, 2021 | DS DP U-1119 | | | |
| <u>GLIPIZIDE - GLIPIZIDE</u> | | | | | | |
| A 202298 001 | | | | >A> PC | | Jul 27, 2016 |
| <u>GLIPIZIDE - GLIPIZIDE</u> | | | | | | |
| A 202298 002 | | | | >A> PC | | Apr 25, 2016 |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|---|-----------|------------------------------|------------------------------|-------------------------------|-------------------------|-----------------------------------|
| <u>GLIPIZIDE - GLIPIZIDE</u> | | | | | | |
| A 202298 | 003 | | | | >A> PC | Apr 25, 2016 |
| <u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u> | | | | | | |
| N 203284 | 001 | 5968979 9254278 | Jul 28, 2018 Mar 09, 2032 | DS DP | U-1378 U-1816 | |
| <u>GLYCOPYRROLATE - SEEBRI</u> | | | | | | |
| N 207923 | 001 | 6582678 | Apr 24, 2018 | DP | | |
| <u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u> | | | | | | |
| N 207930 | 001 | 6582678 6878721 | Apr 24, 2018 Feb 25, 2025 | DP DS DP | U-1773 | |
| <u>GRANISETRON - SANCUSO</u> | | | | | | |
| N 022198 | 001 | 7608282 | Jan 22, 2025 | DP | U-1011 | |
| <u>HALOBETASOL PROPIONATE - ULTRAVATE</u> | | | | | | |
| N 208183 | 001 | | | | NP | Nov 06, 2018 |
| <u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u> | | | | | | |
| N 202880 | 001 | 9265760 >A> 9326982 | Jul 25, 2033 Jul 25, 2033 | | U-1810 U-1810 | |
| <u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u> | | | | | | |
| N 202880 | 002 | 9265760 >A> 9326982 | Jul 25, 2033 Jul 25, 2033 | | U-1810 U-1810 | |
| <u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u> | | | | | | |
| N 202880 | 003 | 9265760 >A> 9326982 | Jul 25, 2033 Jul 25, 2033 | | U-1810 U-1810 | |
| <u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u> | | | | | | |
| N 202880 | 004 | 9265760 >A> 9326982 | Jul 25, 2033 Jul 25, 2033 | | U-1810 U-1810 | |
| <u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u> | | | | | | |
| N 202880 | 005 | 9265760 >A> 9326982 | Jul 25, 2033 Jul 25, 2033 | | U-1810 U-1810 | |
| <u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u> | | | | | | |
| N 202880 | 006 | 9265760 >A> 9326982 | Jul 25, 2033 Jul 25, 2033 | | U-1810 U-1810 | |
| <u>HYDROCODONE BITARTRATE - HYSINGLA</u> | | | | | | |
| N 206627 | 001 | >A> 9289391 | Oct 30, 2021 | DP | | |
| <u>HYDROCODONE BITARTRATE - HYSINGLA</u> | | | | | | |
| N 206627 | 002 | >A> 9289391 | Oct 30, 2021 | DP | | |
| <u>HYDROCODONE BITARTRATE - HYSINGLA</u> | | | | | | |
| N 206627 | 003 | >A> 9289391 | Oct 30, 2021 | DP | | |
| <u>HYDROCODONE BITARTRATE - HYSINGLA</u> | | | | | | |
| N 206627 | 004 | >A> 9289391 | Oct 30, 2021 | DP | | |
| <u>HYDROCODONE BITARTRATE - HYSINGLA</u> | | | | | | |
| N 206627 | 005 | >A> 9289391 | Oct 30, 2021 | DP | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|---|--|--|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>HYDROCODONE BITARTRATE - HYSINGLA</u> | | | | | | |
| N 206627 006 >A> | 9289391 | Oct 30, 2021 | DP | | | |
| <u>HYDROCODONE BITARTRATE - HYSINGLA</u> | | | | | | |
| N 206627 007 >A> | 9289391 | Oct 30, 2021 | DP | | | |
| <u>IBRUTINIB - IMBRUVICA</u> | | | | | | |
| N 205552 001 >A> | 9296753 | Oct 30, 2033 | DS DP | | I-729 >A> ODE | Mar 04, 2019 Mar 04, 2023 |
| <u>IBUPROFEN - CALDOLOR</u> | | | | | | |
| N 022348 001 >A> | 9295639 | Sep 30, 2029 | U-1756 | | | |
| <u>IMATINIB MESYLATE - IMATINIB MESYLATE</u> | | | | | | |
| A 078340 001 | | | | | PC | Jul 30, 2016 |
| <u>IMATINIB MESYLATE - IMATINIB MESYLATE</u> | | | | | | |
| A 078340 002 | | | | | PC | Jul 30, 2016 |
| <u>IMATINIB MESYLATE - GLEEVEC</u> | | | | | | |
| N 021335 001 | RE43932 RE43932*PED | Jul 16, 2018 Jan 16, 2019 | DS DP | | | |
| <u>IMATINIB MESYLATE - GLEEVEC</u> | | | | | | |
| N 021335 002 | RE43932 RE43932*PED | Jul 16, 2018 Jan 16, 2019 | DS DP | | | |
| <u>IMATINIB MESYLATE - GLEEVEC</u> | | | | | | |
| N 021588 001 | 7544799 7544799*PED RE43932 RE43932*PED | Jul 16, 2018 Jan 16, 2019 Jul 16, 2018 Jan 16, 2019 | DS DP DS DP | | Y | |
| <u>IMATINIB MESYLATE - GLEEVEC</u> | | | | | | |
| N 021588 002 | 7544799 7544799*PED RE43932 RE43932*PED | Jul 16, 2018 Jan 16, 2019 Jul 16, 2018 Jan 16, 2019 | DS DP DS DP | | Y | |
| <u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u> | | | | | | |
| N 022383 001 | 6878721 | Feb 25, 2025 | DS DP U-1168 | | | |
| <u>INGENOL MEBUTATE - PICATO</u> | | | | | | |
| N 202833 001 >A> | 7410656 | Oct 10, 2020 | U-1222 | | | |
| <u>INGENOL MEBUTATE - PICATO</u> | | | | | | |
| N 202833 002 >A> | 7410656 | Oct 10, 2020 | U-1222 | | | |
| <u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u> | | | | | | |
| N 021172 004 | 9265893 | Sep 23, 2032 | DP | | | |
| <u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u> | | | | | | |
| N 020986 003 | 9265893 | Sep 23, 2032 | DP | | | |
| <u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN</u> | | | | | | |
| N 021536 002 | 9265893 | Sep 23, 2032 | DP | | | |
| <u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u> | | | | | | |
| N 021081 002 >A> | 9011391 9233211 | Mar 26, 2024 Mar 02, 2024 | U-1832 DP | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|---|-----------|------------------------------|-----------------|-------------------------------|-------------------------|--|
| <u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u> | | | | | | |
| N 206538 001 >A> | 9011391 | Mar 26, 2024 | U-1832 | | | |
| | 9233211 | Mar 02, 2024 | DP | | | |
| <u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u> | | | | | | |
| N 021629 003 >A> | 9011391 | Mar 26, 2024 | U-1832 | | | |
| | 9233211 | Mar 02, 2024 | DP | | | |
| <u>INSULIN HUMAN - HUMULIN R</u> | | | | | | |
| N 018780 004 | 7291132 | Aug 09, 2024 | DP | | | |
| <u>INSULIN RECOMBINANT HUMAN - AFREZZA</u> | | | | | | |
| N 022472 001 >A> | 8950397 | Jul 20, 2021 | DP | | | |
| | 9283193 | Sep 14, 2026 | DP | | | |
| <u>INSULIN RECOMBINANT HUMAN - AFREZZA</u> | | | | | | |
| N 022472 002 >A> | 8950397 | Jul 20, 2021 | DP | | | |
| | 9283193 | Sep 14, 2026 | DP | | | |
| <u>INSULIN RECOMBINANT HUMAN - AFREZZA</u> | | | | | | |
| N 022472 003 >A> | 8950397 | Jul 20, 2021 | DP | | | |
| | 9283193 | Sep 14, 2026 | DP | | | |
| <u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u> | | | | | | |
| N 207793 001 | | | | | ODE | Oct 22, 2022 |
| <u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u> | | | | | | |
| N 206038 001 | 9216969 | Nov 08, 2026 | DS DP | | | |
| <u>IVERMECTIN - SOOLANTRA</u> | | | | | | |
| N 206255 001 | 9233117 | Mar 13, 2034 | U-1631 | | | |
| | 9233118 | Mar 13, 2034 | U-1631 | | | |
| <u>IXAZOMIB CITRATE - NINLARO</u> | | | | | | |
| N 208462 001 | 9233115 | Aug 12, 2024 | U-1778 | | ODE | Nov 20, 2022 |
| <u>IXAZOMIB CITRATE - NINLARO</u> | | | | | | |
| N 208462 002 | 9233115 | Aug 12, 2024 | U-1778 | | ODE | Nov 20, 2022 |
| <u>IXAZOMIB CITRATE - NINLARO</u> | | | | | | |
| N 208462 003 | 9233115 | Aug 12, 2024 | U-1778 | | ODE | Nov 20, 2022 |
| <u>KETOROLAC TROMETHAMINE - ACULAR LS</u> | | | | | | |
| N 021528 001 | 9216167 | May 28, 2024 | U-1800 | | | |
| <u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIIDRIA</u> | | | | | | |
| N 205388 001 | 9278101 | Jul 30, 2023 | U-1518 | | | |
| <u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u> | | | | | | |
| N 205834 001 | 9284342 | Sep 13, 2030 | DS DP U-1470 | | D-158 D-159 D-160 | Feb 12, 2019 Feb 12, 2019 Feb 12, 2019 |
| <u>LESINURAD - ZURAMPIC</u> | | | | | | |
| N 207988 001 | 8003681 | Aug 25, 2025 | DS | | | |
| | 8084483 | Aug 17, 2029 | U-1801 | | | |
| | 8283369 | Nov 26, 2028 | U-1802 | | | |
| | 8283369 | Nov 26, 2028 | U-1804 | | | |
| | 8357713 | Nov 26, 2028 | DP U-1801 | | | |
| | 8357713 | Nov 26, 2028 | DP U-1802 | | | |
| | 8357713 | Nov 26, 2028 | DP U-1803 | | | |
| | 8546436 | Feb 29, 2032 | DS DP | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--|-----------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>LESINURAD - ZURAMPIC</u> | | | | | | |
| N 207988 001 | 8546437 | Apr 29, 2029 | U-1803 | | | |
| | 9216179 | Aug 02, 2030 | U-1806 | | | |
| <u>LEUPROLIDE ACETATE - ELIGARD</u> | | | | | | |
| N 021379 001 | 9283282 | Oct 28, 2018 | DS DP | | | |
| <u>LEUPROLIDE ACETATE - ELIGARD</u> | | | | | | |
| N 021488 001 | 9283282 | Oct 28, 2018 | DS DP | | | |
| <u>LEUPROLIDE ACETATE - ELIGARD</u> | | | | | | |
| N 021731 001 | 9283282 | Oct 28, 2018 | DS DP | | | |
| <u>LINAGLIPTIN - TRADJENTA</u> | | | | | | |
| N 201280 001 | 7407955 | May 02, 2025 | DS DP | | | |
| <u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u> | | | | | | |
| N 201281 001 | 7407955 | May 02, 2025 | DS DP | | | |
| <u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u> | | | | | | |
| N 201281 002 | 7407955 | May 02, 2025 | DS DP | | | |
| <u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u> | | | | | | |
| N 201281 003 | 7407955 | May 02, 2025 | DS DP | | | |
| <u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u> | | | | | | |
| N 022341 001 | 9265893 | Sep 23, 2032 | DP | | >A> M-176 | Apr 22, 2019 |
| <u>LOMITAPIDE MESYLATE - JUXTAPID</u> | | | | | | |
| N 203858 001 | 5712279 | Feb 21, 2020 | DS DP U-1317 | | | |
| | 9265758 | Mar 07, 2025 | U-1316 | | | |
| <u>LOMITAPIDE MESYLATE - JUXTAPID</u> | | | | | | |
| N 203858 002 | 5712279 | Feb 21, 2020 | DS DP U-1317 | | | |
| | 9265758 | Mar 07, 2025 | U-1316 | | | |
| <u>LOMITAPIDE MESYLATE - JUXTAPID</u> | | | | | | |
| N 203858 003 | 5712279 | Feb 21, 2020 | DS DP U-1317 | | | |
| | 9265758 | Mar 07, 2025 | U-1316 | | | |
| <u>LOMITAPIDE MESYLATE - JUXTAPID</u> | | | | | | |
| N 203858 004 | 5712279 | Feb 21, 2020 | DS DP U-1317 | | | |
| | 9265758 | Mar 07, 2025 | U-1316 | | | |
| <u>LOMITAPIDE MESYLATE - JUXTAPID</u> | | | | | | |
| N 203858 005 | 5712279 | Feb 21, 2020 | DS DP U-1317 | | | |
| | 9265758 | Mar 07, 2025 | U-1316 | | | |
| <u>LOMITAPIDE MESYLATE - JUXTAPID</u> | | | | | | |
| N 203858 006 | 5712279 | Feb 21, 2020 | DS DP U-1317 | | | |
| | 9265758 | Mar 07, 2025 | U-1316 | | | |
| <u>LULICONAZOLE - LUZU</u> | | | | | | |
| N 204153 001 | 9199977 | Sep 06, 2033 | DS DP | | | |
| <u>LURASIDONE HYDROCHLORIDE - LATUDA</u> | | | | | | |
| N 200603 001 | 9259423 | May 23, 2031 | U-1822 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|---|-----------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>LURASIDONE HYDROCHLORIDE - LATUDA</u> | | | | | | |
| N 200603 002 | 9259423 | May 23, 2031 | U-1822 | | | |
| <u>LURASIDONE HYDROCHLORIDE - LATUDA</u> | | | | | | |
| N 200603 003 | 9259423 | May 23, 2031 | U-1822 | | | |
| <u>LURASIDONE HYDROCHLORIDE - LATUDA</u> | | | | | | |
| N 200603 004 | 9259423 | May 23, 2031 | U-1822 | | | |
| <u>LURASIDONE HYDROCHLORIDE - LATUDA</u> | | | | | | |
| N 200603 005 | 9259423 | May 23, 2031 | U-1822 | | | |
| <u>MACITENTAN - OPSUMIT</u> | | | | | | |
| N 204410 001 | 9265762 | May 29, 2027 | DP U-1820 | | | |
| <u>MEGESTROL ACETATE - MEGESTROL ACETATE</u> | | | | | | |
| A 203139 001 | | | | | >A> PC | Jan 24, 2016 |
| <u>MELPHALAN HYDROCHLORIDE - EVOMELA</u> | | | | | | |
| N 207155 001 | 8410077 | Mar 13, 2029 | DP | | ODE | Mar 10, 2023 |
| | 9200088 | Mar 13, 2029 | DP | | | |
| <u>MENTHOL; METHYL SALICYLATE - SALONPAS</u> | | | | | | |
| N 022029 001 | 9233184 | Aug 01, 2027 | DP | | | |
| <u>MENTHOL; METHYL SALICYLATE - SALONPAS</u> | | | | | | |
| N 022029 002 | 9233184 | Aug 01, 2027 | DP | | | |
| <u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u> | | | | | | |
| A 091664 001 | | | | | PC | Jul 30, 2016 |
| <u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u> | | | | | | |
| A 091664 002 | | | | | PC | Jul 30, 2016 |
| <u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u> | | | | | | |
| N 200678 001 | | | | | >A> M-175 | Apr 05, 2019 |
| <u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u> | | | | | | |
| N 200678 002 | RE44186 | Jul 31, 2023 | DS DP U-1097 | | >A> M-175 | Apr 05, 2019 |
| | RE44186 | Jul 31, 2023 | DS DP U-1838 | | | |
| <u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u> | | | | | | |
| N 200678 003 | RE44186 | Jul 31, 2023 | DS DP U-1097 | | >A> M-175 | Apr 05, 2019 |
| | RE44186 | Jul 31, 2023 | DS DP U-1838 | | | |
| <u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u> | | | | | | |
| N 022044 001 | 7326708 | Nov 24, 2026 | DS DP U-802 | | | |
| <u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u> | | | | | | |
| N 022044 002 | 7326708 | Nov 24, 2026 | DS DP U-802 | | | |
| <u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u> | | | | | | |
| N 202270 001 | 7326708 | Nov 24, 2026 | DS DP U-1227 | | | |
| <u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u> | | | | | | |
| N 202270 002 | 7326708 | Nov 24, 2026 | DS DP U-1227 | | | |
| <u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u> | | | | | | |
| N 202270 003 | 7326708 | Nov 24, 2026 | DS DP U-1227 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|---|-------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u> | | | | | | |
| N 207960 001 | 8999386 | Aug 14, 2033 | DP | | NP | Dec 04, 2018 |
| | 9295642 | Aug 14, 2033 | DP U-1827 | | | |
| <u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u> | | | | | | |
| N 207960 002 | 8999386 | Aug 14, 2033 | DP | | NP | Dec 04, 2018 |
| | 9295642 | Aug 14, 2033 | DP U-1827 | | | |
| <u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u> | | | | | | |
| N 207960 003 | 8999386 | Aug 14, 2033 | DP | | NP | Dec 04, 2018 |
| | 9295642 | Aug 14, 2033 | DP U-1827 | | | |
| <u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u> | | | | | | |
| N 050444 001 | 9278105 | May 12, 2031 | U-282 | | | |
| <u>MIRABEGRON - MYRBETRIO</u> | | | | | | |
| N 202611 001 | >A> 6346532 | Mar 27, 2022 | DS DP | | | |
| | >A> RE44872 | Nov 04, 2023 | U-1527 | | | |
| <u>MIRABEGRON - MYRBETRIO</u> | | | | | | |
| N 202611 002 | >A> 6346532 | Mar 27, 2022 | DS DP | | | |
| | >A> RE44872 | Nov 04, 2023 | U-1527 | | | |
| <u>MORPHINE SULFATE - MORPHINE SULFATE</u> | | | | | | |
| N 204223 001 | 9248229 | Mar 12, 2034 | DP | | | |
| <u>MORPHINE SULFATE - MORPHINE SULFATE</u> | | | | | | |
| N 204223 002 | 9248229 | Mar 12, 2034 | DP | | | |
| <u>MORPHINE SULFATE - MORPHINE SULFATE</u> | | | | | | |
| N 204223 003 | 9248229 | Mar 12, 2034 | DP | | | |
| <u>MORPHINE SULFATE - MORPHINE SULFATE</u> | | | | | | |
| N 204223 004 | 9248229 | Mar 12, 2034 | DP | | | |
| <u>MORPHINE SULFATE - MORPHINE SULFATE</u> | | | | | | |
| N 204223 005 | 9248229 | Mar 12, 2034 | DP | | | |
| <u>MORPHINE SULFATE - MORPHABOND</u> | | | | | | |
| N 206544 001 | 7955619 | Aug 12, 2028 | DP | | | |
| <u>MORPHINE SULFATE - MORPHABOND</u> | | | | | | |
| N 206544 002 | 7955619 | Aug 12, 2028 | DP | | | |
| <u>MORPHINE SULFATE - MORPHABOND</u> | | | | | | |
| N 206544 003 | 7955619 | Aug 12, 2028 | DP | | | |
| <u>MORPHINE SULFATE - MORPHABOND</u> | | | | | | |
| N 206544 004 | 7955619 | Aug 12, 2028 | DP | | | |
| <u>NALOXONE HYDROCHLORIDE - EVZIO</u> | | | | | | |
| N 205787 001 | 9238108 | Jan 22, 2027 | DP | | | |
| | 9278182 | Feb 01, 2026 | DP | | | |
| <u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u> | | | | | | |
| N 205777 001 | 9205082 | Dec 22, 2018 | DP U-1556 | | | |
| | 9283216 | May 10, 2022 | DP U-1819 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u> | | | | | | |
| N 205777 002 | 9205082 | Dec 22, 2018 | DP U-1556 | | | |
| | 9283216 | May 10, 2022 | DP U-1819 | | | |
| <u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u> | | | | | | |
| N 205777 003 | 9205082 | Dec 22, 2018 | DP U-1556 | | | |
| | 9283216 | May 10, 2022 | DP U-1819 | | | |
| <u>NITISINONE - ORFADIN</u> | | | | | | |
| N 206356 001 >A> | 9301932 | Feb 02, 2033 | DP U-1836 | | | |
| <u>NITRIC OXIDE - INOMAX</u> | | | | | | |
| N 020845 003 | 9265911 | Jan 06, 2031 | DP U-1824 | | | |
| | 9265911*PED | Jul 06, 2031 | | | | |
| | 9279794 | Feb 19, 2034 | DP U-1823 | | | |
| | 9279794*PED | Aug 19, 2034 | | | | |
| | 9295802 | Jan 06, 2031 | DP U-1226 | | | |
| | 9295802*PED | Jul 06, 2031 | | | | |
| <u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u> | | | | | | |
| N 206756 001 | | | | | M-173 | Mar 18, 2019 |
| <u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u> | | | | | | |
| N 205060 001 >A> | 5792795 | May 13, 2017 | DP | | | |
| | >A> 5948818 | May 13, 2017 | DP | | | |
| <u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u> | | | | | | |
| N 022056 001 | 5900424 | May 04, 2016 | DS U-864 | | | |
| | 5900424 | May 04, 2016 | DS U-1817 | | | |
| | 6428810 | Nov 03, 2019 | DP U-864 | | | |
| | 6428810 | Nov 03, 2019 | DP U-1817 | | | |
| <u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u> | | | | | | |
| N 022056 002 | 5900424 | May 04, 2016 | DS U-864 | | | |
| | 5900424 | May 04, 2016 | DS U-1817 | | | |
| | 6428810 | Nov 03, 2019 | DP U-864 | | | |
| <u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u> | | | | | | |
| N 021636 001 | 5840737 | Jul 15, 2016 | U-588 | | | |
| | 6489346 | Jul 15, 2016 | DP U-588 | | Y | |
| | 6645988 | Jul 15, 2016 | DP | | Y | |
| | 6699885 | Jul 15, 2016 | U-588 | | Y | |
| | 6780882 | Jul 15, 2016 | DS DP | | | |
| | 7399772 | Jul 15, 2016 | U-588 | | | |
| | RE45198 | Jul 15, 2016 | U-588 | | | |
| <u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u> | | | | | | |
| N 021636 002 | 5840737 | Jul 15, 2016 | U-623 | | | |
| | 5840737 | Jul 15, 2016 | U-624 | | | |
| | 6489346 | Jul 15, 2016 | DP U-623 | | Y | |
| | 6489346 | Jul 15, 2016 | DP U-624 | | Y | |
| | 6645988 | Jul 15, 2016 | DP | | Y | |
| | 6699885 | Jul 15, 2016 | U-623 | | Y | |
| | 6699885 | Jul 15, 2016 | U-624 | | Y | |
| | 6780882 | Jul 15, 2016 | DS DP | | | |
| | 7399772 | Jul 15, 2016 | U-623 | | | |
| | 7399772 | Jul 15, 2016 | U-624 | | | |
| | RE45198 | Jul 15, 2016 | U-623 | | | |
| | RE45198 | Jul 15, 2016 | U-624 | | | |
| <u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u> | | | | | | |
| N 021849 001 | 7399772 | Jul 15, 2016 | U-588 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|---|-------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u> | | | | | | |
| N 021849 002 | 7399772 | Jul 15, 2016 | U-623 | | | |
| | 7399772 | Jul 15, 2016 | U-624 | | | |
| <u>OSIMERTINIB MESYLATE - TAGRISSO</u> | | | | | | |
| N 208065 001 | | | | | ODE | Nov 13, 2022 |
| <u>OSIMERTINIB MESYLATE - TAGRISSO</u> | | | | | | |
| N 208065 002 | | | | | ODE | Nov 13, 2022 |
| <u>OSPemIFENE - OSPHENA</u> | | | | | | |
| N 203505 001 | 9241915 | Feb 13, 2024 | U-1369 | | | |
| | 9241915 | Feb 13, 2024 | U-1370 | | | |
| <u>OXYBUTYNIN CHLORIDE - GELNIQUE</u> | | | | | | |
| N 022204 001 | 9259388 | Nov 06, 2029 | U-1644 | | | |
| <u>OXYCODONE HYDROCHLORIDE - XTAMPZA ER</u> | | | | | | |
| N 208090 001 | | | | | >A> NP | Apr 26, 2019 |
| <u>OXYCODONE HYDROCHLORIDE - XTAMPZA ER</u> | | | | | | |
| N 208090 002 | | | | | >A> NP | Apr 26, 2019 |
| <u>OXYCODONE HYDROCHLORIDE - XTAMPZA ER</u> | | | | | | |
| N 208090 003 | | | | | >A> NP | Apr 26, 2019 |
| <u>OXYCODONE HYDROCHLORIDE - XTAMPZA ER</u> | | | | | | |
| N 208090 004 | | | | | >A> NP | Apr 26, 2019 |
| <u>OXYCODONE HYDROCHLORIDE - XTAMPZA ER</u> | | | | | | |
| N 208090 005 | | | | | >A> NP | Apr 26, 2019 |
| <u>PALBOCICLIB - IBRANCE</u> | | | | | | |
| N 207103 001 | 7456168 | Jan 16, 2023 | U-1658 | | I-725 | Feb 19, 2019 |
| | 7456168 | Jan 16, 2023 | U-1818 | | | |
| <u>PALBOCICLIB - IBRANCE</u> | | | | | | |
| N 207103 002 | 7456168 | Jan 16, 2023 | U-1658 | | I-725 | Feb 19, 2019 |
| | 7456168 | Jan 16, 2023 | U-1818 | | | |
| <u>PALBOCICLIB - IBRANCE</u> | | | | | | |
| N 207103 003 | 7456168 | Jan 16, 2023 | U-1658 | | I-725 | Feb 19, 2019 |
| | 7456168 | Jan 16, 2023 | U-1818 | | | |
| <u>PALONOSETRON HYDROCHLORIDE - ALOXI</u> | | | | | | |
| N 021372 001 | 9066980 | Jan 30, 2024 | DP U-528 | | | |
| | 9066980*PED | Jul 30, 2024 | | | | |
| | 9125905 | Jan 30, 2024 | DP | | | |
| | 9125905*PED | Jul 30, 2024 | | | | |
| | 9173942 | Jan 30, 2024 | DP | | | |
| | 9173942*PED | Jul 30, 2024 | | | | |
| <u>PALONOSETRON HYDROCHLORIDE - ALOXI</u> | | | | | | |
| N 021372 002 | 9173942 | Jan 30, 2024 | DP | | | |
| | 9173942*PED | Jul 30, 2024 | | | | |
| <u>PAROXETINE MESYLATE - PEXEVA</u> | | | | | | |
| N 021299 001 | 7598271 | May 04, 2025 | DS DP | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>PAROXETINE MESYLATE - PEXEVA</u> | | | | | | |
| N 021299 002 | 7598271 | May 04, 2025 | DS DP | | | |
| <u>PAROXETINE MESYLATE - PEXEVA</u> | | | | | | |
| N 021299 003 | 7598271 | May 04, 2025 | DS DP | | | |
| <u>PAROXETINE MESYLATE - PEXEVA</u> | | | | | | |
| N 021299 004 | 7598271 | May 04, 2025 | DS DP | | | |
| <u>PAROXETINE MESYLATE - BRISDELLE</u> | | | | | | |
| N 204516 001 | >A> 7598271 | May 04, 2025 | DS | | | |
| <u>PERAMPANEL - FYCOMPA</u> | | | | | | |
| N 208277 001 | | | | >A> NCE | | Oct 22, 2017 |
| <u>PHENTOLAMINE MESYLATE - ORAVERSE</u> | | | | | | |
| N 022159 001 | | | | >A> NPP | | Mar 18, 2019 |
| <u>PIMAVANSERIN TARTRATE - NUPLAZID</u> | | | | | | |
| N 207318 001 | | | | >A> NCE | | Apr 29, 2021 |
| <u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u> | | | | | | |
| A 202206 004 | | | | >A> PC | | May 18, 2016 |
| <u>PROPOFOL - PROPOFOL</u> | | | | | | |
| A 205307 001 | | | | | PC | Feb 24, 2016 |
| <u>REGADENOSON - LEXISCAN</u> | | | | | | |
| N 022161 001 | >A> 9289446 | Jun 22, 2019 | DP U-116 | | | |
| <u>RIVAROXABAN - XARELTO</u> | | | | | | |
| N 022406 001 | >A> 7157456 | Aug 28, 2024 | DS DP U-1301 | | | |
| | >A> 7157456 | Aug 28, 2024 | DS DP U-1302 | | | |
| <u>RIVAROXABAN - XARELTO</u> | | | | | | |
| N 022406 002 | >A> 7157456 | Aug 28, 2024 | DS DP U-1301 | | | |
| | >A> 7157456 | Aug 28, 2024 | DS DP U-1302 | | | |
| <u>RIVAROXABAN - XARELTO</u> | | | | | | |
| N 022406 003 | >A> 7157456 | Aug 28, 2024 | DS DP U-1301 | | | |
| | >A> 7157456 | Aug 28, 2024 | DS DP U-1302 | | | |
| <u>ROSUVASTATIN CALCIUM - CRESTOR</u> | | | | | | |
| N 021366 002 | 6858618 | Dec 17, 2021 | U-618 | | | |
| | 6858618 | Dec 17, 2021 | U-1032 | | | |
| | 6858618 | Dec 17, 2021 | U-1807 | | | |
| | 6858618*PED | Jun 17, 2022 | | | | |
| <u>ROSUVASTATIN CALCIUM - CRESTOR</u> | | | | | | |
| N 021366 003 | 6858618 | Dec 17, 2021 | U-618 | | | |
| | 6858618 | Dec 17, 2021 | U-1032 | | | |
| | 6858618 | Dec 17, 2021 | U-1807 | | | |
| | 6858618*PED | Jun 17, 2022 | | | | |
| <u>ROSUVASTATIN CALCIUM - CRESTOR</u> | | | | | | |
| N 021366 004 | 6858618 | Dec 17, 2021 | U-618 | | | |
| | 6858618 | Dec 17, 2021 | U-1032 | | | |
| | 6858618 | Dec 17, 2021 | U-1807 | | | |
| | 6858618*PED | Jun 17, 2022 | | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u> | | | | | | |
| N 205065 001 | 9216178 | Nov 01, 2032 | DP | | | |
| <u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u> | | | | | | |
| N 205065 002 | 7612073 | Nov 17, 2024 | U-1010 | | | |
| | 7612073*PED | May 17, 2025 | | | | |
| | 9216178 | Nov 01, 2032 | DP | | | |
| | RE43797 | Nov 17, 2024 | U-1590 | | | |
| | RE43797*PED | May 17, 2025 | | | | |
| <u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u> | | | | | | |
| N 022350 001 | >A> RE44186 | Jul 31, 2023 | DS DP U-995 | | >A> M-175 | Apr 05, 2019 |
| | >A> RE44186 | Jul 31, 2023 | DS DP U-1837 | | | |
| <u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u> | | | | | | |
| N 022350 002 | >A> RE44186 | Jul 31, 2023 | DS DP U-995 | | >A> M-175 | Apr 05, 2019 |
| | >A> RE44186 | Jul 31, 2023 | DS DP U-1837 | | | |
| <u>SELEXIPAG - UPTRAVI</u> | | | | | | |
| N 207947 001 | 7205302 | Apr 04, 2023 | DS DP U-1797 | | ODE | Dec 21, 2022 |
| | 8791122 | Aug 01, 2030 | DS DP | | | |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| <u>SELEXIPAG - UPTRAVI</u> | | | | | | |
| N 207947 002 | 7205302 | Apr 04, 2023 | DS DP U-1797 | | ODE | Dec 21, 2022 |
| | 8791122 | Aug 01, 2030 | DS DP | | | |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| <u>SELEXIPAG - UPTRAVI</u> | | | | | | |
| N 207947 003 | 7205302 | Apr 04, 2023 | DS DP U-1797 | | ODE | Dec 21, 2022 |
| | 8791122 | Aug 01, 2030 | DS DP | | | |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| <u>SELEXIPAG - UPTRAVI</u> | | | | | | |
| N 207947 004 | 7205302 | Apr 04, 2023 | DS DP U-1797 | | ODE | Dec 21, 2022 |
| | 8791122 | Aug 01, 2030 | DS DP | | | |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| <u>SELEXIPAG - UPTRAVI</u> | | | | | | |
| N 207947 005 | 7205302 | Apr 04, 2023 | DS DP U-1797 | | ODE | Dec 21, 2022 |
| | 8791122 | Aug 01, 2030 | DS DP | | | |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| <u>SELEXIPAG - UPTRAVI</u> | | | | | | |
| N 207947 006 | 7205302 | Apr 04, 2023 | DS DP U-1797 | | ODE | Dec 21, 2022 |
| | 8791122 | Aug 01, 2030 | DS DP | | | |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| <u>SELEXIPAG - UPTRAVI</u> | | | | | | |
| N 207947 007 | 7205302 | Apr 04, 2023 | DS DP U-1797 | | ODE | Dec 21, 2022 |
| | 8791122 | Aug 01, 2030 | DS DP | | | |
| | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| <u>SELEXIPAG - UPTRAVI</u> | | | | | | |
| N 207947 008 | 7205302 | Apr 04, 2023 | DS DP U-1797 | | ODE | Dec 21, 2022 |
| | 8791122 | Aug 01, 2030 | DS DP | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>SELEXIPAG - UPTRAVI</u> | | | | | | |
| N 207947 008 | 9173881 | Aug 12, 2029 | U-1798 | | | |
| | 9284280 | Jun 25, 2030 | U-1831 | | | |
| <u>SEVELAMER CARBONATE - RENVELA</u> | | | | | | |
| N 022318 001 | 9095509 | Dec 06, 2030 | DP | | | |
| <u>SEVELAMER CARBONATE - RENVELA</u> | | | | | | |
| N 022318 002 | 9095509 | Dec 06, 2030 | DP | | | |
| <u>SIMEPREVIR SODIUM - OLYSIO</u> | | | | | | |
| N 205123 001 | | | | | M-171 | Feb 26, 2019 |
| <u>SITAGLIPTIN PHOSPHATE - JANUVIA</u> | | | | | | |
| N 021995 001 | 7326708 | Nov 24, 2026 | DS DP U-802 | | | |
| <u>SITAGLIPTIN PHOSPHATE - JANUVIA</u> | | | | | | |
| N 021995 002 | 7326708 | Nov 24, 2026 | DS DP U-802 | | | |
| <u>SITAGLIPTIN PHOSPHATE - JANUVIA</u> | | | | | | |
| N 021995 003 | 7326708 | Nov 24, 2026 | DS DP U-802 | | | |
| <u>SOFOSBUVIR - SOVALDI</u> | | | | | | |
| N 204671 001 | 9284342 | Sep 13, 2030 | DS DP U-1470 | | | |
| <u>SUGAMMADEX SODIUM - BRIDION</u> | | | | | | |
| N 022225 001 | 7265099 | Aug 07, 2020 | U-1795 | | NCE | Dec 15, 2020 |
| <u>SUGAMMADEX SODIUM - BRIDION</u> | | | | | | |
| N 022225 002 | 7265099 | Aug 07, 2020 | U-1795 | | NCE | Dec 15, 2020 |
| <u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u> | | | | | | |
| N 203684 001 | | | | | I-728 | Mar 31, 2019 |
| <u>SUMATRIPTAN SUCCINATE - ZECURITY</u> | | | | | | |
| N 202278 001 | 9272137 | Sep 07, 2027 | DP | | | |
| <u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u> | | | | | | |
| N 206099 001 | 6715485 | Mar 03, 2020 | DP | | | |
| | 7975690 | Aug 18, 2025 | DP U-1809 | | | |
| | 8047202 | Jul 02, 2023 | DP | | | |
| | 8327844 | Oct 03, 2023 | U-1809 | | | |
| | 8550073 | Oct 22, 2029 | DP | | | |
| | 8555877 | Mar 03, 2020 | DP | | | |
| | 8590530 | Sep 15, 2025 | DP U-1809 | | | |
| | 8875704 | Apr 07, 2028 | DP U-1809 | | | |
| | 8899229 | Aug 18, 2030 | DP | | | |
| | 8978647 | Dec 06, 2030 | DP | | | |
| | 9108015 | Sep 15, 2025 | DP | | | |
| | 9119932 | Apr 23, 2024 | DP | | | |
| <u>T AFLUPROST - ZIOPTAN</u> | | | | | | |
| N 202514 001 >A> | 5886035 | Dec 18, 2022 | DS DP U-778 | | | |
| <u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u> | | | | | | |
| N 203441 001 | 5789379 | Apr 14, 2020 | DS DP U-1320 | | | |
| <u>TESTOSTERONE - ANDROGEL</u> | | | | | | |
| N 021015 001 | 9125816 | Aug 30, 2020 | U-490 | | | |
| | 9125816*PED | Mar 02, 2021 | | | | |
| | 9132089 | Aug 30, 2020 | U-490 | | | |
| | 9132089*PED | Mar 02, 2021 | | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|--|-------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>TESTOSTERONE - ANDROGEL</u> | | | | | | |
| N 021015 001 | 9125816 | Aug 30, 2020 | U-490 | | | |
| | 9125816*PED | Mar 02, 2021 | | | | |
| | 9132089 | Aug 30, 2020 | U-490 | | | |
| | 9132089*PED | Mar 02, 2021 | | | | |
| <u>TESTOSTERONE - ANDROGEL</u> | | | | | | |
| N 021015 002 | 9125816 | Aug 30, 2020 | U-490 | | | |
| | 9125816*PED | Mar 02, 2021 | | | | |
| | 9132089 | Aug 30, 2020 | U-490 | | | |
| | 9132089*PED | Mar 02, 2021 | | | | |
| <u>TESTOSTERONE - ANDROGEL</u> | | | | | | |
| N 021015 003 | 9125816 | Aug 30, 2020 | U-490 | | | |
| | 9125816*PED | Mar 02, 2021 | | | | |
| | 9132089 | Aug 30, 2020 | U-490 | | | |
| | 9132089*PED | Mar 02, 2021 | | | | |
| <u>TESTOSTERONE - ANDROGEL</u> | | | | | | |
| N 022309 001 | 6503894 | Aug 30, 2020 | U-1103 | | | |
| | 6503894*PED | Mar 02, 2021 | | | | |
| | 9125816 | Aug 30, 2020 | U-1103 | | | |
| | 9125816*PED | Mar 02, 2021 | | | | |
| | 9132089 | Aug 30, 2020 | U-1103 | | | |
| | 9132089*PED | Mar 02, 2021 | | | | |
| <u>TESTOSTERONE - ANDROGEL</u> | | | | | | |
| N 022309 002 | 6503894 | Aug 30, 2020 | U-1103 | | | |
| | 6503894*PED | Mar 02, 2021 | | | | |
| | 9125816 | Aug 30, 2020 | U-1103 | | | |
| | 9125816*PED | Mar 02, 2021 | | | | |
| | 9132089 | Aug 30, 2020 | U-1103 | | | |
| | 9132089*PED | Mar 02, 2021 | | | | |
| <u>TESTOSTERONE - ANDROGEL</u> | | | | | | |
| N 022309 003 | 6503894 | Aug 30, 2020 | U-1103 | | | |
| | 6503894*PED | Mar 02, 2021 | | | | |
| | 9125816 | Aug 30, 2020 | U-1103 | | | |
| | 9125816*PED | Mar 02, 2021 | | | | |
| | 9132089 | Aug 30, 2020 | U-1103 | | | |
| | 9132089*PED | Mar 02, 2021 | | | | |
| <u>TESTOSTERONE - AXIRON</u> | | | | | | |
| N 022504 001 | >A> 9289586 | Feb 26, 2027 | U-1390 | | | |
| <u>TESTOSTERONE - VOGELXO</u> | | | | | | |
| N 204399 002 | 9295675 | Feb 11, 2034 | DP U-1531 | | | |
| <u>TESTOSTERONE - VOGELXO</u> | | | | | | |
| N 204399 003 | 9295675 | Feb 11, 2034 | DP U-1531 | | | |
| <u>TIGECYCLINE - TYGACIL</u> | | | | | | |
| N 021821 001 | 9254328 | Mar 13, 2026 | DP | | | |
| <u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u> | | | | | | |
| N 020912 001 | 6770660 | May 01, 2023 | U-1444 | | | |
| <u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u> | | | | | | |
| N 020913 001 | 6770660 | Jun 01, 2023 | U-1444 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|---|-------------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u> | | | | | | |
| N 020913 002 | 6770660 | Jun 01, 2023 | U-1444 | | | |
| <u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u> | | | | | | |
| N 020913 003 | 6770660 | Jun 01, 2023 | U-1444 | | | |
| <u>TOFACITINIB CITRATE - XELJANZ XR</u> | | | | | | |
| N 208246 001 | 6956027 | Mar 25, 2023 | DS | | NCE | Nov 06, 2017 |
| | 6956041 | Dec 08, 2020 | DP | | | |
| | 7091208 | Dec 08, 2020 | U-247 | | | |
| | 7265221 | Dec 08, 2020 | DS | | | |
| | 7301023 | May 23, 2022 | DS | | | |
| | RE41783 | Dec 08, 2020 | DS | | | |
| <u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u> | | | | | | |
| N 204114 001 | 9271941 | Jan 28, 2032 | DP | | M-170 | Nov 20, 2018 |
| <u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u> | | | | | | |
| N 204114 003 | 9271941 | Jan 28, 2032 | DP | | M-170 | Nov 20, 2018 |
| <u>TREPROSTINIL DIOLAMINE - ORENITRAM</u> | | | | | | |
| N 203496 001 | 9278901 | May 24, 2024 | U-1475 | | D-156 D-157 | Jan 28, 2019 Jan 28, 2019 |
| <u>TREPROSTINIL DIOLAMINE - ORENITRAM</u> | | | | | | |
| N 203496 002 | 9278901 | May 24, 2024 | U-1475 | | D-156 D-157 | Jan 28, 2019 Jan 28, 2019 |
| <u>TREPROSTINIL DIOLAMINE - ORENITRAM</u> | | | | | | |
| N 203496 003 | 9278901 | May 24, 2024 | U-1475 | | D-156 D-157 | Jan 28, 2019 Jan 28, 2019 |
| <u>TREPROSTINIL DIOLAMINE - ORENITRAM</u> | | | | | | |
| N 203496 004 | 9278901 | May 24, 2024 | U-1475 | | D-156 D-157 | Jan 28, 2019 Jan 28, 2019 |
| <u>ULIPRISTAL ACETATE - ELLA</u> | | | | | | |
| N 022474 001 | 9283233 | Apr 13, 2030 | U-1821 | | | |
| <u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u> | | | | | | |
| N 205382 001 | | | | | M-172 | Feb 24, 2019 |
| <u>URIDINE TRIACETATE - VISTOGARD</u> | | | | | | |
| N 208159 001 | | | | | ODE | Dec 11, 2022 |
| <u>VENETOCLAX - VENCLEXTA</u> | | | | | | |
| N 208573 001 | >A> 8546399 | Jun 27, 2031 | DS DP | | >A> NCE | Apr 11, 2021 |
| | >A> 9174982 | May 26, 2030 | U-1835 | | >A> ODE | Apr 11, 2023 |
| <u>VENETOCLAX - VENCLEXTA</u> | | | | | | |
| N 208573 002 | >A> 8546399 | Jun 27, 2031 | DS DP | | >A> NCE | Apr 11, 2021 |
| | >A> 9174982 | May 26, 2030 | U-1835 | | >A> ODE | Apr 11, 2023 |
| <u>VENETOCLAX - VENCLEXTA</u> | | | | | | |
| N 208573 003 | >A> 8546399 | Jun 27, 2031 | DS DP | | >A> NCE | Apr 11, 2021 |
| | >A> 9174982 | May 26, 2030 | U-1835 | | >A> ODE | Apr 11, 2023 |
| <u>VISMODEGIB - ERIVEDGE</u> | | | | | | |
| N 203388 001 | 9278961 | Dec 15, 2028 | U-1825 | | | |

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 04 - April 2016

See List footnote for information regarding List content

| APPL/PROD NO | PATENT NO | PATENT EXPIRATION DATE | PATENT CODES | PATENT DELIST REQUESTED | EXCLUSIVITY CODE (S) | EXCLUSIVITY EXPIRATION DATE |
|---|-----------|------------------------------|-----------------|-------------------------------|-------------------------|-----------------------------------|
| <u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u> | | | | | | |
| N 204447 001 | 9227946 | Jun 15, 2027 | U-1668 | | | |
| <u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u> | | | | | | |
| N 204447 002 | 9227946 | Jun 15, 2027 | U-1668 | | | |
| <u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u> | | | | | | |
| N 204447 003 | 9227946 | Jun 15, 2027 | U-1668 | | | |
| <u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u> | | | | | | |
| N 204447 004 | 9227946 | Jun 15, 2027 | U-1668 | | | |
| <u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u> | | | | | | |
| A 204299 001 | | | | | PC | Sep 18, 2016 |
| <u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u> | | | | | | |
| A 204299 002 | | | | | PC | Sep 18, 2016 |
| <u>ZOLPIDEM TARTRATE - EDLUAR</u> | | | | | | |
| N 021997 001 | 9265720 | May 13, 2030 | U-674 | | | |
| <u>ZOLPIDEM TARTRATE - EDLUAR</u> | | | | | | |
| N 021997 002 | 9265720 | May 13, 2030 | U-674 | | | |

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 36th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>